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Background & aims: The inflammatory bowel diseases (IBD), Crohn‟s disease 
(CD) and ulcerative colitis (UC), are common causes of chronic gastrointestinal 
morbidity, affecting up to 1 in 250 of the general population in Northern Europe. Up 
to 25% of IBD is diagnosed during childhood or adolescence. The aims for this thesis 
were to study the epidemiology, natural history and novel genetic determinants of 
childhood onset IBD in Scotland.  
Methods: The existing repository of childhood onset and adult onset IBD patients, 
established at the Western General Hospital in Edinburgh, was used and expanded. 
Thus, anatomical location and behaviour of disease were assessed in 416 childhood 
onset (276 CD, 99 UC, 41 IBDU diagnosed before 17th birthday) and 1297 adult 
patients (596 CD, 701 UC) using the Montreal classification. Additional phenotypic 
(at diagnosis and at regular follow-up intervals) and epidemiological data were 
gathered. In this cohort, genotyping of germline variants in putative susceptibility 
genes (NOD1/CARD4, IL23R, ATG16L1, IRGM, FLG) was performed to enable 
single variant and haplotype-tagging association studies. Genotypic data of 
population-matched healthy controls were obtained locally (n=342) and from the 
Wellcome Trust Case Control Consortium (n=2937).  
Results: Compared with adults, childhood-onset CD was characterized by a more 
extensive, “panenteric” phenotype (ileocolonic plus upper GI; p<0.0001 OR23.3; 
95% CI (13.4–40.6) with less isolated ileal (p<0.0001 OR 0.06 (0.03–0.1) or colonic 
disease (p<0.0001, OR 0.3 (0.2–0.5)). In 39%, the anatomic extent increased within 2 
years. 
UC was also more extensive in children at diagnosis vs adults (p<0.0001 OR 5.1 
(2.7–9.4)). In population-matched and age, sex and postcode-matched case-control 
analysis, childhood onset IBD and CD was associated with asthma (p<0.0001 OR 1.7 
(1.3-2.1) and (p=0.005 OR 2.5 (1.3-4.8), respectively). 
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Inherited variation of NOD1/CARD4 was not a strong determinant of disease 
susceptibility in the Scottish population (both in single marker and haplotype-tagging 
studies, all p>0.05 after Bonferroni correction). 
We found that the allelic frequency of rs11209026*A located within the IL23R gene, 
differed significantly between IBD / CD cases and controls (p=0.01 OR 0.51(0.3-0.9) 
and p=0.04 OR 0.5 (0.3-0.98)). Using a gene-wide haplotype-tagging strategy, we 
demonstrated that the multiple association signals of the IL23R locus are 
independent of rs11209026 in childhood onset IBD and CD. 
In Scottish children, the effect of germline variation of ATG16L1 and IRGM on CD 
susceptibility was relatively small (OR< 1.4), and appeared less than in adult disease. 
Genotype–phenotype analysis demonstrated an association of pure ileal disease with 
the ATG16L1 rs2241880G-allele (p=0.02 OR 1.3 (1.03–1.7)). Using binary logistic 
regression analysis, we confirmed the effect of rs2241880 genotype (GG) on ileal 
disease versus colonic disease (p=0.03 OR 2.4 (1.05–5.6)). 
Null alleles of the epithelial barrier protein FLG have no important effect on IBD 
susceptibility (p>0.4), but contribute to the high prevalence of atopy, notably co-
existent eczema and food allergy (p=0.0003 OR 3.3 (1.7–6.6) and p=0.0001 OR 4.5 
(2.0–10.0), respectively). 
Conclusion: Childhood onset IBD is characterised by extensive intestinal 
involvement and progression of disease after diagnosis. Genetic association studies 
in childhood and adult IBD have provided evidence for a large number of new 
genomic loci. These loci encode genes involved in a number of homeostatic 
mechanisms:  innate pattern recognition receptors, the differentiation of Th17-
lymphocytes, autophagy, maintenance of epithelial barrier integrity and the 
orchestration of the secondary immune response.  
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1 Introduction to the genetics of the innate immune 
response in inflammatory bowel disease 
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Introduction 
1.1.1 Paediatric Inflammatory Bowel Disease 
The inflammatory bowel diseases (IBD), Crohn‟s disease (CD [MIM 266600]) , 
Ulcerative Colitis (UC[MIM 191390]), are common causes of chronic 
gastrointestinal morbidity, affecting up to 1 in 250 of the general population in 
Northern Europe.
1
 Up to 25% of IBD is diagnosed during childhood or adolescence.
2
 
Not only does the well-documented rising incidence of childhood onset IBD in 
Scotland and elsewhere in the UK, pose a significant public health problem affecting 
delivery of care from primary to quaternary level.
3-6
 The high disease burden often 
affects children, young adults (peak age of onset in the third decade of life) and their 
families in a truly pervasive manner. 
Early onset IBD most commonly presents in early adolescence, impacting heavily on 
all aspects of physical, psychological and sexual development.
7
 IBD activity 
influences linear growth, accrual of an adequate peak bone mass, education and 
future employment prospects.  
Crohn‟s disease is characterised by transmural inflammation and granuloma 
formation, affecting the gastrointestinal tract from mouth to anus. The inflammation 
in CD is often patchy, causing so-called „skip-lesions‟. The behaviour of disease is 
dynamic and influenced strongly by the initial location of disease: over time the 




The inflammation in ulcerative colitis is typically limited to the mucosa, affecting the 
large bowel continuously from the rectum to more proximally to a varying degree: 
from isolated proctitis to pancolitis. Disease activity in UC is also highly variable: 
Turner et al. recently reported more than 1 in 4 children with UC resident in the 
Greater Toronto Area required admission for intravenous corticosteroid therapy 




In 10-15% of patients, IBD presents with inflammation limited to the colon without 
clear features to distinguish between CD and UC. IBD- type unclassified (previously 
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indeterminate colitis) is then the preferred diagnosis. In all types of IBD, 
extraintestinal manifestations can occur involving the skin, joints or eyes. 
 
Treatment of the disease is often cumbersome and hampered by a small evidence 
base from appropriately designed trials in childhood.(Wilson DC et al, DDW 2008) 
Indeed, most of the “evidence” in childhood is distilled from adult studies. 
Improving our understanding of disease pathogenesis in childhood will hopefully 
lead to more appropriately designed treatment regimens for children and adults with 
IBD alike. 
 
1.1.2 Innate immunity: a paradigm shift 
Until a few years ago, the perceived dichotomy between innate and 
adaptive/acquired immunity on the one hand and the strong evidence for a T-cell 
driven disease process, susceptible to treatment with immunomodulators, on the 
other hand, led researchers to believe a dysregulation of the adaptive immune system 
was the underlying mechanism in the pathogenesis of the inflammatory bowel 
diseases (IBD). The discovery of NOD2/CARD15 as the first susceptibility gene in 
Crohn‟s disease (followed by the implication in IBD of variant alleles of OCTN, 
DLG5 and TLRs) has shifted the focus of research firmly to the innate immune 
response and the integrity of the epithelial barrier.  
The importance of the commensal bacterial flora and its communication strategies 
with the host is illustrated by the finding of gastrointestinal manifestations similar to 
IBD in several innate immunodeficiency syndromes. Efficient communication 
depends on adequate recognition by the host of the luminal micro-organisms. 
Increasing knowledge of ligands for the main pattern-recognition receptors of the 
innate immune system, Toll-like Receptors (TLRs) and CATERPILLER-proteins 
(including NOD1 and NOD2), has shown innate immunity to be much more complex 
than a mere mechanism to distinguish „self‟ from „non-self‟.  
The picture that is emerging from an exponentially enlarging body of research is that 
of an integrated system capable of maintaining the integrity of the epithelial barrier, 
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recognising commensals as well as potentially dangerous pathogens, inducing 
tolerance or mounting a first line of defence. If necessary, the innate immune system 
can also orchestrate a secondary adaptive immune response while initiating 
resolution of the inflammatory response. 
In this first chapter, I summarize the recent advances in our understanding of the 
influence germline variants of genes regulating the innate immunse system have on 
the development of IBD. Most interest has been concentrated on the family of genes 
coding for pattern-recognition receptors (e.g. TLRs and NOD-LRRs), genes involved 
in epithelial integrity (e.g. MDR1, DLG5 and OCTNs) and mucin genes. 
 
From innate immunodeficiencies to defective innate immunity 
Crohn‟s disease (CD) is now widely thought to arise from a dysregulated response to 
commensal micro-organisms in the normal mucosal flora.
10
 However, recent data 
have suggested that the precipitating event for the chain of immunological responses 
leading to IBD may not be a loss of tolerance towards commensal luminal bacteria 
but rather an immunodeficiency.
11-13
 The discovery of NOD2/CARD15 as the first 
susceptibility gene in CD, the elucidation of its functional properties and the 
association of NOD2/CARD15 homozygous variants with a younger age at 
diagnosis, have strengthened this hypothesis further.
14-22
  
Furthermore, enterocolitides resembling IBD have been found in a myriad of rare 
(congenital) immunodeficiency syndromes (see Table 1). Many of these rare 
immunodeficiency syndromes share a quantitative or qualitative neutrophil function 
defect.
23-26
 Although a primary neutrophil defect in CD remains a contentious area of 
research, various neutrophil abnormalities have been described in CD. Neutrophil 
chemotaxis (triggered by IL-8) was found to be impaired in CD, irrespective of 
NOD2/CARD15 genotype.
27-30
 However, other groups have presented conflicting 
results with regards to IL-8 secretion in CD.
31-33
 Superoxide generation defects have 
been demonstrated, not related to IBD activity.
34-36
 Phagocytosis and microbial 
killing too were found to be affected in CD.
37;38
 A defect of adequate neutrophil-
mediated clearance of mucosal micro-organisms may lead to chronic inflammation 
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and the perpetuation of the T-cell driven process in IBD.
27
 In therapeutic trials, 
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), a hematopoietic 
growth factor which stimulates cells of the intestinal innate immune system, has been 




Table 1-1: Immunodeficiency syndromes with IBD like enterocolitis 






































IBD Genetics in Scottish Children 
6 Ch. 1: Genetics of the innate immune response in inflammatory bowel disease 
Epithelial barrier: interface between intestinal flora and mucosal 
immunity 
 
1.1.3 Intestinal flora 
Considerable evidence now suggests that the immune response in IBD is not directed 
to specific pathogens but rather to ubiquitous luminal bacteria.
10;66;67
 In health, the 
intestinal flora consists of up to 100 trillion bacteria and undergoes very few changes 
after it is established during infancy.
68;69
 The initial colonisation of the gut is 
facilitated by the delayed production of gastric acid and pancreatic proteases by the 
newborn infant, glycopeptides (promoting the growth of Bifidobacterium and 
Lactobacillus and limiting Bacteroides species) and immunomodulating agents (eg 
TGF-β, IL-10, sCD14, GCSF) in human milk.
70-76
 Recent, animal data have 
demonstrated that the intestinal antimicrobial peptides undergo a complete 
developmental switch in innate immune effector expression and anatomical 
distribution shortly after birth.
77
 The expression of cathelicidin-related antimicrobial 
peptide was limited to the first two weeks after birth and gradually disappeared with 
the onset of increased stem cell proliferation and epithelial cell migration along the 
crypt-villus axis.
77
 After the neonatal period, Paneth-cell derived enteric 
antimicrobial peptides provide protection from intestinal infection and maintenance 
of enteric homeostasis, as discussed later in this chapter. 
Breastfed infants are less often colonised with bacteria other than Bifidobacteria, 
compared with formula-fed infants.
78
 However, the protective effect of breastfeeding 
on the development of IBD has recently been under discussion.
79-81
 Other factors 
influencing the colonisation of the gut in the newborn like maternal smoking and 




Clear differences have been observed between CD patients compared to healthy 
controls with regards to faecal flora composition, protection provided by the mucus 
layer and mucosal colonisation.
66;87-90
 Aggressive species (eg adherent-invasive 
E.Coli, Enterobacteriaceae and Bacteroides species) are abundant on the mucosal 
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surface in comparison with protective genera, both in adults and children with 
IBD.
66;91-93
 In comparison, a recent study on commensal flora in healthy subjects, 
reported that bacteria were only observed at the luminal side of the mucus layer and 
the bacterial microflora present in the faeces was similar to that in the mucus layer of 
the terminal ileum and colon.
94
 Frank et al. have recently provided further evidence 
for the unique changes which occur in the microflora of IBD: a depletion of 




The above findings suggest that changes in both the bacterial microflora and the 
mucus layer are important in IBD pathogenesis.
96
 Episodes of infectious 
gastroenteritis lead to an increased risk of developing IBD, especially in the first year 
post-gastroenteritis.
97
 Furthermore, using pre-, pro- and synbiotics to manipulate the 
enteric microflora (and restore the beneficial predominance of Lactobacillus and 
Bifidobacterium at the expense of eg  Enterobacteriaceae and Bacteroides species) 
has proven to be particularly successful in the treatment of pouchitis and mild-to-
moderate ulcerative colitis.
98-100
 There is also presumptive evidence that antibiotics 
(metronidazole +/- ciprofloxacin) are effective in pouchitis, perianal fistulae, Crohn‟s 




1.1.4 Intestinal Mucins 
The mucus layer acts as a lubricant and protective physical barrier between the 
mucosal surface and the luminal contents. It consists of mucus glycoproteins 
(mucins) and trefoil factors, secreted by goblet cells.
101;102
 Mucins are very large 
filamentous molecules containing tandemly repeated peptide domains which are 
highly O-glycosylated.
101
 Large numbers of sulphate and sialic acid residues added 
to these carbohydrate chains are responsible for the negative surface charge of 
mucins.
103




Mucins can be divided into three main categories: 
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1) secretory, gel-forming mucins: MUC2, MUC5AC, MUC5B and MUC6: all 
located in the gene cluster on 11p15 
2) membrane-bound mucins: MUC1 (1q22), MUC3A, MUC3B, MUC11, 
MUC12, MUC17 (all on 7q22 (an IBD susceptibility locus), MUC4 (3q29 (also 
an IBD susceptibility locus)) 




Secretory mucins are produced in specialised mucous cells of glandular tissues and 
goblet cells of the gastrointestinal tract.
110
 MUC2 is the predominant mucin in the 
small and large intestine, located in bulky apical granules of goblet cells.
111-113
 
MUC5B is expressed in small quantities in a subset of goblet cells at the bottom of 
colonic crypts.
114
 MUC5AC and MUC6 are expressed in the gastric epithelium while 
MUC6 is also expressed in Brunner‟s glands of the duodenum.
115;116
 The membrane-





In IBD, the colonic mucus layer varies in thickness compared with controls.
118
 The 
reduction of the thickness in ulcerative colitis is believed to reflect the depletion of 
goblet cells.
101
 The increase in bacteria in the mucus layer of IBD patients 
contributes to further mucus degradation by the production of mucinase, sulphatase 
and glycosidase.
119-121
 Recently, altered colonic glycoprotein expression in 
unaffected identical twins of IBD patients was found to be associated with pre-
clinical NFκB activation.
122
 A previous report had found these changes in 




The influence of cytokines, bacteria (including probiotics), bacterial components and 
bacterial metabolites (e.g. butyrate) on mucin expression and structure was first 
shown in vitro.
124-129
 IL-10 deficient (
–/–
) mice, a widely accepted mouse model of 
IBD, crossed to human
 
MUC1-transgenic mice, were recently shown to develop 
MUC1
+
 IBD characterized by an
 
earlier age of onset, higher inflammation scores, 
and a much
 
higher incidence and number of colon cancers compared with IL-10
–/– 
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mice.
130
 In animal models of inflammation using Dextran Sodium Sulphate (DSS) – 
treated mice, MUC2 gene expression was not modified by colitis, whereas MUC1, 3 







experiments demonstrated that MUC2 deficiency leads to inflammation of the colon 
and contributes to the onset and perpetuation of experimental (DSS) colitis.
102
 In the 
same study, Van Der Sluis et al. demonstrated de novo expression of MUC6 in the 
goblet cells of MUC2
-/-
 mice reflecting a possible compensatory mechanism through 
the induction of an Ulcer Associated Cell Lineage (UACL) from intestinal stem 
cells.
132
 Another murine model was crucial in demonstrating the influence of IL-10 
on MUC2 synthesis.
133
 Dietary manipulations including prebiotics, probiotics or 
amino acids supplements were shown to influence mucin expression in animal 
models.
134-136
 Recently, a recombinant cysteine-rich, Epidermal Growth Factor-like 





MUC2 protein synthesis, secretion and sulphation are decreased in active ulcerative 
colitis although Myerscough et al. found MUC2 and MUC4 mRNA to be similar to 
controls.
118;138-141
 MUC1 and  MUC3 mRNA were reduced in ulcerative colitis in 
this study.
141
 In Crohn‟s disease, decreased mRNA levels of MUC3, MUC4 and 
MUC5B were found in healthy and inflamed ileal mucosa compared with controls, 
whereas MUC1 mRNA was reduced in inflamed mucosa only.
142
 Using different 
assays, Buisine et al. reported normal expression of MUC2 and MUC3 in non-
inflamed ileal mucosa from CD patients compared with controls. In inflamed ileal 
biopsies, heterogeneous staining was observed although overall levels of 
hybridisation were still similar to controls.
143
 In the UACL in the inflamed ileum 
from CD patients, expression of MUC1, 3, 4, 5AC, 5B and 6 but not MUC2 were 
demonstrated.
143;144
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Different genetic variations in the MUC3A have been associated with UC and 
CD.
146;147
 Polymorphisms of variable number of tandem repeats (VNTRs) within this 
gene in Japanese and Caucasian ulcerative colitis samples were described.
146
 In this 
study, Kyo et al found the frequency of rare VNTR alleles in UC patients to be 
increased relative to controls. In further work, the same group described how non-
synonymous single nucleotide polymorphisms of MUC3A, involving a tyrosine 
residue with a proposed role in cell signaling, may confer genetic predisposition to 
familial, but not sporadic CD.
147
 Recently, DNA sequence changes in MUC2 have 
been associated with CD whereas allelic variation of MUC4 and MUC13 genes was 





1.1.5 Trefoil factors 
The integrity of the epithelial barrier not only depends on adequate protection by a 
stable mucus layer but also on swift restitution of epithelial continuity after injury. 
The process of restitution entails epithelial cell migration across the site of injury and 
involves the rapid disassembly of cell-cell and cell-substratum adhesions, de-
differentiation as well as spreading of surface cells.
149
 Secretory TFF (trefoil factor 
family) peptides TFF1 (also known as pS2), TFF2 (also called spasmolytic peptide 
(SP)) and TFF3 (or intestinal trefoil factor (ITF)) are key players in this early repair 
sequence.
150
 They are co-localised with mucin in mucus-secreting cells and 
abundantly secreted by these cells onto the mucosal surface of the gastrointestinal 
tract.
144;151
 The compact structure of TFFs results from the formation of characteristic 
intra-chain disulphide bonds and renders these small molecules resistant to protease 
degradation.
152
 All three TFFS are encoded together in a cluster on 21q22.3.
153;154
 





TFF1 is normally found in foveolar cells from the body to the pyloric sphincter of the 
stomach mucosa.
155
 TFF1 expression is comparable in normal gastric tissue, 
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superficial gastritis, atrophic gastritis and intestinal metaplasia.
156
 TFF1 knockout 
mice displayed gastric and small intestinal mucosa abnormalities and 
tumorigenesis.
157
 TFF1 acts as a gastric tumor suppressor and is also involved in 
differentiation pathways of distinct gastric progenitor cells and the reduction of 
induced cell apoptosis.
155
 TFF1 deficiency leads to small intestinal inflammatory 
disorders, possibly due to loss of mucin polymerisation.
155;158
 Both in healthy 
mucosa and in IBD, TFF1 is co-packaged and co-secreted with MUC5AC in mucous 
and neuroendocrine cells.
144;159;160
 To date, association studies between genetic 
(promoter) variants of TFF1 and IBD have not been performed. 
 
TFF2 is expressed (together with MUC6) in the antral and pyloric glands of the 
stomach, within Brunner‟s glands of the duodenum and in the UACL.
144;161
 TFF2 
knockout mice displayed only mild phenotypic changes unless chemically 
challenged.
162
 However, in these TFF2 knockout mice alterations in both antigen 
presentation through MHC Class I molecules and mouse defensin (cryptidin) 
expression were observed.
163;164
 Another Paneth cell product, cysteine-rich intestinal 
protein (CRIP) mRNA, was also upregulated in TFF2 deficient mice.
163
 CRIP plays a 
role in regulation of the cytokine balance and consequently the immune response.
165
 
These observations have led to a reappraisal of the role of TFF2, and TFFs in 
general, as modulators of the inflammatory response rather than merely secretory 
proteins, interacting with mucins. TFF2‟s ability to regulate nitric oxide production 
and modulate expression of adhesion molecules is illustrative of this more complex 
role.
166;167
 These findings explain previous observations in a rat colitis model where 
exogenous TFF2 reduced the inflammatory infiltrate.
168
 So far, no association studies 
between allelic (promoter) variants of TFF2 and IBD have been performed. 
 
TFF3 is present in large amounts within the apical storage compartment of goblet 
cells and is secreted, together with MUC2, throughout the small and large 
intestine.
144;149
 Their co-localisation in the mucus layer has an additive effect on the 
protection against a variety of chemical and microbial insults when compared with 
the their individual protective properties.
169;170
 In the TFF3 knockout mouse model, 
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DSS administration resulted in widespread, superficial colonic ulceration and 
restitution was absent.
171
 Like TFF2, TFF3 also modulates NO production through 
inducible nitric oxide synthase in a mucin-dependent manner.
172
 In intestinal 
epithelial cells, TFF3 can also modulate the expression of Decay-Accelerating Factor 
(DAF / CD55), a plasma membrane protein regulating the communication between 
the complement system and T cell immunity.
173;174
 The TFF3 peptide is thought to 
have a protective role against complement activation through the induction of DAF 
in intestinal epithelial cells.
164;174
 Through its effect on the complement system, DAF 
is a negative modulator of T cell immunity.
175
 In the human intestinal tract, DAF 
expression is upregulated during inflammation.
176-178
 Recent reports on reduced IL-8 
production and increased IL-10 secretion in intestinal epithelial cells and monocytes, 
respectively, provide further evidence for the immunoregulatory properties of 
TFF3.
179;180
 No association studies have been performed between genetic (promoter) 
variants of TFF3 and IBD. Therapeutic use of TFF3 via enema and via a novel 




Inflammatory cytokines IL-1β, IL-6 and TNF-α are important regulators of TFF gene 
transcription.
185;186
 Whereas TNF-α has been shown to negatively regulate TFF3 
gene transcription in vitro via NK-κB,  the in vivo effect of IL-6 seems to be an 
induction of TFF3 via STAT3 (signal transducer and activator of transcription 
3).
187;188
 However, at least for IL-6 the effect appears to depend critically on which 
signal transduction pathway is activated.
185;186;188
 On the other hand, Th2 cytokines 
IL-4 and IL-13 increase TFF3 (and MUC2) expression, dependent on STAT6.
189
 In 
gastric cells, ligands of the peroxisome proliferators-activated receptor γ (PPARγ) 
induce TFF1 and TFF2 transcription.
190
 The influence on TFFs of PPARγ variants, 
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1.1.6 Genetics and the intestinal epithelial barrier 
Until recently, intestinal epithelial cells (IECs) were considered passive mechanical 
barrier components of the innate immune system.
192
 However, the discovery of 
nucleotide binding oligomerisation domain 2 (NOD2/CARD15) / caspase-
recruitment domain family member 15 (CARD15) has changed this.
14-16
 The 
characterisation of a multitude of pathogen associated molecular pattern (PAMP) 
receptors, able to recognise bacterial, viral and fungal as well as the ability of at least 
some of these receptors to sense cellular stress signals have put the IECs forward as 
active members of the first line of defence.
193-196
  
Pro-inflammatory cytokines (eg TNF-α , IFN-γ and IL-13) cause epithelial barrier 
abnormalities through apoptosis and apoptosis-independent effects on tight junctions 
and transcellular absorption.
197-204
 IL-10, MDR-1 and N-Cadherin knockout mice 
develop intestinal inflammation, presumably due to changes in epithelial 
permeability.
205-209
 Recently, IEC –specific cytolytic CD8+ effector T cells were 
identified as the earliest initiators of the inflammatory chain reaction leading to IEC 
apoptosis and disruption of the mucosal barrier.
210;211
 
Increased permeability has been described in IBD patients, as well as in healthy 
relatives and spouses.
212-219
 Similarly, subclinical inflammation has been found in 
healthy relatives of IBD patients.
220
 In vitro studies and intra-familial work by 
Buhner et al suggested that NOD2/CARD15 variants are involved in determining the 
intestinal permeability in CD patients and healthy relatives, thus integrating genetic 
discoveries and environmental risk factors into the model of an altered intestinal 
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1.1.6.1 MDR1(ABCB1) and PXR/NR1I2 
A number of genes involved in epithelial cell function have been studied as candidate 
susceptibility genes in human IBD. The strongest evidence to date favours MDR1. 
The MDR1 gene (Multidrug Resistance 1/ATP Binding Cassette, subfamily B, 
member 1), which encodes P-glycoprotein 170, is located in an IBD susceptibility 
locus on Chromosome 7q21.
107;108
 The MDR1 gene encodes an efflux pump of 
amphipathic toxins and is highly expressed at the apical surface of epithelia of the 
colon and distal small bowel.
223
 Even under specific pathogen-free conditions, MDR-
1 knockout mice are susceptible to developing a severe, spontaneous intestinal 
inflammation which is preventable by and treatable with antibiotics.
207
 As is the case 
with many of the other candidate genes studied so far, studies into the MDR1 
C3435T have revealed significant heterogeneity in patient and control allelic 
frequency in different populations. Associations between 3435T and UC have been 
reported in the German and Scottish population.
224-226
 In contrast, replication studies 
from Germany, Great Britain, North America, Slovenia, Italy, Spain and the 
Netherlands have been negative.
227-232
 However, a meta-analysis of 9 association 
studies of C3435T showed a significant association of the 3435T allele with UC, but 
not CD.
233
 The 2677G variant was found by Brant et al. to be associated with IBD.
228
 
Ho and colleagues did not find an association between this polymorphism and IBD 
but a haplotype 3435T/2677G was significantly associated with UC.
226
 
Contrastingly, 2677T was associated with UC by Potočnik et al. and Onnie et 
al.
229;233
 Using a gene-wide haplotype tagging strategy, Ho et al. observed a highly 
significant association between the common MDR1 haplotypes and UC, but not 
CD.
234
 This association was critically dependent on one haplotype tagging SNP, 
intronic variant rs3789243. The effect of this tagging SNP was independent of 




The hypothesis that a defective mucosal detoxification system might be predisposing 
to increased risk of intestinal inflammation was further supported by DNA 
microarray analysis involving non-affected colonic tissue of CD and UC.
235
 In this 
study, Langmann et al showed marked downregulation of a number of detoxification 
genes (of the glutathione and sulfo-transferase family) and ABC transporters 
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(including MDR1) in UC, together with the near complete loss of the transcriptional 
regulator pregnane X receptor (PXR).
236
 PXR is a nuclear hormone receptor for a 
large number of structurally and pharmacological diverse endogenous and exogenous 
compounds (including pregnanes, corticosteroids, rifampicin and bile acids).
237-240
 
PXR regulates the induction of many genes including CYP3A4 and the ABC 
transporter family genes (including MDR1).
241
 Dring and colleagues showed that 
germ-line variants of the PXR/NR1I2 gene located on 3q13.33 (an IBD susceptibility 
locus), confered susceptibility to IBD.
107;242
 This effect was most significant for two 
polymorphisms in the promoter region of this gene (rs3814055 and rs1523127) in the 
Irish population.
242
 However, a gene wide
 
association study using a haplotype 
tagging strategy to assess
 
the overall contribution of this gene to disease 





Further fine mapping of an IBD susceptibility locus on the pericentromeric region of 
Chromosome 10 led to the identification of the DLG5 (Drosophila Discs Large 
Homolog 5) gene, a member of the MAGUK (Membrane Associated Guanylate 
Kinase) family, as a CD suscepitiblity gene.
244;245
 MAGUKs are known to form 
scaffolds for proteins involved in intracellular signal transduction. DLG5 is 
important in maintaining the epithelial structure, and the genetic variants in DLG5 
could therefore interfere with the epithelial barrier.
246
 The DLG5 is expressed most 
strongly in placental tissue and less so in heart, skeletal muscle, liver, small bowel, 
and colon.
247
 Stoll and colleagues first identified two extended DLG5 haplotypes that 
influenced disease susceptibility in the German population.
244
 The first haplotype 
was characterised by the presence of a polymorphism (G113A) that resulted in an 
amino change at position 30 from arginine to glutamine (R30Q). Stoll et al found 
carriage of the 113A variant to be associated with CD in a case control study and on 
transmission disequilibrium testing (TDT) but did not replicate this finding in a 
second TDT population reported in the same publication.
244
 In silico analysis 
suggests that the 113A (R30Q) variant may impair DLG5 scaffolding function, but as 
yet no expression or functional studies in IBDs have been conducted. Evidence of 
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epistasis between the 113A variant of DLG5 and NOD2/CARD15 variants was also 
observed in the CD cohort. A second haplotype, haplotype A was tagged by eight 
marker SNPs and was observed to be significantly under transmitted in the IBD 
group, suggesting the haplotype may be protective.
244
 Since the publication of the 
paper by Stoll et al., these variant alleles of the DLG5 gene have been the subject of 
a large number of association studies (summarised in Table 1-2), generally with 
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Table 1-2: DLG5 association studies 
Table 1-2a - DLG5 susceptibility studies examining the 113G/A variant: case-control 
studies 
















* 525 13.2% 515 9.0% 0.001 
Canadian/Italian
261
 332 11.0% 202 5.9% 0.003 
UK
261
 689 9.3% 493 9.7% ns 
Scottish
248
 652 11.4% 255 13.1% 0.30 
German
251
 970 10.1% 972 10.8% ns 
USA
263
 281 8.5% 479 10.3% ns 
German
255
 400 8.0% 422 10.9% 0.19 
Hungarian
255
 268 8.9% 205 11.2% 0.26 
Italian
253
 227 8.6% 160 11.1% 0.22 
Greek
259
 205 0% 100 0% ns 
Norwegian
256
 386 9.2% 226 10.9% 0.34 
English
254
 1104 10.1% 750 11.6% 0.32 
Belgium
260
 577 11.8% 301 10.8% ns 
Hungarian
252
 773 11.3% 150 15.0% 0.06 
Japanese
262
 484 0% 345 0% ns 
UK
264
 1148 9.9% 749 10.1% ns 
Canadian
257
 581 8.2% 537 8.7% 0.62 
New Zealand
265
 820 11.5% 416 10.0% 0.27 
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* Cases were European, controls were German only 
 
Table 1-2b - DLG5 susceptibility studies examining the 113G/A variant: family-based 
association studies 







 457 0.004 0.04 
German/UK
244
 485 0.09 0.07 
Canada 
261
 182 ns*  not given 
UK 
261
 124 0.017 not given 
Pooled UK/Canada 
261
 306 0.018 not given 
Belgium
260
 373 0.01** 0.006** 
Scottish
266
 270 0.045 0.18 
* Exact value not stated. ** Significant undertransmission.
1
Footnote to table 2b.  
1.1.6.3 IBD5 locus / OCTN1&2 
The first detailed evidence for a susceptibility locus on 5q31 was obtained through 
linkage analysis of Canadian affected sibling pair families, especially in early-onset 
CD.
267
 Multimarker analysis across multiple haplotype blocks defined a 250-kb 
region that confered susceptibility to CD.
268
 This region with extensive linkage 
disequilibrium contains a cytokine gene cluster with several genes important in 
maintenance of epithelial integrity and/or immunoregulation: interferon regulatory 
factor-1 (IRF1), interleukin-4,5 and 13, OCTN1&2 (organic cation transporters 
1&2), PDLIM4 (PDZ and LIM domain protein 4), P4HA2 (Prolyl 4-hydroxylase 
alpha-2 subunit precursor).
269
 As long range regulatory elements may exist with the 
                                                 
1
 Footnote to table 2b: The TDT results to date for variants of the DLG5 113G/A SNP in different 
publications demonstrate a modest effect on IBD susceptibility in 3 independent populations out of 7 
studied. Only one study
244
 has demonstrated significant disease susceptibility for Crohn‟s disease. 
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IBD5 risk haplotype, the nearby location (<0.5Mb) of GM-CSF precursor CSF2 
could also be important.
270
 Several studies, including 2 recent childhood-onset cohort 
analyses, have replicated the association with CD (see Table 3).
251;271-279
 Although 
evidence regarding CD location is conflicting, IBD5 may be associated with more 
severe disease behaviour.
260;269;271
 This is reflected in childhood onset CD by an 
association of the IBD5 risk haplotype with indices of faltering growth.
278
 The IBD5 
risk haplotype has also been associated with increased susceptibility to UC in adults 
and children.
272;278
 There is also evidence for epistasis with NOD2/CARD15 variant 
carriage in both CD and UC.
272;273;280
  
The organic cation transporter genes (OCTN1&2) are within a single haplotype 
block (block 7) of the IBD5 locus. Peltekova et al. identified mutations within 
OCTN1 (SLC22A4 1672C/T) and OCTN2 (SLC22A5–207G/C)) and found an 
association between a combined TC- haplotype of these two variant alleles with 
increased susceptibility to CD, independent of the IBD5 risk haplotype as assessed 
by IGR2078 (located in block 4, ~100 kb and 3 recombination hotspots away from 
1672C/T and -207G/C).
281
 However, more detailed analysis by inclusion of 
haplotype tagging SNPs on block 5-7 have shown the contribution of the OCTN 
variants is not independent of the extended IBD5 haplotype, leaving the question 
which is the causative IBD5 variant as yet unanswered.
271;278;279;282
 Association 
studies of the IBD5 locus with IBD, to date, have been summarised in Table 3. 
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 787/330/457 CD 870 Case-control 
UK
283
 1104/496/512 CD/UC 750 Case-control 
Belgian
260






  608/472/120 None 305 Case-control 
Scottish
278






 299/200/74 CD/UC 256 Case-control 
Scottish
271
 679/374/305 CD 294 Case-control 
UK/German
273






 1072/684/388 CD 701 Case-control 
UK
274






 178 CD None 156 Case-control 
Canadian
281
  503 CD CD 390 Case-control 
Swedish
284
 178 CD CD 143 Case-control 
German
251
 988/625/363 CD 1012 Case-control 
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 488/241/247 None 270 Case-control 
Japanese
262
 484 CD None 345 Case-control 
USA
279
 264 CD CD 527 Case-control 
and Family 
association   
Italian
253
 227/134/93 None 164 Case-control 
Hungarian
287
 74 CD None 49 Case-control 
Italian
288
 386/200/186 CD 347 Case-control 
Italian
288






 1200 CD 1200 Case-control 
Italian
289
 1199/570/629 CD 357 Case-control 
Italian
290
 899/444/455 CD/UC 611 Case-control 
Spanish
291
 309 CD CD 408 Case-control 
1.1.6.4 Myosin IX B 
Recently, variant alleles of the myosin IX B gene (MYO9B, located on 19p13, an 
IBD susceptibility locus), have been associated with IBD (especially UC) in a large 
multicentre study and more recently, in two studies from Southern Europe.
292-294
 
Myosin IX B is expressed in leukocytes and epithelial cells and thought to influence 
intestinal permeability. Although, MYO9B variants have previously been associated 
with celiac disease in the Dutch population, replication studies in Scandinavian and 
British celiac disease cohorts were negative.
295-297
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Molecular mechanisms of recognition of pathogen-associated motifs 
The innate immune response is not non-specific, as was originally thought, but rather 
is able to discriminate between „healthy self‟ and a variety of pathogenic/ „danger‟ 
signals.
298-300
 As ever increasing numbers of immunostimulatory ligands are being 
identified, the ability of the innate immune system to recognise tissue-derived signals 
in the absence of pathogens as well as its role in normal physiological processes, 
such as transport of blood lipids and development, has dramatically increased the 
relevance of a thorough understanding of pattern recognition by the innate immune 
system.
299;301;302
 The innate immune system exerts its effects through three different 
kinds of receptors: secreted receptors for opsonization of pathogens (mannan-binding 
lectin), receptors for phagocytosis (macrophage scavenger receptor) and pattern-
recognition receptors (PRRs).
303
 Mannan binding lectin (MBL) gene polymorphisms 
have been associated with lower plasma levels of MBL and are protective against UC 
(but not CD).
304
 Reports have been conflicting regarding their association with 




The identification of the trinity of cellular PRRs comprising of Toll-like receptors 
(TLRs), NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs) has led to 
significant advances in our understanding of innate immunity (see Figure 1).
307
 To 
date, TLRs have been implicated in recognition of bacteria, viruses, fungi, protozoa 
as well as „danger‟ signals such as heat shock proteins, β-defensins, hyaluronan, 
cardiolipin, surfactant protein and fibronectin.
299
 NLRs (also known as 
CATERPILLERs: CARD (caspase-recruitment domain) transcription enhancer, R 
(purine)-binding, pyrin, lots of leucine repeats) recognise bacterial degradation 
products as well as cellular stress signals such as uric acid.
308-311
 RLRs are 
intracellular viral sensors.
307
 All PRRs recognise microbial components, also called 
pathogen-associated molecular patterns (PAMPs), that are essential for the survival 
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1.1.7 Toll-like receptors  
Since the first description of a mutant „Toll‟ fruitfly in 1985 and the characterisation 
of Toll paralogues in mammals in the mid-1990s, a total of 13 members of the 
mammalian TLR family have been identified.
298;312-314
 Medzhitov and Janeway made 
the breakthrough discovery that one of these TLRs activates NK-κB, suggesting that 
these receptors may link innate and adaptive immunity.
313
 Shortly thereafter, 
bacterial lipopolysaccharide (LPS) was identified as the ligand for TLR4.
315;316
 To 




1.1.7.1 Ligand specificity 
TLRs are type I integral membrane glycoproteins characterised by an extracellular 
domain containing varying numbers of leucine-rich-repeat (LRR) motifs and a 
cytoplasmic signalling domain homologous to that of the interleukin-1 receptor (IL-
1R), called the Toll/IL-1R  homology (TIR) domain.
298;318
 Although TLRs can be 
further divided into several subgroups, each of which recognising related PAMPs, 
ligand promiscuity (eg TLR2 and TLR4) has been puzzling for Toll-researchers and 
mucosal immunologists alike.
299;319
 For example, TLR4 recognises a very divergent 
collection of ligands such as LPS, the fusion protein of respiratory syncytial virus, a 
subunit of bacterial fimbriae, fibronectin, β-defensin and heat-shock proteins.
298;299
 
One attractive explanatory hypothesis proposed by Matzinger et al. is that these 
receptors have evolved to recognise the hydrophobic portions of molecules when 
these become exposed after injury.
299
 LPS, peptidoglycan, lipoteichoic acid and 
many other immunostimulatory microbial products (e.g. flagellae) have large 
hydrophobic portions that are exposed when microorganisms are damaged.
299
 
Hydrophobic portions are also integral parts of endogenous immunostimulators like 
defensins and uric acid.
320;321
 
The subfamily of TLR1, TLR2 and TLR6 (individually or in heterodimers) 
recognises lipids.
298
 TLR2 plays a major role in detecting Gram-positive bacteria and 
is involved in the recognition of a variety of microbial components, including 




 TLR2 is able to dimerise with TLR1 and TLR6, thereby increasing the 
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discriminatory capacity to recognise subtle changes in the lipid portion of 
lipoproteins.
322-324
 Reports by Fukase et al and Travassos et al have recently 
questioned the previously held assumption that peptidoglycan recognition was TLR2 
– dependent.
317;325;326
 Similarly, impurities of LPS preparations have caused 
confusion regarding its TLR2 – stimulating activity.
327;328
 To date, only chemically 
pure lipopeptides have been unambiguously demonstrated to be TLR2 stimulators.
298
 
Crystallographic studies followed by mutational analysis were successful in 
identifying the specific ligand binding site of dsRNA to TLR3.
329;330
 LPS (from 
Gram-negative bacteria) triggers signalling through TLR4 after associating with LPS 
binding protein, CD14 (a glycosylphosphatidylinositol linked protein expressed on 
the cell surface of phagocytes) and MD-2.
331;332
  
CD14 is located on the IBD susceptibility locus on Chromosome 5q13.
107
 The CD14 
promoter polymorphism -159C/T has been associated with CD in a Greek (with 
evidence for epistasis with NOD2/CARD15/CARD15) and German study.
333;334
 In a 
Japanese IBD cohort, this polymorphism has been associated with UC.
335
 No 
significant effect of CD14-159C/T was observed in an Australian IBD population.
336
 
In Scottish and Irish CD patients, Arnott et al. found that the CD14-159C/T variant 
frequency did not differ from controls.
337
 
TLR5 binds the constant domain of flagellin, the major protein constituent of 
bacterial flagellae.
338;339
 Although this domain is relatively conserved among 
different species, important gastrointestinal pathogens like Helicobacter pylori and 
Campylobacter jejuni avoid flagellin-specific immune responses through the 
production of flagellins lacking pro-inflammatory properties.
340
 TLR3, TLR7, TLR8 
and TLR9 recognise nucleic acids. Unmethylated CpG dinucleotides from bacterial 





Expression of TLRs is modulated by pathogens, cytokines and environmental 
stresses. While TLRs 1,2,4,5 and 6 are expressed on the cell surface, TLRs 3,7,8 and 
9 are found in intracellular compartments such as endosomes.
298
  TLRs are expressed 
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by a variety of cells throughout the gastrointestinal tract, including intestinal 
epithelial cells.
331;343-348
 To avoid continuing recognition of commensal bacterial 
ligands by healthy epithelium, TLR2 and TLR4 expression is downregulated at the 
luminal surface and maybe limited to the basolateral membrane for TLR5.
345-348
 
Thus, flagellin would only be recognised by the host when bacteria have invaded the 
epithelium.
298
 However, Bambou et al. have shown in polarised cell lines and in ex 
vivo models that luminal stimulation of intestinal cells with flagellin does result in 
signalling through TLR5.
349
 During inflammation, TLR2 and TLR4 expression is 
upregulated in intestinal macrophages.
344
 In active IBD, TLR4 expression is 




1.1.7.3 Signal transduction 
Upon ligand binding, TLR signalling is initiated by dimerization of TLRs, which can 
form homodimers (such as TLR4) or heterodimers (such as TLR1, 2 and 6).
332
 
Dimerisation leads to conformational changes necessary for the recruitment of one of 
the TIR (Toll/interleukin-1 receptor)-domain containing adaptor molecules: MyD88, 
TIRAP/MAL, TRIF/TICAM1, TRAM and the recently identified negative regulator 
of TRIF-dependent signalling SARM.
314;350-354
 Except for TLR3, all TLR signalling 
is MyD88-dependent. The diversity and specificity of TLR function is determined by 
the selective use of these intracellular adaptor molecules.
332
 A collection of 
downstream kinases (IRAKs: IL-1 receptor associated kinases) is then recruited, 
ultimately leading to the degradation of the IKK complex and activation of NF-κB. 
In addition to the effect on NF-κB, TLR activation also results in activation of a wide 




This is further illustrated by the findings of Rakoff-Nahoum et al in MyD88 
knockout mice.
358
 MyD88 knockout mice, and to a lesser extent TLR2 and TLR4 
knockout mice, showed massive ulceration and denudation in the epithelial cell layer 
very soon after DSS administration due to a greatly decreased capacity to produce 
cytoprotective factors such as interleukin-6 and KC (Keratinocyte Chemoattractant)-
1 chemokine in response to TLR signalling by commensal organisms.
359
 On the other 
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hand, treatment with a synthetic TLR4 antagonist, blocking the interaction of LPS 
with
 
the immune system, was able to inhibit the development of moderate-to-severe
 
disease in two mouse models of colonic inflammation: the dextran
 
sodium sulphate 






1.1.7.4 Regulation of TLR signalling 
Close regulation of TLR signalling takes place 1) in the extracellular space, 2) by 





1) Extracellularly, soluble decoy TLRs (eg sTLR2, sTLR4) may act to prevent 
overactivation of the host response against microbial products through competitive 
inhibition. Although multiple TLR4 mRNAs have been detected in humans (from a 
single copy of the TLR4 gene on Chromosome 9q33), indicating that sTLR4 could 
exist in humans, only murine sTLR4 has been characterised conclusively.
361
 A 
soluble form of human TLR2 was identified by LeBouder et al. sTLR2 





2) Transmembrane protein regulators of TLR signalling are ST2 (IL-1Receptor 
Like1/FIT-1), SIGIRR (single immunoglobulin and toll-interleukin 1 receptor (TIR) 
domain) and TRAILR (TNF-related apoptosis-inducing ligand receptor 1).
332
 Of 
these only SIGIRR is located in an IBD susceptibility locus on Chromosome 11p15.5 
but no germline variant studies have been undertaken to date.
107
 Like ST2, SIGIRR is 
an orphan receptor that does not induce NF-κB activation.
363-365
  In vitro SIGIRR has 
been shown to interact with TLR4, IRAK and TRAF6.
363
 In vivo, SIGIRR-deficient 
mice displayed increased susceptibility to endotoxin shock.
363;366
 Recent ex vivo 
patient data showed increased SIGIRR expression during sepsis.
367
  SIGIRR is 
highly expressed in gut epithelial cells and immature dendritic cells.
368
 Its important 
role in regulation of intestinal inflammation is illustrated by the development of more 
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3) Intracellular negative regulators of TLR signalling include MyD88s (the short 
form of MyD88), IRAKM, SOCS1, NOD2/CARD15, PI3K, TOLLIP and A20. 
 
SOCS1 (Suppressor Of Cytokine signalling 1) is one of eight members of the SOCS 
family.
369
 Macrophages from SOCS1 deficient mice produce increased levels of pro-
inflammatory cytokines in response to stimulation with TLR4 and TLR9 
ligands.
370;371
 The gastrointestinal phenotype of SOCS1/T-cell receptor α (TCRα) 
double knockout mice is characterised by the earlier development of a more severe 
colitis compared with TCRα-knockout mice dependent on IFNγ and IL-4, resembling 
human UC.
372
 On the other hand, transgenic mice overexpressing SOCS1 also 
developed spontaneous colitis with age and were more susceptible to TNBS (2,4,6-
trinitrobenzene sulphonic acid) induced colitis associated with increased expression 
of IFNγ and TNF α and reduced levels of transforming growth factor β.
373
 The 
SOCS1 gene is located on chromosome 16p13.13 in the IBD1 locus.
107;245;374;375
 To 
date, association studies of sequence variants of SOCS1 with IBD have not been 
performed. 
 
TOLLIP (Toll-interacting protein) is critical in maintaining the intestinal epithelium 
hyporesponsive to TLR2 ligands.
376
 Overexpression of TOLLIP resulted in inhibition 
of TLR2- and TLR4- mediated NF-κB activation dependent on the N-terminal C2 
domain of TOLLIP.
377-380
 A mutation of a lysine residue to glutamic acid (K150E) 
within this C2 domain causes an inability of TOLLIP to inhibit LPS-induced NF-κB 
activation.
380
 The TOLLIP gene (Chr 11p15.5) lies in the IBD locus on chromosome 
11.
107;381;382
 No genetic variants of TOLLIP have been studied in IBD so far. 
 
Another intracellular regulator of TLR signalling is NOD2/CARD15. The 
NOD2/CARD15 gene is situated in the IBD1 locus (Chromosome 16q12.1).
107;374
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Watanabe et al described how Muramyl Dipeptide (MDP) (the ligand of 
NOD2/CARD15) suppressed TLR2-ligand-induced Th1-cell responses in wild-type 
mice but not in NOD2/CARD15-deficient mice.
383
 In contrast, two recent reports did 
not support this inhibitory hypothesis.
384;385
A further study by Netea et al provided 
evidence for a complex regulation of TLR signalling through induction of both pro- 




4) Reduction of TLR expression is achieved by degradation of TLRs through 
ubiquitinylation, inhibition of TLR expression by anti-inflammatory cytokines (eg 
TGF-β and IL-10) and TLR regulated apoptosis.
332;387
 In health, intraepithelial cells 





1.1.7.5 Germline variants of TLR genes in IBD 
DNA sequence variants of TLR genes in IBD have received substantial research 
interest.
389
 TLR2 (4q31.3), TLR3 (4q35.1), TLR4 (9q33.1) and TLR9 (3p21.3) are 
all located in regions associated with IBD by genome wide searches (see Table 4).
107
 
A detailed study analysing single nucleotide polymorphisms in the coding sequence 
or promoter region of TLRs 1,2,5,6,7 in a Flemish case-control study did not show 
any association with IBD susceptibility, but genotype-phenotype associations 
between TLR1R80T and TLR2R753G variants and pancolitis in UC were 
reported.
303
 The same authors also described negative associations between UC with 




The TLR4 Asp299Gly polymorphism leads to altered recognition of LPS by the 
extracellular domain of TLR4.
390
 This TLR4 polymorphism was associated with 
Crohn‟s disease and ulcerative colitis in a Belgian study.
391
 In Greek, German and 
Dutch populations the association of the Asp299Gly polymorphism with Crohn‟s 
disease was replicated and an association with colonic disease was described.
333;392-
394
 Further support for an association of this variant with CD and IBD (OR 1.45 
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(1.11-1.90) and OR 1.36 (1.01-1.84), respectively) came from a recent meta-analysis 
by Browning et al.
395
 In one German cohort, an association was demonstrated 
between ulcerative colitis and the TLR4 Thr399Ile polymorphism.
396
 However, there 
is substantial heterogeneity between populations, and no association was noted 
between the Asp299Gly polymorphism and inflammatory bowel disease in either a 
Hungarian study or the Scottish dataset.
337;397
 Recent data suggest that neither of 




Polymorphisms of the TLR5 gene were associated with severity of Crohn‟s disease 
in Ashkenazi Jews.
399
 In another Jewish cohort, a dominant-negative TLR5 C1174T 
polymorphism was protective against development of CD, but not UC.
400
 However, 
this inactivating mutation is also present in 5-10% of healthy individuals.
401
  
A variant allele of TLR9, -1237C was found to be associated with CD in a German 
cohort.
396
 In a recent study, a combined carriership of the alleles TLR9 -1237C and 
CD14 -260T was increased in the chronic relapsing pouchitis group when compared 




1.1.8 Caterpillers – Nod-LRRs – Nacht-LRRs – NLRs 
Following on from the success in characterization of Toll-like receptors, a new 
family of intracellular pattern recognition receptors, the CATERPILLER (CARD 
(caspase-recruitment domain) transcription enhancer, R (purine)-binding, pyrin, lots 
of leucine repeats) gene family was described in early 2000.
403;404
 The MHC class II 
transactivator (MHC2TA - a protein with a nucleotide-binding domain followed by 
leucine-rich repeats (LRRs)) offered the blueprint for the identification of an 
increasingly large family of proteins – found in both plants and mammals.
405
 This 
family of proteins has also been called NACHT (domain present in NAIP, C2TA, 
HET-E and TP1)-leucine-rich repeat (LRR).
406
 In general, members of this family 
contain an amino (N) -terminal domain that consists of protein-protein interaction 
cassettes (eg CARDs and pyrin domains), a central nucleotide-binding 
oligomerization domain (NOD), which facilitates self-oligomerization and has 
ATPase activitiy, and a carboxy (C) -terminal LRR domain, which is involved in 
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ligand recognition.
407
 The 4 main subgroups within the CATERPILLER family are 
distinguished by their N-terminal domains: acidic (e.g. MHC2TA), pyrin (e.g. 
NALP3, NOD6, NOD8), CARD (e.g. NOD1/CARD4, NOD2/CARD15), baculoviral 
inhibitory repeat (eg NAIP) and unclassified (e.g. NOD3, NOD9).
311
 NOD1/CARD4 
contains a single CARD at the N-terminus, whereas NOD2/CARD15 contains two 
CARDs. 
 
A high number of genes within this family are associated with immunological 
disorders. Allelic variants of the MHC2TA gene/promoter region are associated with 
bare lymphocyte syndrome, rheumatoid arthritis, multiple sclerosis and myocardial 
infarction.
408;409
 NALP3 (also known as CIAS1/cryopyrin) binds uric acid crystals 
and is associated with gout and pseudogout.
310
 NALP3 variants are associated with 
familial-cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal-
onset multisystem inflammatory disease.
410;411
 Although not part of the 
CATERPILLER family, the pyrin protein (encoded by the Mediterranean Fever gene 
(MEFV)), which shares the pyrin domain found in the largest subgroup of 
CATERPILLER proteins, is noteworthy.
412;413
 Recently, variants in this gene, 









1.1.8.1 Ligand specificity 
Bacterial peptidoglycan (PGN) derivatives have now confidently been identified as 
the ligands for NOD1/CARD4 and NOD2/CARD15. NOD1/CARD4 recognises 
intracellular γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP), a breakdown 
product of PGN from Gram-negative bacteria and a limited number of Gram-positive 
bacteria.
417-420
   
NOD2/CARD15 is an intracellular PAMP receptor for Muramyl Dipeptide (MDP), a 
breakdown product of bacterial PGN of both Gram-negative and Gram-positive 
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bacteria.
418;421;422
 In contrast to early reports, it has become
 
evident that neither 
NOD1/CARD4 nor NOD2/CARD15 sensed LPS directly but rather
 
detected 





 Recently, monomeric flagellin was identified as the ligand for 
CARD12 (IPAF).
425-428
 Similar to TLRs on the cell surface, NOD proteins may have 




These PGN motifs can enter the cell through phagocytosis (as is suggested for 
APCs), active transport or through pathogen induced mechanisms.
407
 It has recently 
been shown that recognition of Helicobacter Pylori by NOD1/CARD4 is dependent 
on „injection‟ of PGN into epithelial cells through a type IV secretion system, 
encoded in H. Pylori‟s cag pathogenicity island.
431
 MDP binds directly to the LRR 
region of the NOD2/CARD15 molecule, after transport across the cell membrane of 
IECs by hPEPT1.
417;432
 Membrane recruitment of NOD2/CARD15 in intestinal 
epithelial cells is necessary for MDP recognition and does not occur in subjects 





Both NOD1/CARD4 and NOD2/CARD15 are expressed mainly in the cytosol.
429
 
NOD1/CARD4 is constitutively and inducibly expressed in a wide variety of tissues 
and immunoregulatory cells.
194;434
 NOD2/CARD15 has been shown to be expressed 
by antigen-presenting cells (APCs, e.g. macrophages, dendritic cells) and epithelial 
cells, inducible by TNF-α and IFN-γ.
195;435
 Whereas most intestinal epithelial cell 
lines (IECs) transcribe the NOD2/CARD15 gene to mRNA, translation to protein is 
absent or limited.
193;195
 Significant expression of NOD2/CARD15 seems to be 
limited to Paneth cells, which are located at the base of the intestinal crypts.
436
 
Consistent with upregulation by inflammatory cytokines, NOD2/CARD15 
expression is increased in involved intestine in both epithelial cells and macrophages 
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1.1.8.3 Signal transduction 
Ligand binding to the LRR domain is followed by a complex conformational change 
in the CATERPILLER molecule, making the NOD domain available for self-
oligomerization.
439;440
 This facilitates recruitment-activation of RICK (receptor-
interacting serine/threonine kinase; also known as RIPK2 (Receptor-interacting 
serine/threonine-protein kinase 2) or CARDIAK) through a CARD-CARD 
interaction at the plasma membrane.
441-443
 This activation then further initiates 
various signalling pathways, including activation of NF-κB  and mitogen-activated 




A rapidly increasing number of intracellular proteins are being identified that 
influence downstream signalling after NOD1/CARD4 or NOD2/CARD15 activation. 
By means of a Yeast Two-Hybrid screen, Podolsky et al. identified GRIM19 (gene 
associated with retinoid-IFN-induced mortality 19, located on Chromosome 19p13.2, 
an IBD susceptibility locus) as a novel interacting protein with NOD2/CARD15 (but 
not NOD1/CARD4).
107;445
 GRIM19 was required for regulation of NF-κB activation 
and expression is decreased in inflamed mucosa of IBD patients.
445
 These findings 
are puzzling as GRIM19 is a mitochondrial protein and NOD2/CARD15 does not 
seem to co-localise with this organelle.
446
 In a recent report, Ferreira et al. did not 
find evidence for association of germline variation of GRIM19 with CD.
447
 
Through biochemical and Yeast Two-Hybrid screens, Erbin (Erbb2-interacting 
protein) was identified as a novel NOD2/CARD15 inhibitory protein.
448;449
 
NOD2/CARD15 and Erbin co-localize at the entry foci of Shigella Flexneri and 
maximal affinity between the two proteins was observed after 30-40 minutes of 




TAK1 (TGFβ-activating kinase 1, located within the IBD locus on Chromosome 
3p25 – also known as NR2C2 (nuclear receptor subfamily 2, group C, member 2)) 
interacts with NOD2/CARD15 through the LRR domain and reciprocally negatively 
regulates NOD2/CARD15 mediated NF-κB activation.
107;446;450
 TAK1 knockout 
mice develop age-related colitis through the loss of regulatory T-cells.
451
 None of the 
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genes associated with these proteins have been the subject of association studies in 
IBD so far. 
 
CARD-CARD binding of NOD2/CARD15 to procaspase-1 leads to increased 
secretion of IL-1β.
452
 Although CARD12 activation leads to the induction of 
expression of IL-1β, NOD-NOD binding of NOD1/CARD4 or NOD2/CARD15 to 
activated CARD12 may lead to inhibition of NOD1/CARD4- and NOD2/CARD15- 
mediated activation of NF-κB and production of IL-1β.
453;454
 CARD6 competitively 
inhibits NOD1/CARD4 (but not NOD2/CARD15) mediated  NF-κB activation 
through RICK.
455
 Recently, another adaper protein CARD9 was demonstrated to 
have a critical function of NOD2/CARD15 mediated activation of p38 and Jnk in 
innate immune responses to intracellular pathogens by means of challenging CARD9 
deficient mice with Listeria Monocytogenes and in wild-type cells.
456
 Another level 
of complexity was unveiled by Rosenstiel et al. when they described the peculiar 
interaction of NOD2/CARD15 with a transcript isoform of NOD2/CARD15, NOD2-
S, generated by the skipping of the third exon, which encodes for a protein that is 
truncated within the second CARD.
457
 NOD2-S is preferentially expressed in the 
human colon and is upregulated by the anti-inflammatory cytokine IL-10. NOD2-S 
interacts with NOD2/CARD15 and RICK/RIPK2 and inhibits the oligomerisation of 
NOD2/CARD15, thus downregulating NF-κB activation and IL-8 release. 
Taken together, these findings are likely to change our view on NOD-protein 
signalling from a highly discrete response to a mosaic of responses by a network of 
interacting family members.
407
 The discovery that MDP is able to trigger IL-1β 





1.1.8.4 Germline variants of CATERPILLER genes in IBD 
The NOD1/CARD4 gene is located within the putative IBD susceptibility locus on 
chromosome 7p14.3 (see Table 4).
108
 McGovern et al. described the association of 
the deletion variant of a complex intronic insertion/deletion polymorphism (32656) 
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of NOD1/ CARD4 with susceptibility to IBD, demonstrating a gene-dosage effect of 
the deletion variant on age of onset in CD and IBD.
459;459
 In contrast, other groups 
studying variants of the coding-sequence of NOD1/CARD4 or the 32656 ins/del 
polymorphism have not found an association with IBD.
460-464
 Heterogeneity of the 
control populations for the NOD1/CARD4+32656 deletion allele frequency between 
England, Scotland and Germany underlie the negative replication data.
462-464
 These 
findings will be discussed in greater detail in the chapter on the role of inherited 
variation of NOD1/CARD4 in IBD. 
 
The discovery of NOD2/CARD15 is widely accepted as a landmark in complex 
disease genetics. The NOD2/CARD15 gene is located within the IBD1 locus on the 
pericentromeric region of Chromosome 16.
14-16
 The 3 major CD-associated 
polymorphisms (Arg702Trp, Gly908Arg and Leu1007fsinsC) are located in or near 
the LRR domain, interfering with the ability of NOD2/CARD15 to recognize 
MDP.
18;389;437
 These variants have also been associated with increased transplant 
related mortality in bone marrow transplant patients.
465
 NOD2/CARD15 variant 
alleles associated with Blau syndrome and early-onset sarcoidosis are located within 
the NOD region and lead to increased basal and MDP-induced NF-κB activity.
466;467
 
A recent meta-analysis (of more than 40 association studies) and a pooled analysis of 
more than 7000 patients, confirmed the association of NOD2/CARD15 allelic LRR 
variants with susceptibility to Crohn‟s disease as well as genotype-phenotype 
associations with small bowel involvement and a more aggressive disease 
behaviour.
468;469
 In the genome-wide association studies to date and a recent meta-
analysis have confirmed the importance of NOD2/CARD15 in CD in the Western 
World, population-specific effects are noteworthy.
470-472
 The small and absent 
contribution of NOD2/CARD15 status to CD in Northern European and Japanese 





NOD2/CARD15 deficient mice do not demonstrate spontaneous intestinal 
inflammation.
383;385
 In addition, colonic inflammation following DSS in 
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NOD2/CARD15 deficient mice is not different from wildtype.
385
 However, enhanced 
colonic inflammation after DSS exposure does occur in mice expressing the 
Leu1007fsinsC NOD2/CARD15 variant, mediated by IL-1β.
384
 Mouse macrophages 
carrying this NOD2/CARD15 variant show increased NF-κB activity compared to 





1.1.8.5 TLR – NOD synergy 
The complexity of the response to innate immune ligands is demonstrated by the 
synergistic effects NOD1/CARD4 and NOD2/CARD15 stimulation have on TLR 
responses, both pro- and anti-inflammatory.
17;383;385;386;477-483
 Conflicting reports have 
been published on the influence of the CD-associated Leu1007fsinsC 




Recent work by Watanabe et al. in a mouse model of experimental colitis 
demonstrated that MDP activation of NOD2/CARD15 regulates innate responses to 
intestinal microflora by downregulating multiple TLR responses, not just TLR2. 
Thus, they obtained in vivo confirmation of in vitro experiments with Dendritic Cells 
which showed that prestimulation of cells with MDP reduces cytokine responses to 
multiple TLR ligands and that this reduction was dependent on enhanced IFN 
regulatory factor 4 activity.
486
  
Netea and colleagues have reported that peripheral blood mononuclear cells from 
patients with Crohn‟s disease homozygous for the frameshift NOD2/CARD15 
mutation displayed a loss of cross-tolerance between NOD2/CARD15 and TLR4, 
leading to uninhibited release of TNF-α by TLR4 ligands and intestinal bacteria. 
Crohn‟s disease carrying a wild-type NOD2/CARD15 showed no loss of this cross-




Discerning the precise contribution each individual PAMP receptor makes to the 
innate immune response has been complicated by the presence of contaminants in the 
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preparations used and by the milieu (e.g. patients vs. animal models, cell lines vs. 
mononuclear cells)-specific effects of these receptors. This is illustrated by the 
conflicting results reported on the interaction between TLR-2 and NOD2/CARD15 
signalling by Watanabe et al. (who studied splenocytes from NOD2/CARD15 
deficient mice, macrophages of mice expressing the Leu1007fsinsC NOD2/CARD15 
variant and performed a luciferase reporter gene experiment in a differentially 
transfected HT-29 intestinal cell line) and Netea et al. (who studied human 
mononuclear cells, murine peritoneal macrophages and hamster ovary transfected 
cell lines).
383;386
 As there is emerging evidence that the mucosal immune system 
keeps the systemic immune system largely ignorant of the (commensal) bacteria it 
interacts with, observations in transfected cell lines or even peripheral blood 
mononuclear cells may only be of limited relevance to further our understanding of 





At present there is great interest in the putative importance of defective production of 
anti-microbial peptides by epithelial cells in the pathogenesis of IBD. Antimicrobial 
proteins of the innate immune system include defensins, cathelicidin and the newly 
discovered RegIIIγ (regenerating islet 3 gamma), a C-type lectin.
13;489;490
 
Defensins are a family of evolutionarily related antimicrobial peptides with a 
characteristic β-sheet-rich fold and a framework of six disulphide-linked cysteines, 
first identified in humans more than twenty years ago.
491-493
 In addition to their 
antimicrobial properties, defensins have also been implicated in cell differentiation 
processes as well as in immunomodulation (bridging innate and adaptive immunity) 





There has been rapid evolution of the more than forty defensin genes identified so far 
in humans.
495
 This is believed to reflect an evolutionary response of the immune 
system to the ever-changing environmental microbial flora.
496;497
  Distinct defensin 
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gene clusters have been identified on Chromosome 6p21 (an IBD locus), 8p21-23, 




In humans, α-defensins are expressed constitutively and inducibly in leukocytes, the 
reproductive tract and small intestinal Paneth cells.
489;495
 Human neutrophil α-
defensins (Human Neutrophil Peptides HNPs, 1-4) are stored in granules, which fuse 
with phagosomes during phagocytosis of microbes.
495
 HD-5 and HD-6 are human 
enteric α-defensins expressed in Paneth cells. Pro-HD-5 requires Paneth cell trypsin 
to be converted to active HD-5 after its release from apical storage granules upon 
stimulation by bacterial products such as MDP (via NOD2/CARD15) and bacterial 
DNA (via TLR9).
435;436;498;499
 Disruption of matrix metalloproteinase-7 (matrilysin, 
the enzyme responsible for activation of α-defensins in mice) led to increased 
virulence of orally administered Salmonella typhimurium.
500
 Transgenic mice 





Following the observation that the production of α-defensins may be reduced in ileal 
CD, Wehkamp et al. also described this reduction was more pronounced in carriers 
of CD associated NOD2/CARD15 mutations.
502;503
 As CD associated 
NOD2/CARD15 variants also lead to loss of synergy with TLR9 in mononuclear 
cells, the negative effect of NOD2/CARD15 variants on Paneth cell function may 
also be TLR9 mediated.
478
 So far, germline variation of HD-5 and HD-6 in IBD has 
not been studied. Copy number variation does not influence HD-5 and HD-6 





β-defensins are expressed in a wide variety of tissues including epithelial cells of the 
gastrointestinal tract.
489
 Whereas HBD-1 (human β-defensin 1) is constitutively 
expressed in the lower gastrointestinal tract without significant up-regulation in 
response to inflammation, HBD-2,3 and 4 are inducibly expressed in inflammatory 
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conditions (e.g. infection and in response to pro-inflammatory cytokines).
505
 HBD-
2,3 and 4 are up-regulated in UC with no induction or even down-regulation in CD. 
506-508
 TLR2 and TLR4 have been implicated in inducible expression of HBD-2 in 
intestinal epithelial cells after stimulation with PGN and LPS through an NF-κB 
dependent pathway.
509;510
 Pathogens like Salmonella and Cryptosporidium have 
developed a virulence strategy to suppress intestinal epithelial α- and β-defensin 
expression, respectively.
511;512
  Voss et al. identified defective HBD-2 production by 
human embryonic kidney 293 cells transfected with NOD2/CARD15 variants in 
response to MDP.
513
   
In contrast to HD-5 & 6, the DNA copy number of the β-defensin gene cluster on 
8p23.1 is highly polymorphic within the healthy population. Recently, DEFB4 
(encoding the HBD-2 protein) gene copy number of <4, has been associated with 
diminished mucosal HBD-2 mRNA expression and increased susceptibility to 
colonic CD.
514
 In this study by Fellermann et al. healthy individuals, as well as UC 
patients and CD patients with ileal resections/disease had a median of 4 (range 2-10) 
HBD-2 copies per genome. Intriguingly, a higher copy number of β-defensin genes 









The contribution of germline variants of genes regulating the innate immune 
response to development of IBD has received a great deal of research interest since 
the discovery of NOD2/CARD15/CARD15 as the first susceptibility gene in CD, 7 
years ago. The intestinal epithelial cell is increasingly recognised as a key player in 
this innate immune response through the production of mucins and defensins as well 
as the expression of pattern-recognition receptors. Germline variants of MUC-, 
NOD-LRR- and TLR- genes have been associated with IBD in different populations 
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but replication of these findings in independent cohorts has proved troublesome. The 
relative risk effect of many of these variants is likely to be small making large case-
control cohorts necessary. Pooling of datasets in collaborative efforts such as the 
National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes 
of Health) NIDDK(NIH)) and European IBD genetics consortia has overtaken single 
centre studies with relatively low statistical power. However, controversies such as 
those surrounding the contribution of DLG5, MDR1 and TLR4 to development of 
IBD have taught us that pooling of genotyping data from studies in different 
populations has its risks and might mask population-specific effects. This has 
become increasingly important when interpreting genome wide association data. 
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Table 1-4: IBD candidate genes involved in the innate immune response 
Gene Genomic location IBD susceptibility locus 
MUC3A 7q22  
MDR1/ABCB1 7q21  
PXR/NR1I2 3q13  
DLG5 10q22  
OCTN1&2 5q31  
MyosinIX B 19p13  
TLR2 4q31  
TLR3 4q35  
TLR4 9q33  
TLR5 1q42  
TLR6 4p14  
TLR9 3p21  
SIGIRR 11p15  
SOCS1 16p13  
TOLLIP 11p15  
MEFV 16p13  
NOD1/CARD4 7p14  
NOD2/CARD15 16q12  
GRIM19 19p13  
Erbin 5q12  
TAK1/NR2C2 3p25  
HD-5&6 and HBD-2 8p23  
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Figure 1-1: Innate immunity pattern – recognition receptors and signal 
transduction pathways of relevance to IBD pathogenesis. 
TLR: Toll-like receptor. LPS (Lipopolysaccharide) triggers signalling through TLR4 
after associating with LPS binding protein, CD14 (a glycosylphosphatidylinositol 
linked protein expressed on the cell surface of phagocytes) and MD-2. Except for 
TLR3, all TLR signalling is MyD88-dependent. SIGIRR (single immunoglobulin 
and toll-interleukin 1 receptor (TIR)) and SOCS1 (Suppressor Of Cytokine signalling 
1) inhibit TLR4 signalling. TOLLIP (Toll-interacting protein) is critical in 
maintaining the intestinal epithelium hyporesponsive to TLR2 ligands. Activation of 
a collection of downstream kinases (IRAKs: IL-1 receptor associated kinases) leads 
to the degradation of the IKK complex and activation of NF-κB via TRAF-6 (TNF 
receptor-associated factor 6). NOD1/CARD4 (Nucleotide binding Oligomerisation 
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Domain 1/ Caspase Recruitment Domain-containing protein 4) recognises 
intracellular γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP). NOD2/CARD15 
(Nucleotide binding Oligomerisation Domain 2/ Caspase Recruitment Domain-
containing protein 15) is an intracellular receptor for Muramyl Dipeptide (MDP). 
RIPK2 (Receptor-interacting serine/threonine-protein kinase 2) interacts with 
NOD2/CARD15 and NOD1/CARD4 through a CARD-CARD interaction. This 
activation then further initiates various signalling pathways, including activation of 
NF-κB. GRIM19 (gene associated with retinoid-IFN-induced mortality 19) interacts 
with NOD2/CARD15 (but not NOD1/CARD4). Erbin (Erbb2-interacting protein) 
was identified as a novel NOD2/CARD15 inhibitory protein. TAK1 (TGFβ-
activating kinase 1) interacts with NOD2/CARD15 and is required for 
NOD2/CARD15 mediated NF-κB activation.  
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2 Patients, materials and methods 
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Definitions 
2.1.1  “Early-onset” patients 
Definitions of childhood, adolescence and adulthood are highly dependent on 
sociocultural and socioeconomical trends. The definition of early-onset IBD is 
therefore equally arbitrary. The definitions used for early onset patients in IBD have 















 and even <40 years.
521
 Rioux et 
al. defined an age cut off at less than 16 years in the Canadian IBD population. This 
study demonstrated a bimodal age distribution of patients with IBD and used 
Gaussian distribution curves to set this age limit.
267
  
Our project has targeted children with an age at diagnosis of IBD less than 17 years. 
Clinical follow-up of IBD patients in the paediatric gastroenterology centres across 
Scotland is typically till the end of secondary education.  It is important to recognise 
that a large number of older teenagers will never be referred to the paediatric 
gastroenterology services due to admission guidelines in Accident & Emergency 
departments (eg <13 years at RHSC Edinburgh) or primary referral to adult surgical 
or gastroenterology services. A UK-wide study into the investigation and 
management of newly diagnosed IBD in childhood (June 1998-1999) showed more 
than 50% of teenagers with IBD are looked after by adult services.
522
 Although it is 
important to point out the radical overhaul that has taken place of the care of these 
young patients since the introduction of dedicated paediatric GI teams across 
Scotland (second half of the 1990s), our study can not be considered truly 
population-based. This has important implications for both interpretation of genetic 
data as well as anthropometric data. Older teenagers who have not been affected by 
pubertal/growth delay and who are managed successfully without high-end 
immunosuppression are therefore less likely to be referred primarily or secondarily to 
paediatric GI services across Scotland. 
IBD Genetics in Scottish Children 
45  Ch.2: Patients, Materials and Methods  
 
Figure 2-1: Specialist involvement in IBD care of childhood onset patients by region in the UK.  
Figure 2.1: Adapted from Sawczenko et al.
522
 Selected specialist involvement by 
country. Paed GI, paediatric gastroenterologist; adult, adult gastroenterologist and/or 
adult surgeon; ROI, Republic of Ireland. Variations between countries for Paed GI 
and Adult, both p <0.001, χ2 test. Scotland has the highest level in the UK of 
involvement of adult services in the care of newly diagnosed paediatric IBD (n=71), 
assessed from June 1998-June 1999. 
 
2.1.2 Disease definition 
The diagnosis of IBD was based on standard criteria as set out by Lennard-Jones.
523
 
After exclusion of enteric infection (standard coproculture +/- Clostridium Difficile 
toxin assay), these criteria were used to classify a patient as having either ulcerative 
colitis or Crohn‟s disease. A checklist based on these criteria was constructed by Dr 
Richard Russell and Hazel Drummond to ensure each patient entering the study 
definitely fulfilled the criteria for having Crohn‟s disease (appendix 1): only if they 
met the definitions in three or more section criteria, were children labelled as CD. 
After discussion with Hazel Drummond, exceptions to this rule were patients who 
IBD Genetics in Scottish Children 
46  Ch.2: Patients, Materials and Methods  
had isolated colonic Crohn‟s disease who had granulomas and a pancolitis with 
inflammatory type disease behaviour: using these criteria a score of only 1 or 2 may 
be generated by such patients but the presence of epitheliod granulomas in these 
circumstances was deemed enough to classify the patient as having Crohn‟s disease, 
as noted in the classification itself.  
Patients were diagnosed with ulcerative colitis when they had uniform inflammation 
that commenced in the rectum (although macroscopic rectal sparing was acceptable) 
and continued for a varying extent more proximally. In addition to chronic 
inflammation on histology the patients had evidence of ulceration, cryptitis, crypt 
abscess formation together with goblet cell/mucin depletion without any epitheliod 
granulomata.  
A patient was categorised as having “indeterminate colitis”/IBD type unclassified (in 
the Montreal classification) if definite evidence of chronic inflammatory bowel 
disease affecting the colon only was present, but the patient remained unclassifiable 
as either CD or UC, after considering all clinical, radiological, endoscopic and 
pathological findings and discussion with Hazel Drummond to limit interobserver 





2.1.3 Patients and parents 
Patients and parents were recruited from the three tertiary paediatric gastroenterology 
centres in Scotland based in the specialist childrens‟ hospitals in Edinburgh, Glasgow 
and Aberdeen between 2002 and 2008 (by Dr Richard Russell and Ms Linda Smith 
from 2002-August 2005) and from January 2006 also from the paediatric 
gastroenterology clinic in Ninewells Hospital, Dundee. Patients attending the 
Western General Hospital (Edinburgh) diagnosed with IBD under the age of 17 years 
were also recruited to the study. Age-appropriate information leaflets explaining the 
background to and the purpose of the study were supplied to all patients and parents 
prior to approaching them for study enrolment (appendices 2 and 3 respectively). In 
those patients and families who agreed to take part written consent was then obtained 
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from patients and parents prior to participation in the study (appendices 4 and 5 
respectively).  
Adult IBD patients were recruited from the Gastrointestinal Medicine Department at 
the Western General Hospital, Edinburgh. Informed consent from all study 
participants was obtained before recruitment into the study.  
 
2.1.4 Blood collection  
Each patient had up to 10 millilitres (mls) of blood collected into EDTA and Lithium 
Heparin tubes. The blood was usually collected when the patients were having blood 
taken as part of their on going clinical care as requested by their supervising clinician 
and not merely for participation in the research study, as stated in the information 
leaflets. A topical local anaesthetic cream [Eutectic Mixture of Lidocaine and 
Prilocaine (EMLA Astra-Zeneca) or Amethocaine base 4.0%w/w (Ametop Smith 
& Nephew)] was applied if requested by the patient or family, prior to venapuncture. 
Parents each gave 10mls of whole blood collected into an EDTA tube collected in a 
Vacutainer (Nu-care) system. In the case of “parents” who were not the genetic 
parents of the child, as disclosed in confidence by the guardian to the researcher, 
“sham” blood taking was undertaken by placing a plaster on the carer‟s arm, to avoid 
disclosure of any potentially sensitive information to the child in the course of the 
family agreeing to take part in the study. On rare occasions, the parent‟s GP kindly 
took the blood sample and information leaflets and consent sheets were mailed. 
 
2.1.5 Healthy control recruitment 
Healthy adult controls were recruited from healthy volunteers and from volunteers 
recruited from the Scottish blood transfusion service. The number of controls used in 
each of the genetic studies varied and the exact number used in the study of each of 
the candidate genes is listed individually in the subsequent chapters.  
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2.1.6 Ethical approval 
Ethical approval was given for all participating centres (Edinburgh, Lothian Research 
Ethics Committee (LREC) Reference Number: LREC/2002/6/18; Aberdeen, 
Grampian Research Ethics Committee (GREC) reference number: GREC 03/0273; 
Glasgow, Yorkhill Research Ethics Committee (YREC) reference number: YREC 
number P12/03). In order to extend our recruitment to Ninewells Hospital (Dundee), 
a new COREC application was submitted in January 2006 with a request for a Site 
Specific Assessment of Ninewells Hospital (local Principal Investigator: Dr Gamal 
Mahdi). The application received a favourable ethical opinion and the Lothian 
Research Ethics Committee was henceforth named as the Main REC. 
Additional favourable ethical opinions were obtained for substantial amendments 
pertaining to the accrual of a paediatric control cohort (age-, sex-, postcode-matched 
to our paediatric IBD patients), both for epidemiological and genetic studies (using 
non-invasive saliva-kits to extract DNA from). In order to comply with Caldicott-
regulations, GPs were asked to forward recruitment packs to matched healthy 
children from their practice database. Age-appropriate information leaflets and 
consent sheets were designed and approved by the LREC. (see Appendix 6)   
A favourable ethical opinion by the LREC had previously been obtained for the 
recruitment of adult patients with IBD at the Western General Hospital, Edinburgh. 
(put down LREC number – get it from Colette) 
 
2.1.7 Data collection  
Retrospective data were collected on patients using case note review and a 
questionnaire (previously devised by Dr Richard Russell). All paediatric IBD 
patients and their parents completed a questionnaire during face-to-face interview 
with a member of the research team (Dr Richard Russell, Ms Linda Smith or JVL), 
collecting information on patient and parental smoking details, ethnicity and a 
detailed family history of IBD and other diseases (see appendix 7). Additional 
clinical data was collected on patient demographics, age at IBD symptom onset and 
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diagnosis, medications, extraintestinal manifestations, history of atopic disease 
(eczema, asthma, allergic rhinitis and food allergy) and need for surgery.   
 
Disease phenotype  
All childhood patients recruited to the study were phenotyped by either Dr Richard 
Russell, Dr Johan Van Limbergen, Mrs Hazel Drummond, Miss Nikki Round (a 
fourth year medical student, as part of her SSC4 project under supervision of Dr 
David Wilson and JVL). Data entry onto a Microsoft Access database (designed by 
Dr Richard Russell and Mrs Hazel Drummond; Microsoft Corporation, Redmond, 
WA, USA) and quality control were performed by Mrs Hazel Drummond (database 
manger). Previously designed proforma sheets were used to collect the data in a 
consistent manner and to further reduce the chances of inter-observer error for 
Crohn‟s disease and Ulcerative/Indeterminate Colitis (Appendices 8 and 9, 
respectively). The phenotypic criteria used were the Montreal classification for 
patients with Crohn‟s disease 
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 as well as a more detailed scoring system of each 
anatomical location affected by IBD including extra-intestinal manifestations and 
bone health. 
Phenotypic information was collected at diagnosis and reassessed in 2 yearly 
intervals for CD patients for the first 10 years post diagnosis and then collected at 5 
year intervals subsequently. In patients with UC/IC phenotypic details were collected 
at diagnosis and the time of last follow-up. 
Detailed phenotyping of adult IBD patients occurred under the supervision of Mrs 
Hazel Drummond by a number of researchers from our unit (including among others 
Dr Ian Arnott, Dr Gwo-Tzer Ho and Dr Colin Noble).  
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2.1.8 The Montreal classification of Crohn’s disease 
A summary of the classification appears in Table 2-1. 
Age at diagnosis 
A1 16 y or younger   
  
   
A2 17 – 40 years 
A3 Over 40 years 
Disease location 
L1 Terminal Ileum (TI) L1 + L4 TI + Upper GI 
L2 Colon L2 + L4 Colon + Upper GI 
L3 Ileocolon L3+L4 Ileocolon + Upper GI 





penetrating + perianal 
B2 Stricturing B2p Stricturing + Perianal 
B3 Penetrating B3p Penetrating + Perianal 
Table 2-1: The Montreal classification of Crohn’s Disease 
2.1.8.1 Age at diagnosis 
The age (A) category is assigned by the patient‟s age at diagnosis. The Montreal 
classification has addressed some of the difficulties of previous systems in 
classifying paediatric IBD: a childhood onset category was introduced (<17 years at 
diagnosis, A1); A2 for patients diagnosed between 17 and 40 years of age; A3 for 
patients > 40 years old at diagnosis. 
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2.1.8.2 Disease location 
The Montreal classification divided disease location into four different disease 
locations prefixed by the letter L for location: L1 for ileal disease and was defined as 
disease in the distal third of small bowel (on our database more strictly interpreted as 
disease limited to the terminal ileum), with or without caecal involvement; L2 for 
CD limited to the colon only; L3 for ileocolonic disease; L4 represented disease in 
the upper gastrointestinal tract anywhere proximal to terminal ileum. In addition to 
the four disease locations described in the Vienna classification (ileal, colonic, ileo-
colonic and upper GI, L1-4) the Montreal classification added three further 
subcategories; these were the first three categories (L1-L3) with the addition of L4 
where the disease sites coexisted, meaning the L4 disease location no longer negated 




It is noteworthy that patients with CD limited to the mouth and/or perianal, were not 
classifiable using the Montreal classification. This shortcoming of the Montreal 
classification will be further discussed in the chapter on the distinct phenotype of 
childhood onset IBD.  
Disease extent was defined as the maximum disease involvement prior to the first 
surgical resection. Macroscopically, the minimum criteria for involvement of a 
disease location were ulceration or the presence of an aphthous lesion. Erythema 
and/or oedema did not suffice to score a site as affected by CD. 
 
2.1.8.3 Disease behaviour 
The Montreal classification divided disease behaviour into three different categories 
prefixed by the letter B: B1 for inflammatory (thus non-stricturing/non-penetrating) 
CD; B2 for stricturing disease (defined as a constant luminal narrowing on radiology, 
at the time of endoscopy or surgery with a pre-stenotic dilatation or if accompanied 
by clinical signs and symptoms of intestinal obstruction); B3 for penetrating disease 
defined as intra-abdominal fistulas, inflammatory masses plus or minus abscess 
formation at any time excluding complications arising in the immediate post 
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operative period but not penetrating perianal disease. In the Montreal classification, 
recognition was given to the fact that enteric and perianal fistulae may represent 
different disease phenotypes. Thus, perianal disease was removed from the B3 
category and instead added as a suffix “p” to any of the disease categories, B1-3. 
Like disease location, disease behaviour can not be down graded at follow-up.  
 
2.1.9 The Montreal classification of ulcerative colitis 
In patients with ulcerative colitis disease extent was divided into three categories: E1 
for patients with a proctitis (inflammation limited to the rectum), E2 for left sided 
disease distal to the splenic flexure and E3 for extensive disease proximal to the 
splenic flexure. 
Table 2-2: The Montreal classification of ulcerative colitis 
Disease extent in ulcerative colitis 
E1 Proctitis 
E2 Left sided (distal) 
E3 Extensive (pancolitis) 
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2.1.10 Detailed anatomical location of paediatric IBD  
In the absence of a recognised paediatric classification, a more detailed scoring 
system of anatomical involvement of the GI tract was also used. In patients with 
Crohn‟s disease, location was categorised and analysed according to individual 
disease locations, regardless of disease involvement elsewhere in the gastrointestinal 
tract in contrast to the hierarchical model of the Montreal classification. The extent 
of ulcerative colitis was also scored in greater detail than suggested by the Montreal 
classification. Although extremely useful to explore detailed genotype-phenotype 
relationships, this more detailed model was used sparingly during the analysis of 
genotypic data to avoid stastical errors because of multiple testing. 
 
2.1.10.1 Crohn’s disease 
2.1.10.1.1 Disease Location 
For each anatomical location (based on findings from endoscopy, biopsy, surgery or 
barium follow through) within the gastrointestinal tract (oral, oesophageal, gastric 
antrum and body, duodenal, jejunal, ileal, caecal, ascending, transverse, descending 
and sigmoid colon, rectum and perianal area), presence or absence of CD was noted. 
Oral Crohn‟s disease was defined by macroscopic changes (mucosal tags, deep linear 
ulceration, cobblestoning, lip swelling and fissuring) after examination by a 
paediatric dentist/oral medicine specialist only.  The presence of epitheloid 
granulomata on buccal biopsy was also classified as oral Crohn‟s disease. The term 
oral CD was preferred to the term oro-facial granulomatosis.  
Patients were diagnosed with Crohn‟s disease of the upper GI tract (oesophagus, 
stomach, duodenum or jejunum) when biopsies from any of these sites confirmed the 
presence of epitheliod granulomas (not merely in the presence of chronic 
inflammation) and/or when features of macroscopic disease were present as defined 
above. The presence of a chronic gastritis in the absence of other features of Crohn‟s 
disease was not sufficient to indicate disease involvement of the gastric body/antrum.  
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Perianal disease was defined by the presence of fissures, fistulae, abscess formation 
or perianal ulceration but not by the presence of skin tags alone.  
 
2.1.10.2 Disease behaviour 
The definitions for disease behaviour were the same as those used in the Montreal 
classification.
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 Perianal disease, using the suffix p, was only scored when case note 
review indicated the presence of penetrating complications such as deep ulceration, 
abscess formation or fistulisation. In the analysis, Montreal penetrating perianal 
disease was analysed separately (B1p-or-B2p-or-B3p versus B1-or-B2-or-B3).  
 
2.1.10.3 Ulcerative colitis  
2.1.10.3.1 Disease location  
The Montreal classification has offered the first widely accepted system to classify 
disease extent in ulcerative colitis. In order to prepare for more detailed genotype-
phenotype relationship analyses, the disease extent of UC was further divided into 6 
categories depending on the maximum disease extent defined by either macroscopic 
appearance or histology (rectum, sigmoid, descending, transverse, ascending and 
pancolitis when inflammation involved the whole colon). It was also noted whether 
the patient had a comprehensive assessment in line with investigative guidelines 
summarised in the Porto-criteria of the European Society of Paediatric 
Gastroenterology Hepatology and Nutrition (colonoscopy, upper GI endoscopy +/- 
Barium Follow Through) or a limited assessment (i.e. sigmoidoscopy) as well as a 
subjective assessment of whether the examination was adequate (eg good bowel 
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2.1.10.4 Surgery 
Surgery was defined as any operative intervention for IBD, thus excluding 
examination under anaesthesia, and divided into resective surgery, drainage 
procedures or other types of operations (eg fistula-, pouch-surgery). 
 
2.1.10.5 Growth data 
The basic anthropometric data collected in all patients were weight (in kilograms) 
and height (in metres) at diagnosis and at follow-up. All patients had their height 
measured on a wall mounted stadiometer and weight measured on regularly 
calibrated scales. Quetelet‟s body mass index (BMI) was then calculated by dividing 
the patients weight by their height squared. Standard UK centile charts (based on the 
UK 1990 population data (© Child Growth Foundation 1996)) were used to allocate 





































). The collected 
anthropometric data were further expressed as z-scores (British 1990 Growth 
Reference for height, weight and BMI ©Child Growth Foundation, 2 Mayfield 
Avenue, London W4 1PW) to assess deviation from the mean, expressed in units of 
its distribution's standard deviation prefixed by + or -.  
Assessment of pubertal status was also recorded but the inconsistency of case note 
documentation of this parameter made it unsuitable for further detailed analysis. 
  
2.1.10.6 Haematological and biochemical disease markers 
Using proforma sheets, data were collected for all patients who had blood tests 
performed at the time of diagnosis and at designated times of follow-up i.e. 2 yearly 
for patients with CD and at diagnosis and last follow up for patients with UC/IC 
(appendix 8). Abnormal blood tests were defined as follows: Albumin <35 g/l, 
Erythrocyte sedimentation rate (ESR) > 10mm in the first hour. C- reactive protein 
(CRP) was recorded as normal or high (the specific units used varied between 
various laboratories used by the participating centres in the study). Abnormal values 
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for haemoglobin concentration were age dependent: age 1-3 years <110 g/l, 3-6years 
<117g/l, >6 years <120g/l and platelets >400 x10
9
/l. The normal ranges for vitamin 
B12 were 193–982 nanograms/l
-1
 and for serum folate 3–7g/l
-1
. Faecal Calprotectin 




The demographics of childhood onset IBD patients are shown in Table 2.3. 
Table 2-3: Demographics of Scottish childhood onset IBD patients 
Childhood IBD 
N=416 
CD UC IBDU  
N 276 99 41 
M / F 164 / 112  
 
48 / 51 
 
19 / 22  
Median Age at 
diagnosis (Q1-Q3) 
11.5 years (8.9-13.2) 10.9 years (8.8-10.8)   10 years (7.6-12.5)  
Caucasian 97.8 % (270/276)  
 
  94.9% (94/99)  
 
97.5% (40/41)  
Median Duration of 
follow-up (Q1-Q3) 
3.7 years (1.7 – 6.0) 3.5 years (1.1-4.8) 
 





1.6% / 95.3% / 3.1% 
 
IBD Genetics in Scottish Children 
57  Ch.2: Patients, Materials and Methods  
Several genetic determinants were analysed in children as well as adults with IBD 
(n=1297). Detailed demographics of the adult IBD cohort from the Western General 
Hospital are presented in Table  
 
Table 2-4: Demographics of Scottish adult onset IBD patients 
Adult IBD 
n=1297 
CD UC  
N 596 701 
M / F 216 / 380  342 / 359  
Median Age at 
diagnosis (Q1-Q3) 
29.7 years (23.7-43.5)  34.5 years (26.0-50.0) 
Caucasian 99.3% (578/582) 97.3% (673/688) 
Median Duration of 
follow-up (Q1-Q3) 





43.9% / 44.4% / 11.7% 19.2% / 49.9% / 30.9% 
 
Database 
All study data were entered into a Microsoft Access 2000
© 
database. Anonymised 
data were stored in this password-secure Access database, which was designed and 
maintained for the purpose of this study and the parallel genetic studies in adult IBD 
patients by Dr Richard Russell and Mrs Hazel Drummond. All data were backed up 
on compact disc weekly, or after a period of large data entry before being stored in 
secure fire-resistant container.  A dedicated computer without connection to the 
internet was used for storage of the study data. 
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Statistics 
2.1.12 General statistics 
Minitab statistical software version 13 (Minitab ltd, Coventry, UK) and GraphPad 
Instat (version 3.06 for Windows 98, GraphPad Software, San Diego California 
USA, www.graphpad.com) were used to analyse genotypic data and genotype- 
phenotype associations using Chi-squared or Fisher‟s exact test (for n<5) for 
unifactorial analysis. Non-parametric data were analysed using the Mann-Whitney U 
test or Kruskall-Wallis test (for analysis of age at diagnosis as a function of 
genotype) in Minitab.   
Multifactorial analysis applying binary logistic regression analysis was performed 
using Minitab software. Interaction between the genetic factors entered in the 
multifactorial models was also assessed. 










The PedCheck programme (Department of Human Genetics, University of 
Pittsburgh, Pittsburgh, PA) was used to check for genotyping error and potential 
cases of non-paternity.
530
 Any family trios with inconsistent results incompatible 
with normal patterns of inheritance were excluded from further genetic analyses.  
 
2.1.14 Transmission disequilibrium testing 
Transmission disequilibrium testing analysis was performed using the TRANSMIT 
package (Version 2.5, David Clayton, Cambridge, UK).
531
 This method makes full 
use of the data available using inferred genotypes if genotypic data from both parents 
are not available. Assistance with data analysis with the TRANSMIT programme 
was provided by Dr Niall Anderson (Senior lecturer in statistical genetics, Edinburgh 
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University). Latterly, single and multiple marker TDT analyses were performed 
using FBAT software (version 1.7.3, available from 
http://www.biostat.harvard.edu/~fbat/fbat.htm). 
532
 Odds Ratios (ORs) (99.5% 




For the analysis of Filaggrin, DAB1, TTC29 and IRGM SNPs, PLINK software was 





2.1.15 Integration of case-control and TDT-analyses 
The method for integrating results from case-control studies and TDT to provide a 
combined estimate of disease-marker association was described by Kazeem and 
Farall.
535
 As this approach is only useful when the samples of subjects used in the 
two analyses are independent of each other, yet share the same genealogy, we based 
this calculation on our TDT cohort of early onset IBD and our samples of adult onset 
IBD patients in the case-control analysis. 
 
Cellular methods 
2.1.16 DNA extraction 
Until January 2006, genomic DNA was extracted from blood using a modified 
salting-out technique (Appendix 10).
536
 Thereafter, the Nucleon kit (Tepnel Life 
Sciences PLC, Manchester, United Kingdom) was used by staff at the MRC Human 
Genetics Unit to extract DNA from peripheral blood. DNA samples were then 
subjected to the PicoGreen
®
 dsDNA Quantitation Reagent (an ultra-sensitive 
fluorescent nucleic acid stain for quantitating double-stranded DNA (dsDNA)) at the 
Wellcome Trust Clinical Research Facility. The solution was then re-suspended in an 
appropriate volume of 1xTE (10mM Tris (pH8.0), 1m EDTA (pH8.0)) to give a final 
DNA concentration of 100ng/μl. 
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2.1.17 Validation of DNA quality extracted from saliva 
The problems associated with obtaining a peripheral blood sample of children with 
IBD after they have entered remission, children with difficult venous access or 
needle phobia and the ethical considerations rendering the establishment of a 
paediatric (blood) DNA control cohort unacceptable, made us consider the use of kits 
to extract DNA from a saliva sample. 
DNA Genotek (DNA Genotek Inc., 29 Camelot Drive, Ottawa, Ontario, Canada, 
http://www.dnagenotek.com/) produce the Oragene DNA Self-collection kit. I 
performed an initial validation of the performance of this extraction method based on 
1) DNA size, 2) performance in PCR/sequencing and 3) concordance of blood- and 
saliva-derived DNA on the Illumina 550k chip. 
1) 1 microgram of DNA from 10 individuals, extracted from their saliva using the 
Oragene DNA protocol, was run on a standard agarose gel for 90 minutes together 
with a Lambda Hind III DNA ladder (http://www.abgene.com) (Figure 2-2). The 
dsDNA fragments all proved to be greater than 20,000 basepairs in length. 
2) Next, I performed a standard PCR reaction of the DNA sequence flanking the 
Vitamin D receptor BSM I allele, baring in mind the necessity of good quality DNA 
for this PCR to be successful (background, protocol and primers obtained from Dr 
Stuart Bear, Bone Research Group (Professor Stuart Ralston), Molecular Medicine 
Centre)).
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 For this experiment, paired blood and salivary DNA from 6 individuals 
was used (Figure 2-3). Consistent DNA product lengths were obtained in unevenly 
numbered columns (containing blood derived DNA) and evenly numbered columns 
(containing saliva derived DNA). Both performed equally well when reading the 
DNA sequence. 
3)  Lastly, Angie Fawkes and Lee Murphy from the WTCRF kindly offered to assess 
the performance of saliva derived DNA on the Illumina 550k chip. From 3 
individuals, paired blood and saliva derived DNA was analysed. The call rates and 
reproducibility rates are shown in Table 2-5. 
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Table 2-5: Call rates and reproducibility rates for paired blood/saliva DNA samples on 
Illumina550k Chip 
Sample Nr Call Rate Saliva/Blood DNA Reproducibility Rate 
RR1096 95.03% / 98.85% 99.7% 
RR1284 98.15% / 98.82% 99.9% 
RR1285 98.12% / 99.48% 99.9% 
 
Figure 2-2: Lambda Hind III dsDNA ladder versus salivary DNA 
 
Figure 2-2: Standard Agarose Gel run for 90 minutes as discussed below. Lambda 
Hind III ds DNA ladder was run in the first column. The next 10 column contain 1 
microgram of DNA extracted from saliva of 10 volunteers (parents and children with 
IBD). The DNA size was shown to be greater than 20 kilobases. 
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Figure 2-3: PCR of Vitamin D receptor BSM 1 allele flanking sequence 
 
 Colums 1 2 3 4 5 6 
Figure 2-3: PCR of Vitamin D Receptor BSM1 allele flanking sequence using 
paired blood/salivary DNA samples from 6 individuals, shows consistent 
fragment lengths between uneven (containing blood derived DNA) and even 
(containing saliva derived DNA) columns. 
 
2.1.18 Lymphocyte and Plasma extraction 
Peripheral blood lymphocytes were extracted from the Lithium Heparin samples 
collected from children with IBD. The lymphocytes were then cryopreserved. Plasma 
was isolated at the time of peripheral blood lymphocytes extraction and samples 
were stored at -80
o
C until use. The lymphocyte extraction and separation of plasma 
was carried out by the staff in the Wellcome Trust clinical research facility, 
University of Edinburgh. 
 
2.1.19 PCR  
All standard Polymerase chain reactions (PCR) were run on a Techne Touchgene 
Gradient machine or on a Peltier Thermal Cycler (DNA Engine Tetrad 2). The 
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reagents used and the specific reaction conditions are discussed for the individual 
SNPs in the subsequent chapters. 
 
2.1.20 DNA sequencing 
Direct sequencing was performed on the 7900 HT sequence detection system 
(Applied Biosystems, Foster City, Ca, USA) by the Technical Services section of the 
MRC Human Genetics Unit, Edinburgh. DNA sequences were analysed using 
Sequencher v 4.5 (Gene Codes Corporation, Ann Arbor, MI, USA). 
 
2.1.21 SNP selection for haplotype -tagging approach 
Haplotype-tagging SNPs were selected using genotypic data from the CEU-study 
group (Thirty U.S. trios with Northern and Western European ancestry, collected by 
the Centre d'Etude du Polymorphisme Humain (CEPH)), available from the HapMap 
project (Release 21, July 2006; http://www.hapmap.org/cgi-
perl/gbrowse/hapmap_B35/).  SNPs were selected using Haploview software 
(version 3.32, freely available from http://www.broad.mit.edu/mpg/haploview/). 
SNPs were identified using a haplotype-tagging strategy based on solid spine of 
linkage disequilibrium (r
2
>0.8, haplotype frequency > 5%, minor allele frequency > 
10%). A more detailed description of the SNP selection process for each of the genes 




The majority of genotyping was performed using TaqMan® (© Biosystems) and was 
performed in the Welcome Trust Clinical Research Facility (WTCRF) located within 
the Western General Hospital, Edinburgh. This PCR-based assay uses laser scanning 
technology that excites fluorescent dyes present in specifically designed probes. The 
system includes a built-in thermal cycler, a laser to induce fluorescence, CCD 
(charge-coupled device) detector, real-time sequence detection software, and 
TaqMan® reagents for the fluorogenic 5' nuclease assay. The cycle-by-cycle 
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detection of the increase in the amount of PCR product is quantified in real time as 
the special probes, "reporter dye", fluoresces when the "quencher" is removed from 
the fragment during the PCR extension cycle. 
2.1.22.1 SNP design 
TaqMan genotyping was ordered using primers from an Assay on Demand Assay for 
SNPs that had previously been genotyped or, the target sequence for each SNP was 
submitted to the Assay by Design Service for Custom SNP Genotyping Assays. The 
Assays from these services consist of a mix of unlabelled primers and TaqMan 
Minor Groove Binder probes. Genotyping was performed using DNA plated in 384 
(4x96) well-plates, using the TaqMan polymerase chain reaction-based method. In 
each plate, negative control wells are used to check the quality of reaction. 
  
2.1.22.2 PCR reaction 
The final volume PCR reaction was 5 micro litres (µl) using 20 nanograms of 
genomic DNA, 2.5 µl of TaqMan Master Mix and 0.125μl of 40x Assay By design 
Genotyping Assay Mix, or 0.25µl of 20x  if using Assay On Demand Genotyping 
Assay. The cycling parameters were as follows: 95° for 10 minutes, followed by 40 
cycles of denaturation at 92° for 15 seconds and annealing/extension at 60° for 1 
minute. PCR plates were then read on ABI PRISM 7900HT (Applied Biosystems) 
instrument with Sequence Detection System (Applied Biosystems) version 2.1 
software.  
2.1.22.3 Allele discrimination 
Allelic discrimination using this chemistry is based on the design of two TaqMan 
probes, specific for the wild type allele and the mutant allele separated using laser 
scanning technology. Each of the two probes is labelled with a different fluorescent 
tag 6-carboxy-fluorescein (FAM) and VIC®. Each probe is designed with the gene 
mutation affecting the middle part of the probe sequence. The binding efficiency of 
the wild type TaqMan probe to the mutant allele and vice versa is low, due to the 
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mismatch within the TaqMan probe and the target sequence; therefore, mismatched 
binding is highly reduced.  
 
2.1.22.4 Results 
Allocation of allele status as homozygous wild type, heterozygote or homozygous 
mutant was made by personnel in the WTCRF blinded to the study aims. The results 
from TaqMan studies were then collected onto an Excel 2000
©
 spreadsheet before 
being entered onto the Access 2000
©
 study database, with results matched using pre-
assigned unique study numbers.  
 
Primers  
Primers for sequencing the TNF-α promoter region, the insertion/deletion 
polymorphism +32656 of NOD1/CARD4, and the exons of IRGM gene were 
designed using data from Ensembl (www.ensembl.org). Primers for the sequencing 
of the CpG-island of the promoter region of NOD2/CARD15 were designed by 
entering data from Ensemble into the MethPrimer Program 
(http://www.urogene.org/methprimer/ ). The primers used in analysis of the above 
genes are listed in the relevant chapters. 
 
Haplotypes 
Haplotypes were calculated using Haploview version 3.32. 
 
Gels used for PCR reactions                                        
2.1.23 Preparation 
Multipurpose agarose (2.25g) was added to 150 millilitres (ml) of half strength TBE 
(53g of Tris base, 27.5g o boric acid and 20ml of 0.5M EDTA for 1 l of 5X solution, 
then diluted to 0.5 X) into a 250 ml beaker. This was then microwaved on full power 
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for between 2 and 3 minutes agitating half way through until all of the agarose had 
dissolved into solution. The agarose was then cooled to around 50C by running 
under a cold water tap, before 10 microlitres (µl) of ethidium bromide, latterly 15 
microliters of SYBR® Green (http://www.invitrogen.com ) was added and then 
agitated further to ensure even distribution. The agarose solution was then poured 
into a transparent gel-casting tray, which was sealed at each end using autoclave 
tape. Four combs containing either 12 or 16 wells were then inserted into the gel. The 
gel was then left to cool and solidify at room temperature for at least 30 minutes. 
 
2.1.24 Electrophoresis 
The gel was removed from its tray and case removed before being placed into an 
electrophoresis tank filled with half strength TBE. Before loading the PCR mix in 
question 5 µl of orange G loading buffer (20g of Sucrose in 40ml water, dissolve 
100mg of Orange G in above solution, q.s. to 50ml with water) had been added to 
20µl of PCR mix. The mixture was then pipetted into the wells in the gel before 
running the electrophoresis. The running time varied dependent on optimal 
conditions for the PCR reaction in question but a standard running time of 30 
minutes (depending on the size of the DNA fragment) and 150 Watts of power was 
used for most gels. 
 
2.1.25 Interpretation  
After the gel had completed electrophoresis it was then removed from the tank and 
placed in a covered ultraviolet hood. Images were then recorded using a digital 
camera image loaded onto a designated computer. 
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3 Phenotypic characteristics of childhood onset IBD 
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Introduction 
The inflammatory bowel diseases (IBD), Crohn‟s disease (CD) and ulcerative colitis 
(UC), are complex polygenic diseases, and are a major cause of morbidity in Europe 
and North America, where up to 1/250 of the general population are affected.
1
 The 





As many as 25% of patients first present during childhood or adolescence.
2
 In 
children, these diseases have been marked by a steady rise in incidence over the last 
4 decades, with disease presenting most commonly immediately before the start of 
the teenage years, thereby impacting on emotional and physical development as well 




It has remained a topic of great debate whether childhood-onset disease is 
etiologically distinct from adult-onset disease – a debate recently catalysed by the 
search for susceptibility genes in CD and UC. Clinical experience, including the 
early requirement for second line immunomodulatory drugs 
539;540
 in childhood-onset 
disease, suggests that childhood-onset disease may have a more “severe” phenotype.  
This hypothesis has been supported to some extent by the limited available data 
suggesting that childhood-onset CD may be characterised by extensive intestinal 
involvement at presentation.
541-543
 However, rigorous studies investigating the 
progression of intestinal involvement and behaviour in childhood disease are not 
available to help explore this hypothesis further.  
 
 
In contrast to childhood-onset disease, the development of internationally accepted 
disease classification systems in recent years has facilitated longitudinal studies 
addressing changes in disease phenotype in adults with IBD.
521
 A series of careful 
studies have consistently demonstrated the stability of disease location over time, as 
well as the  progression of the behaviour phenotype from purely inflammatory 
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disease to either stricturing or penetrating disease.
544
 The most recent classification 
system, proposed by the Montreal working party, attempted to integrate the 
increasing knowledge basis that had evolved since previous groups in Rome and 
Vienna had addressed these issues.
516
 Although best considered a work in progress, 
the Montreal classification has formed the basis of phenotypic classification in many 
published adult clinical and genetic studies since 2005. 
 
In the present study we have described the presenting phenotype and progression of 
disease phenotype in childhood-onset CD and UC. We have used the phenotypic sub-
classification system for disease behaviour and location suggested in the report of the 
Montreal working party, and we have used the age of 16 years or younger at 
diagnosis to define childhood-onset disease (A1 in the Montreal classification).  We 
also studied the phenotype of IBD in the subgroup of children diagnosed in early 
childhood – before the eighth birthday. We evaluated the need for 
immunosuppressive medication and surgery in childhood-onset disease, and 
compared time to first surgery in childhood-onset and adult-onset IBD.  Finally, we 
assessed whether the phenotype of childhood-onset IBD may be different from adult-





416 children with IBD diagnosed before their 17th birthday were recruited from all 
the paediatric gastroenterology centres in Scotland as part of an ongoing childhood 
onset IBD genetics project. Children were investigated according to the ESPGHAN 
„Porto‟-criteria for diagnosis of IBD.
526;545
 Detailed demographics are presented in 
Table 2-3.  
1297 patients with adult onset IBD were recruited from the Western General 
Hospital, Edinburgh. Detailed demographics are presented in Table 2-4. 
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The study was approved by the local Research Ethics Committee. Informed personal 
or parental consent was obtained. 
 
3.1.2 Classification of IBD 
The diagnosis of IBD was based on standard criteria as set out by Lennard-Jones.
523
 
All patients were phenotyped using the Montreal classification (Tables 2-1 and 2-2) 
which has addressed some of the difficulties of previous systems in classifying 
paediatric IBD: a childhood onset category was introduced (<17 years at diagnosis) 
and the Vienna-classification was modified so that upper gastrointestinal (GI) disease 
could „co-exist‟ with lower GI locations of disease (see Figure 3-1).
516;546
 A 
dedicated database manager (HE Drummond) performed quality control of 
phenotypic data entered onto a Microsoft Access database (Microsoft Corporation, 
Redmond, WA). Oral Crohn‟s disease was defined by macroscopic/biopsy changes 
after examination by a paediatric dentist/oral medicine specialist only.   
We scored the progression of anatomical involvement of the GI tract and disease 
behaviour in 2-yearly intervals to 4 years in childhood CD. Adult CD location was 
assessed at last clinical follow-up and adult CD behaviour was analysed after 5-years 
clinical follow-up. Childhood and adult onset UC was assessed at diagnosis and at 
last clinical follow-up.  
When comparing childhood and adult onset IBD, the location was defined as the 




3.1.3 Statistical analysis 
In order to avoid statistical errors generated by multiple testing, we opted to analyse 
our data first as contingency tables consisting of columns of Montreal categories 
versus rows of different time points of clinical follow-up. Following this, unifactorial 
analyses were performed using χ
2
 or Fisher‟s exact test (when n<5 per field of 2x2 
table) to calculate Odds Ratios (OR) and 95% Confidence Intervals (CI).  Minitab 
software (Release 13.20, Minitab Inc., State College, PA, USA) and GraphPad Instat 
software (v 3.06, San Diego, Ca, USA) were used. Kaplan-Meier curves to assess 
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time from diagnosis to 1
st
 surgical resection were calculated using GraphPad Prism 
software (v 4.0, San Diego, Ca, USA).  Analysis of time to use of 
immunomodulatory drug therapy (first use of any of azathioprine, methotrexate or 
biological therapy) was also assessed and is presented as a Kaplan-Meier curve in the 
childhood-onset group only.  Differences between Kaplan-Meier curves were 
compared using a logrank test automatically calculated in Prism. 
 
Figure 3-1: The Montreal classification of Crohn’s disease 
 
 
Figure 3-1: The Montreal classification of Crohn’s disease. Adapted from an 
original image by the National Cancer Institute (http://www.cancer.gov/). 
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Results 
3.1.4 Phenotypic characteristics of childhood onset CD 
CD at diagnosis - CD affected the small as well as large bowel (L3+/-L4) in 50.5%, 
the colon (L2+/-L4) in 36.3% and the ileum (L1+/-L4) in 5.9%. More than half of 
children (50.9%) were affected by CD proximal to the terminal ileum at diagnosis 
(any L4). Follow-up of at least 2 years was completed in 196/273 (71.8%). Follow-
up data of at least 4 years were available in 132/273 (48.4%).(Table 3-1) 
 
CD location changed with time. Detailed analysis of the 196 childhood-onset CD 
patients who had at least two years follow-up demonstrated a large proportion of 
these children experienced extension of anatomical involvement of the 
gastrointestinal tract. At diagnosis, 53/196 (27.0%) already had the maximum disease 
extent (L3+L4). Of the 143 children who could therefore change CD location at 2-
years follow-up, 56 (39.1%) children did. These changes were due to the inclusion of 
findings on upper GI endoscopy in 15/56 (26.8%) only; in the majority (41/56, 
73.2%), changes were due to extension from localised disease to more extensive 
disease involving the lower GI tract. This extension of anatomical involvement was 
more likely to be due to increasing ileal involvement over time (27/56 (48.2%) 
patients (ileal: 23; ileocolonic: 4)) rather than colonic involvement with time (11/56 
(19.6%) (p=0.001 OR 3.81 (1.64-8.84)). 
 
CD behaviour also changed with time. Disease behaviour progressed significantly 
from diagnosis to four years follow-up (p=0.001). By two years follow-up, the 
behaviour of CD changed with an increase in stricturing disease (±perianal) from 
4.4% to 9.6% (p=0.02 OR 0.43 (0.20-0.91)) and a decrease in inflammatory disease 
(±perianal) from 91.2% to 82.7% (p=0.005 OR 2.16 (1.24-3.78)). By 4 years after 
diagnosis, both stricturing disease (±perianal) and penetrating disease (±perianal) 
increased from 4.4% to 12.9% (p=0.001 OR 0.31 (0.14-0.67)) and from 4.4 % to 
11.4%. (p=0.008 OR 0.36 (0.16-0.79)), respectively. Inflammatory disease 
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(±perianal) decreased from 91.2% at diagnosis to 75.8%. (p <0.0001 OR 3.32 (1.86-
5.92)). Perianal disease increasingly complicated the other behaviour phenotypes 
over time, rising from 13.9% at diagnosis to 22.2% after 4 years follow-up (p=0.04 
OR 0.57 (0.34-0.98)). 
Table 3-1: The phenotype of childhood onset CD at diagnosis and follow-up 
Childhood 
onset CD 
At diagnosis At follow-up ≥ 2 years  At follow-up ≥ 4 years 
CD phenotype – location* 
L1 10 / 273 (3.7%) 5 / 196 (2.6%)  4 / 132 (3.0%)  
L2 57 / 273 (20.9%) 30 /196 (15.3%) 24 / 132 (18.2%)  
L3 53 / 273 (19.4%) 32 / 196 (16.3%)  20 / 132 (15.2%) 
L1+L4 6 / 273 (2.2%) 4 / 196 (2.0%)  3 / 132 (2.3%)  
L2+L4 42 / 273 (15.4%) 32 / 196 (16.3%)  24 / 132 (18.2%)  
L3+L4 85 / 273 (31.1%) 86 / 196 (43.9%)  51 / 132 (38.6%)  
L4 6 / 273 (2.2%) 2 / 196 (1.0%)  2 / 132 (1.5%) 
P  0.61  
CD phenotype – behaviour 
B1(±p) 215 / 273 (no p) (78.8%) 
249 / 273 (± p) (91.2%) 
136 / 197 (69.0%) 
163 / 197 (82.7%)  
81 / 132 (61.4%) 
100 / 132 (75.8%) 
B2(±p) 9 / 273 (no p) (3.3%) 
12 / 273 (±p) (4.4%) 
14 / 197 (7.1%)  
19 / 197 (9.6%) 
10 / 132 (7.6%)  
17 / 132 (12.9%) 
B3(±p) 11 / 273 (no p) (4.0%) 
12 / 273 (±p) (4.4%) 
14 / 197 (7.1%)  
15 / 197 (7.6%)  
12 / 132 (9.1%) 
15 / 132 (11.4%) 
P  0.001  
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Table 3-1: Comparison of Montreal disease location and behaviour at diagnosis, 
at follow-up of at least 2 years and follow-up of at least 4 years in paediatric 
Crohn’s disease patients. *At diagnosis 14 children had oral (7)/ oral+perianal 
(4)/ perianal (3) disease only. At ≥2 year follow-up 5 children had oral (1) / 
oral+perianal (4) disease only. At ≥4 year follow-up 4 children had oral (1) / 
oral+perianal (3) disease. 
 
3.1.5 Phenotypic characteristics of childhood onset UC 
UC phenotype was assessed at diagnosis and at last follow-up (Table 4). 
Pancolitis/extensive colitis was present in 74.7% at diagnosis. 73/95 of children with 
childhood onset UC had follow-up data recorded (median duration of follow-up 3.5 
years). At last follow-up, the proportions of disease location had not changed 
significantly.  
 
Of those children with follow-up data available, 49/73 of childhood onset UC already 
had the maximum extent (E3) at diagnosis. Of the 24 who could possibly increase 
extent at follow-up, 46% extended their disease location from less extensive to 
extensive colitis/pancolitis (11/24).  
Table 3-2: The phenotype of childhood onset UC at diagnosis and follow-up 
UC phenotype At diagnosis At last follow-up p 
E3 71/95 (74.7%) 60/73 (82.2%)  
E2 20/95 (21.1%) 12/73 (16.4%) 0.39 
E1 4/95 (4.2%) 1/73 (1.4%)  
Table 3-2: Comparison of Montreal disease location and behaviour at diagnosis 
and at last follow-up in paediatric ulcerative colitis patients.  
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3.1.6 Is there a distinct phenotype of childhood IBD diagnosed before 
8 years of age? 
82/408 (20.1%, 8/416 children had incomplete data) children were diagnosed with 
IBD before their 8
th
 birthday (age cut-off as previously described by Heyman et al. 
541
): 53 CD (64.6%), 19 UC (23.2%) and 10 IBDU (12.2%). In children older than 8 
at the time of diagnosis (n=326, 79.9%), CD was diagnosed in 220/326 (67.5%), UC 
in 78/326 (23.9%) and IBDU in 28/326 (8.6%). At diagnosis in children under 8, 
IBD was more likely to be localised to the colon (L2+UC+IBDU) than in older 
children (47/82 (57.3%) vs 145/326 (44.5%), p=0.03 OR 1.68 (1.03-2.73)). CD 
presenting below the age of 8 was characterised by more isolated colonic disease 
(L2) (34.0% vs 17.7%, p=0.009 OR 2.39 (1.23-4.64)),  less ileal involvement 
(L1±L4 and L3±L4: 21/53 (39.6%) vs 133/220 (60.5%), p=0.006 OR 0.43 (0.23-
0.79)) and less „panenteric‟ CD (L3+L4) (18.9% vs 33.6%, p=0.03 OR 0.46 (0.22-
0.96)).  CD limited to the mouth and/or perianal region occurred more commonly in 
children younger than 8 years at diagnosis (7/53 (13.2%) vs 6/220 (2.7%), p=0.001 
OR 5.43 (1.74-16.90)). 
 
3.1.7 Immunomodulator usage in childhood-onset IBD 
 
The time to use of immunomodulatory drug therapy (first use of any of azathioprine, 
methotrexate or biological therapy) was assessed and presented as Kaplan-Meier 
curves in the childhood-onset group only (Figure 3.2). These data involve 408 cases, 
with missing data for the 8 (1.9 %) remaining cases.  There was a significant 
difference between these curves (logrank test p=0.008), with the median time to any 
immunomodulator usage 17 months for CD, 28 months for UC and 63 months for 
IBDU.  At 120 months of follow-up, the proportion of cases of CD, UC and IBDU 
who had not been exposed to any immunomodulation were 11.5%, 40.5% and 38.4% 
respectively. 
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Figure 3-2: The time to use of immunomodulatory drug therapy in childhood-onset IBD 
 
Figure 3-2: Kaplan-Meier curves showing time from diagnosis to first use of 
immunomodulatory drug therapy (any of azathioprine, 6-mercaptopurine, 
methotrexate or biological therapy) in the cohort of childhood-onset IBD 
patients. 
 
3.1.8 Need for resectional surgery in childhood-onset and adult-onset 
IBD 
Kaplan-Meier curves assessing the time from diagnosis to first resection/colectomy 
are shown for childhood-onset and adult-onset CD (data available for n=585) and UC 
(data available for n=654). (Figures 3.3&3.4)  
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Significant differences were seen in the Kaplan-Meier curves between the childhood-
onset and adult-onset cohorts, in CD and UC (logrank test p<0.001 and p=0.03, 
respectively). 
 
17.1% of childhood-onset CD patients required surgery compared with 52.8% of 
adult-onset CD patients (p<0.0001 OR 0.18 (0.13-0.26)). 5 years after diagnosis 
20.2% of childhood-onset CD patients had undergone surgery versus 42.8% of adult 
onset CD patients. By 10 years follow-up these percentages were 34.5% and 55.5%, 
respectively. The median time to surgery in childhood-onset and adult-onset CD was 
13.7 and 7.8 years respectively.(Figure 3.3)  
 
Figure 3-3: Time from diagnosis to surgery in childhood-onset CD and adult-onset CD. 
 
Figure 3-3: Kaplan-Meier curves showing time from diagnosis to surgery in 
childhood-onset CD and adult-onset CD. 
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20.0% of childhood-onset UC patients underwent colectomy compared with 21.7% 
of adult-onset UC patients (p=0.70, OR 0.90 (0.53–1.54)). 5 years after diagnosis, 
26.1% of childhood-onset UC patients had undergone surgery versus 15.5% of adult-
onset UC patients. By 10 years follow-up, 40.9% of childhood-onset UC patients and 
19.9% of adult-onset UC patients had had a colectomy. Based on the Kaplan-Meier 
analysis, the median time to surgery was 11.1 years in childhood-onset UC compared 
with >50 years in adult-onset UC.(Figure 3.4) 
 
Figure 3-4: Time from diagnosis to surgery in childhood-onset UC and adult-onset UC. 
 
Figure 3-4: Kaplan-Meier curves showing time from diagnosis to surgery in 
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3.1.9 Is the phenotype of childhood onset IBD different to that of adult 
onset IBD? 
Phenotypic data on 416 children and 1297 adults with IBD were compared at the 
time of last follow-up (Table 3-3). In childhood-onset CD, there was a clear male 
predominance compared to adult-onset CD (59.4% vs 36.2%, p<0.0001 OR 2.58 
(1.92-3.45)). UC was equally likely to occur in both sexes in childhood-onset and 
adult-onset disease. A family history of IBD (in any member of the family) was more 
common in childhood-onset than adult-onset disease (33.9% vs 19.6%, p<0.0001 OR 
2.11 (1.65-2.69)).  
 
Location of CD (defined by the Montreal system as maximum extent by the time of 
last follow-up but before the first resection) showed statistically significant 
differences between childhood-onset and adult-onset disease (p<0.001). Childhood-
onset CD was characterised by less isolated ileal involvement (L1) 2.6% versus 
31.5% (p<0.0001 OR 0.06 (0.03-0.12)) and less isolated colonic disease (L2) 15.0% 
versus 36.1% (p <0.0001 OR 0.31 (0.21 -0.46)). Childhood-onset IBD was 
characterised by more „panenteric‟/extensive Crohn‟s disease (L3+L4) 43.2% vs 
3.2% (p<0.0001
 
OR 23.36 (13.45-40.59)).  
 
In order to overcome the confounding factor of different investigation protocols in 
adult-onset and childhood-onset CD with regards to the use of upper GI endoscopy 
and small bowel assessment, we also analysed the location of CD controlling for 
involvement of the GI tract proximal to the terminal ileum (L4) by means of a 
contingency table containing the categories L1+/- L4, L2 +/- L4, L3 +/-L4 and L4.  
 
The extent of involvement of the GI tract in childhood-onset CD remained 
statistically different from adult-onset CD both when assessed at last follow-up and 
when only the patients with a minimum of 5 years follow-up were included (both 
p<0.001, also see Table 3-4).  There is a highly significant association of ileal disease 
location with stricturing/penetrating disease behaviour and of colonic disease 
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location with inflammatory disease behaviour when disease behaviour is stratified 
for disease location in both childhood-onset and adult-onset CD after at least 5 years 
follow up (Table 3-4; p<0.001). 
 
Comparing disease behaviour at 5 year follow-up, the behaviour of CD was similar 
in the two groups (p=0.17). 
 
UC in the childhood-onset cohort was more extensive (p<0.001), with extensive 
colitis (E3) in 82.2% of childhood-onset but only 47.6% of adult-onset UC 
(p<0.0001, OR 5.08 (2.73-9.45)).  
 
Table 3-3: Comparison of location and behaviour between childhood onset and adult onset IBD 
patients using the Montreal classification 
 Scottish childhood onset  Scottish adult onset  
N 416 1297 
CD phenotype – 
location* 
At last follow-up At last follow-up 
L1 7 / 273 (2.6%) 160 / 507 (31.5%) 
L2 41 / 273 (15.0%) 183 / 507 (36.1%) 
L3 52 / 273 (19.0%) 99 / 507 (19.5%) 
L1+L4 5 / 273 (1.8%) 21 / 507 (4.1%) 
L2+L4 43 / 273 (15.8%) 8 / 507 (1.6%) 
L3+L4 118 / 273 (43.2%) 16 / 507 (3.2%) 
L4 2 / 273 (0.7%) 13 / 507 (2.6%) 
p <0.001 
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CD phenotype – 
behaviour 
At 4 years At 5 years 
B1(±p) 99/136 (72.7%) 249/377 (66.0%) 
B2(±p) 20/136 (14.7%) 54/377 (14.3%) 
B3(±p) 17/136 (12.6%) 74/377 (19.7%) 
p 0.17 
UC phenotype At last follow-up At last follow-up 
E3 60/73 (82.2%) 271/569 (47.6%) 
E2 12/73 (16.4%) 201/569 (35.3%) 
E1 1/73 (1.4%) 97/569 (17.0%) 
p <0.001 
Table 3-3: Comparison of location and behaviour between childhood onset and 
adult onset IBD patients using the Montreal classification: * 5 children had oral 
(1)/ oral+perianal disease (4). 7 adults had oral (4)/ oral+perianal (1)/ perianal 
(2) disease. 
Table 3-4: CD phenotype – behaviour stratified for disease location  
                        Childhood-onset CD               Adult-onset CD 
 B1(+/-p) B2(+/-p) B3(+/-p) B1(+/-p) B2(+/-p) B3(+/-p) 
L1 +/- L4 1/95 2/20 4/17 63/246 35/54 40/74 
L2 +/- L4 36/95 7/20 6/17 122/246 4/54 9/74 
L3 +/- L4 57/95 10/20 7/17 58/246 11/54 24/74 
L4 1/95 1/20 0/17 3/246 4/54 1/74 
p ^ <0.001 
CD phenotype – behaviour stratified for disease location 
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(childhood-onset and adult-onset CD) 































Table 3-4: Comparison of childhood-onset CD with adult-onset CD. CD location 
assigned at last follow-up (at least 5 years). Analysis of behaviour after 5 years 
stratified for disease location is presented. ^: excluded L4 category for 3x3 χ2 
analysis due to low numbers: χ2 – statistic 15.65 (due to small numbers, 
calculation of p-value not reliable). In the analysis of behaviour stratified for 
disease location, the sum of childhood-onset and adult-onset CD patients is 
given in bold. The number between brackets in italics is the expected number. 
The highly significant p-value is due to the association of ileal disease location 
with stricturing/penetrating disease behaviour association whereas colonic 
disease location is associated with inflammatory disease behaviour. 
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The present study represents not only a detailed application of the Montreal 
classification of IBD in a large cohort of patients with childhood-onset disease, but 
also provides new robust data on disease evolution, as well as need for 
immunomodulation and surgery in childhood-onset disease. Rigorous follow-up of 
416 children with IBD in the three paediatric gastroenterology centres in Scotland 
has allowed us to document these aspects, notably the progression of disease location 
and behaviour. Data were collected by structured case notes review, and measures 
taken to overcome inter-observer bias.  
 
A number of our findings are likely to be important and pertinent both to basic 
research, as well as to clinical practice, and may be useful in patient counselling. We 
have demonstrated that the presenting phenotype of childhood-onset IBD was 
characterised by extensive anatomical involvement, with strikingly high rates of 
„panenteric‟ CD (small bowel, large bowel and upper GI tract involvement) as well 
as extensive UC. Furthermore, disease extent was remarkably dynamic in childhood-
onset disease: even within 2 years of diagnosis, childhood-onset CD progressed to 
more extensive anatomical involvement in greater than 1 in 3 patients. Disease 
behaviour rapidly progressed to complications of stricture formation or the 
development of fistulae. Disease extent in 46% of the few cases of childhood-onset 
UC also showed extension within the period of follow-up. 
 
We have provided compelling evidence for the high prevalence of an extensive or 
panenteric disease phenotype at presentation in childhood-onset CD. Recent data 
from the North American Pediatric IBD Consortium Registry are consistent with our 
findings, albeit using a distinct disease classification system.
543
 Gupta et al. presented 
their findings in 600 paediatric CD patients at diagnosis: 61.5% of children had small 
bowel and colon involvement (compared with 50.5% in our study). Baldassano et al. 
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recently described a small cohort of 142 children with CD: 86% had involvement of 
the small bowel and colon (± upper GI tract).
547
 Cucchiara et al. showed in an Italian 
cohort of paediatric CD patients with at least 1 year follow-up (n=200), that 58% had 




Our data in UC are also consistent with the hypothesis that childhood-onset disease 
has a very high bias towards extensive disease. This observation is also consistent 
with other datasets. Previously reported rates of pancolitis in patients with UC, from 
prospective childhood studies (80-90%) 
541;549;550
 are far higher than those from 
prospective adult studies (24% pancolitis
551
 or 33% extensive colitis 
552
). Our study 
not only provides further replication of these data but also directly compares a 
childhood-onset and adult-onset cohort within the same population using the 
Montreal classification (82% of childhood-onset UC patients had extensive colitis at 
last follow-up compared with 47% of adult-onset UC).   
 
Moreover, we provide evidence that disease phenotypic characteristics are dynamic, 
and changeable, rather than stable, in childhood-onset disease. Detailed analysis of 
our patients with childhood-onset CD demonstrated that the anatomical extent of 
disease progressed to more extensive involvement soon after diagnosis in 39%. In the 
vast majority, these changes were not due to the inclusion of findings on upper GI 
endoscopy but rather to progression from limited disease (oral/perianal, L1, L2 or 
L4) to involve both small and large bowel (L3). In almost 50% of patients who 
progressed in anatomical involvement, this was due to involvement of the ileum. The 
data contrast with the stability of disease location repeatedly reported in adult 
CD.
553;554
 Louis et al. followed 125 adult patients with CD and found at 10 years 
following diagnosis only 15% had changed disease location (location was defined 
using the Vienna classification).
553
 Henriksen et al. observed a change of (Vienna) 
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In our CD cohort, our data intriguingly suggest heterogeneity even within childhood-
onset phenotype. We have shown that involvement of the ileum is age-dependent: 
children under 8 years at time of diagnosis had significantly less involvement of the 
ileum and more isolated colonic disease than children older than 8 years at diagnosis, 
thus confirming previous studies.
541;542;555
 In a large study of nearly 1400 North 
American early onset patients, Heyman et al demonstrated by multifactorial analysis 
that a colonic predominant phenotype exists in IBD diagnosed under the age of 8 
years.
541
 Paul et al. studied 413 paediatric IBD patients and also demonstrated a 




In addition to the dynamic nature of disease location, we have also demonstrated that 
childhood-onset CD behaviour was not stable over time: inflammatory disease 
behaviour progressed with the development of stricturing/intestinal penetrating 
complications. This progression is also seen in adult-onset disease.(see Table 5) In 
the landmark study of disease behaviour in 2000 CD patients, Cosnes and colleagues 
demonstrated that 40% had penetrating disease as defined by the Vienna criteria at 5 
years and 70% by 20 years.
8
 Similar data from Belgium and Scotland were reported 
subsequently.
556;557
 Detailed analysis of disease behaviour stratified for disease 
location demonstrated a highly significant association of stricturing/penetrating 
disease complications with ileal CD and of inflammatory disease with colonic CD 
(both in childhood-onset and adult-onset CD; Table 3-4). 
 
Direct comparison of the phenotypic characteristics in adult-onset and childhood-
onset disease also emphasised the extensive intestinal involvement in children, 
although these comparisons are limited by the retrospective nature of the present 
study. The increased intensity of investigation in childhood-onset disease compared 
with adult-onset IBD is noteworthy.
526;545;558
 This line of argument has been 
previously suggested to underlie the high prevalence of upper GI disease reported in 
children, when compared with adults – upper GI endoscopy is rarely performed in 
adult IBD assessments and historic (adult) datasets typically have less small bowel 
assessment. In the absence of clear upper GI-related symptoms, 
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oesophagogastroduodenoscopy (OGD) is rarely performed in the investigation of 
adult-onset CD.
558;559
 However, involvement of the upper GI tract has been reported 




Notwithstanding this issue, which is difficult to resolve without a longitudinal 
prospective study both in children and adults, analysis based on the Montreal 
categories which treats upper GI disease as a modifier (ileal, colonic or ileocolonic 
disease each with or without CD proximal to the terminal ileum), confirmed the 
statistically significant differences between CD location in childhood-onset and 
adult-onset onset CD.  
 
In an attempt to further define the “severity” of childhood-onset IBD, we evaluated 
the need for both immunomodulation and surgery (Figures 3.1-3).  By 12 months 
from diagnosis, 45.9 % of childhood-onset CD, 37.9% of IC and 35.1% of UC have 
commenced immunomodulator therapy.  However, interpretation of these data as a 
surrogate for severity is problematic, and confounded by multiple factors, most 
notably the variability amongst individual physicians in thresholds for the use of 
these agents. Physician preferences have undoubtedly altered in the last decade, both 
for adults and in children.  Increasing use of immunomodulatory therapy early in the 
course of disease has become a well-established treatment paradigm in paediatric 
IBD practice, following the  landmark publication by Markowitz et al. 
562
; in adults, 
data from our own centre clearly illustrate similar temporal trends towards early use  
-  significantly higher rates of  6MP/Azathioprine usage of 47.9% at 12 months were 
seen in an inception cohort diagnosed between 2003-7 compared to a rate of 13.3% 
in a cohort diagnosed in 1998-2002.
563
   
 
Many may regard the need for surgery after diagnosis as a potential “gold-standard“ 
marker of disease severity. For this reason, we have analysed need for surgical 
intervention in our cohort. Intriguingly, these data suggest that surgical intervention 
may occur earlier in childhood-onset UC than in adult-onset UC: but that the 
opposite relationship is seen for CD. However, there are multiple possible 
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confounding variables in using these data as a surrogate for severity, especially when 
comparing practice for children and teenagers with CD against practice in adults.  
The more extensive panenteric disease of childhood-onset CD may preclude referral 
for early surgery, as do the frequently strong reservations of children and their 
families concerning early surgical intervention (especially if formation of a stoma is 
required). We suggest that these factors impact significantly on the data in 
childhood-onset CD, and lead to the escalation of medical therapy rather than 
surgery, notwithstanding disease severity. In UC, the higher surgical rates we 
demonstrate in childhood-onset disease are interesting, in the context of the high 
prevalence of extensive colonic involvement in these children, and may well reflect 
“severity” more accurately. Notwithstanding these controversies, the different trends 
in time to first surgery in childhood-onset CD and UC are of interest and require 
further evaluation.     
 
The findings of our study may have clinical implications for management in 
childhood-onset IBD. It might be considered that early use of biological agents and 
immunosuppressants may ideally be targeted preferentially on children with 
aggressive disease. However, it is increasingly apparent that other factors need also 
be considered in highlighting either all or a sub-group of childhood-onset IBD as the 
group for whom “top-down” intervention is appropriate - most notably the recent 
concerns regarding the development of hepatosplenic T cell lymphoma in patients 
treated with combined immunomodulation, together with the lack of any evidence-
based strategies for discontinuation of anti-TNF therapies, or even thiopurines.
564
 
Thus, we propose that the initial application of our data may be in the translational 
research setting. Identifying specific laboratory markers of disease susceptibility or 
phenotype - genetic, serological or proteomic - critically depends on the availability 
of an appropriate classification system. Our study has applied the Montreal 
classification in a large cohort of childhood-onset IBD patients, and demonstrates the 
potential usefulness of this system in studies of pediatric IBD. 
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4 Environmental risk factors for childhood-onset IBD in 
Scotland: a case-control study 
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Introduction 
4.1.1 The incidence of IBD in Scotland 
The increasing incidence of IBD poses a real public health problem.
565
 In Scotland, 
incidence of both CD and UC in patients aged ≤16 rose by 30% between 1981 and 
1995. 
4
 According to a prospective study, Scotland now has the highest incidence of 
IBD in patients <16 in the British Isles, at 6.5/100 000. 
5
 This is roughly twice the 
incidence reported in 1983.
3
 Paediatric CD (4.2/100 000) predominates over UC 
(1.8/100 000) in Scotland as in most parts of the world.
2
 A study of juvenile-onset 
CD in Scotland found increased incidence in northern as compared to southern 
Scotland and an association with increased affluence as determined by the postcode-
linked Carstairs Deprivation Category (DepCat) score (replaced in 2004 with the 




Numerous studies from across Western Europe have published a rapid increase in 
incidence of IBD in children, this trend being strongest for childhood CD. 
567-569
 The 




However, getting a true estimate of changing childhood incidence is problematic 
since definitions of “childhood” vary between studies. The increasing incidence 
reported could reflect increased awareness among health professionals. Nevertheless, 
evidence for increasing incidence among children is compelling. Most of the 
available incidence and prevalence data in childhood IBD is around a decade old, so 
updated figures for adults and children are eagerly awaited. 
571
 
Although recent advances in elucidating the genetic factors predisposing to IBD have 
led to great optimism, the increasing incidence of IBD during the last 4 decades is 
clearly due to environmental factors or their epigenetic effects.
3;4;566;572
 The study of 
environmental factors associated with inflammatory bowel disease has led to a great 
deal of confusion/frustration among researchers and the public alike, as illustrated 
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Figure 4-1: The rising incidence of childhood onset Crohn’s disease in Scotland: association with 
northern latitude and affluence. 
Figure 4-1: The rising incidence of childhood onset Crohn‟s disease in Scotland: 







IBD Genetics in Scottish Children 
91  Ch.4: Environmental risk factors for childhood-onset IBD  
4.1.2 Aetiology of IBD: nature vs nurture 
 
Strong evidence for the genetic contribution to IBD susceptibility came from twin 
studies conducted in the UK, Sweden and Denmark. Combined results give a 
concordance rate for CD of 36% in monozygotic twins
575-577
  compared with 4% in 
dizygotic twins. Equivalent results for UC were 16% and 4%, thus suggesting that 
the genetic contribution is stronger in CD than in UC. 
578
 Were IBD exclusively 
genetic in aetiology, we would expect concordance between monozygotic twins to 
approach 100%. The rise in CD in the past century and the marked geographical 




In utero – and early childhood events influence health and disease in later life. 
Obesity, coronary heart disease, and diabetes are but a few of the conditions for 
which an increasing evidence base exists relating to their programming early in 
development.
579
 As the first exposure to colonising micro-organisms and 
enteropathogenic bacteria occurs post-natally, the development of the intestinal 
immune system is likely to be influenced/(epigenetically) modified during these first 
contacts through e.g. breastfeeding. Additional environmental factors can also be 
crucial during childhood with clear relevance to development of IBD later in life, e.g. 
passive smoking, appendicectomy/appendicitis and the presence of atopic disease.  
 
Oral contraceptive medication (OCP) has clearly been shown recently to influence 
the subsequent development of both CD and UC.
580
 The pooled relative risk (RR) for 
CD for women currently taking the OCP was 1.51 (95% confidence interval [CI] 
1.17–1.96, P = 0.002), and 1.46 (95% CI 1.26–1.70, P <0.001), adjusted for smoking. 
The RR for UC in women currently taking the OCP was 1.53 (95% CI 1.21–1.94, P 
= 0.001), and 1.28 (95% CI 1.06–1.54, P = 0.011), adjusted for smoking. The RR for 
CD increased with the length of exposure to OCP. In our exclusively paediatric 
cohort and control group, we were unable to study these effects adequately and have 
therefore opted to focus on passive smoking, appendicectomy, atopic disease and 
breastfeeding. 
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4.1.2.1 Passive smoking 
In adults, smoking significantly protects against UC and improves its course.
581
  This 
also manifests as a slightly elevated risk in the first year following smoking 
cessation.
581
  The mechanism of action remains unclear. A meta-analysis suggests 
that ex-smokers are 70% more likely than those who never smoked to develop UC.  
In contrast, smoking predisposes to CD being associated with the development and 
increased severity of CD.
581;582
  Bernstein et al suggests that smoking represents an 




Childhood exposure to tobacco smoke may influence the eventual development of 
IBD, especially CD, where a few studies have shown childhood passive smoking to 
increase risk of IBD. 
83;584-586
  
For UC, the relationship is more controversial; some studies show passive smoking 
as a risk factor 
83
, others indicate it has no effect 
81;585;587
 and one other shows passive 
smoking to have a protective influence.
82
 Few studies examine passive smoking as a 
risk factor for paediatric IBD specifically. Those that do, present opposing 
results.
81;83;84
 A recent meta-analysis by Jones et al. showed that there was no clear 
relationship between childhood passive smoke exposure and the later development of 
IBD, either CD or UC, with an important caveat of drawing conclusions from the 
small number of heterogeneous studies performed to date.
588
 
If anything, these studies have illustrated the importance of investigating tobacco 
smoke exposure during different periods, from prenatal to time of IBD diagnosis. 
This could help elucidate which type(s) of exposure are most significant to the 
aetiology of paediatric IBD.   
 
4.1.2.2 Appendicectomy 
Appendicectomy has been identified as reducing risk of UC. Gilat et al first provided 
evidence for this in a 1987 multicentre study
589
. The association has since been 





studies report that the reduction in risk is greatest if appendicectomy is performed 
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before the age of 20 years.
590;591;593
 Additionally, Kurina et al noted the association 
was strongest for those undergoing appendicectomy between 10 and 14 years of 
age.
590
  This group suggested that it is the appendicitis rather than the 
appendicectomy that confers protection.
590
 Frisch and colleagues provided robust 
evidence for the protective effect of appendicectomy associated with appendicitis or 
mesenteric adenitis.
594
 They studied a large cohort of 709 353 Swedish (1964-2004) 
and Danish (1977-2004) patients who had undergone appendicectomy and who were 
followed up for subsequent ulcerative colitis. The impact of appendicectomy on risk 
was also studied in 224 483 people whose parents or siblings had inflammatory 
bowel disease. During 11.1 million years of follow-up in their appendicectomy 
cohort, 1192 patients developed ulcerative colitis (10.8 per 100 000 person years). 
Appendicectomy without underlying inflammation was not associated with reduced 
risk (standardised incidence ratio 1.04, 95% confidence interval 0.95 to 1.15). Before 
the age of 20, however, appendicectomy for appendicitis (0.45, 0.39 to 0.53) or 
mesenteric lymphadenitis (0.65, 0.46 to 0.90) was associated with significant risk 
reduction. A similar pattern was seen in those with affected relatives, whose overall 
risk of ulcerative colitis was clearly higher than the background risk (1404 observed 
v 446 expected; standardised incidence ratio 3.15, 2.99 to 3.32). In this cohort, 
appendicectomy without underlying appendicitis did not modify risk (rate ratio 1.04, 
0.66 to 1.55, v no appendicectomy), while risk after appendicectomy for appendicitis 




In Crohn‟s disease, the evidence for an association with appendicectomy appears less 
straightforward. However, the effect of underlying inflammation as the precipitating 
event to undertake appendicectomy, is also increasingly recognised. Radford-Smith 
et al. found that appendicectomy delays the onset and mitigates the clinical course of 
both UC and CD.
592
 Kaplan and colleagues reported the findings of a large study of 
709 353 appendectomy patients in Sweden and Denmark: they concluded that the 
increased risk of CD after appendicectomy was likely due to diagnostic bias.
595
 No 
effect was observed when appendicectomy occurred before the age of 10. Long-term 
increased CD risk up to 20 years after the appendectomy was seen only in 
appendectomy patients without appendicitis or mesenteric lymphadenitis.
595
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4.1.2.3 Atopic disease 
In adults, IBD has been linked with other immune-mediated conditions such as 
asthma.
596
 Incidence of IBD and other immune-mediated conditions increased 
significantly over the last 50 years while infectious disease like rheumatic fever, 
hepatitis A and tuberculosis decreased.
597
 (Figure 4-2)  
In this context, it is important to consider the “hygiene hypothesis” and the gut-
equivalent of this theory: “the old friends hypothesis”.
574;598
 Children who are less 
exposed to (low grade) infectious organisms (including helminths) may be more 
susceptible to immune-mediated disorders. In the recent KOALA-study, Penders et 
al. showed that differences in gut microbiota (eg E. Coli and C. Difficile) 
composition precede the development of atopy.
78;599
 In this model, it is important to 
note that socioeconomic status, passive smoking and breastfeeding are confounding 
factors. 





vaccination and early gastroenteritis
602




Figure 4-2: The decreasing incidence of infectious diseases over the last 5 decades is 
accompanied by an increase in immune-mediated disorders. 
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Figure 4-2: The decreasing incidence of infectious diseases over the last 5 
decades is accompanied by an increase in immune-mediated disorders. Adapted 
from Bach J-F. N Engl J Med 2002;347(12). 
4.1.2.4 Breastfeeding 
The effect of breastfeeding on the subsequent susceptibility to paediatric IBD is 
controversial. There are few exclusively paediatric studies. Infant feeding practices 
may play a role in the development of IBD by affecting the early exposure to dietary 
antigens, through alteration of the enteric microflora and thus altered development of 
the enteral mucosa-associated lymphoid system, as discussed in Chapter 1.
574
  
 Breastfeeding is shown as a protective factor in most studies, particularly in relation 
to CD 
79;603-605
. The large multicenter study by Gilat et al. found no significant 
difference between IBD patients and control subjects in the frequency of 
breastfeeding.
589
 One study has suggested breastfeeding may be associated with an 





Using data from publicly available databases and our own data obtained via face-to-
face interview of young IBD patients and their families and matched control data 
obtained via postal questionnaire, this study aims to investigate the relationship 
between childhood IBD and atopic disease and to assess the effect of putative 
environmental risk factors (such as breastfeeding, immunisations, active and passing 
smoking exposure), surgical and medical history and family history of bowel cancer 
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The cohort of paediatric IBD patients as described in detail in Chapter 3 was used. 
The following data had been obtained during face-to-face interview: ethnicity, 
postcode, sex, age at symptom onset and disease diagnosis, personal and parental 
smoking, breastfeeding, vaccination history, other medical problems (including 
asthma, eczema, hayfever/allergic rhinitis and food allergy) and family history (IBD, 
bowel cancer, coeliac disease and autism).  
 
4.1.4 Controls 
The initial study design was to obtain controls, defined as a child of the same age (± 
1 year), postcode (as a proxy for affluence as determined by the DepCat score) and 
sex as the matched case who does not have IBD at a defined point in time. GPs of 
cases would be contacted and asked to identify two controls per case (due to 
expected response rate of 50-60%). Data collection would be via a questionnaire 
asking for detailed environmental information, similar to the one used for IBD 
patients (see Appendices).  We devised age-appropriate cover letters and consent 
forms for controls, based on readability indices for children older and younger than 
13 years. To ensure the study complied with the Data Protection Act, we planned to 
ask GPs to forward questionnaires to controls. 
 
Due to a delay in obtaining full ethical approval, we consulted publicly available 
population data. 
 
From the Scottish Health Survey 2003, we gained data for: 
 Doctor-diagnosed asthma prevalence in children aged 2-15 from across the 
whole of Scotland. 
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The Information Services Division (ISD) (NHS Scotland) provided population data 
for: 
 Breastfeeding prevalence for children born in 1996 from Lothian and Greater 
Glasgow 
 Immunisation prevalence at 24 months for children born Jan-Dec 1993 in 
Lothian, Greater Glasgow and Grampian. 
 
 
After obtaining ethical approval via a substantial amendment to our project 
(LREC/2002/6/18), the study as planned originally ran from 3/08 to 7/08. We hoped 
to achieve one population control for each case therefore only the first reply was 
used for matching.  The responses were recorded and stored in a specially designed 
Microsoft Access database (designed by Richard K Russell).  
A previous project conducted by Richard K Russell and Rana Farhadi had recruited 
62 matched controls (55% matching rate), using similar methodology in SE Scotland 
alone in August-October 2004 (Rana Farhadi, SSC4 project).  There were 308 cases 
remaining whose GPs had not been yet been contacted.  Of these 308 cases 
identified, 193 GPs were willing and able to select controls (63% participation rate).  
Therefore 193 controls were identified with 64 unique matches responding in time to 
be included in the analysis (33% response rate). Thus, the second, Scotland-wide, 
phase of this epidemiology project achieved a 21% matching rate (64/308). 
Combined with the data obtained by Farhadi and Russell, this gives an overall 
matching rate of 30% (126/416). 
 
4.1.5 Matched cases and controls – demographics 
 
Of the 126 pairs of matched IBD cases and controls, median age at IBD diagnosis 
was 9.8 years (Q1-Q3: 7.5-11.7), representing an earlier onset sample compared to 
our complete database of childhood onset IBD patients (Table 4-1).  Genders were 
matched between cases and controls.  Except one control of Pakistani ethnicity, all 
were Caucasian.   
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Table 4-1: Median Age at diagnosis and ethnicity of all IBD patients in database 
 CD UC IC 
Median Age at 
diagnosis (years) 
(Q1-Q3) 
11.5 (8.9-13.2) 10.9 (8.8-10.8) 10 (7.6-12.5) 
Caucasian 
97.8 % (270/276)  
 
94.9% (94/99)  
 
97.5% (40/41)  
 
Table 4-2: Gender of matched IBD cases  
 Male Female 
IBD 67 57 
CD 46 35 




Using Pearson‟s chi-squared test, population data were compared with patient data to 
assess the association between IBD and different environmental exposures. 
Uncorrected p-values, odds ratios (OR) and 95% Confidence Intervals (CI) are given.  
Due to interdependence of the assessed variables, a stringent Bonferroni correction 
for multiple testing would be too conservative. For borderline associations, we 
commented on the biological/statistical reliability of the association compared with 
our other findings. We analysed data for IBD and for UC and CD separately. 
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Results 
 
In sections 4.5.1-4.5.3, the results of our population-matched case-control analysis 
will be presented. The data on the subsequent sex, age and postcode-matched case-




4.1.7 Population-matched case-control analysis: Asthma 
 
In the control group (taken from the Scottish Health Survey 2003, in which children 
aged 2-15 throughout Scotland were surveyed), 14% of girls (203/1449) and 21% of 
boys (318/1516) had doctor-diagnosed asthma. The total weighted percentage of 
Scottish children aged 2-15 with doctor-diagnosed asthma is thus 17.6% 
(521/2965).(Table 4-3) 
Asthma is significantly associated with paediatric IBD in the Scottish population 
(p<0.0001 OR 1.67 (1.32-2.10). This association is driven exclusively by the high 
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Table 4-3: Population-matched case-control analysis: asthma prevalence in IBD 





4.1.8 Population-matched case-control analysis: Immunisations 
history  
 
After correction for multiple testing, there were no significant differences between 
cases and controls regarding vaccination against Diptheria, Tetanus, Pertussis, HIb3 




















All IBD patients 115/439 (26.2%) 
CD patients 74/274 (27.0%) 0.0002 1.74 
(1.31-2.30) 
UC patients 22/101 (21.8%) 0.3383 1.31 
(0.81-2.12) 
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Diphtheria 












All IBD patients 403/411 (98.1%) 
CD patients 260/268 (97.0%) 0.6011 0.89 
(0.44 -1.80) 
UC patients 95/95 (100%) 0.1971              
HIb3 






All IBD patients 406/422 (96.2%) 
CD patients 250/264 (94.7%) 0.0166 0.55 
(0.32-0.94) 
UC patients 93/95 (97.9%) 0.8483 1.42 
(0.35-5.78) 
MMR 






All IBD patients 401/423 (94.8%) 
CD patients 249/264 (94.3%) 0.8536 1.09 
(0.64-1.84) 
UC patients 91/97 (93.8%) 0.8202 0.99 
(0.43-2.27) 
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Tetanus 












All IBD patients 403/411 (98.1%) 
CD patients 260/268 (97.0%) 0.5943 0.88 
(0.44-1.79) 
UC patients 95/95 (100%) 0.1982               - 
Table 4-4: Population-matched case-control analysis: Immunisations history 



















All IBD patients 402/411 (97.8%) 
CD patients 260/268 (97.0%) 0.2268 1.62 
(0.80-3.28) 
UC patients 95/95 (100%) 0.0531                 - 
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4.1.9 Population-matched case-control analysis: Breastfeeding 
 
Breastfeeding is defined as exclusive breastfeeding or mixed breast- and bottle-
feeding.  
Breastfeeding data from cases was included only where breastfeeding duration was 
recorded. Breastfeeding was defined as having been breastfed for a) 1 week or more 
and b) 2 weeks or more. This provides the most accurate comparison with controls, 
for which breastfeeding was recorded at the health visitor‟s visit at 10 days. Control 
data were available for children born in 1996. 
 
Results were analysed for all IBD and stratified for CD and UC. Results were 
stratified by deprivation using the Carstairs Deprivation Score. This score uses the 
following variables to calculate deprivation category by postcode: overcrowding in 
the home, male unemployment, low social class (by type of occupation) and „no car‟. 
 
For IBD, CD and UC, there were no significant differences between cases and 
controls regarding breastfeeding (Tables 4-5 and 4-6). This was true for 
breastfeeding lasting 1 week or more and for breastfeeding lasting 2 weeks or more. 
No significant differences were found when results were stratified by deprivation or 
geographical region. 
Analysis of controls showed marked differences in breastfeeding rates (for more than 
1 week) between Lothian and Greater Glasgow (4368/8196 (53.3%) vs. 2270/6775 
(33.5%) p<10
-4
 OR 2.26, 95%CI 2.12-2.42)  
Breastfeeding rates in IBD cases were significantly different between DepCat 1-2 
and DepCat 6-7 (53/79 (67.1%) vs. 17/67 (25.4%), p<10-4 OR 6.00 CI (2.91-12.36)). 
This difference was also present in controls (4226/6648 (63.6%) vs. 1768/7750 
(22.8%) p<10
-4
 OR 5.90 CI 5.49-6.35). 
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Table 4-5: Breastfeeding for 1 week or more: IBD cases compared with controls 
Table 4-5: Breastfeeding for 1 week or more: IBD cases compared with 
population-matched controls 
 
Table 4-6: Breastfeeding at 2 weeks: IBD cases compared with controls. 





 Cases Controls  














 Cases Controls  
Number 
breastfed 
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 Cases Controls  














Table 4-7: Breastfeeding for one week or more by diagnosis: cases compared 
with population-matched controls. 
 
Greater Glasgow 
 Cases Controls  
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Table 4-8: Breastfeeding for 2 weeks or more by diagnosis: cases compared with population-
matched controls. 
 




 Cases Controls  
Number breastfed Number breastfed p OR  
95% CI 








 Cases Controls  
Number breastfed Number breastfed p OR 
95% CI 
Crohn’s Disease 39/93 (41.9%) 2270/6775 (33.5%) 0.10 1.43  
(0.95-2.17) 
Ulcerative colitis 16/41 (39.0%) 2270/6775 (33.5%) 0.56 1.27 
(0.68-2.38) 
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Table 4-9: Breastfeeding for 1 week or more by deprivation category: cases compared with 
population-matched controls 
Table 4-9: Breastfeeding for 1 week or more by deprivation category: cases 
compared with population-matched controls. * 1= least deprived, 7= most 
deprived 
 Cases Controls   
Depcat 
score* 
Number breastfed Number breastfed p OR 
95% CI 
1-2 53/79 (67.1%) 4226/6648 (63.6%) 0.59 1.17 
(0.73-1.87) 
3-5 119/254 (46.9%) 9046/22475 (40.2%) 0.03 1.31 
(1.02- 1.68) 
6-7 17/67 (25.4%) 1768/7750 (22.8%) 0.72 1.15 
(0.66-2.00) 
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Table 4-10: Breastfeeding for 2 weeks or more by deprivation category: cases compared with 
population-matched controls 





Number breastfed p OR 
95% CI 
1-2 52/79 (65.8%) 4226/6648 (63.6%) 0.76 1.10 
(0.69-1.76) 
3-5 111/254 (43.7%) 9046/22475 (40.2%) 0.29 1.15 
(0.90- 1.48) 
6-7 17/67 (25.4%) 1768/7750 (22.8%) 0.61 1.15 
(0.66-2.00) 
Table 4-10: Breastfeeding for 2 weeks or more by deprivation category: cases 
compared with population-matched controls. * 1= least deprived, 7= most 
deprived 
 
4.1.10 Matched case-control analysis: past medical history 
 
Invididual past medical histories did not differ significantly between IBD cases and 
age, sex and postcode-matched controls, except for atopic disease which will be 
discussed in detail below.  1 control suffered from coeliac disease.  1 from each 
group suffered from autism.  Minor surgical procedures were occurred in both 
groups: 6 cases (4.8%) versus 12 controls (9.7%) have undergone tonsillectomy 
(p=0.14).  5 cases (4.1%) compared to 1 control (0.8%) have undergone 
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4.1.11 Matched case-control analysis: Family History (FH) 
 
Of the IBD patients, 40 (32.5%) compared to 14 (12.6%) controls had a positive FH 
(OR3.34; 95% CI (1.70-6.56), p=0.0003).  In CD 28 (35.0%) patients had a positive 
FH (OR 3.34 (1.48-7.51) P=0.002). 
Coeliac disease (n cases=5; n control=2), and autism (n cases=4; n control=3) did not 
differ significantly between families of IBD sufferers and matched control families 
(p=0.31 and 0.80, respectively). 
Family History of Bowel cancer (n cases=21; n control=11) was more common in 
the families affected by a child with IBD compared with matched control families 
but this did not reach statistical significance on univariate analysis.(p=0.06).   
 
4.1.12 Matched case-control analysis: Atopic Disease 
 
Overall, children with IBD were significantly more affected by self-reported atopic 
disease than matched controls (p=0.01, OR 1.88 (1.13-3.13)). It should be noted that, 
in order to facilitate data recording using the questionnaires in both cases and 
matched controls, no distinction was made between allergic asthma, exercise-induced 
asthma, cough-variant asthma etc.(see Appendices) Asthma (p=0.005 OR 2.48 (1.28-
4.78)), eczema (p=0.001 OR 2.83 (1.50-5.36)) and food allergy (p=0.03 OR 2.98 
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Table 4-11: Self-reported atopic diseases: cases compared with matched controls 
 IBD Cases Matched controls p value  OR 
Any atopy 66/124 (53.2%) 46/122 (37.7%) 0.01  1.88 (1.13-3.13) 
Asthma  34/124 (27.4%) 16/121 (13.2%) 0.005  2.48 (1.28-4.78) 
Eczema  39/124 (31.5%) 17/122 (13.9%) 0.001  2.83 (1.50-5.36) 
Hayfever  23/124 (18.5%) 29/122 (23.8%) 0.31 
Food allergy  14/124 (11.3%) 5/122 (4.1%) 0.03  2.98 (1.04-8.54) 
Table 4-11: Self-reported atopic diseases: cases compared with matched 
controls 
 
When results were stratified for CD as in Table 4-12, the association was as strong as 
for IBD.  Atopy, asthma, eczema and food allergy all showed significant associations 
with CD.  Atopy was 2.28 times more likely in those with CD, a higher number than 
found with combined IBD data. 
 
 
Table 4-12: Self-reported atopic Disease: CD cases versus matched controls 
 CD Cases Matched Controls p value OR (95% CI) 
Any atopy  45/81 (55.6%) 28/79 (35.4%) 0.01  2.28 (1.21-4.30) 
Asthma  25/81 (30.9%) 11/78 (14.1%) 0.01  2.72 (1.23-6.01) 
Eczema  27/81 (33.3%) 10/79 (12.7%) 0.001  3.45 (1.54-7.74) 
Hayfever  14/81 (17.3%) 16/79 (20.3%) 0.63 
Food allergy  8/81 (9.9%) 1/79 (1.3%) 0.03  8.54 (1.04-70.06) 
Table 4-13: Self-reported atopic Disease: CD cases versus matched controls 
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4.1.13 Matched case-control analysis: Immunisations History 
Table 4-13: Self-reported immunisations history: IBD and CD cases compared with matched 
controls 
Immunisation Matched Controls p value OR  
(95% CI) 




0.0007  8.81 
(1.98-39.23) 




0.001  14.72 
(1.88-#) 




<0.0001  47.76 
(11.30 – #) 




<0.0001  84.87  
(11.25-#) 




<0.0001   23.52 
(5.51-#) 




<0.0001   15.16  
(3.44-66.84) 




0.05   4.10 
(0.85-19.73) 






Table 4-13: Immunisations history: IBD and CD cases compared with matched 
controls 
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We compared the rate of self-reported immunisation history for all common 
childhood immunisations between IBD cases and matched controls. For IBD cases, 
these data were obtained during an interview with one of the researchers. When the 
parents were unable to recall precisely which immunisations had been given, one of 
the researchers would then ask whether any immunisations such as MMR were ever 
refused. For matched controls, as no such interview was possible logistically and in 
view of Data Protection Regulations, these data were gathered from a list of 
immunisations which the control parents/control subjects had to tick to confirm that 
the respective immunisations had been administered. Significant differences between 
IBD/CD cases and matched controls were found regarding self-reported 
immunisation history against DPT, HIB and Men C.  Self-reported MMR showed a 
borderline association with IBD but a significant difference in immunisation rate 
between CD cases and matched controls.  
 
 
4.1.14 Matched case-control analysis: Breastfeeding 
 
Results were analysed for all IBD and stratified for CD.  For IBD and CD,  there 
were no significant differences between cases and controls regarding breastfeeding 
(IBD: 52.5% vs. 54.9% in controls, p=0.71, CD: 57.3% vs. 60.0% in controls, 
p=0.73).  Duration of breastfeeding was not different between IBD cases and 
matched controls: in the IBD cases the median duration was 20 weeks (Q1-Q3: 12-
36) and for matched controls the median was 17 weeks (Q1-Q3: 7.75-40), p=0.52, 
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4.1.15 Matched case-control analysis: Passive smoking 
 
None of the matched IBD cases and only 3/123 controls were current smokers.  1 
control was an ex-smoker. 
Parental smoking was assessed as smoking around the time of pregnancy, birth, 
currently smoking or ex-smoker.  Analysis was performed on the basis of whether 
the mother and/or the father smoked (from now on referred to as „parental smoking‟) 
as this represents passive smoking exposure in the household.   
 
Table 4-14: Parental smoking during pregnancy, at birth and current status: IBD cases 
compared with matched controls  








0.02 OR 1.85 
(1.09-3.15) 




0.01 OR 1.96 
(1.15-3.35) 




0.007 OR 2.13 
(1.22-3.71) 
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0.03 OR 1.90 
(1.04-3.44) 

























Table 4-14: Parental smoking during pregnancy, at birth and current status: 
IBD cases compared with matched controls  
 
On univariate analysis parental smoking at pregnancy, birth or currently significantly 
correlates with the later development of IBD in the child.  When maternal and 
paternal smoking were examined separately, only maternal current smoking retained 
significance (p=0.03). In this context, it is noteworthy that the overall IBD cohort (ie 
not just the IBD cases for whom a matched control was available), the maternal 
smoking rate during pregnancy and after birth was higher at 123/440 (28.0%) and 
138/439 (31.4%), respectively. On analysis of the matched CD case-control cohort, 
no significant differences were noted with regards to parental or maternal smoking 
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Table 4-15: Parental smoking during pregnancy, at birth and current status: CD cases 
compared with matched controls  
 CD cases Matched controls P value  
Parental 
smoking  
Pregnancy  32/73 (43.8%) 27/80 (33.8%) 0.20 
Birth  31/72 (43.1%) 25/80 (31.3%) 0.13 
Current  29/74 (39.2%) 21/79 (26.6%) 0.09 
Mother Pregnancy  18/78 (23.1%) 15/80 (18.8%) 0.50 
Birth  20/78 (25.6%) 14/80 (17.5%) 0.21 
Current  24/78 (30.8%) 14/79 (17.7%) 0.05 
Table 4-15: Parental smoking during pregnancy, at birth and currently: CD 
cases compared with matched controls 
 
4.1.16 Matched case-control analysis: Multifactorial Analysis 
 
Multifactorial analysis was performed using binary logistic regression. Significant 
findings from unifactorial analysis were entered in the model.(Table 4-16) The 
factors contributing significantly to IBD were FH of IBD, FH of bowel cancer and an 
individual‟s history of asthma and eczema.   
The significant findings on unifactorial analysis of association with parental smoking 
during pregnancy, at birth and currently were not replicated.  Entering the FH of IBD 
as an interacting variable with the smoking history did not alter this. For CD, the 
same conclusions were drawn.(Table 4-17) 
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Table 4-16: Matched IBD case-control analysis: Multifactorial analysis 
 p OR  95% CI 
Parental Smoking  
 During pregnancy 
0.353      0.41 0.06-2.68 
Parental Smoking  
 At birth 
0.148      4.45      0.59-33.65 
Parental Smoking  
 At time of diagnosis 
0.335      1.57      0.63-3.89 
Atopy 0.237      0.59      0.24-1.42 
Asthma 0.045      2.59      1.02-6.58 
Eczema 0.015      3.09      1.25-7.64 
Food Allergy 0.105      2.86      0.80-10.20 
FH of IBD <0.001 4.07 1.89-8.75 
FH of bowel cancer 0.033      2.72  1.09-6.81 
Table 4-16: Matched IBD case-control analysis: Multifactorial analysis 
 
Table 4-17 Matched CD case-control analysis: Multifactorial analysis 
 p OR  95% CI 
Asthma 0.045 3.52 1.03-12.06 
Eczema 0.029      3.89      1.15-13.13 
FH of IBD 0.003      4.41      1.68-11.52 
FH of bowel cancer 0.025      4.14      1.20-14.32 
Table 4-17: Matched CD case-control analysis: Multifactorial analysis 
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Using both population-matched and sex,age and postcode-matched control data, we 
have shown the novel association of childhood onset IBD and CD with asthma in the 
high incidence Scottish population. We did not observe any association between 
paediatric IBD/CD/UC and either immunisation history or breastfeeding after 
stratification for geographical region and affluence using population-matched data.  
 
Before considering our findings in view of the relevant literature for each of our 
main findings, it is pertinent to address some of the methodological issues studies 
like this are faced with. 
 
In the first phase of this study, we used population-matched data as control data. For 
immunisation history and breastfeeding, we matched the area of residence of the 
cases and controls. We selected control data from Lothian, Grampian and Greater 
Glasgow (to match the place of residence of our cases). We also endeavoured to 
match cases and controls by age. 92% of our cases were born between 1985 and 
2000: 40% between 1985 and 1990; 39% between 1991 and 1995 and 13% between 
1996 and 2000. Control immunization data came from children born in 1993.  
 
For the asthma data, controls are from the whole of Scotland as breakdown by 
health-board was unavailable. Our asthma controls were children aged 2-15 in 2003, 
i.e. children born between and 1988 and 2001. However, given that asthma 
prevalence is increasing, matching children individually for date of birth is preferable 
and was be performed in the second phase of this study which ran from March till 
July 2008. The definition of asthma merits further discussion: in cases, results relied 
on parental reporting of the child‟s “asthma” whereas for controls, population-data 
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(from the surveyed GP surgeries) on “doctor-diagnosed asthma” was used. 
Furthermore, no distinction was made between true atopic/allergic asthma, exercise-
induced asthma, cough-variant asthma and nocturnal asthma.  
Although the issue of self-reporting compared with doctor-diagnosed asthma could 
have influenced our finding of increased asthma prevalence among cases, our 
subsequent matched case-control analysis confirmed this association was a true 
finding. 
 
Breastfeeding population control data came from children born in 1996 (this was the 
only complete set of population-data available) and were stratified according to 
geographical location (Glasgow vs Lothian) and according to Deprivation Category. 
In the cohort of IBD cases, recall bias may influence our breastfeeding data. Parents 
were asked during face-to-face interview about the duration of breastfeeding (in 
weeks). For population-matched controls, breastfeeding in the different health boards 
was recorded by a health visitor (at 10 days). These considerations should be viewed 
in the light of the increased power of our study due to the use of large population-
based datasets. As breastfeeding rates also tend to change over time, the matched 
case-control analysis in a subset of IBD patients was conducted to address this. 
 
This type of study is subject to recall bias. Parents of IBD cases were asked about 
their child‟s exposure to environmental risk factors. Our population-matched control 
group for immunisations used GP records to establish immunisation status, thus 
limiting recall bias. However, recall bias may exist in the case group and hence affect 
comparisons. Although it would be methodologically preferable to use GP 
immunisation records for both cases and controls, we opted, for logistical and Data 
Protection reasons, to use the same questionnaire for cases and controls in the second 
phase of this study.  
We then encountered additional methodological difficulties due to the use of a postal 
questionnaire to ascertain immunisations history in our sex, age and postcode-
matched controls. This led to the marked underreporting of administered 
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immunisations as control subjects/control parents had to tick a list of immunisations 
to confirm they had been administered, which was crucially different to the way the 
questionnaire was filled out during the recruitment of IBD cases (when a member of 
the research team would ask if the parents had ever refused for their children to have 
an immunisation). We therefore feel that these data should be interpreted with great 
caution, especially when compared with the better-powered case-control analysis 






The current study found asthma to be more prevalent in paediatric IBD patients than 
in the Scottish paediatric population as a whole (p < 0.0001 OR 1.67 (1.32-2.10) and 
in age, sex and postcode matched controls (p=0.005 OR 2.48 (1.28-4.78)). 
This is consistent with findings of two recent case-control studies. Smaller studies 
find respiratory symptoms to be more common in IBD patients than in the general 
population.
606-608
 In the paediatric IBD population, the finding of an association 
between asthma and IBD is novel. 
Table 4-14: Prevalence of asthma in IBD patients: overview of available literature  



















12,601 cases  1.5 
(1.5-2.3) 
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Becker et al. have shown immune-mediated disease susceptibility loci exhibit non-
random clustering, so there may be a common genetic basis for these disorders.
610
 A 
number of studies note the clustering of immune-mediated diseases other than 











 all appear to be more prevalent among 
IBD patients.  
 
The association of IBD with asthma should be viewed in light of the recent paradigm 
shift in the regulation of the T-helper lymphocytic response. Recent advances in the 
biology of the T-helper cell regulation, have demonstrated that categorising immune-
mediated diseases into those driven by Th1 cells (CD, type 1 diabetes and multiple 
sclerosis) and those driven by Th2 cells (asthma, allergic rhinitis and atopic 
dermatitis), is not doing the complex regulation of these responses justice. Indeed, 
recent data in suggest that even within Crohn‟s disease (both in human tissue and in 
the mouse model SAMP/Yit), which was long thought to be a Th1-driven disease 
process, time of assessment relative to the onset of the disease process is crucial in 





Epidemiological evidence showing the coincidence of diseases driven by TH 1 and by 
TH 2 suggests there may be a common pathway for both types of immune-mediated 
disease, perhaps even with sex-specific effects. 
616;617
 The association between CD 
(Th1) and asthma (Th2) in our exclusively paediatric study as well as in recent 
reports by Weng et al. and Bernstein et al. provide further epidemiological evidence 
for common regulatory pathways of the inflammatory response.
596;609
 In addition to 
advances in our knowledge of the T-regulatory cell, it has been the characterisation 
of Th17 cells, the elucidation of the role which IL23 plays in the differentiation of 
these cells, together with functional data on interleukin 17 (IL-17) in immune-
mediated tissue injury that has produced a true schism with the old school doctrine of 
a Th1/Th2 dichotomy.
618
 IL17 is involved in organ-specific immunity in the 
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intestine, allergic disorders of lungs and skin, and microbial infections of the 
intestines and nervous system.
618
 The advances in our understanding of Th17 biology 
only preceded the new genetic susceptibility data implicating the IL23 receptor by a 
few years. 
470
   
 
In addition to the influence of germline variation on immune sytem regulation, the 
association of IBD with immune-mediated diseases such as asthma, also necessitates 
the investigation of environmental triggers (with putative epigenetic effects) in view 
of the “hygiene/old friends hypothesis”. The “hygiene hypothesis” is based on 
observations that exposure to infections in early life reduces the incidence of 
bronchial asthma. 
619
 Recent data by Green and colleagues have suggested that 





In many epidemiological studies surrogate markers for childhood hygiene are 
assessed: number of siblings and birth order, crowding in the home, urban versus 




, drinking of unpasteurised 
milk
584
 and availability of a hot water tap 
591;622
. Socioeconomic status is often used 
as an indicator of less crowded living space and better hygiene.
566
 Many of these 
studies show positive associations between increased childhood hygiene and risk of 
IBD. It is postulated that people protected from infections in childhood are ultimately 
more susceptible to chronic intestinal inflammation due to altered regulation of the 




It is prudent to point out that no study has found all markers of childhood hygiene to 
be associated with disease and some studies have contradicted the theory. 
591;623
 One 
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The current study finds breastfeeding is not associated with paediatric IBD. It also 
shows that breastfeeding prevalence decreases with increasing deprivation, both for 
cases and controls. We were careful to stratify our data also for this confounding 
factor but found no difference between breastfeeding rates in cases and controls.  
Our results present important negative findings in the current climate of confusion 
regarding this issue. Studies examining association between breastfeeding and IBD 





Breast milk provides the neonate with direct immunological protection and contains 
components that enhance the development of the immune system. It also affects the 
pattern of exposure to micro-organisms in the neonatal period. A protective effect of 
breastfeeding may be the result of the development of oral tolerance to specific 
microflora and food antigens. Additionally, oligosaccharides present in human milk 
have been to shown to have an anti-inflammatory effect, inhibiting leucocyte rolling 
and adhesion. This could help to explain the lower incidence of inflammatory 
conditions in breastfed infants, although a recent systematic review suggests the 
protective effect of breastfeeding is mainly due to its protective effect against 
infections early in life, rather than against the development of allergic conditions 
later.
626-628
 The role of breastfeeding in the establishment of the intestinal microflora 
should also be considered with regards to its potential of influencing subsequent 
development of allergic diseases and IBD (also see Chapter 1). As yet unknown 
environmental factors influence the establishment of this gut flora very early in life 
(as illustrated by the diversity of flora between Estonian and Swedish children at one 
week of age, in the study by Bjorksten et al.) and less microbial diversity has been 
demonstrated in atopic infants, with increased levels of Clostridium.
627;629-631
 Penders 
et al reported the association of C.difficile in the stool of infants at 1 month of age 
with the later development of atopy in the KOALA-birth cohort study.
78;599
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 It is noteworthy that supplementation with probiotics (from before birth to 12 
months of age) is able to influence the development the allergic (IgE associated) 
eczema, with the only negative study commencing probiotic treatment 
postnatally.
627;632;633
 Even more striking is the observation that the specific 
constituents of the maternal vaginal flora at 22-24 weeks gestation (e.g. Ureaplasma 
and Staphylococci) are associated with subsequent asthma in the children.
634
 This 
effect of maternal flora is further illustrated by the association of subsequent 
development of asthma with caesarean section.
78;635-637
 The risk of developing 
childhood diabetes is possibly also associated with alterations of the maternal flora, 
as suggested by the increased risk of childhood diabetes associated with the use of 
certain antimicrobials (e.g. macrolides and quinolones).
638
 A previous study from our 
group by Russell et al. associating perinatal exposure to smoking with the later 
development of IBD, could therefore also be viewed from the perspective maternal 
smoking has on the composition of the vaginal microflora.
84;639
 In contrast, maternal 
smoking early in pregnancy has been associated with a protective effect on later 




Conversely, breastfeeding may predispose to IBD. Delayed infection occurring at 
weaning, leading to inappropriate immune response and persistence of intestinal 
inflammation could explain this.
81
 Breast milk pollution in industrialised areas may 
predispose to IBD. Industrial chemicals and environmental contaminants have indeed 
been found in breast milk. 
640
 Fine and ultrafine particles may be present in 
breastmilk and are known to be potent adjuvants in the antigen-mediated immune 
response but their role in IBD remains unclear.  
Few studies have investigated breastfeeding as a risk factor for juvenile-onset IBD 
specifically. Table 4-10 summarises paediatric case-control studies to date.  
 
Our study shows a lack of association between breastfeeding and both CD and UC. 
Two studies support our findings; Koletzko et al
641
 and Baron et al
81
 showed no 
association between breastfeeding and UC. However, our finding of a lack of 
association between breastfeeding and paediatric CD is novel. Other studies show 
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breastfeeding to have a protective effect (stronger in CD than UC).
603;605
 In contrast, 
Baron et al showed breastfeeding as a risk factor for paediatric CD.
81
  
One study found the relative risk of IBD to decrease as duration of breastfeeding 
increased.
605
 The current study was unable to address this question. 
 
Table 4-19:  Paediatric case-control studies testing association of breastfeeding with CD and UC 
Table 4-19: Paediatric case-control studies testing association of breastfeeding 
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Ulcerative Colitis 




























Other studies examining association between breastfeeding and IBD use patients 
with disease-onset at any age as their study population. Like the paediatric studies, 
the results of these investigations are heterogeneous. Several studies suggest an 
inverse association between breastfeeding and IBD. For example, Acheson and 
Truelove
642
 and Whorwell et al
602
 found breastfeeding to decrease the risk of UC but 
not CD. Bergstrand and Hellers found breastfeeding to decrease the risk of CD
643
. 




A meta-analysis of 17 studies, including data from both children and adults, showed 
breastfeeding to reduce the risk of CD and UC. When the 8 highest quality studies 
were statistically analysed, the pooled odds ratio was 0.45 (95% CI: 0.26, 0.79) for 
CD and 0.56 (95% CI ; 0.38,0.81) for UC.
79
 However, Klement et al. acknowledge 
that reviewing studies on this subject is problematic. Exclusivity and duration of 
breastfeeding are often ill-defined. Additionally, recall bias affects all the studies, 
thus ORs quoted in this meta-analysis should not be considered definitive.  













is a risk factor 
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4.1.19 Immunisations 
 
The current study presents important negative findings regarding the association of 
vaccinations with paediatric IBD, CD or UC. We found no significant differences 
between cases and controls for vaccination against diphtheria, tetanus, pertussis, 
MMR or HIb3 after correction for multiple testing in our large sample size study. We 
have identified clear methodological issues precluding the interpretation of 
immunisation history data from our age, sex and postcode-matched cohort. 
 
Of all vaccinations, MMR has caused most controversy in relationship to IBD; 
specifically the live attenuated measles element of this vaccination. In 1995, 
Thompson et al presented evidence that measles vaccination was linked to increased 
odds of developing UC and CD, giving ORs of 2.53 and 3.01 respectively. 
645
 
Interest in the subject increased and new studies emerged. It was proposed that 
measles virus can persist in intestinal tissue and that IBD could in fact result from 
granulomatous vasculitis in response to chronic infection.
601;646;647
 Additionally, 
evidence suggested that measles virus can cause prolonged disruption of immune 
function, particularly in the helper T cell response. 
648
 It was therefore suggested that 




However, methodological concerns were raised about the Thompson study and, since 
1995, studies have contradicted this evidence. A UK case-control study (1997)  
found no correlation between measles vaccination and either CD, UC or all IBD 
combined.
649
 Indeed, no convincing link between either wild-type or attenuated 
measles virus and IBD has been established.
650
 Our more reliable, population-
matched results are in agreement with this.  
 
Ecological studies also support our findings. For example, Hermon-Taylor et al 
showed that the increase in CD in the UK started some 20 years prior to the 
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In 1998, a report reignited public concern because it detailed 12 children with non-
specific colitis, ileal-lymphoid-nodular hyperplasia and developmental disorders 
attributed to MMR vaccination.
652
 However, concerns about this report include 





Our population-matched results supplement the strong evidence base for lack of 
association between MMR and IBD. For health professionals and the general public 
alike, the safety-affirmation of childhood immunisations with regards to IBD, 
particularly MMR, could contribute to the prevention of a further decline in 
vaccination uptake and subsequent rise in vaccine-preventable diseases.
655;656
 
Whether specific sub-groups of children (e.g. with metabolic disorders) are more at 
risk than others of immunisation-related adverse events, remains the topic of intense 
debate in high impact journals, as illustrated recently in Pediatrics and the New 
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5 Germline variation of NOD1/CARD4 in IBD in Northern 
Europe 
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Introduction 
The breakthrough in IBD genetics when NOD2/CARD15 was discovered as the first 
susceptibility gene in CD heralded extensive analyses of signalling pathways of the 
innate immune system implicated in the pathogenesis of CD.
406;407
 NOD2/CARD15 
is an intracellular pathogen-associated molecular pattern receptor for muramyl 
dipeptide (MDP), a breakdown product of bacterial peptidoglycan of both Gram-
negative and Gram-positive bacteria.
418;421;422
 The contribution of NOD2/CARD15 
variants to CD susceptibility in the Scottish population is markedly smaller than in 
other populations studied (Central and Southern Europe, North America and 
Canada), but comparable to the Scandinavian population.
337;473;660-664
 
Like NOD2/CARD15, NOD1/CARD4 is a member of the phylogenetically 
conserved Nod-like receptor family.
665;666
 The NOD1/CARD4 gene contains 14 
exons (54 kb) and is located within the putative IBD susceptibility locus on 




Structurally the NOD1/CARD4 protein is similar to NOD2/CARD15, but only has 
one CARD domain.
311
 At its Leucine Rich Repeat (LRR)-domain NOD1/CARD4 
binds intracellular γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP), a breakdown 
product of peptidoglycan from Gram-negative bacteria and a limited number of 
Gram-positive bacteria (e.g. Listeria monocytogenes).
417-420;667
 In contrast to 
NOD2/CARD15, NOD1/CARD4 is constitutively expressed in epithelial cells 
throughout the gastrointestinal tract.
194;434;668
. Recent work has implicated 
NOD1/CARD4 in the response against Helicobacter pylori and Gram- negative 
enteric pathogens like Escherichia coli  which avoid recognition by Toll-like 
Receptors (TLRs).
431;668;669
 Like NOD2/CARD15, NOD1/CARD4 initiates a pro-
inflammatory response largely dependent on NF-κB activation.
418;424;446
 Investigators 
from the Philpott lab have shown that stimulation alone was sufficient to drive 
antigen-specific immunity with a predominant Th2 polarization profile.
670
 In 
conjunction with TLR stimulation, however, NOD1/CARD4 triggering was required 
to instruct the onset of Th1 and Th2 as well as Th17 immune pathways. Pretreatment 
of macrophages with TLR ligands revealed that innate immune responses induced by 
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bacterial infection relied on NOD1/CARD4 and NOD2/CARD15 and their adaptor 
RICK/RIPK2.
671
  Cells outside of the hematopoietic lineage provided the early 
signals necessary to orchestrate the development of Nod1-dependent immune 
responses.
446;672
 These findings highlight NOD1/CARD4 as a key innate immune 
trigger in the local tissue microenvironment that drives the development of adaptive 
immunity.   
Taken together, these observations make NOD1/CARD4 a strong functional and 
positional IBD candidate gene. 
A number of groups have investigated whether germline variation of NOD1/CARD4 
is associated with increased susceptibility to IBD.
459-461;463;464;673
 Of these, the 
positive study by McGovern et al has received the greatest attention. These 
investigators from Oxford suggested the association of the deletion variant of a 
complex intronic insertion*2/deletion*1 polymorphism (32656) of NOD1/CARD4 
with susceptibility to IBD using a combination of TDT and case-control analysis.
459
 
In a cohort of 556 trios, these investigators observed distortion of transmission of this 
NOD1/CARD4 variant in IBD and UC, but not CD. Single SNP case-control 
analysis (664 IBD patients and 335 controls) showed significant associations with 
IBD and CD (especially onset <25 years), but not UC. They went on to perform a 
sliding haplotype TDT analysis, a new approach in IBD genetics, obtaining 
significance for a two-marker haplotype spanning a large section of the LRR domain. 
In addition, a gene-dosage effect of the deletion variant on age of onset in CD and 
IBD was demonstrated.
459
 The same group also described an association of the 
insertion allele of this complex insertion/deletion with high IgE levels and asthma.
434
  
However, well-designed replication studies (including the data presented later in this 
chapter) involving a combined total of over 10,000 subjects have been negative, 
thereby shedding doubt on the contribution of this single NOD1/CARD4 
SNP.
463;464;674
 Tremelling et al. assessed 1370 IBD patients and 760 controls from the 
Cambridge area and did not find evidence for association of this NOD1/CARD4 
variant with IBD (p=0.74).
463
 Franke and colleagues were also unable to replicate the 
suggested association in a German case-control analysis of 1015 IBD patients and 
886 controls (p=0.51) and a TDT of 775 IBD trios (p=0.24).
464
 These replication 
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studies had >95% power to replicate the effect size (odds ratio 2.0 for CD), as 
calculated in the initial study by the Oxford group. 
In this study, our aims were twofold. First, we set out to assess the contribution of the 
NOD1/CARD4 insertion/deletion polymorphism to susceptibility to adult- and 
childhood-onset IBD in Northern Europe and to examine genotype-phenotype 
associations. We also sought to investigate the interaction between this 
NOD1/CARD4 polymorphism and NOD2/CARD15 variant alleles in determining 
IBD susceptibility and phenotype.  
Our second aim was to assess the overall contribution of NOD1/CARD4 to IBD 
susceptibility, using a robust gene-wide haplotype tagging approach. We examined 
the influence of NOD1/CARD4 haplotypic variation on IBD phenotype and 
investigated the interaction between germline variants of NOD1/CARD4 and 
NOD2/CARD15 in determining IBD susceptibility and phenotype. Together, these 
two lines of investigation provide strong evidence that inherited variation of 
NOD1/CARD4 is not a strong determinant of disease susceptibility in the Scottish 





5.1.1.1 NOD1/CARD4+32656 ins/del polymorphism 
3962 Northern European individuals were studied in total, comprising of 1791 IBD 
patients, 522 parents (293 mothers and 229 fathers) of IBD patients under the age of 
16 at diagnosis and 1649 healthy controls (HCs). 97% of patients were Caucasian. 
Patient demographics are presented in Table 5-1. 
Scottish early onset IBD / TDT Cohort  
The group of IBD patients aged under 16 years of age at diagnosis was recruited 
from the three tertiary paediatric gastroenterology centres in Scotland (Edinburgh, 
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Glasgow and Aberdeen) and at the Western General Hospital in Edinburgh, a tertiary 
referral centre for IBD.
516
 There were 217 complete family trios (69%). 
Scottish adult onset IBD Cohort   
The group of Scottish IBD patients (male 389 / female 437) was recruited from the 
IBD clinic at the Western General Hospital.  
Scottish Control Cohort  
The control group consisted of 1372 healthy Caucasian subjects (male 555 / female 
557): Scottish blood donors (n=260), healthy volunteers (as assessed by 
questionnaire) recruited as part of the local study of IBD genetics (n=110) or healthy 
subjects recruited in the course of a Scotland-wide study of colorectal cancer 
genetics (n=1002). Data regarding the first two have been reported in previous 
studies.
248;271
 The latter group consists of Caucasian subjects resident in Scotland 
with detailed ancestry (over 66% having at least three grandparents born in 
Scotland). 
Swedish adult onset IBD Cohort  
The group of Swedish IBD patients (362 male / 270 female) was recruited from 
hospitals in Stockholm County, Sweden. 
Swedish Control Cohort 
The Swedish control group consisted of 277 Caucasian healthy subjects (male 126/ 
female 151: healthy volunteers from the Karolinska University Hospital and 
orthopaedic day case surgery patients undergoing arthroscopic procedures; the 
majority for sports related complaints. All were free of any known chronic medical 
disease). 
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Table 5-1: Demographics of IBD populations genotyped for the NOD1/CARD4+32656 ins/del 
 Scottish early onset  Scottish adult onset Swedish adult onset 
N 313 826 632 




11.1 (8.6–12.9) 31.1 (23.3 – 46.0) 26.6 (19.7-39.6) 
CD 205 (65.5%) 344 (41.6%) 244 (38.6%) 
UC 81 (25.9%) 482 (58.4%) 388 (61.4%) 
IBDU 27 (8.6%) - - 
Asthma 82/309 (26.5%) - - 
Any atopic 
disease 
153/309 (49.5%) - - 
Caucasian 97.6% 98.3% 99.4% 
 
5.1.1.2 Haplotype-tagging approach 
2296 subjects comprising of 1323 IBD patients (of which 356 children with IBD) 
(662 CD, 628 UC, 33 IBDU), 603 parents and 370 controls were genotyped. IBD 
patients (male 624/ female 699; median age at diagnosis [Quartile 1 – Quartile 3] 
26.08 years [14.83 years- 39.91 years]) were recruited from the Western General 
Hospital and the three tertiary paediatric gastroenterology centres in Scotland 
(Edinburgh, Glasgow and Aberdeen). The cohort of children with IBD used in the 
TDT analysis was also used for the Scottish IBD case-control analysis (combined 
and childhood onset). Control subjects consisted of Scottish blood donors (n=260) 
and healthy volunteers (as assessed by questionnaire) recruited as part of the local 
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study of IBD genetics (n=110). More than 97% of the study population (patients and 
controls) was Caucasian. There were 246 complete family trios (69%). 
 
5.1.2 Data collection 
The diagnosis of IBD was based on standard criteria.
523
 Data were collected 
retrospectively by review of patient files and questionnaire as previously 
described.
271;660
 The Montreal classification was used to classify disease location and 




5.1.3 Haplotype-tagging SNPs selection 
The NOD1/CARD4 gene is located between positions 30,430,672 and 30,484,833 
(Ensembl Release 43 - ENSG00000106100). Haplotype-tagging SNPs were selected 
using genotypic data from the CEU-study group (Thirty U.S. trios with Northern and 
Western European ancestry, collected by the Centre d'Etude du Polymorphisme 
Humain (CEPH)), available from the HapMap project (Release 21, July 2006; 
http://www.hapmap.org/cgi-perl/gbrowse/hapmap_B35/ ). (see  Figure 5-1 and Table 
5-2) SNPs were selected using Haploview software (version 3.32, 
http://www.broad.mit.edu/mpg/haploview/). SNPs were identified using a haplotype-
tagging strategy based on solid spine of linkage disequilibrium (r
2
>0.8, haplotype 
frequency > 5%, minor allele frequency > 10%). Tagging of the 5‟ region of 
NOD1/CARD4 was achieved by tagging the rs2529447 variant of (block 5 - Fig 1) at 
position 30,501,735. The 3‟ region was tagged to position 30,437,394 (rs10267377, 
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Figure 5-1: NOD1/CARD4 genomic region with haplotype-tagging SNPs 
 
Figure 5-1:View of the genomic region containing NOD1/CARD4 generated 
from HapMap (Release 21) project data using Haploview software. The 
haplotypic variation of the NOD1/CARD4 is tagged by 9 SNPs shown in the 
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Table 5-2: NOD1/CARD4 haplotype-tagging SNPs 
NOD1/CARD4 haplotype-tagging SNPs 



















Table 5-2: NOD1/CARD4 tagging SNPs: rs-number, genomic location and 
flanking sequences 
5.1.4 Genotyping 
The NOD1/CARD4+32656 insertion*2/deletion*1 and the nine NOD1/CARD4 
tagging SNPs were genotyped using TaqMan (7900HT sequence detection system; 
Applied Biosystems, Foster City, CA, USA). Failed TaqMan samples for the ins/del 
polymorphism were genotyped by direct sequencing and analysed by Sequencher 
v4.5 (Gene Codes Corporation, Ann Arbor, MI, USA). (5‟-3‟ 
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AATCTCTGAGGTTGGGTGAGTAGAA; 3‟-5‟ GGTCCTTCTGGTGTACTG 
ATGTATG; probes CCCCCACACACACAG / CCCCCCACACACAG). In 252 
samples, NOD1/CARD4+32656 ins/del genotyping by TaqMan was compared with 
results obtained by direct sequencing with 100% genotype concordance. 
 
5.1.5 Statistics 
5.1.5.1 NOD1/CARD4+32656 insertion/deletion 
The NOD1/CARD4+32656 insertion*2/deletion*1 polymorphism was analysed for 
association with IBD, CD, UC and IBDU by case-control study and TDT. Genotype-
phenotype analyses based on the Montreal classification were performed.
516
 Allelic, 
carrier and genotype frequencies were compared between patients and healthy 
controls in the association study. In the genotype-phenotype analyses, these 
parameters were compared between patients with a particular phenotype and patients 
without that phenotype. For subgroup analyses, CD patients were further stratified 
according to NOD2/CARD15 variant carriage.  
Power calculations for the case-control analyses were based on a comparison by 
allele (carriage versus no carriage) and those for the TDT analyses used the 
calculation method of Knapp under a multiplicative genotypic risk model.
675
 Both 
sets of calculations assumed a population risk allele frequency of 0.7, a population 
prevalence of 0.004 for IBD or 0.002 for CD or UC and a significance level of 0.05. 
SPSS (Version 13.0; SPSS Inc., Chicago, IL, USA) and Minitab (Release 13.20, 
Minitab Inc., State College, PA, USA) statistical packages were used. Case-control 
analysis was performed using χ
2
 or Fisher exact test as appropriate. Multifactorial 
genotype-phenotype analyses were performed applying a binary logistic regression 
model. Gene-gene interactions were assessed as interaction categorical variables in 
the logistic regression model. We assessed the influence of NOD1/CARD4+32656 
genotype on age at diagnosis by comparing the median age at diagnosis for each 
genotype, applying the Kruskal-Wallis test. Transmission disequilibrium testing 
analysis (TDT) was performed using the TRANSMIT package (Version 2.5, David 
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Clayton, Cambridge, UK).
531
 This method makes full use of the data available using 
inferred genotypes if data from both parents are not available. 
5.1.5.2 NOD1/CARD4 haplotype-tagging approach 
Allelic, genotype and haplotype frequencies were compared between cases and 
controls using χ
2
 (Minitab software, Release 13.20, Minitab Inc., State College, PA, 
USA and GraphPad Instat software version 3.06, San Diego, Ca, USA) and 
Haploview software (version 3.32). Single and multiple marker TDT analyses were 
performed using FBAT software (version 1.7.3, available from 
http://www.biostat.harvard.edu/~fbat/fbat.htm). 
532
 Odds Ratios (ORs) (99.5% 
Confidence Interval) for each of the SNPs were calculated using TDTHAP, run in R 
2.5.0.
533
 Log-likelihood analysis was carried out using PM software (1000 
permutations – random seeds).
527
 Power calculations were performed using 
QUANTO version 1.2 (http://hydra.usc.edu/gxe).
528;529
 The method for integrating 
results from case-control studies and TDT to provide a combined estimate of disease-
marker association was described by Kazeem and Farall (Table 7).
535
 As this 
approach is only useful when the samples of subjects used in the two analyses are 
independent of each other, yet share the same genealogy, we based this calculation 
on our TDT cohort of early onset IBD and our samples of adult onset IBD patients in 
the case-control analysis. 
 
Results 
5.1.6 Power calculations 
5.1.6.1 NOD1/CARD4+32656 insertion/deletion 
All Scottish IBD patients (childhood onset + adult onset) were analysed in a case-
control analysis with 1372 control samples.The case-control analysis had 80% power 
to detect an effect size of OR 1.21 for IBD and OR 1.27 for CD/UC. Assuming a 
multiplicative risk model, the TDT analysis was adequately powered (>80%) to 
detect an effect size of Odds Ratio (OR) 1.5 for IBD, OR 2 for CD and OR 2.5 for 
UC.  
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5.1.6.2 NOD1/CARD4 haplotype-tagging approach 
We have first analysed the power associated with the analysis of individual SNPs, as 
the power of each analysis is dependent upon the allelic frequency. We estimated the 
population risk to IBD as 0.004 (0.002 for CD and UC), based on population-based 
data by Rubin et al.
676
 In this study, the age-sex adjusted point prevalence for 
ulcerative colitis on 1st January 1995 was 243.4/100 000 (Confidence Interval (CI): 
217.4-269.4) and for Crohn's disease 144.8/100 000 (CI: 124.8-168.8). The most 
recent childhood onset IBD prevalence data in the Scottish population were derived 
from hospital discharges and date back to the period before 1997 (symptom onset 
1981-1995).
4
 Armitage et al. estimated the combined (CD+UC) crude prevalence of 
childhood onset IBD in Scotland to be 22.9/100 000 (13.7/100 000 CD, 9.2/100 000 
UC) of the population aged 0-16 years. It is pertinent to point out that both the Rubin 
and Armitage study reflect reported disease prevalence more than a decade ago. 
Since then, the incidence of IBD has continued to rise and more up-to-date data from 
the Scottish Executive are awaited. 
In comparison with dominant and recessive risk models, we assessed the 
multiplicative risk model to be more appropriate for the investigation of a complex 
polygenic disease. Using a multiplicative risk model, our case-control analysis had 
90% power to detect an OR of 1.5 to IBD and 1.6 for CD based on case-control 
analysis of the tagging SNPs with α = 0.005 to allow for multiple testing. (Table 5-7) 
By comparison, the index paper by McGovern et al. quoted an OR 2.0 for CD.
459
 
Effect sizes excluded (calculated as OR), are given in Tables 5-x and 5-x for the IBD 
population overall, as well as for the early onset IBD cohort.  
In addition, we have revised the power calculation concerning the haplotype 
analysis, and are able to demonstrate that for the nine-marker haplotypes with 
frequency >5% (77 % of haplotypes), our study was adequately powered to exclude 
OR of 1.8 for IBD with 90% power. For this calculation α was again set at 0.005 to 
stringently correct for multiple testing of the 9 most common haplotypes. (Table 5-9) 
For all analyses, the 99.5% CIs are given to ensure compatibility with the statistical 
threshold of significance, α = 0.005, as obtained after Bonferroni correction. 
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The true power of this study to demonstrate an effect of each SNP on disease 
susceptibility is best estimated by integrating case-control analysis and TDT analysis. 
Results of this analysis, which was first described by Kazeem and Farall, are given in 
Table 5-11. 
 
5.1.7 NOD1/CARD4+32656 insertion/deletion polymorphism 
5.1.7.1 NOD1/CARD4+32656: Case – control analysis Scottish IBD 
Genotyping was successful in 95% of Scottish IBD patients and 90% of Scottish 
controls. All Scottish IBD patients (childhood onset + adult onset) were analysed in a 
case-control analysis with 1372 control samples. The case-control analysis had 80% 
power to detect an effect size of OR 1.21 for IBD and OR 1.27 for CD/UC. Results 
of the Scottish case-control analysis (including stratification for age at diagnosis) are 
shown in Tables 5-3 and 5-4. 
None of the genotypes studied differed significantly between IBD (p=0.96), CD 
(p=0.81) or UC (p=0.81) patients and controls. Subgroup analyses of genotype 
frequencies per age at diagnosis (according to Montreal classification) of IBD, CD, 
UC and IBDU in patients versus controls, showed no significant differences (p>0.15 
for all age groups). (Table 5-4) 
Using the Kruskal-Wallis test, no influence of NOD1/CARD4+32656 genotype on 
age at diagnosis of IBD was observed in Scottish IBD patients (CD p=0.69, UC 
p=0.51). No significant effect of NOD2/CARD15 variant carriage on the influence of 
NOD1/CARD4+32656 genotype on CD susceptibility was observed (p=0.49 and 
p=0.14 for CD patients carrying a NOD2 variant and NOD2 wildtype CD patients 
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Table 5-3: Case-control analysis of NOD1/CARD4+32656 in Scottish IBD 



















































  7 
(25.9%) 
 1  
(3.7%) 
0.22 
Table 5-3: Genotype frequencies in Scottish IBD patients and controls of 
NOD1/CARD4+32656*1: deletion allele - *2: insertion allele. Allelic and 
genotype frequencies are shown for IBD, CD, UC, IBDU and controls 
Table 5-4: Genotype frequencies of NOD1/CARD4+32656 in Scottish IBD patients stratified for 
age at diagnosis 

























680/940  237 206 27  0.36 
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(72.3%)  (50.5%)  (43.8%) (5.7%) 













































































Table 5-4: Genotype frequencies in Scottish IBD patients stratified for age at 
diagnosis and controls - NOD1/CARD4+32656*1: deletion allele - *2: insertion 
allele. Allelic and genotype frequencies are shown for IBD, CD, UC and 





5.1.7.2 NOD1/CARD4+32656: Case-control analysis in Swedish IBD 
Genotyping was successful in 99% of Swedish IBD patients and 100% of Swedish 
controls. In the independent Swedish adult onset case-control analysis no significant 
association was observed between NOD1/CARD4+32656 and IBD (p=0.64), CD 
(p=0.75) or UC (p=0.64). (Table 5-5) 
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Table 5-5: Case-control analysis of NOD1/CARD4+32656 in Swedish IBD 













































Table 5-5: Genotype frequencies in Swedish IBD patients and controls. 
NOD1/CARD4+32656*1: deletion allele - *2: insertion allele. Allelic and 
genotype frequencies are shown for IBD, CD, UC and controls. 
5.1.7.3 NOD1/CARD4+32656 TDT analysis in early onset IBD trios 
Assuming a multiplicative risk model, the TDT analysis was adequately powered 
(>80%) to detect an effect size of Odds Ratio (OR) 1.5 for IBD, OR 2 for CD and 
OR 2.5 for UC. No distortion of transmission towards affected offspring was seen for 
NOD1/CARD4/CARD4 +32656 in IBD (p=0.47), CD (p=0.62) or UC (p=0.40). 
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Table 5-6: NOD1/CARD4+32656 TDT analysis in Scottish early onset IBD trios 
TDT 
NOD1/CARD4+32656 
IBD CD UC 







458 / 453.2 293/295.6 119/116.2 
Allele2 160 / 164.8 111 / 108.4 41/43.8 
Global Chi-squared 
(1 df) 
0.484 0.219 0.602 
Global p-value for  
transmission 
0.471 0.628 0.408 
Table 5-6: Transmission Disequilibrium Test of NOD1/CARD4+32656 in early 
onset IBD trios (n=315). The ratio of observed transmission over expected 
transmission for the NOD1/CARD4+32656*1 allele is shown. 
5.1.7.4 Genotype – Phenotype Analysis – Scottish IBD 
Detailed phenotypic data allowing the use of the Montreal classification were 
available for 84% (697/826) and 91% (263/286) of Scottish adults and children with 
IBD, respectively. Analysing adult CD patients‟ allelic, carriage and genotype 
frequencies using the Montreal classification, did not demonstrate any significant 
influence of NOD1/CARD4+32656 on disease location or behaviour (p>0.08 for all). 
In childhood CD, multifactorial analysis (also controlling for NOD2/CARD15 
variant carriage) showed that carriage of the NOD1/CARD4+32656 insertion*2 
allele was associated with gastric body disease (p=0.01 OR 4.77 CI 1.32-17.27) and 
ileal disease (p=0.03 OR 3.92 CI 1.11-13.89) at diagnosis and with perianal disease 
(as defined by the Montreal classification) at follow-up (p=0.03 OR 12.09 CI 1.27-
114.61). However, these results are based on relatively small numbers of patients and 
do not remain significant after stringent correction for multiple testing. 
NOD1/CARD4+32656 did not significantly influence disease extent in UC (p>0.12 
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for all). We did not find evidence for a significant association between 
NOD1/CARD4+32656 and extra-intestinal manifestations of disease in CD/UC. 
 
5.1.8 NOD1/CARD4 gene-wide haplotype-tagging approach 
5.1.8.1 NOD1/CARD4 Haplotype-tagging SNPs: Case-control analysis 
The haplotype structure of the genomic region spanning NOD1/CARD4 with the 
position of identified tagging SNPs is provided in Figure 5-1 (based on HapMap data 
Release 21). Nine SNPs were genotyped in 2296 subjects of which 1323 were IBD 
patients, including 356 children with IBD and their parents. For all patients and 
controls, all SNPs conformed to the Hardy-Weinberg equilibrium (p>0.01).  
We assessed association with IBD, CD and UC by using single- and multiple marker 
case-control analysis, Transmission Disequilibrium Testing (TDT) and log-
likelihood analysis. 
No significant associations were observed between any of the nine NOD1/CARD4 
SNPs studied and IBD, CD or UC when assessing allelic and genotype frequencies 
(after Bonferroni correction p>0.05 for all) (Table 5-7).  Although, the rs932272 
showed weak association with IBD and CD (p=0.04 in combined adults + paediatric 
IBD/CD, p=0.02, p=0.01 in paediatric IBD and CD, respectively), these findings did 
not retain significance after Bonferroni correction.  
Similarly, when disease susceptibility was studied in case-control analysis of 
haplotype frequencies, no significant effect of NOD1/CARD4 on IBD susceptibility 
was observed (corrected p>0.05 for IBD, CD and UC) (Table 5-9). 
After stratification of CD patients and controls for carriage of the three common 
NOD2/CARD15 variant alleles (R702W, G908R and Leu1007fsinsC), none of the 
haplotype variants of NOD1/CARD4 was associated with CD (corrected p>0.05).  
The two-marker haplotype rs2970500/rs2075820 overlaps with the area of strongest 
association in the report by McGovern et al (rs6958571/rs2907748).
459
 Case-control 
analysis of this two-marker haplotype was non-significant in IBD, CD and UC 
(p>0.16, p>0.33 and p>0.11, respectively). 
IBD Genetics in Scottish Children 
146 Ch.5: Germline variation of NOD1/CARD4 in Northern Europe   
We also assessed whether germline variation of NOD1/CARD4 influences the 
phenotype of IBD. We used the Montreal guidelines for classification of disease 
behaviour and disease location of CD and UC in our analyses. No significant 
influence of NOD1/CARD4 haplotype variants on phenotype was evident.
516
 
Stratification for NOD2/CARD15 variant carriage (R702W, G908R or 
Leu1007fsinsC) did not influence the observed lack of effect of NOD1/CARD4 on 
phenotype in CD or UC. 
 
5.1.8.2 NOD1/CARD4 Haplotype-tagging SNPs: childhood onset IBD case-control 
analysis 
 
We assessed in detail whether the haplotypic variants of NOD1/CARD4 were 
associated with increased susceptibility in our cohort of 356 children.
459
 Sub-group 
susceptibility analysis of patients with early onset IBD (diagnosed at < 17 years of 
age), did not show any of the tagging SNPs (either assessed as single – marker or in 
haplotypes) to be associated significantly with IBD, CD or UC (corrected p>0.05 for 
all) (Table 5-8). Also in early onset CD patients, NOD2/CARD15 variant carriage 
did not play a significant role in determining the contribution of NOD1/CARD4 to 
disease susceptibility (corrected p>0.05). 
Genotype-phenotype analysis in childhood onset CD and UC, based on the Montreal 
classification, did not show any significant effect of NOD1/CARD4 haplotypic 
variation on disease phenotype at diagnosis. 
 
 
5.1.8.3 NOD1/CARD4 Haplotype-tagging SNPs: Transmission Disequilibrium Test 
 
Results of single marker TDT analysis for IBD, CD and UC are shown in Table 5-10. 
No significant distortion of transmission was observed for any of the markers, after 
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correction for multiple analyses. Multiple marker TDT, followed by permutation 
analysis, in IBD, CD and UC trios yielded no significant distortion of transmission of 
any of the haplotypes studied (p=0.74 for IBD, p=0.77 for CD and p=0.68 for UC - 
haplotype frequencies > 2% were studied comprising all 9 tagging SNPs). The two-
marker haplotype rs2970500/rs2075820 which overlaps with the area of strongest 
association in the report by McGovern et al (rs6958571/rs2907748), showed no 




5.1.8.4 Log-likelihood analysis 
 
Using log-likelihood analysis (heterogeneity model – 1000 permutations), set χ
2
 
statistics (degrees of freedom=511) were reached 103, 396 and 35 times for IBD, CD 
and UC, respectively (corresponding uncorrected p-values 0.10, 0.39 and 0.03). 
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Table 5-7 - Genotype frequencies of nine NOD1/CARD4 haplotype-tagging 
SNPs in healthy controls and patients with IBD, CD and UC. p-values were 
obtained by 2x2 
2
-analysis of allelic frequency. Uncorrected p-values and Odds 
Ratio (OR) (99.5% Confidence Interval (CI)) are shown, followed by effect with 
OR excluded with 90% power using a multiplicative risk model [in brackets], 
assuming a population risk of 0.004 for IBD (0.002 CD/UC). To allow for 
multiple testing, α was set to 0.005 for the power calculation. 
 
Table 5-8: Genotype frequencies of nine NOD1/CARD4 haplotype-tagging SNPs 
in healthy controls and children/adolescents with IBD, CD and UC, diagnosed 
before age 17. p-values were obtained by 2x2 
2
-analysis of allelic frequency. 
Uncorrected p-values and OR (99.5% CI) are shown, followed by effect with 
Odds Ratio (OR) excluded with 90% power using a multiplicative risk model [in 
brackets], assuming a population risk of 0.00023 for IBD (0.00014 CD, 0.00009 
UC). To allow for multiple testing, α was set to 0.005 for the power calculation. 
 
Table 5-9: Haplotypes consisting of 9 NOD1/CARD4 tagging SNPs (haplotype 
frequency >1%) in Scottish IBD patients (adult + pediatric combined) and 
controls. p-values, Odds Ratios (OR) and 99.5% Confidence Intervals (CI) are 
given. Effect sizes (90% power) excluded for each of the haplotypes are given 
(expressed as OR). For this power calculation, α was set to 0.005 to account for 
multiple testing of the 9 most common haplotypes. 
 
Table 5-10: Results of TDT analysis in families with early onset IBD – analysis 
using FBAT software package. Odds Ratios (ORs) (99.5% Confidence Interval) 
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Table 5-11: A combined estimate of disease-marker association by integration of 
TDT and case-control analysis is given. This calculation is based on our TDT 
cohort of early onset IBD and our samples of adult onset IBD patients in the 
case-control analysis.
535
 OR, Variance (Var) and 99.5 % CI are shown. Allelic 
frequencies of 1 and 2 allele in IBD cases and controls are given: a = (IBD cases 
allele 1), b = (IBD cases allele 2), c = (controls allele 1), d = (controls allele 2). 
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Table 5-7: NOD1/CARD4 haplotype tagging SNPs genotype and allelic frequencies in Scottish IBD 
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Table 5-8: NOD1/CARD4 haplotype tagging SNPs genotype and allelic frequencies in Scottish children with IBD 
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Table 5-9: Haplotypes consisting of nine NOD1/CARD4 haplotype -tagging SNPs in Scottish IBD patients (adult + childhood onset combined) and controls 
 
Table 5-10: NOD1/CARD4 haplotype-tagging SNPs: TDT analysis 
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Discussion 
We have demonstrated in three independent cohorts (from two Northern European 
populations with similar small contribution of NOD2/CARD15 variants to CD), that 
NOD1/CARD4+32656 genotype does not influence susceptibility to IBD, CD or UC, 
independent of NOD2/CARD15 variant carriage.
337;473;660
  We did not observe an 
effect of NOD1/CARD4+32656 genotype on age at diagnosis of CD or UC. For this 
variant, we have reliably excluded an effect size of OR greater than 1.21 for IBD and 
1.27 for CD/UC in the Scottish IBD population. Our data concur with recently 
published reports from East-Anglia and Germany, but contrast with the conclusion of 
McGovern et al. from Oxford.
459;463;464
  
The counterintuitive concept of association of the most common allele with disease 
susceptibility and the influence of the analysis used (TDT versus case-control) was 
reviewed recently by Mitchell et al.
677
 An extensive review of the literature by these 
authors (identifying 29 TDT and 182 case-control analyses) demonstrated that 59% 
of TDT analyses showed an association between the most common allele and 
susceptibility to disease versus only 31% of case-control analyses (p=3.6x10
-6
). In 
their opinion, the tendency of the TDT to identify the most common allele as a risk 
factor is a direct effect of the presence of undetected genotyping errors. We have 
been very careful to minimise the possibility of genotyping error in our study: we 
used a high-throughput centre for our TaqMan analysis (Wellcome Trust Clinical 
Research Facility, Western General Hospital campus) and validated the TaqMan 
assay by comparing it with direct sequencing in 252 samples with 100% concordance 
between the two analyses.  
In accordance with the common disease-common allele hypothesis, the 
NOD1/CARD4+32656 deletion allele (or a marker in linkage disequilibrium with 
this variant) may yet be associated with IBD in our study populations, but the effect 
size is clearly smaller than OR 1.3 (compared with OR 2 (1.2-3.5) for CD, as 
calculated by McGovern et al.).
459;678
 The recent reports from East-Anglia and 
Germany, both corroborating our results, have further cast doubt on the importance 
of this NOD1/CARD4 polymorphism in determining susceptibility to IBD.
463;464
 In 
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addition, for a disease-predisposing allele to become the most common allele in a 
population, clear effects on reproductive ability must be present. The relatively weak 
association with asthma and IgE of the NOD1/CARD4+32656 insertion allele is 
probably not important enough in this respect.
434
 It is noteworthy that the clustering 
of chronic inflammatory conditions (e.g. asthma) and IBD, as observed in our 
childhood onset cohort, has been reported previously in adult IBD.
596
  
The study of the contribution of NOD1/CARD4 to IBD has seen replication studies 
unable to confirm a positive index study, mirroring the experience in other complex 
diseases.
679
 The significant differences between frequencies of the deletion allele in 
control populations, in the UK studies, are noteworthy, as it seems that these 
differences, rather than differences between allelic frequencies in patients underlie 
the discrepancies between centres.
674
 Whether true genetic heterogeneity, phenotypic 
differences between IBD cohorts or population admixture underlie these differences 
has often been difficult to elucidate. In IBD, only for NOD2/CARD15 has true 
genetic heterogeneity been demonstrated with certainty.
337;389;474
   
The difference (68.2% vs 74.3%, p=0.003) between the control allelic frequency of 
the NOD1/CARD4+32656 deletion allele in the Oxford and Cambridge studies 
seems more likely to be explained by a statistical false positive result or population 
stratification rather than by genetic heterogeneity. Although true heterogeneity 
between different populations has been demonstrated for NOD2/CARD15, 
considering the short geographical distance between the two centres, this possibility 
seems highly unlikely compared to admixture of the control population.
337
 Indeed, 
the single variant TDT analysis, not subject to this confounding element, was 
negative for CD in the Oxford study. It is noteworthy that in the most recent 
regression analysis by McGovern and colleagues from Oxford, carriage of the 





The present study of almost four thousand individuals does not implicate the 
NOD1/CARD4+32656 variant as important in determining susceptibility to IBD in 
these genetically homogenous, high-incidence populations.  
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We therefore pursued the investigation of NOD1/CARD4 as an IBD susceptibility 
gene further by performing the first gene-wide haplotype tagging approach to assess 
the contribution of germline variation of NOD1/CARD4 to IBD susceptibility and 
phenotype. We have made use of data of the second phase of the HapMap project to 
select SNPs tagging the haplotypic variation of the NOD1/CARD4 gene.
681
 This has 
allowed us to assess the contribution of NOD1/CARD4 to IBD in a more robust 
manner compared to previously performed single SNP analysis. In this study 
comprising 2296 subjects, we have used three different methods (case-control 
analysis [single marker and haplotype], TDT [single marker and haplotype] and log-
likelihood analysis) to provide robust support for a lack of association between 
germline variation of NOD1/CARD4 and IBD. Detailed power calculations, both for 
single SNP and haplotype analysis, have demonstrated our study was adequately 
powered to detect an OR of 1.5 and 1.6 for IBD and CD, respectively, after applying 
stringent criteria for multiple testing (α = 0.005). This compares favourably with the 
calculated OR for CD of 2.0 in the index paper from Oxford, reporting association of 
NOD1/CARD4+32656 with IBD/CD.
459
 Furthermore, access to our large cohort of 
patients with childhood onset IBD (n=356), characterised by a small but definite 
contribution of NOD2/CARD15, has permitted us to conclude that common 
haplotypic variation of NOD1/CARD4 is not an important genetic determinant of 
early onset disease. Detailed analysis of a two-marker haplotype overlapping with 
the haplotype of strongest association in the Oxford study, also failed to show any 
association with IBD, CD or UC. 
 
Notwithstanding these conflicting genetic findings, NOD1/CARD4 has remained a 
strong functional IBD candidate gene in view of its important role in regulating the 
innate immune response. The expression pattern of NOD1/CARD4 across the 
gastrointestinal tract as well as the presence of different splice variants with altered 
binding properties of the LRR domain, illustrate the importance of NOD1/CARD4 in 
the ability of the mucosa to sense the microbial content of the gut lumen.
434;670
 
Functional work has also provided evidence for interaction with Toll-like receptor 
pathways, again suggestive of a crucial role for NOD1/CARD4 in the innate immune 
response against bacteria.
431;477
 This is further supported by the recent association of 
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serological markers in IBD patients with the insertion/deletion polymorphism of 
+32656 of NOD1/CARD4.
682
 Indeed, the presence of an altered mucosa-associated 
microflora in IBD patients is indicative of an innate immune response which is either 
unable to recognise these micro-organisms appropriately (due to altered expression 
or altered ligand binding) or unable to orchestrate an effective second line immune 
reaction to clear them.
91;93;666
 
The problems associated with analysis of single SNPs, have stimulated researchers to 
turn to haplotype-tagging based approaches to assess the gene-wide contribution to 
the disease under study. The use of a gene-wide haplotype-tagging strategy has 
already proven successful in the analysis of other IBD candidate genes, in which 
equivocal evidence had been provided by single SNP analyses in different 
populations. 
Applying this approach to capture the haplotypic variations of the Multi Drug 
Resistance 1 (MDR1) gene, Ho et al. observed a highly significant association in the 
Scottish adult population between the common haplotypes of MDR1 and UC (p=4.22 
x 10(-7)) but not CD (p=0.22).
234
 These data provided really clear evidence of an 
important contribution to susceptibility and phenotype, in the face of inconsistent 
reports from other populations, and have been supported by meta-analysis.
223
 Ho and 
colleagues also confidently refuted the role of the pregnane X receptor gene 
(PXR/NR1I2) in IBD in the same population after application of a gene-wide 
haplotype tagging approach.
243
   
In our study, a tagging approach based on HapMap data available for this region, has 
excluded an important role of common germline NOD1/CARD4 variation in our 
high-incidence population. Increasing data support the validity of this approach.  
There is now good evidence that tagging SNP identification based on sample sizes 
like those of the HapMap project is appropriate to capture common variants (mean 
allelic frequency > 5%) with little loss of power if a causal variant is represented by 
tagging rather than by direct genotyping.
683;684
 The transferability of tagging SNPs in 
genetic association studies across different populations has also been studied.
685
 In 
recent reports by de Bakker et al and Conrad et al, the portability of tagging SNP 
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selection based on HapMap data across multiple populations was demonstrated, in 




To date, analysis of candidate genes in our early-onset Scottish IBD population has 
demonstrated only weak effects of the IBD5 locus (OCTN1&2 genes), DLG5 and 
NOD2/CARD15 on disease susceptibility.
266;278;660
 In view of the high incidence of 
disease, it is likely other important determinants are present, underlying 
susceptibility in our and other populations.  
 
It is noteworthy that none of the genome-wide association studies (GWAS) to date 
report association with NOD1/CARD4 in Crohn‟s disease. Thus, the North-
American genome-wide association study did not find any evidence for association 
between ileal CD and any of the marker SNPs in the region of NOD1/CARD4 (1991 
cases and 1214 controls were studied).
687
 (Judy Cho, personal communication)  Our 
own detailed analysis of WTCCC data does not reveal association with CD in the 
British population (1746 cases vs. 10603 controls).
472
 (http://www.wtccc.org.uk/) 
Although we did not have access to the primary data, the studies by Hampe et al. and 
Libioulle et al. also do not report any association between CD and NOD1/CARD4 
SNPs.
471;688
 The meta-analysis of the NIDDK/WTCCC/Belgian-French CD cohorts 
also concluded germline NOD1/CARD4 variation is not associated with CD, with 
increased power compared our cohort and the separate GWAS cohorts. 
 
In summary, we have examined in detail, both in adult- and childhood-onset IBD, the 
role of germline variation of NOD1/CARD4. Although the importance of 
NOD1/CARD4 in maintaining intestinal epithelial homeostasis through adequate 
recognition of mucosa-associated bacterial flora is undeniable, the present data argue 
strongly against a contribution of common haplotypic variation to inherited 
susceptibility to IBD. 
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6 The contribution of germline variation of IL23R to the 
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The impetus for the detailed study of the IL23 signalling pathway in CD 
susceptibility came from the discovery of association of germline variation of the 
IL23R gene with CD in the first published Genome Wide Association Study 
(GWAS) by the North American IBD Genetics Consortium in 2006.
470
 The North 
American IBD genetics consortium performed a genome-wide association study 
testing 308,332 markers in 567 ileal CD patients and 571 controls of non-Jewish 
European ancestry.
470
 The same authors demonstrated replication of the protective 
effect of the rare IL23R allele (Arg381Gln, frequency 1.9% in non-Jewish ileal CD 
vs. 7.0% in non-Jewish controls) in an independent case-control association study of 
Jewish ileal CD patients, as well as in a family-based association analysis (n=833).  
 
IL23 belongs to a family of cytokines which also consists of soluble cyliary 
neutrotrophic factor receptor/cardiothrophin-like cytokine (sCNTFR/CLC), 
CLC/cytokine-like factor-1, IL12, IL27 and IL35.
689
 The members of this family, 
which use interchangeable parts for both ligand and receptor, therefore have 
signalling characteristics in common as well as discrete functional capacity rendering 
the elucidation of their biology complex (see Table 6-1).
689
 IL23 was described by 
Oppmann et al. as a novel heterodimeric cytokine, consisting of a p40 subunit 
(shared with IL12) and a unique p19 subunit (see Figure 6-1).
690
 IL23 uses a 
heterodimeric receptor, composed of IL12Rβ1 and IL23R (similar to gp130) to exert 
its effect on the terminal differentiation (and stabilisation) of the Th17 T-cell 
population.
691
 IL23R is mainly expressed by T-cells, natural killer cells, and to a 
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Table 6-1: The members of the IL12 family, their components and their impact on immune 
regulation (adapted from Tato et al.)
689
 
Designation Components Receptor Primary function 
IL12 p35 and p40 IL12Rβ1 and 
IL12Rβ2 
Differentiation of Th1 T-cells 
IL23 p19 and p40 IL12Rβ1 and 
IL23R 
Terminal differentiation of Th17 
T-cells 
IL27 p28 and EBI3 WSX-1 and 
gp130 
Induction of early Th1 as well as 
strong anti-inflammatory effects 
on both Th1 and Th17 
IL35 p35 and EBI3 unknown Immune suppression 
EBI3: Epstein-Barr virus-induced gene 3 
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Figure 6-1: Crystal structure of IL23 – adapted from Beyer et al.
692
 
The signal transduction pathway downstream of IL23R contains JAK2 and 
STAT3.
693
 (see Figure 6-2) Recently, germline variation of both JAK2 and STAT3 
has been implicated in the pathogenesis of CD by the meta-analysis of GWAS.
694
 It 
is noteworthy that, before the studies discussed below implicated the IL23 signalling 
pathway in CD, functional data in the mouse model characterised by ileal 
inflammation, the Samp1/Yit mouse already demonstrated STAT3 activation via IL6 
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Figure 6-2: Differentiation of CD4+ T-cell lymphocytes under the influence of IL12, IL4, TGFβ, 
IL6 and IL23. The signalling pathway downstream of IL23R is illustrated.  
 
The description of IL23R germline variation as a confirmed determinant of inherited 
susceptibility to IBD occurred almost simultaneously with the discovery of a new 
subset of effector T-cells, Th17 cells. IL23 is involved in the terminal differentiation, 
stabilisation and pathogenic capacitation of this subset of CD4+ T cells. Th17 cells 
are characterised by the ability to produce a unique set of inflammatory cytokines, 
such as IL17A, IL17F, IL6 and TNFα under the influence of the transcription factor 
RORγt (Retinoid-related orphan receptor γ t, also known as RORγ2) and 
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This latter observation is particularly relevant for our understanding of IBD 
pathogenesis. Increasingly a novel dichotomy, reminiscent of the antiquated Th1/Th2 
paradigm, is being proposed between T-regulatory cells and Th17 cells. T-regulatory 
cells maintain intestinal immunotolerance/anergy by secreting TGFβ and IL10. 
696-698
 
It is noteworthy that the tissue with the highest expression of IL23 is the gut, with 
IL23 perhaps acting as a switch factor inhibiting the function of TGFβ-dependent T-
regulatory cells while enhancing the activities of inflammatory Th17 cells, thus 
promoting chronic inflammation.
689
 Zhou et al. recently demonstrated that a precise 
regulation of the development of naive CD4+ T-cells requires a tight regulation of 
the cytokine milieu, notably TGFβ, IL6, IL21and IL23.
698
 The first therapeutic trial 
of a monoclonal antibody, ustekinumab, targeting the common p40 subunit of IL12 
and IL23 (encoded by the IL12B gene which will be discussed later), has shown 




After the index report in Science by the North American consortium, the first 
replication studies of the IL23R association came from the UK. The Wellcome Trust 
Case Control Consortium (WTCCC) replicated the protective effect of the rare 
IL23R allele in CD (n=1902) and UC (n=975) versus healthy controls (n=1345).
700
 
Although initially identified in a cohort of ileal CD, IL23R germline variation has 
subsequently also been associated with UC.
700-703
 Since these initial studies, the 
association of CD with this locus has been replicated widely and confirmed recently 
in the meta-analysis of GWAS where the rs11465804 variant (D‟=1 and r
2
=0.88 with 
the Arg381Gln variant (rs11209026)) achieved a highly significant p value of 10
-63
 in 
the combined cohort, with in the case-control analysis an effect with OR 2.50, 




The index study by Duerr et al. had already shown that the CD association signal of 
this locus was not limited to the Arg381Gln variant of the IL23R gene. Raelson et al. 
and Taylor et al. have since performed studies to confirm this effect of gene-wide 
variation of IL23R on the genetic susceptibility to CD.
704;705
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In this chapter, we describe the results in our own cohort of childhood onset IBD, 
using single marker and haplotype-tagging association analyses, both case-control 
and family-based. In brief, we confirm the role of IL23R as a genetic determinant of 
childhood onset IBD and we show that, in order to appreciate fully the contribution 
of this locus to the genetic susceptibility of IBD, a gene-wide approach is more 





6.1.1 Subjects and genotyping 
6.1.1.1 IL23R Arg381Gln single marker association study 
 
To assess the contribution of the Arg381Gln variant (rs11209026) of IL23R in 
determining susceptibility and phenotype in childhood onset IBD in Scotland, 1294 
subjects comprising 358 IBD patients < 17 years at diagnosis (Table 1), 594 parents 
and 342 controls were genotyped for rs11209026 G/A using TaqMan (7900HT 
sequence detection system; Applied Biosystems, Foster City, CA, USA). We also 
sought to investigate the interaction between carriage of any of the 3 common 
NOD2/CARD15 variants, previously genotyped by Dr Russell, and carriage of this 




Demographics and IBD phenotype of IBD patients diagnosed before 17 years of age, 
based on Montreal guidelines for classification of CD/UC, are shown in Table 6-2, 
and were described in greater detail in Chapter 3.
516;710
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Table 6-2: Demographics and IBD phenotype of childhood onset patients studied in the single 
marker analysis of rs11209026 G/A (Arg381Gln). 
n 358 
M / F 205 / 153 
Median Age at diagnosis (Q1-Q3) 11.1 years (8.6 – 12.9) 
CD / UC / IBD type unclassified 239 / 88 / 31 
Caucasian 97 % 
Montreal CD location L1±L4: 13  L2±L4: 81 L3±L4: 131 L4: 3 
Montreal CD behaviour B1(±p): 214  B2(±p): 9 B3(±p): 9 Bx(p): 27 
Montreal UC extent E1:4 E2: 17 E3: 63 
CD:  L1: ileal; L2: colonic; L3: ileocolonic; L4: upper gastrointestinal tract;  
B1: not-stricturing, not-penetrating; B2: stricturing; B3: penetrating; 
p: penetrating perianal;  
UC:  E3: extensive colitis; E2: left-sided colitis; E1: proctitis only 
6.1.1.2 IL23R haplotype tagging study 
 
In order to facilitate a better appreciation of the gene-wide contribution of germline 
variation of IL23R to childhood IBD susceptibility and phenotype, and to investigate 
gene-gene interaction with NOD2/CARD15, we performed a detailed haplotype 
tagging investigation in 709 subjects, consisting of 357 childhood IBD patients (233 
CD, 86 ulcerative colitis, 38 IBD- type unspecified) and 352 population-matched 
controls, as described previously.
711
 Eight IL23R haplotype tagging SNPs 
(rs3762318, rs4655679, rs12041056, rs6656929, rs10889668, rs10489630, 
rs1004819, rs790631) were identified using HapMap data (minor allelic freq >10%, 
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haplotype freq >5%, based on solid spine of Linkage Disequilibrium (LD), see 
Figure 6-2) and genotyped using TaqMan. 
 
6.1.2 Analysis & Statistics  
 
Allelic and genotype frequency comparisons between cases and controls using χ
2
 and 
transmission disequilibrium testing (TDT) were applied to assess association of 
IL23R rs11209026 with IBD, CD and UC. IL23R rs11209026G/A (Arg381Gln) 
Transmission Disequilibrium Testing in trios with childhood onset IBD, assessed 
using FBAT software (version 1.7.3, available from 
http://www.biostat.harvard.edu/~fbat/fbat.htm ). 
 
Eight IL23R haplotype tagging SNPs were used in allelic, genotype and haplotype 
frequency case-control analysis, log-likelihood analysis (using PM software as 





Subjects were stratified for carriage of any of the three common NOD2/CARD15 
variant alleles in both single marker and haplotype tagging analyses. 
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Figure 6-3: Eight IL23R haplotype tagging single nucleotide polymorphisms (SNPs) (rs3762318, 
rs4655679, rs12041056, rs6656929, rs10889668, rs10489630, rs1004819, rs790631) were 
identified using HapMap data (minor allelic freq >10%, haplotype freq >5%, based on solid 
spine of LD) and visualised using Haploview software. 
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Table 6-3: Eight IL23R haplotype tagging SNPs, the non-synonymous Arg381Gln variant and 
their respective genomic locations  
rs3762318 67,369,707 C/T 
rs4655679 67,372,245 C/T 
rs12041056 67,399,848 C/T 
rs6656929 67,433,629 A/T  
rs10889668 67,433,832 T/C 
rs10489630 67,435,210 T/G 
rs1004819 67,442,801 C/T  
rs790631 67,449,510 C/T 
rs11209026 67,478,546 G/A  
Table 6-3: Eight IL23R haplotype tagging SNPs, the non-synonymous Arg381Gln variant and 
their respective genomic locations (based on Ensembl release 41 – October 2006) relative to the 
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Results 
6.1.3 IL23R Arg381Gln analysis 
 
In cases and controls, rs11209026 was in Hardy-Weinberg equilibrium. 
The allelic frequency of rs11209026*A differed significantly between IBD / CD 
cases and controls (2.9% / 3.0% vs 5.5%, p=0.01, OR 0.51 95% CI 0.30-0.88 and 
p=0.04, OR 0.53 CI 0.28-0.98) (Table 6-3). 
 
Table 6-4: IL23R rs11209026G/A (Arg381Gln) genotype and allelic frequencies in controls and 
patients with IBD, CD and UC (diagnosed < 17 years of age). Hardy-Weinberg equilibrium 
(HWE) p-values are given. 
Table 6-4: IL23R rs11209026G/A (Arg381Gln) genotype and allelic frequencies in controls and 




Control IBD p CD p UC p 





















AA 0 0  0  0  
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The GG genotype was associated with increased risk of IBD / CD (p=0.01, OR 2.01 
CI 1.15-3.49 and p=0.03, OR 1.96 CI 1.03-3.70). TDT analysis showed significant 
overtransmission of the G allele for IBD (p=0.004) and CD (p=0.04), with a trend 
towards significance in UC, hindered by a small number of informative UC families 
(Table 6-4).  
 
 
Table 6-5 - IL23R rs11209026G/A (Arg381Gln) Transmission Disequilibrium Testing in trios 
with childhood onset IBD, assessed using FBAT software (version 1.7.3, available from 
http://www.biostat.harvard.edu/~fbat/fbat.htm ). 










IBD 34 59 50.5 0.004 
CD 23 39 34 0.04 
UC 9 16 13.5 0.09 
 
In CD, there was no difference (p=0.94) in allelic frequency between 
NOD2/CARD15 wildtype and NOD2/CARD15 variant carrying patients. However, 
due to the small numbers of cases and controls carrying this IL23R variant, our study 
was not adequately powered to formally assess epistasis with NOD2/CARD15. 
Genotype-phenotype analysis in CD and UC based on the Montreal classification did 
not demonstrate any significant effect of IL23R rs11209026. Specifically we were 
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6.1.4 IL23R haplotype tagging investigation 
 
We observed significant associations of four of the tagging SNPs (rs3762318, 
rs6656929, rs10889668, rs1004819) with IBD/CD on analysis of allelic/genotype 
frequency, however without correction for multiple comparisons. 
Table 6-6: Case-control analysis of eight IL23R haplotype tagging SNPs in childhood onset 
IBD/CD/UC (genotype and allelic frequency)
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Table 6-6: Case-control analysis of eight IL23R haplotype tagging SNPs in childhood onset IBD/CD/UC (genotype and allelic frequency) 
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In order to assess the validity of our positive findings on allelic/genotype frequency 
case-control analysis (bearing in mind that a stringent Bonferroni-correction for 
multiple comparisons is likely to be overconversative), we entered our genotypic 
data in a haplotype log-likelihood analysis of IBD and CD. We confirmed the gene-
wide association signal of the IL23R gene (recessive model (1000 permutations) 
p=0.01 and p=0.002, respectively). No significant associations with UC were 
demonstrated on any of the above analyses, possibly due to the small UC cohort 
available and the ensuing lack of power in our investigations. 
 
Table 6-7: IL23R log-likelihood analysis in childhood onset IBD 
1000 permutations  
User-specified model chi-squared statistic (3.60) was reached 677 times 
Recessive model chi-squared statistic (64.04) was reached 12 times 
Dominant model chi-squared statistic (49.20) was reached 142 times 
Model-free chi-squared statistic (64.04) was reached 14 times 
Heterogeneity model chi-squared statistic (67.92) was reached 16 times 
Empirical p-values for these statistics are as follows: 
T1 - User specified model:       p-value = 0.6770  
T2 - Mendelian recessive model:  p-value = 0.0120  
T3 - Mendelian dominant model:   p-value = 0.1420  
T4 - Model-free analysis:        p-value = 0.0140  
T5 - Heterogeneity model:        p-value = 0.0160  
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Table 6-8: IL23R log-likelihood analysis in childhood onset CD 
1000 permutations  
User-specified model chi-squared statistic (1.44) was reached 871 times 
Recessive model chi-squared statistic (68.12) was reached 2 times 
Dominant model chi-squared statistic (51.90) was reached 53 times 
Model-free chi-squared statistic (68.12) was reached 3 times 
Heterogeneity model chi-squared statistic (70.36) was reached 3 times 
Empirical p-values for these statistics are as follows: 
T1 - User specified model:       p-value = 0.8710 
T2 - Mendelian recessive model:  p-value = 0.0020  
T3 - Mendelian dominant model:   p-value = 0.0530  
T4 - Model-free analysis:        p-value = 0.0030  
T5 - Heterogeneity model:        p-value = 0.0030  
 
Haplotype analysis demonstrated a significant protective effect of the 11221211 
haplotype on IBD (2.1% versus 4.4% in healthy controls, p=0.02 OR 0.49 (0.26-
0.92)) and CD (2.0%, p=0.02 OR 0.46 (0.22-0.97)). By then extending the haplotype 
analysis to include the previously genotyped Arg381Gln variant, we were able to 
show that the protective effect the 11221211 haplotype was independent of the 
Arg381Gln variant (r
2
 with tagging SNPs ≤0.05; IBD: p=0.02 OR 0.50 (0.27-0.93); 
CD: p=0.02 OR 0.46 (0.22-0.96)) (see Figure 6-3) 
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Figure 6-4: IL23R haplotype analysis including the Arg381Gln SNP. The protective IL23R 
haplotype, composed of the eight tagging SNPs (11221211 or AACCACAA), is independent of 
the Arg381Gln variant (with very low (≤0.05) r
2 
with the tagging SNPs). Note: 1 or A denotes the 
common, ancestral allele and 2 or C denotes the minor allele. 
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Figure 6-4: IL23R haplotype analysis including the Arg381Gln SNP.  
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When assessing the association signal for each haplotype block (based on solid spine 
of LD (see Figure 6-4 for CD), we observed association with both 5‟- and 3‟-end 
haplotype blocks. After correction for multiple comparisons, no significant genotype-
phenotype associations were seen. In homozygous wildtype NOD2/CARD15 
children affected by CD and controls, we observed association with a novel risk 
haplotype (21121212, 4.7% vs 0.9% p=0.002 OR 5.17 (1.49-17.90)). 
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Discussion 
 
The successful identification of IL23R as a novel IBD susceptibility gene has 
provided proof of principle for the applicability of genome-wide association studies 
in the genetics of complex diseases. In the present study, we show that IL23R 
variation influences IBD and CD susceptibility, but not phenotype, in an exclusively 
paediatric IBD cohort. We have also demonstrated in our high-incidence population 
of childhood onset IBD that the haplotypic association signals of the IL23R locus are 
complex and that they can not be simply attributed to LD with the Arg381Gln 
variant.  
 
Medio 2009, it is pertinent to address the contribution of the IL12/IL23 pathway to 
the development of IBD at both the genetic (single marker and haplotypic analysis) 
and the functional level. In addition, we will discuss the novel avenue of pathway-
based analysis briefly as a bridge between these two approaches. 
 
In the first phase of this study, we assessed the IL23R Arg381Gln SNP, reported by 
Duerr et al. in their landmark Science publication.
470
 We were able to show 
association with childhood onset IBD and CD using both case-control and TDT 
analyses. Our study was not adequately powered to comment on the association with 
UC. 
 
Adequately powered replication studies in populations of North America and Europa, 
investigating the association of germline variation of IL23R with the genetic 
susceptibility to IBD (CD as well as UC) have been unequivocally positive, both in 
adult and childhood onset IBD.
470-472;687;694;700-706;712-732
 Yamazaki et al. showed that 
in Japanese patients affected by CD, inherited variation of IL23R does not determine 
disease susceptibility to the same degree as in populations of European descent.
733
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Duerr and colleagues had already described in their index publication that the 
association signal at the IL23R locus is wider than just the Arg381Gln variant.
470
 
Various other groups have studied multiple variants across this locus and have 
reported strong(er) associations of other IL23R variants with CD.
701;704;705;718
 This 
complex association signal, accompanied by a large number of IL23R splice variants, 
have contributed to the frustration of investigators studying the precise impact of 





Raelson et al. demonstrated that distinct association signals occur at the 5‟ and 3‟ 
regions of the gene.
704
 These authors also reported that it is highly unlikely that the 
non-synonymous Arg381Gln variant fully explains the functional role of this locus in 
CD etiology, as the CD associated SNP does not occur consistently in all risk and 
protective haplotypes. 
 
In view of this complex association signal, it may be more appropriate to select a set 
of tagging SNPs based on HapMap project data.
681
 Taylor and colleagues adopted 
this approach and performed haplotypic association analysis in adult CD.
705
 These 
researchers clearly demonstrated that several haplotype blocks across this locus have 
distinct risk effects, both increased and decreased. 
 
In addition to being the first IL23R haplotype tagging study in paediatric IBD, our 
study adds to the literature described above, by assessing the contribution of the 
Arg381Gln in addition to the association signal provided by the haplotype tagging 
SNPs. Firstly, we confirm using haplotype association and log-likelihood analyses 
that gene-wide inherited variation of the IL23R locus is a genetic determinant of 
childhood onset IBD (and CD). Secondly, we show that the gene-wide association 
signal of the eight haplotype tagging SNPs is not altered by inclusion of the 
Arg381Gln. Indeed, the common „risk‟ allele of Arg381Gln (rs11209026G) is 
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inferred to reside on the „protective‟ haplotype (as described in Figure 6-4) without 
altering the strength of the association, compared with the eight-marker haplotypic 
protective effect. Indeed, r
2
 of rs11209026 with the IL23R tagging SNPs is very low 
(≤0.05). 
 
Two recent studies have added a further layer of complexity to the elucidation of the 
functional repercussions of these genetic findings. Wang et al. applied pathway 
analysis to data from GWAS to date in IBD, including the dataset to which we 
contributed our samples, of the International Pediatric IBD Genetics Consortium.
736
 
GWAS typically focus on single-locus analysis, which may not have the power to 
detect the majority of genuinely associated loci. Wang and colleagues applied 
pathway analysis, using Affymetrix SNP genotype data from the Wellcome Trust 
Case Control Consortium (WTCCC), and uncovered significant association between 
CD and the IL12/IL23 pathway, harboring 20 genes (p = 8 x 10
-5
). Interestingly, the 
pathway contains multiple genes (IL12B and JAK2) or homologs of genes (STAT3 
and CCR6) that were recently identified as genuine susceptibility genes only through 
meta-analysis of several GWAS.
694
 In addition, the pathway contains other 
susceptibility genes for CD, including IL18R1, JUN, IL12RB1, and TYK2, which do 
not reach genome-wide significance by single-marker association tests. The observed 
pathway-specific association signal was subsequently replicated in three additional 
GWAS of European and African American ancestry generated on the Illumina 
HumanHap550 platform, including the paediatric IBD GWAS discussed in Chapter 
9.  This novel pathway analysis suggests that examination beyond individual SNP 
hits, by focusing on genetic networks and pathways, is important to unleashing the 
true power of GWA studies.
736
 Further evidence for this new layer of complexity was 
provided in a recent study by McGovern et al. describing genetic epistasis between 
IL17 and IL23 pathway genes.
737
 These authors showed that a significant association 
between CD and the widely replicated IL23R variants is only seen in the presence of 
IL17A or IL17RA variants. 
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Since its description in 2000 by Oppmann et al., the role of IL23 in the inflammatory 
response has been widely investigated.
690
 In addition to its role in dysregulated 
inflammation, there is also mounting evidence that IL23 and the Th17 axis mediate 
beneficial events in host protective immunity and barrier function in the intestine.
738
 
The discovery of IL23, specifically of its heterodimeric structure (IL12 p40 and an 
IL23 specific p19 subunit) as shown in Figure 6-1, has led to a re-evaluation of the 
role of IL12 in inflammatory disease.
738
 Following groundbreaking work in the IL23 
knockout mouse model which demonstrated that IL23 rather than IL12 was the 
cytokine driving experimental autoimmune encephalitis, IL23 has been identified as 
the causative agent in a number of inflammatory disorders in intestinal 
inflammation.
739-743
 IL23 expression is notably increased in the intestine rather than 
systemically during intestinal inflammation, indicating a tissue-specific role in the 
inflammatory response.
738;742;744
IL23 is increasingly recognised as a pivotal player in 
the homeostasis of the intestinal immune response via its role in T-cell differentiation 
(via stabilisation of the Th17 population and the suppression of T-regulatory cell 
differentiation) and because of the observation that innate immune pathways can 
trigger its expression.  
 
Several confirmed IBD susceptibility determinants are also regulators of IL23R 
expression or signalling. For example, TLR3,4 and 8 stimulation have been shown to 
differentially regulate IL12 and IL23 in myeloid cells (in favour of IL12).
745
 By 
contrast, stimulation of TLR2 (alone or in combination with NOD2/CARD15 
induces expression of IL23, as shown by Van Beelen and colleagues.
745;746
 Dectin-1 
agonists, such as curdlan, induce a striking IL23 response via CARD9.
747
 Veldhoen 
et al. showed that zymosan, a component of the cell wall of Saccharomyces 
cerevesiae (a TLR2 and dectin-1 agonist), induces IL23 production as well as 




CD is associated with elevations of IL12, IL23, IFN-γ and IL17.
749-754
 Together with 
the overwhelming evidence for a genetic association of the IL12 – IL23 – IL17 axis 
with CD, their is now a real need to integrate these findings. Schmechel and 
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colleagues analysed the effect of carriage of any of the CD associated IL23R SNPs 
on IL22 expression.
755
 These authors demonstrated that IL23R genotypes influence 
IL-22 serum expression, linking genetic CD susceptibility to Th17 cell function. 
However, NOD2/CARD15 mutations in DCs have been linked to a decreased ability 
to prime Th17 responses in vitro: upon stimulation with TLR2 and NOD2 agonists, a 
failure to upregulate IL23 may be harmful rather than protective.
738;746
 Our own 
observation that homozygous wildtype NOD2/CARD15 CD is associated with a 
different IL23R risk haplotype, is perhaps best assessed with these novel functional 
data in mind. Although an epistatic finding in a subgroup of childhood onset CD 
patients such as this, would not stand up against stringent correction for multiple 
testing, it is clear from these in vitro studies that functionally none of these proteins 
act alone. A genetic correlate of these functional interactions is therefore highly 
likely (as evident from small studies with pairwise assessment of epistasis, e.g. 
McGovern et al. in the case of IL17 and IL23), even though our latest efforts at 




In summary, we have demonstrated using a single SNP and a gene-wide haplotype 
tagging strategy that the multiple association signals of the IL23R locus are 
independent of the Arg381Gln variant in childhood onset IBD and CD. In our high-
incidence population characterised by low NOD2/CARD15 variant carriage, we have 
observed interaction of the IL23R locus with NOD2/CARD15 through the 
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Introduction 
 
The ability to adapt to environmental change is essential for survival. This is true for 
the organism as a whole and for individual cells alike. The eukaryotic cell has 
developed myriad processes to recognise nutritional or microbial changes, both 
extra- and intracellularly. During cellular stress or starvation, the evolutionarily 
conserved autophagy response is used to recycle nutrients from non-essential or 
defunct cell organelles. In addition, the cell uses autophagy to clear its intracellular 
milieu of misfolded proteins or invading microorganisms. 
 
Autophagy is a cellular pathway involved in protein and organelle degradation and 
likely evolved as a single cells adaptation to starvation. In times of nutrient starvation 
the cell can self-digest some non-essential components via autophagy to sustain its 
minimal growth requirements until a food source becomes available. The recent 
identification of the importance of autophagy genes in the genetic susceptibility to 
Crohn‟s disease suggests that in addition to non-selective, starvation-induced 
autophagy, the selective, autophagic response to microorganisms may play a crucial 
role in the pathogenesis of common complex immune-mediated diseases. In this 
chapter, we will discuss how autophagy has already been implicated in the 
pathogenesis of an increasing number of medical conditions (notably cancer, 
neurodegenerative diseases as well as inflammatory bowel disease). This recent 
progress has in turn led to great interest in the therapeutic potential of manipulation 
of both selective and non-selective autophagy in established disease.   
 
The term autophagy encompasses several distinct processes involving the delivery of 
portions of the cytoplasm to the lysosome for degradation: chaperone-mediated 
autophagy, micro-autophagy and macro-autophagy.  More recently, the concept of 
classifying autophagy into selective and non-selective has regained interest.  
In chaperone-mediated autophagy, proteins that contain a specific pentapeptide 
motif are translocated directly into the lysosome for degradation and this process 
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requires the action of cytosolic and lysosomal chaperones. Micro-autophagy 
sequesters cytosol directly at the lysosomal surface while macro-autophagy 
sequesters cytosol into a distinct double membraned structure called the 
autophagosome which then fuses with and delivers its cargo to the lysosome for 
degradation.(Figure 8-1) Here we will focus on macro-autophagy (herein referred to 
as autophagy) and in particular an adaptation to autophagy for the selective removal 
of pathogens (bacteria, viruses, fungi and parasites) that have entered the cytosol, 
also  termed xenophagy. 
 
During autophagy, proteins and organelles that are targeted for destruction are 
sequestered into large double-membraned vesicles, called autophagosomes, which 
fuse with lysosomes to form autolysosomes where they are degraded through the 
action of lysosomal hydrolases.
756
 In turn, the resulting macromolecules are released 
back into the cytosol through membrane permeases. Autophagosomes are formed by 
expansion of a structure called a phagophore or a pre-autophagosomal structure 
(PAS) but the origin of the phagophore remains unknown. Genetic studies in the 
yeast Saccharomyces cerevisiae identified the core 17 autophagy (Atg) genes that 
constitute the basic machinery for autophagosome formation and many of the 
corresponding proteins have homologues in mammals. 
 
Although first described in the 1960s, the last decade really has seen autophagy 
research come of age through a series of molecular breakthroughs in the regulation of 
autophagy.
757
 Most recently, investigators in North America and Europe, studying 
the inherited susceptibility to Crohn‟s disease, have recently identified germline 
variants of the autophagy genes ATG16L1 (Autophagy-related 16-like 1) and IRGM 
(immunity-related GTPase family M) to be involved in the genetic predisposition to 
Crohn‟s disease.
471;472;687;688;704;758;759
 These findings have led researchers in the field 
of IBD genetics to join the expanding group of autophagy-investigators from a 
myriad of research disciplines: cancer biology, apoptosis, heart disease, liver disease, 
myopathies, neurodegenerative diseases, innate and adaptive immunity and even 
lifespan extension.
756;757;760
 A better understanding of macro-autophagy in particular, 
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offers great hope for the successful manipulation of autophagy. This therapeutic 
potential is notably for diseases characterized by dysregulation of the immune 
response against microorganisms (such as Crohn‟s disease), of intracellular 
processing of misfolded proteins (such as in Crohn‟s disease) or of apoptosis 
(implicated in Crohn‟s disease and cancer). I will therefore focus on macro-
autophagy (herein referred to as autophagy) and specifically on selective autophagy 
(e.g. induced by misfolded proteins or microorganisms entering the cytosol) rather 
than non-selective (starvation-induced) autophagy. 
Figure 7-1: The autophagic machinery. 
 
Figure 7-1: Schematic Depiction of Autophagy. (a, b) cytosolic material is 
sequestered by an expanding membrane sac, the phagophore. (c) a double 
membrane vesicle, the autophagosome, then forms at the phagophore and 
encloses proteins, organelles or pathogens to be degraded. (d) the 
autophagosome then fuses with the lysosome to form the autolysosome where its 
contents are degraded. 
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7.1.1 The molecular mechanisms of autophagy 
 
Autophagy can be divided into 3 distinct stages: vesicle nucleation (formation of the 
so-called phagophore), vesicle elongation (growth and closure of the 
autophagosome) and fusion of the autophagosome with a lysosome to form an 
autolysosome.
761
 This process is controlled by the Atg (autophagy-related) 
proteins.
762
 Atg proteins form distinct functional complexes, including a protein 
serine/threonine kinase complex that responds to upstream signals such as mTOR 
(mammalian Target of Rapamycin), which will be discussed in detail in the section 
on the regulation of autophagy. Initially cytosolic material is sequestered by an 
expanding membrane sac, the phagophore or isolation membrane. Although the 
phagophore assembly site (PAS) is the proposed site for autophagosome formation, 
the precise mechanisms of isolation membrane formation are unknown.  In 
Saccharomyces cerevisiae, the PAS is a peri-vacuolar site to which most core Atg 
proteins localise.
763;764
 Despite the lack of  comprehensive studies, the colocalisation 
of the core Atg proteins to the PAS has also been observed in mammalian cells.
765-767
 
For a comprehensive review of the core molecular machinery of autophagosome 
formation readers are referred to Xie and Klionsky.
762
   
 
In brief, autophagosomal membrane-formation and expansion is mediated by two 
ubiquitin-like protein conjugation systems, the LC3 (Atg8) and Atg12 systems 
(Figure 2). Initially, the LC3 precursor is processed by the cystine protease Atg4 into 
the mature form of LC3 (LC3-I), which can then be modified by the ubiquitin E1-
like protein Atg7 and the ubiquitin E2-like protein Atg3 to generate a smaller 
lipidated form of LC3 (LC3-II). Recruitment of LC3-II to the growing isolation 
membrane depends on the Atg12 system. Atg12 is activated by Atg7 then further 
modified by the ubiquitin E2-like protein Atg10 and eventually covalently linked to 
Atg5. The Atg5-Atg12 complex then associates with Atg16 to initiate the elongation 
stage of isolation membrane formation by recruiting the lipidated LC3-II. Atg16 
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LC3 is the only Atg protein in higher eukaryotes that remains associated with the 
mature autophagosome. The yeast Atg8 has multiple paralogs in mammals termed 
LC3A (with two splice isoforms, a and b in humans), LC3B, GABARAP, 
GABARAPL1, and GABARAPL2 (GATE-16), encoded on different chromosomes, 
with the exception of LC3B and GABARAPL2, which are linked on chromosome 16 
in the human genome.
770




The conversion of LC3-I to the membrane associated, lipidated form LC3-II  forms 
the basis for one of the assays that monitor autophagy levels.
771-773
 Upon completion 
of the autophagosome, the Atg5-Atg12-Atg16 complex dissociates from the outer 
autophagosomal membrane and is recycled together with LC3 (which then needs 
further delipidation by Atg4).
774
 In the maturation stage, the fraction of LC3 trapped 
on the luminal membrane of the autophagosome is degraded in the 
autolysosome.
761;772
 Finally, a recycling pathway (comprising Atg2/Atg9/Atg18) 
mediates the disassembly of Atg-proteins from matured autophagosomes. 
 
Autophagosomal membrane-formation differs between non-selective and selective 
autophagy.
762
 Both these forms of autophagy require specific adaptations of the core 
autophagic machinery.
762
 In non-selective autophagy, autophagosomes contain 
primarily bulk cytoplasmic contents.
762
 In contrast, selective autophagy in yeast (e.g. 
containing peroxisomes or bacteria) results in autophagosomes with a configuration 
similar to the cargo it envelops.
775-777
 The autophagic machinery is able to respond to 
information from the cargo to use it as a scaffold. In yeast, adaptor-proteins Atg11 
and Atg19, interact with the core machinery (Atg1/LC3/Atg9) to wrap the isolation 
membrane around the cargo.
778
 These adaptations in selective autophagy have also 
been observed in mammalian cells in response to invading bacteria.
779
 Both PIP3, a 
product of the Vps34/beclin1 complex (see below), and LC3 have been suggested as 
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Figure 7-2: Molecular machinery of autophagosome formation.  
 
Figure 7-2: Molecular machinery of autophagosome formation. 
Autophagosomal membrane formation and expansion is mediated by two 
ubiquitin-like protein conjugation systems, the Atg8 (LC3) and Atg12 systems, 
while a recycling pathway mediates the disassembly of Atg proteins from 
matured autophagosomes (Atg2, Atg9, Atg18). PE: phosphatidylethanolamine; 
G: Glycine. 
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7.1.2 The regulation of autophagy 
 
Early autophagy research implicated autophagy in the generation of energy during 
cellular starvation.
782-787
 Firstly, metabolic hormones were shown to regulate 
autophagy, with glucagon inducing autophagy and insulin being inhibitory.
788
 Later, 
Mortimore et al. and Seglen et al. discovered the regulatory role of amino acids, the 
inhibitory action of 3-methyladenine and the first evidence for the regulatory effects 
of protein kinases and phosphatases on autophagy.
789-791
 These findings underpinned 
our understanding of autophagy as an energy-generating catabolic mechanism at 
times of cellular starvation via the catabolism of cell components after their 
sequestration into autophagolysosomes. 
 
In contrast to the ubiquitin proteasome system which selectively degrades single 
proteins, autophagy can degrade large protein aggregates and whole organelles by 
both selective and non-selective mechanisms. Starvation induced autophagy is non-
selective and involves large-scale degradation of the cytoplasm, therefore excessive 
levels of autophagy would be undesirable. On the other hand, autophagy is required 
to maintain minimal growth requirements and viability during starvation, therefore 
insufficient autophagy would also be undesirable: studies in C. elegans have shown 
that both low levels or excessively high levels of autophagy signal death in response 
to starvation, whilst intermediate levels signal survival.
792
 Autophagy is normally 
maintained at a constitutive/basal level, and is activated in response to a myriad of 
stimuli including nutrient deprivation, pathogens, cytokines, protein aggregates and 
damaged organelles, thus autophagy must be a tightly regulated process. 
 
The breakthrough in the investigation of the molecular regulation of autophagy came 
with the identification of the Target of Rapamycin (TOR) gene and the observation 
that rapamycin, as an inhibitor of TOR, acts as an autophagy-inducer.
793;794
 In 
mammalian cells, the best characterized regulatory pathways include the class I PI3K 
(phosphoinositide-3-kinase) and mammalian target of rapamycin (mTOR) which act 
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to inhibit autophagy, and the class III PI3K Vps34 which is paradoxically involved in 
both mTOR activation and the initiation of autophagosome formation (Figures 7-2 & 
7-3). 
 
Before mammalian cells become committed to grow and proliferate, sufficient 
nutrients and energy must be available. A key pathway that senses and signals this 
information is the mTOR pathway (Figure 7-3). The serine/threonine kinase mTOR 
forms two types of multi-subunit complex involving distinct partner proteins: 
TORC1 and TORC2.
795
 The form of mTOR that directly regulates cell growth is 
TORC1, which contains mTOR in complex with Raptor (regulatory associated 
protein of mTOR), PRAS40 (proline-rich Akt substrate of 40kDa, an inhibitor of 
mTOR) and GL.
795
 The second complex, TORC2, differs in that it contains the 
binding partner Rictor (rapamycin-insensitive companion of TOR).
795
 TORC1 is 
sensitive to rapamycin, whereas mTORC2 is insensitive to this compound. Only 
TORC1 (hereafter referred to as mTOR) is linked to the control of cell growth and 
autophagy. mTOR regulates the phosphorylation of a number of components of the 
translational machinery. In particular phosphorylation and activation of 4E-BP1 and 





The TSC complex is a heterodimer composed of tuberin (TSC2) and hamartin 
(TSC1) and is the major regulator of the mTOR signalling pathway.
797
 TSC2 
contains a GTPase-activating protein (GAP) domain that converts the small GTPase 
Rheb (Ras homolog enriched in brain) to its inactive GDP-bound form. mTOR 
activity is stimulated by the active GTP-bound form of Rheb, thus the TSC complex 
acts to inhibit mTOR function.
797
 The TSC complex integrates growth factor and 
cellular energy signalling with mTOR activity. 
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Figure 7-3: Signalling, the regulation of non-selective autophagy and therapeutic options 
available to manipulate the autophagic response.  
 
Figure 7-3: Signalling, the regulation of non-selective autophagy and 
therapeutic options available to manipulate the autophagic response.  For 
details of the signalling pathways and inhibitors indicated in the figure the 
reader is referred to the main text ). P: signal transduction through direct 
phosphorylation.   
 
Signals from growth factor receptors are transduced to TSC1/2 via the class I 
PI3K/Akt and Ras/Mek/Erk pathways, and from cellular energy sensing via the 
LKB-AMPK pathway.
797
 Factors which mediate nutrient (amino acid) signalling to 
mTOR include the class III PI3K Vps34 and the Rag family of GTPases.
798;799
 
Insulin stimulates Akt via the class I PI3K pathway and, once active, Akt stimulates 
mTOR via phosphorylation of both TSC2 (inhibiting its Rheb-GAP activity) and of 
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PRAS40 (relieving its inhibition of mTOR).
800
 Growth factor signalling also 
stimulates the Ras/Mek/Erk pathway; once active, Erk phosphorylates TSC2 at 
different sites from Akt, also resulting in the inhibition of its Rheb-GAP activity.
801
 
Conversely, metabolic stresses that reduce energy levels in the cell activate the LKB-
AMPK pathway. AMPK has two inhibitory effects on mTOR: it phosphorylates 




mTOR inhibits autophagy indirectly by inhibiting the activities of the 
serine/threonine kinase Atg1.
803;804
 Starvation signals sensed by mTOR are 
transmitted to the Atg proteins, many of which accumulate at the PAS (Figure 2). In 
yeast, Atg1 interacts with Atg13 and Atg17, and its kinase activity is required for 
autophagy induction.
805;806
 The Atg1 complex (Atg1/Atg13/Atg17) is essential for 
the recruitment of other Atg proteins to the PAS during non-specific autophagy, 
however this does not require Atg1 kinase activity.
807;808
 In mammals, two Atg1 
homologues have been discovered; ULK1 and ULK2. The role of ULKs in 
autophagy induction has not yet been properly characterised, however ULK kinase 
activity increases under starvation conditions, and kinase-dead mutants of ULK exert 
a dominant-negative effect on autophagosome formation.
809
 In addition focal 
adhesion kinase (FAK) family interacting protein of 200kDa (FIP200), an ULK-
interacting protein, is required for autophagosome formation as autophagosome 
formation is almost completely blocked in FIP200-deficient cells.
809
 It was also 
observed that ULK1, ULK2 and FIP200 localize to isolation membranes, suggesting 





The class III PI3K, Vps34, has been extensively studied in the context of vesicular 
trafficking processes, and recent work has shown that Vps34 also plays an important 
role in the ability of cells to respond to changes in nutrient conditions.
810
 The activity 
of Vps34 requires the association of the protein kinase Vps15 (Figure 2).
811
 When 
amino acids are plentiful, Vps34-Vps15 contributes to mTOR activation, thereby 
repressing autophagy. By contrast, the Vps34-Vps15-beclin1 (Atg6) complex 
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initiates autophagosome formation.
811
 The Vps34-beclin1 complex can be activated 
by the beclin1 interacting proteins UVRAG (UV radiation resistance gene) and 
AMBRA1 (activating molecule in beclin1-regulated autophagy), and inhibited by 
another beclin1-interacting partner Bcl-2 (B-cell lymphoma 2).
811
 Thus, depending 
on its binding partners, Vps34 is subject to different modes of regulation leading to 
activation or inhibition of autophagy.  
 
Beclin1, the first identified mammalian autophagy gene interacts with several 
cofactors to activate the lipid kinase Vps34, thereby inducing autophagy.
812;813
 
Beclin1 is a BH3-domain-only protein that binds to the BH3 domain of the anti-
apoptotic proteins Bcl-2/Bcl-XL.
814
 Under normal conditions, beclin-1 is bound to 
and inhibited by Bcl-2 or the Bcl-2 homolog Bcl-XL and the dissociation of beclin1 
from Bcl-2 is essential for its autophagic activity.
813
 Nutrient deprivation stimulates 
the dissociation either by activating BH3-only proteins (such as Bad) that can 





Although mTOR is still considered to be the central regulator of autophagy, other 
types of regulation independent of mTOR like Bcl-2/beclin1-complex and Atg4-
regulation via c-Jun-N-terminal-kinase (JNK) and reactive oxygen species (ROS), 
have been described.
757;815-817
  In addition, lowering the levels of the secondary 
messenger myo-inositol-1-4-5 triphosphate (IP3) also induces autophagy in an 
mTOR-independent manner. The primary function of IP3 is to release calcium from 
the endoplasmic reticulum (ER) to the cytoplasm, suggesting that autophagy might 
be modulated by calcium.  
 
Recently, the NAD-dependent deacetylase Sirt1 has been implicated in the regulation 
of autophagy.
818
 Transient increased expression of Sirt1 is sufficient to stimulate 
basal rates of autophagy. Sirt1-/-  mouse embryonic fibroblasts do not fully activate 
autophagy under starved conditions but reconstitution with wild-type Sirt1 restores 
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autophagy. Sirt1 interacts with Atg5, Atg7 and Atg8 and the absence of Sirt1 leads to 
markedly elevated acetylation of these proteins.  
 
7.1.3 Autophagy in Inflammatory bowel disease 
 
Both childhood and adult onset CD are characterised by a progressive disease course 
in terms of location of disease as well as disease behaviour (e.g. structuring or 
fistulising complications).
710
 The involvement of the ileum is noteworthy as this is 
rarely a presenting feature in childhood but becomes involved as children with CD 
approach adulthood.
710;819
 The anti-microbial Paneth cells are abundantly present in 
the crypts of the ileum in the healthy state, but in CD they characteristically are also 
present in the colon, then termed „Paneth cell metaplasia‟. 
  
The autophagy genes Atg16L1 and IRGM are among the more than 30 susceptibility 
loci for CD that have been identified to date using genome-wide-association-studies 
(GWAS).
694
 Autophagy has been implicated in limiting inflammation by eliminating 
pathogens, blocking cell necrosis and controlling NF-K signalling. 
  
Tumour cells that have not been successfully removed by apoptosis or autophagy are 
removed by necrotic cell death. Necrosis leads to activation of inflammatory 
responses,
820
  thus preventing cell necrosis is an important mechanism through which 
autophagy regulates inflammation. It has been demonstrated that the removal of 
apoptotic cell corpses and necrotic cell debris is necessary to avoid excessive 
recruitment of neutrophils and to prevent chronic inflammation.
820;821
  Consistent 
with this, mice lacking Atg5 display a defect in apoptotic corpse engulfment during 
embryonic development.
822
 Interestingly, loss of tolerance against self-antigens due 
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Another mechanism through which autophagy may regulate inflammation is via NF-
Kβ. NF-K is a master regulator of the inflammatory response and, as mentioned 
previously, autophagy can selectively degrade NIK and IKK resulting in activation 
of NF-Kβ signalling.
824;825
 Whether any or all of  inadequate removal of 
apoptotic/necrotic cells, misregulation of NF-K signalling, or defective pathogen 
clearance through a defect in the autophagic machinery contribute to inflammatory 
bowel disease is currently the subject of intense investigation.  
 
The different GWAS in CD and the meta-analysis of several of these GWAS have 
identified a number of genes involved in the regulation of the Th17-cell population, 
notably IL23R, JAK2, STAT3 and ICOSLG.
470-472;687;694;732
 The recent report by Guo 
et al. demonstrating that Th17-mediated autoimmune disease (in this case a murine 
model of Multiple Sclerosis) is constrained by TRIF-dependent type I IFN 
production and its downstream signalling pathway, is also pertinent for our 
understanding of the pathogenesis of CD, as it provides the first evidence for a 
potential link between the autophagy pathway and the development of Th17 cells.
826
 
In the remainder of this section, we will discuss the autophagy genes ATG16L1 and 
IRGM as well as putative CD susceptibility genes LRRK2 and XBP1 in view of their 
relevance to the autophagy pathway. 
7.1.3.1.1 ATG16L1 
 
Hampe et al. were the first group to implicate the autophagy pathway in CD.
688
  
These authors performed a genome-wide association study of 19,779 non-
synonymous SNPs in 735 CD patients and 368 controls and demonstrated association 
with a coding variant of the ATG16L1 gene (Autophagy-related 16-like 1 gene,  
Ala197Thr polymorphism, rs2241880A/G) gene, on  Chromosome 2q37.1. In their 
paper, the association was replicated in 2 other independent cohorts. Haplotype and 
regression analysis confirmed this variant carries virtually all the disease risk exerted 
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ATG16L1 is expressed in colon, small bowel, intestinal epithelial cells, leukocytes 
and spleen and multiple splice variants have been reported.
687;688
 The Ala197Thr 
variant  leads to an amino acid change from the polar threonine to the non-polar 
alanine at the evolutionary conserved position 300 in the N-terminal WD-repeat 




Rioux and colleagues confirmed the association of this variant allele with ileal CD in 
the North-American genome-wide association study using case-control analysis and 
family-based association analysis.
687
 Of note, all CD patients had ileal involvement 
as a criterion for entry into this study. These authors also provided novel functional 
data: utilizing oligo-based silencing RNA directed against ATG16L1 isoforms, 
autophagy induced by S. Typhimurium was significantly different in ATG16L1 
knockdown HEK293 cells when compared with control cells.
687
 However, Hampe et 
al. observed no clear difference in tissue expression of ATG16L1 between controls 
and CD patients and expression was independent of the rs2214880 genotype, both at 
protein and cDNA level.
688
 Recently, Glas et al. confirmed these findings in CD 
patients and a mouse model of ileitis.
827
 
The association of the Ala197Thr single nucleotide polymorphism (SNP) with 
susceptibility to CD has now been replicated in several independent cohorts, of 




Recent studies have explored genotype-phenotype associations in adult onset CD, 
and to a more limited extent in paediatric disease. Prescott et al found that this 
ATG16L1 variant is associated specifically with ileal CD, but not with isolated 
colonic disease.
828
 Based on a sub-group analysis of 140 CD patients diagnosed 
before their 17
th
 birthday, these authors suggested an association between the 
Ala197Thr variant allele and early onset CD, as well as an effect of ATG16L1 
genotype on age at diagnosis. Subsequently, Baldassano et al. replicated this 
association in a cohort of 142 children from Philadelphia with Crohn‟s disease.  
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As discussed in chapter 3, it is pertinent for the introduction of the genotype-
phenotype analysis conducted of the ATG16L1variant, that the phenotype in early 
onset IBD in Scotland and Scandinavia differs from adult onset disease and is 
characterised by the extensive nature of disease.
830;831
 Childhood onset CD is 
characterised by extensive colonic disease and the relative rarity of purely ileal 
involvement. 
 
Recent reports by Cadwell, Saitoh and Kuballa constitute a real breakthrough in our 
understanding of ATG16L1 function and firmly implicate the homeostasis and anti-
microbial properties of the Paneth cell.
832-834
 Cadwell and colleagues showed that, in 
the epithelium of the ileum, ATG16L1 and ATG5 are crucial for Paneth cell 
biology.
832
 ATG16L1-deficient Paneth cells exhibit notable abnormalities in the 
granule exocytosis pathway and increased expression of genes involved in 
peroxisome proliferator-activated receptor (PPAR) signalling as well as several acute 
phase reactants and adipocytokines (notably leptin and adiponectin). Crohn‟s disease 
patients homozygous for the risk allele, identified by Hampe et al., displayed Paneth 




On the other hand, Saitoh and colleagues showed in ATG16L1-deficient mice that 
ATG16L1 is required to survive the period of neonatal starvation, as shown before 
for ATG5 and ATG7, and also an increased severity of colitis when induced by 
dextran sulphate sodium.
833
 Loss of ATG16L1 in macrophages caused aberrant LPS-





Using a knockdown-reconstitution strategy in human epithelial cells (HeLa and 
Caco2), Kuballa and colleagues demonstrated that homozygosity for the ATG16L1 
risk allele, identified by Hampe et al, resulted in a reduced capture of S. 
Typhimurium within autophagosomes.
834
 These authors further demonstrated that the 
wildtype (ATG16L1*300T) and mutant (*300A) coding variants are both fully 
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competent in mediating basal autophagy and that there is no difference between the 
two in allowing dimerisation or binding to Atg5, in HeLa and HEK293T cells 
respectively. Taken together, these studies implicate several distinct functions of 
Paneth cell biology, notably the capture of microorganisms within autophagosomses,  
the exocytosis of antimicrobial peptides and the orchestration of the immune 
response. However, the true effect of some of these genetic variants may only 
become clear when these genetic variants are studied in the setting of a high 
microbial load and when other genetic variants associated with CD susceptibility are 




Table 7-1: Overview of the key ATG16L1 association studies published to date. 
Odds Ratio (OR) calculations are based on allelic frequencies in cases vs. 
controls of each population. *: p= 0.007 vs Scottish early onset CD; **: p=0.009 
vs Scottish early onset CD. 
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Table 7-1: Overview of the key ATG16L1 association studies published to date. Odds Ratio (OR) calculations are based on allelic frequencies in cases vs. 































































































  178/280 
(63.6%) 
(OR 1.65)** 
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A few months after the genetic association of CD with ATG16L1, another autophagy 
gene, IRGM, was implicated by the large Wellcome Trust Case Control Consortium 
study. Reported by Parkes et al, these investigators performed a genome-wide 
association study in individuals with Crohn‟s (n=1748) and 2938 healthy controls 
(1500 individuals from the 1958 Birth cohort and 1500 individuals selected from 
blood donors recruited as part of the WTCCC) and detected strong association at four 





They subsequently tested 37 SNPs from these and other loci for association in an 
independent case-control sample (n=1182 CD vs n=5746 non-autoimmune WTCCC 
cases (bipolar disorder, coronary artery disease and hypertension) crucially assuming 
no overlap with Crohn‟s disease etiology).
472;835
 Of the 37 SNPs, twelve SNPs 
showed a difference in allele frequency between these two groups who were then 
genotyped in 2,024 independent population controls from the 1958 British Birth 
Cohort to test formally for association. Of the new loci, the strongest replication 
adjacent to a known gene was for SNPs rs13361189 and rs4958847 (preplication= 6.6 x 
10-4 and 3.1 x 10-4, respectively) immediately flanking IRGM on chromosome 
5q33.1. Association in the combined panels of 2,930 cases and 4,962 controls was 
highly significant (pcombined= 2.1 x 10
-10




The long coding exon of human IRGM encodes a 20-kDa protein of 181 amino 
acids.
836;837
 As none of the associated SNPs were known to be functional, Parkes et 
al. resequenced the coding exon of IRGM and the four small putative downstream 
exons in 48 affected individuals homozygous or heterozygous for risk alleles. They 
detected two new nonsynonymous sequence variants, 51G/C (E17D) and 281C/A 
(T94K) and an exonic synonymous SNP, 313T/C, (rs10065172, L105). These SNPs 
were then genotyped in 769 unselected CD patients and 705 controls. Only the silent 
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313T/C variant was associated with Crohn‟s disease (p=0.008) and was found to be 
in near perfect Linkage Dysequilibrium with SNP rs13361189 (r
2
 = 0.91). 
Sequencing of the IRGM coding region in another 100 unselected affected 




Parkes and colleagues therefore suggested that the causal variant(s) do not change 
the amino acid sequence of IRGM. They may lie in regulatory sequences in LD with 
the associated SNPs and affect IRGM expression, or the exonic (313T/C) SNP itself 




IRGM is expressed in several tissues notably the colon, small bowel, peripheral 
blood leukocytes and U937 monocytic cell line, as assessed by PCR screening of 
uncloned cDNA transcription. As discussed briefly in section 8.2.2, IRGM belongs 
to the p47 immunityrelated GTPase family. Its mouse homolog, LRG-47 (encoded 
by Irgm), critically controls intracellular pathogens by autophagy, and Irgm–/– mice 
show markedly increased susceptibility to Toxoplasma gondii and Listeria 
monocytogenes.
838
 Consistent with this, IRGM induces autophagy and thereby 
control of intracellular Mycobacterium tuberculosis in human macrophages.
837
 The 
role of IRGM in protecting mature effector CD4+ T-lymphocytes against IFN-γ 
induced autophagic cell death, has demonstrated a feedback mechanism in the Th1 
response that limits the detrimental effect of IFN-γ on effector T-lymphocyte 
survival while facilitating the antimicrobial functions of IFN-γ.
839
 An alteration in 
IRGM regulation, due to a common deletion polymorphism in the promoter region of 






The meta-analysis of three GWAS in Crohn‟s disease led to the identification of 21 
novel loci in addition to confirming 11 previously reported loci.
694
 One of the novel 
loci meeting stringent criteria of genome-wide significance contains, in addition to 
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the MUC19 gene ,  also the gene LRRK2 (leucine-rich repeat kinase 2), which 
encodes a multi-domain protein expressed mainly in the cytoplasm of neurons, 
myeloid cells and monocytes. LRRK2 mutations are the single most common genetic 
cause of Parkinson disease, accounting for 1–40% of all cases depending on the 
population studied.
841
 Recently, Plowey and colleagues reported that  transfection of 
LRRK2 cDNA containing the common G2019S mutation resulted in significant 
decreases in neurite length, which were not observed in cells transfected with wild 
type LRRK2 or its kinase-dead K1906M mutation.
842
 G2019S LRRK2 transfected 
cells also exhibited striking increases in autophagic vacuoles. RNA interference 
knockdown of LC3 or Atg7 reversed the effects of G2019S LRRK2 expression on 
neuronal process length, whereas rapamycin potentiated these effects. These results 
in Parkinson‟s and Crohn‟s disease offer further support for the role of autophagy in 
disease pathogenesis, although it remains to be elucidated whether LRRK2 affects 
the autophagy pathway directly or indirectly (e.g. through other signalling pathways 
such as MAPK). 
 
Our group has investigated haplotypic variation of the MUC19 gene (A. Phillips et 
al. presented at DDW 2009).
843
 The lack of association with CD in our adequately-
powered Scottish adult CD cohort, further points to the LRRK2 gene as a novel 
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7.1.4 Aims 
 
In the Scottish population, we have previously demonstrated that the effect of 
germline variation of NOD2/CARD15, the IBD5 locus and IL23R on susceptibility 
is similar in adult onset and early onset disease.
271;278;337;660;700;706
 In this study, we set 
out to address whether the ATG16L1 Ala197Thr variant and germline variation of 
the IRGM gene are independent determinants of susceptibility to childhood onset 
IBD, by studying this polymorphism in 361 childhood onset IBD patients. Following 
this, we genotyped these variants in 855 adult onset IBD, all from Scotland. We have 
also made use of the Wellcome Trust Case Control Consortium data to expand our 
control cohort yielding increased power to our study. We have explored in detail the 
relationship between disease phenotype and the Ala197Thr polymorphism of 






2418 subjects consisting of 392 childhood IBD (262 CD, 96 UC, 34 IBDU; median 
age 11.2 years (Inter-Quartile range (Q1-Q3: 8.7-13.1)), 685 parents, 979 adult IBD 
(442 CD, 537 UC; median age 32.2 years (Q1-Q3: 24.8-46.7)) and 362 population-
matched controls were genotyped for rs2241880 (ATG16L1) and 3 IRGM variants 
(rs10065172, rs13361189, rs4958847). Scottish healthy controls consisted of blood 
donors and locally recruited healthy controls, as described previously.
248
 More than 
95% of the Scottish subjects were Caucasian. 
In addition, 1958 British Birth Cohort control data and WTCCC healthy blood 
donors were used for the analysis (n=2937). 
This study was approved by the Local Research Ethics Committee. 
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7.1.6 IBD Phenotyping 
 
IBD was diagnosed by standard criteria.
523
 Detailed sub-phenotypic data based on 
the Montreal classification for the adult and childhood Scottish CD cohorts are given 
in chapter 3.
516
 Of particular note, early onset CD patients were characterised by a 
low frequency of isolated ileal disease (L1±L4 (ileal disease with or without upper 





 In addition, the frequency of ileocolonic disease (L3±L4 (ileo-
colonic disease with or without upper gastrointestinal tract disease) differed 
significantly between childhood onset CD and adult onset CD (147/257 (57.2%) and 
83/360 (23.1%), respectively, p<10
-4
).  
Data collection in childhood onset CD also included height, weight and Body Mass 
Index (BMI) at diagnosis. Z-scores were calculated using nomograms from the 
British 1990 growth reference (Child Growth Foundation, 2 Mayfield Avenue, 
London W4 1PW). 
 
7.1.7 SNP selection and genotyping 
7.1.7.1 ATG16L1 
Haploview software (version 3.32) was used to assess HapMap data of the region on 
Chromosome 2 spanning the ATG16L1 gene (position 233,914,305 to 234,014,304). 
681
 This confirmed the results of the analysis by Hampe et al. that germline variation 
at this locus can be tagged satisfactorily by the rs2241880 variant (analysis based on 
solid spine of linkage disequilibrium, minor allelic frequencies >10%, haplotype 
frequencies >10%).
688
 (Figure 8.1) 
All individuals were genotyped for the ATG16L1 rs2241880A/G variant using the 
TaqMan system (7900HT sequence detection system; Applied Biosystems, Foster 
City, CA, USA) at the Wellcome Trust Clinical Research Facility (Western General 
Hospital campus) with call rates in all populations >91%. The rs2241880 genotype 
frequencies in controls were in Hardy-Weinberg equilibrium. The 3 most common 
NOD2/CARD15 polymorphisms (R702W, G908R and Leu1007fsinsC) and the 
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3 IRGM variants (rs10065172, rs13361189, rs4958847) were selected for 
genotyping. rs13361189 (position 150,203,580) and rs4958847 (position 
150,219,780) are the SNPs with the strongest replication signal in the WTCCC, 
immediately flanking IRGM of Chromosome 5q33.1.
472
 The synonymous, exonic 
rs10065172 (position 150,208,191) was selected as it was the only SNP to retain an 
association signal with CD, of the 3 SNPs studied in the last phase of the WTCCC 
study, described above.
472
 In 48 CD patients, detailed sequencing of all 5 IRGM 
exons and exon-intron boundaries was performed. In the childhood onset trios and 
controls, an additional SNP (rs6869426, position 150,213,197) tagging the haplotype 
block containing the IRGM gene was studied (haplotype frequency >10%, minor 
allelic frequency (MAF)>1%, based on solid spine of linkage disequilibrium: 
HapMap SNP data, version 3.32 – 200kb region spanning the IRGM gene 
(150,207,888-150,260,491) is shown in Figure 8.2).
681
 All individuals were 
genotyped for these variants using the TaqMan system (7900HT sequence detection 
system; Applied Biosystems, Foster City, CA, USA) at the Wellcome Trust Clinical 
Research Facility (Western General Hospital campus), with call rates >92% and 
satisfying the Hardy-Weinberg in all control cohorts (p>0.05).  
Figure 7-5: HapMap data analysis using Haploview software of 100kb region 
spanning the ATG16L1 region. Position of the rs2144880 variant is indicated 
(arrow). This variant tags the haplotype block, which contains only the 
ATG16L1 gene. 
 
Figure 7-6: HapMap data spanning the 200kb region containing the IRGM 
gene. The tagging SNP rs6869426 is indicated (red arrow). 
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Figure 7-4: HapMap data spanning the ATG16L1 region. 
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Figure 7-5: HapMap data spanning the 200kb region containing the IRGM gene. 
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7.1.8 Statistical analysis 
 
Allelic and genotype frequencies of the ATG16L1 and IRGM variants were 
compared between cases and controls using χ
2
 (Minitab software, Release 13.20, 
Minitab Inc., State College, PA, USA and GraphPad Instat software version 3.06, 
San Diego, Ca, USA). TDT analysis was performed using FBAT software (version 
1.7.3, available from http://www.biostat.harvard.edu/~fbat/fbat.htm).
532
 Detailed 
genotype-phenotype analysis was performed using Minitab. The effect of ATG16L1 
rs2241880 genotype on age at diagnosis was further assessed using the Kruskal-
Wallis test. ANOVA (+ Hsu‟s Multiple Comparisons with the Best (set to the 
rs2241880 AA genotype)) was used to assess the relationship between rs2241880 
genotype and z-score of height, weight and BMI at diagnosis. 
 
7.1.8.1 Power calculations 
 
Power calculations were performed using QUANTO version 1.2 
(http://hydra.usc.edu/gxe).
528;529
 Based on the most recent prevalence data of Scottish 
paediatric CD (14/100 000 of the population <17 years), our childhood onset CD 
study had 80% power to detect an effect with OR>1.3 for ATG16L1 (when using the 
sum of Scottish controls + WTCCC controls, p>0.05 when comparing allelic 




This compares favourably with the OR >1.60 as calculated in the British early onset 
cohort from Prescott et al. (n=140) and also with data derived in a cohort of North-
American patients with early onset CD from Baldassano et al.(n=142) for the 
ATG16L1 variant.
547;828
 (Table 8-1) 
Our adult CD cohort had 80% power to detect an OR of 1.26 for the rs2241880 
ATG16L1 variant (sum of Scottish controls + WTCCC controls, population risk 
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144/100 000).
1;676;835
 The combined adult + childhood onset CD cohort vs the sum of 
WTCCC + Scottish controls had 80% power to detect an effect with OR 1.20. 
 
Power calculations for the IRGM variants are given in Table 8.2 (80% power – 
prevalence data as above) and compared with the ORs obtained in the index WTCCC 
study: 
 
Table 7-1: Power calculations based on log-additive risk model for childhood onset and overall 
CD in Scotland for 4 IRGM variants 
 Scottish childhood CD Scottish CD overall WTCCC 
rs10065172 OR 1.51 OR 1.31 OR 1.44 
rs13361189 OR 1.46 OR 1.33 OR 1.51 
rs4958847 OR 1.40 OR 1.27 OR 1.35 
rs6869426 OR 1.41 N/A N/A 
 
 Results 
7.1.9 The influence of ATG16L1 Ala197Thr/ rs2241880 on Scottish 
childhood onset IBD susceptibility 
 
No association of ATG16L1 with CD was seen in our early onset CD case-control 
analysis (frequency of rs2241880 G allele in CD was 291/538 (54.1%) vs. Scottish 
controls 372/690 (53.9%), p=0.95 OR 1.01 (0.80-1.26)). (Table 8-3)  
Comparing the allelic frequency in the two available control cohorts showed there 
was no statistically significant difference in allelic frequency (372/690 (53.9%) vs 
3052/5872 (51.9%), p=0.33). We therefore proceeded to analyse the CD cases vs the 
expanded cohort consisting of the sum of WTCCC and Scottish controls. 
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The allelic frequency in early onset CD also did not differ significantly from the 
allelic frequency in the expanded control cohort. (54.1% vs 3052/5872 + 372/690= 
3424/6562 (52.2%), p=0.39).  
Transmission disequilibrium testing (TDT) did not show any distortion of 
transmission in CD trios (p=0.51). No significant differences in genotype or allelic 
frequency of the rs2241880 variant allele were observed between early onset UC and 
controls (G allele frequency 84/174 (48.3%), p=0.18 OR 0.80 (0.57-1.11) versus 




Table 7-4: Genotype and allelic frequencies of ATG16L1 rs2241880 in cases 
(stratified for age at diagnosis <17 years and >17 years) and controls. p-values 
are calculated using genotype/allelic frequency in cases vs. controls. Allelic 
frequency of rs2144880 G differed significantly between CD<17 and CD>17 
(p=0.01). 
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7.1.10 Genotype-phenotype analysis in Scottish childhood onset IBD 
In childhood onset CD, we observed the lowest frequency of the rs2144880G variant 
allele in isolated colonic disease (L2±L4: 87/172 (50.6%)), increasing to 55.4% 
(163/294) in ileocolonic disease (L3±L4) and 62.5% (25/40) in pure ileal disease 
(L1±L4) (p=0.28 OR 1.44 (0.74-2.80), L1±L4 vs other CD locations). Genotype-
phenotype analysis of disease behaviour in children with CD showed no significant 
associations. ANOVA assessment of z-scores of height, weight and BMI at CD 
diagnosis did not show any association with ATG16L1 genotype (p=0.79, 0.61 and 
0.65, respectively). 
 
7.1.11 The influence of ATG16L1 Ala197Thr/rs2241880 on susceptibility 
to adult onset IBD  
rs2144880 was genotyped in our adult IBD cohort, comprising 360 Scottish CD and 
495 Scottish UC patients. When comparing the allelic frequency of rs2241880G in 
the Scottish adult CD cohort with population-matched controls (n=345), a significant 
association of ATG16L1 with CD was present (p=0.01 OR 1.32 (1.07-1.63)).(Table 
8-3). This association was confirmed when we compared Scottish adult CD with the 
expanded WTCCC+Scottish control cohort (60.6% vs 52.2%, p<10-4 OR 1.42 (1.21-
1.66). 
Adult Scottish UC patients did not differ from control subjects when assessing 
genotype or allelic frequency of the rs2241880 variant (G allele frequency 525/990 
(53.0%), p=0.72 OR 0.97 (0.79-1.17)). 
 
Table 7-5: Genotype and allelic frequencies of ATG16L1 rs2241880 in adult + 
childhood onset CD cases and controls. p-values are calculated using 
genotype/allelic frequency in cases vs. controls.  
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OR 1.34  
(1.03-1.74) 
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7.1.12 Genotype-phenotype analysis in adult onset IBD 
In adult onset CD, we observed the lowest frequency of the rs2144880G variant 
allele in isolated colonic disease (55.0% (143/260) in L2±L4), increasing to 56.2% 
(99/176) in ileocolonic disease (L3±L4) and 62.5% (165/264) in pure ileal disease 
(L1±L4) (p=0.08 OR 1.30 (0.96-1.77), allelic frequency in L1±L4 vs. other CD 
locations). Genotype-phenotype analysis of disease behaviour in adults with CD 
showed no significant associations. 
 
7.1.13 Genotype-phenotype analysis in combined childhood and adult 
onset CD cohorts 
A combined genotype-phenotype analysis of early onset and adult onset CD is 
presented in Table 7-5. The allelic frequency of rs2144880G differed significantly 
between patients with L1±L4 and other CD patients (p=0.02, OR 1.34 (1.03-1.74)). 
Binary logistic regression analysis (correcting for NOD2/CARD15 variant carriage, 
IBD5 (OCTN1&2) genotype and age at diagnosis) confirmed the effect of ATG16L1 
rs2241880 genotype (GG) on pure ileal disease vs. pure colonic disease (p= 0.03 OR 
2.43 (1.05-5.65)), in addition to the known effect of NOD2/CARD15 variant carriage 
(p<0.001 OR 3.13 (1.71-5.73)) and older age at diagnosis (p=0.02 OR 1.02 (1.00-
1.03)) per 1 year age increment.  
There was no significant difference in frequency of the rs2241880 G allele between 
males and females with CD (333/584 (57.0%) vs. 399/682 (58.5%), p=0.59 OR 0.94 
(0.75-1.18)).  
ATG16L1 rs2241880 genotype did not influence age at CD diagnosis significantly 
(Kruskal-Wallis test, p=0.51). 
 
7.1.14 Interaction between ATG16L1 and NOD2/CARD15 
In adult CD, we found evidence for an interaction between ATG16L1 and 
NOD2/CARD15. Adult CD patients (>17 years at diagnosis) not carrying any of the 
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3 common NOD2/CARD15 polymorphisms demonstrated a higher frequency of the 
rs2241880G allele than patients carrying at least one variant NOD2/CARD15 allele 
(303/474 (63.9%) vs. 79/148 (53.3%), p=0.02 OR 1.55 (1.07-2.25)) This difference 
between NOD2/CARD15 variant carriers and wild-type cases was not present in 
early onset CD, possibly due to the small number of childhood onset CD patients 
carrying at least one of the NOD2/CARD15 variants (n=59). These findings mirror 
those by Hampe et al. that ATG16L1 germline variation is a risk factor in adult CD, 




7.1.15 The influence of IRGM germline variation on CD susceptibility 
7.1.15.1 Susceptibility analysis in childhood and adult onset CD 
The results of the case-control association analysis are presented in Tables 7-6, 7-7, 
7-8 and 7-9. No association was seen between any of the 4 studied IRGM variants 
and childhood onset CD. Analysis are presented as Scottish CD (overall as well as 
stratified for age <17 and >17 at diagnosis) compared with Scottish Healthy controls 
and the sum of Scottish Healthy controls + WTCCC controls. Healthy control 
genotyope frequencies were not significantly different between Scottish controls and 
WTCCC controls (p>0.05).  
TDT analysis in CD trios was negative for all variants (p>0.05). 
In adult onset CD, the IRGM rs13361189C allele was associated with CD (9.2% vs 
6.8%, p=0.01 OR 1.39 (1.06-1.82)). However, after stringent Bonferroni-correction 
for multiple testing, all IRGM variants studied did not differ significantly between 
CD cases and controls. 
Tables 7-6, 7-7, 7-8: Case-control analysis of rs10065172, rs13361189, rs4958847 
in Scottish CD vs Scottish + WTCCC healthy controls. p*: comparison Scottish 
CD vs Scottish healthy controls. p**: Scottish CD vs sum of WTCCC and 
Scottish healthy controls. p***: Scottish CD stratified for age <17 and >17 vs 
sum of WTCCC healthy controls and Scottish healthy controls.p****: WTCCC 
CD vs WTCCC controls. p*****: Scottish healthy controls vs WTCCC controls.
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Table 7-4: Case-control analysis of IRGM rs10065172 in Scottish CD vs Scottish + WTCCC healthy controls 
IRGM 
rs10065172 






































































































0.007 OR 1.44 
(1.10-1.88) 
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Table 7-5: Case-control analysis of IRGM rs13361189 in Scottish CD vs Scottish + WTCCC healthy controls 
IRGM 
rs13361189 
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Table 7-6: Case-control analysis of IRGM rs4958847 in Scottish CD vs Scottish + WTCCC healthy controls 
IRGM 
rs4958847 
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Table 7-7: Case-control analysis of the IRGM rs6869426 haplotype tagging SNP in Scottish childhood onset CD vs Scottish healthy controls 
IRGM 
rs6869426 






























































Table 7-9: Case-control analysis of the IRGM rs6869426 haplotype tagging SNP in Scottish childhood onset IBD (CD/UC/IBDU) vs 
Scottish healthy controls. Uncorrected p-values are given. 
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7.1.15.2 Detailed sequencing of the 5 IRGM exons 
 
By detailed sequencing of the 5 IRGM exons (including exon-intron boundaries) in 
48 (24 adult + 24 childhood onset) CD patients, we identified 12 variants of which 7 
were informative alleles in our population. (Figure 7-7 represents an overview of 
these variants generated in Haploview to illustrate the LD across this region) The 3 
WTCCC variants genotyped in the whole Scottish CD cohort (rs10065172, 
rs13361189 and rs4958847) were then added to the analysis, giving 10 SNPs to 
perform haplotype analysis on: D‟ 1, paired r
2
>0.82 except with rs4958847. 
Haplotypic variation (of haplotypes with frequency >1%) in this block was tagged by 
the two-marker haplotype consisting of rs10065172 and rs4958847. The informative 
alles were rs13361189 T/C (150,203,580: WTCCC SNP intronic), rs10065172 C/T 
(150,208,191: WTCCC SNP exon 1 (150,207,888-150,208,424) synonymous 
Leucine to Leucine at position 105), rs7705542 G/A (150,208,511: intronic), 
rs4958847 G/A (150,219,780: WTCCC SNP intronic), rs1428555 C/T (150,237,584: 
intronic), rs1428554 A/G (150,237,809: exon 2 (150,237,735-150,237,869) only 
present in 2 isoforms (IRGMc and IRGMe) however this SNP is not translated to 
aminoacid) and rs1428553 G/A (150,237,820: exon 2 (as for rs1428554)). 
It is important to note that even on the most recent version of Ensembl (Release 49 – 
March 2008) the IRGM gene is not recognised as such. The reading frame of the 
genomic region containing the sequence corresponding to the IRGM gene, given on 
Ensembl, does not correspond with the work performed by Bekpen et al.
836
 and by 
Prescott et al. (Natalie Prescott, personal communicaton unpublished data). As the 
numbering by Prescott et al. is the one used in the WTCCC paper, we have used this 
in our analysis. 
Figure 7-7: Detailed sequencing of the 5 IRGM exons (including exon-intron 
boundaries) in 48 CD patients. Of the 12 variants were identified of which 7 
were informative in our population – genotype results of the three WTCCC 
SNPs were added to complement the haplotype analysis: D’ 1, paired r2>0.82 
except with rs4958847. 
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Figure 7-6: Detailed sequencing of the 5 IRGM exons (including exon-intron boundaries) 
 
 
7.1.15.3 Haplotype susceptibility analysis and log-likelihood analysis 
Haplotypic variation (including haplotype frequency >1%) of the genomic region 
containing the IRGM was tagged by the two-marker haplotype consisting of 
rs10065172 and rs4958847. 
This two-marker haplotype was then used to perform a haplotype CD susceptibility 
analysis using Haploview software (10 000 permutations). No significant association 
of either the single markers or the two-marker haplotype was demonstrated. (in both 
the overall Scottish CD cohort and the adult onset CD cohort) 
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We then performed a log-likelihood analysis (1000 permutations) using this two-
marker haplotype, as shown below for the overall Scottish CD cohort:  
Log-likelihood analysis using 2-marker haplotype 
 
Chi-squared statistic for user-specified model = 0.10, df=3, p=0.9918 
Chi-squared statistic for recessive model   = 1.68, df=3, p=0.6414 
Chi-squared statistic for dominant model        = 1.62, df=3, p=0.6548 
Chi-squared statistic for model-free analysis  = 1.78, df=4, p=0.7761 
Chi-squared statistic for heterogeneity model = 1.70, df=3, p=0.6369 
 
Random number seed = 1407 
Number of replicates = 1000 
 
User-specified model chi-squared statistic (0.10) was reached 304 times 
Recessive model chi-squared statistic (1.68) was reached 428 times 
Dominant model chi-squared statistic (1.62) was reached 416 times 
Model-free chi-squared statistic (1.78) was reached 446 times 
Heterogeneity model chi-squared statistic (1.70) was reached 423 times 
 
Empirical p-values for these statistics are as follows: 
T1 - User specified model:       p-value = 0.3040  
T2 - Mendelian recessive model:  p-value = 0.4280  
T3 - Mendelian dominant model:   p-value = 0.4160  
T4 - Model-free analysis:        p-value = 0.4460  
T5 - Heterogeneity model:        p-value = 0.4230 
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Log-likelihood analysis of the adult onset CD cohort is shown below: 
Chi-squared statistic for user-specified model = 0.22, df=3, p=0.9743 
Chi-squared statistic for recessive model        = 3.56, df=3, p=0.3131 
Chi-squared statistic for dominant model        = 3.34, df=3, p=0.3421 
Chi-squared statistic for model-free analysis   = 3.84, df=4, p=0.4281 
Chi-squared statistic for heterogeneity model   = 3.58, df=3, p=0.3105 
 
Random number seed = 1306 
Number of replicates = 1000 
 
User-specified model chi-squared statistic (0.22) was reached 115 times 
Recessive model chi-squared statistic (3.56) was reached 177 times 
Dominant model chi-squared statistic (3.34) was reached 195 times 
Model-free chi-squared statistic (3.84) was reached 195 times 
Heterogeneity model chi-squared statistic (3.58) was reached 175 times 
 
Empirical p-values for these statistics are as follows: 
T1 - User specified model:       p-value = 0.1150  
T2 - Mendelian recessive model:  p-value = 0.1770  
T3 - Mendelian dominant model:   p-value = 0.1950  
T4 - Model-free analysis:        p-value = 0.1950  
T5 - Heterogeneity model:       p-value = 0.1750 
 
 
IBD Genetics in Scottish Children 
229 Ch.7: Autophagy in Northern European IBD: the role of ATG16L1 and IRGM   
 
7.1.15.4 IRGM genotype-phenotype analysis in childhood and adult onset CD 
Detailed genotype-phenotype analysis were performed (based on allelic frequency) 
in childhood and adult onset CD. In both adult onset and childhood onset, the 
Montreal location (at last follow-up but assigned before the first resection) was used. 
In childhood onset, CD behaviour was analysed in the group with at least 2 years 
follow-up. In adult onset disease, CD behaviour was analysed in the group with at 
least 5 years follow-up. Neither disease location nor disease behaviour were 
significantly influenced by any of the 3 IRGM variants (rs10065172, rs13361189 and 




The high incidence of familial disease in children with Crohn‟s disease and 
ulcerative colitis is well-documented, and provides a strong catalyst in the search for 
genes that predispose to early onset disease. Our primary objectives were to establish 
whether the ATG16L1 variant rs2144880A/G and the IRGM variants (rs10065172, 
rs13361189 and rs4958847) are independent determinants of susceptibility to 
childhood onset CD, as suggested in datasets presented by Prescott et al. and 




Although our study was well-powered to replicate the findings in the Prescott and 
Baldassano reports, we did not observe association of the rs2144880G allele with 
childhood onset CD in our population. In our extension studies in the Scottish adult 
population, we were able to demonstrate an effect of this ATG16L1 polymorphism 
on CD susceptibility. Detailed genotype-phenotype analysis showed that the overall 
association signal was driven by a distinct effect on purely ileal involvement, which 
is uncommon in childhood onset disease in Northern Europe. 
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Inadequate power is a common reason for non-replication of positive genetic 
associations, in follow-up studies. Our study involving 269 children with CD had 
more than 97% power to replicate the association of germline variation of ATG16L1 
with susceptibility to early onset CD with an effect size of OR>1.60,  as calculated in 
the two smaller series.
547;828
 (Table 7-1)  
We increased the power of our study even further (to 80% power to detect an effect 
with OR 1.30 in childhood onset CD and OR 1.26 in adult onset CD) by adding the 
WTCCC control cohort to our group of controls. These two sets of controls were not 
significantly different and could therefore be added (comparing the allelic frequency 
in the two available control cohorts showed there was no statistically significant 
difference in allelic frequency (372/690 (53.9%) vs 3052/5872 (51.9%), p=0.33)). 
The allelic frequency in early onset CD also did not differ significantly from the 
allelic frequency in the expanded control cohort. (54.1% vs 3052/5872 + 372/690= 
3424/6562 (52.2%), p=0.39).  
In spite of this power, we did not replicate the association of ATG16L1 with CD in 
our early onset CD case-control analysis (frequency of rs214480 G allele in CD was 
291/538 (54.1%) vs. controls 372/690 (53.9%), p=0.95 OR 1.01 (0.80-1.26)). (Table 
7-3)  
 
We explored two possible explanations for the apparent discordance in results 
compared with other reports. Firstly, by also examining the Scottish adult IBD 
population, we searched for genetic heterogeneity in the contribution of ATG16L1 to 
CD susceptibility between our population and the other populations studied to date. 
We hypothesised that a lack of association in adults, as well as children would 
provide substantial evidence for true heterogeneity between the Scottish and other 
populations analysed so far. In this context, we, and others have previously 
documented striking population-related differences in the contribution of 
NOD2/CARD15.
389
 Recent reports have also described a similar geographical 
gradient for other key components of the innate immune response such as Toll-like 
Receptors 1,4,6 and 10.
835;844
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When comparing the allelic frequency of rs2144880G in the Scottish adult CD 
cohort (comprising 360 CD and 495 UC patients ) with population-matched controls 
(n=345), a significant association of ATG16L1 with CD was present (p=0.01 OR 
1.32 (1.07-1.63)) and confirmed in the expanded control cohort (60.6% vs 52.2%, 
p<10
-4
 OR 1.42 (1.21-1.66)).(Table 7-3)  
 
These positive findings in adult disease are clearly not consistent with the hypothesis 
that the lack of observed association of ATG16L1 with Scottish early-onset CD is 
due to population-specific factors alone. Indeed, further analysis showed that the G 
variant allelic frequency in CD patients <17 years at diagnosis from Scotland, 
differed significantly from Scottish CD patients >17 years at diagnosis (p=0.01) and 
from the other early onset cohorts reported to date.(Tables 7-1 and 7-3)  
 
We therefore investigated, and provided strong evidence in favour of our alternative 
hypothesis, namely that the observed lack of allelic association in our early onset 
cohort related directly to the characteristic disease phenotype of early onset disease, 
specifically the low proportion of isolated ileal disease and the high incidence of 
colonic involvement. The distribution of CD location in our childhood onset cohort is 
comparable to other populations in reports from Northern France, Sweden, Canada 
and the European childhood IBD registry under the auspices of ESPGHAN 
(European Society for Pediatric Gastroenterology and Nutrition).
541;542;569;845-847
  
We found the allelic frequency of the rs2144880G variant to be lowest in isolated 
colonic disease (L2±L4: 87/172 (50.6%)), increasing to 55.4% (163/294) in 
ileocolonic disease (L3±L4) and 62.5% (25/40) in pure ileal disease (L1±L4). This 
trend was also present in adult onset CD. 
Thus, detailed genotype-phenotype analysis demonstrated that this difference in 
contribution of ATG16L1 can be attributed to the relative rarity of pure ileal disease 
in CD diagnosed before the age of 17 years (only occurring in 20/257 (7.8%) of our 
early onset CD cohort).
516
 Indeed, the allelic frequency of rs2144880G differed 
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significantly between pure ileal disease (L1±L4) CD patients and other CD patients 
(p=0.02, OR 1.34 (1.03-1.74)).(Table 7-4)  
 
We confirmed the effect of ATG16L1 rs2241880 genotype (GG) on pure ileal 
disease versus pure colonic disease (p= 0.03 OR 2.43 (1.05-5.65)), in addition to the 
known effect of NOD2/CARD15 variant carriage (p<0.001 OR 3.13 (1.71-5.73)) and 
older age at diagnosis (p=0.02 OR 1.02 (1.00-1.03)) on multifactorial analysis using 
logistic regression, while also controlling for OCTN1&2 (IBD5) genotype. 
 
We have demonstrated that replication of the effect of ATG16L1 on susceptibility to 
CD is critically dependent on the presence of a high ratio of ileal („pure 
ileal‟(L1±L4) + ‟ileocolonic‟ (L3±L4)) disease to colonic („pure colonic‟ (L2±L4)) 
disease in the CD population under study. In our early onset CD population this ratio 
is less than 2 ((20+147)/86), and there is no overall association of ATG16L1 with 
early onset CD in Scotland. In comparison, in the recent report from Philadelphia, 
Baldassano et al. replicated the association of early onset CD and germline variation 
of ATG16L1 in a smaller cohort characterised by a strikingly high frequency of 
ileocolonic CD (86.6%) and a low frequency of isolated colonic disease (5.7%).
547
 
The difference in phenotype between this and other paediatric cohorts bears 
consideration. 
 
In our adult onset cohort, the association of CD with ATG16L1 rs2241880G is 
present with an OR similar to other adult CD studies reported to date. The strong 
effect of disease location on the susceptibility signal provided by the cohort under 
study is further illustrated by the strength of this signal (higher allelic frequency (G 
allele, 63.9%) and OR (1.49)) in the NIDDK IBD GC study which focused on „pure 
ileal‟ CD.
687
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In contrast with the clear evidence in favour of the role of ATG16L1 in CD 
susceptibility in Scotland, is the picture emerging from our analysis of the 3 SNPs of 
greatest significance on the locus containing the IRGM gene.  
Should this come as a surprise? Were we, as a single centre study focussing on 
childhood onset disease, not likely to be underpowered to replicate the latest findings 
of the genome-wide association studies? Or put differently, is the „low-hanging fruit‟ 
been picked with the widespread replication/confirmation of NOD2/CARD15, IBD5, 
IL23R and ATG16L1?  
The answer to the power-question is clearly negative. Our detailed power-
calculations have shown that (admittedly by using the expanded WTCCC control 
cohort + Scottish healthy controls), our overall Scottish CD cohort had 80% power to 
replicate all of the strongest hits on the IRGM locus. 
The composition of our Scottish CD cohort (ie the large proportion of early onset 
disease compared with other cohorts) is another possible explanation for the lack of 
association. Indeed for one of the IRGM variants, we did observe association (based 
on allelic frequency but without stringent Bonferroni-correction) with adult onset 
CD, but not childhood onset. The difference between these two cohorts‟ allelic 
frequencies was not statistically significant (rs13361189: 9.2% in adult onset CD vs 
6.8% in childhood onset CD, p=0.12). The same was true for the two other IRGM 
variants studied. 
In view of our findings for the ATG16L1 variant, we were careful to exclude a 
similar effect of phenotype on the susceptibility signal. For all three IRGM variants, 
no clear distribution of the allelic frequency based on ileal involvement was seen 
(neither in adult onset CD, nor in childhood CD). 
In order to avoid missing population-specific low-frequency variants which would 
not have been sufficiently tagged by the genotyped IRGM SNPs in our CD cohort, 
we resequenced the 5 putative exons and exon-intron boundaries in 48 CD patients. 
According to our analysis, haplotype-frequencies >1% were tagged by the two-
marker haplotype consisting of rs10065172 and rs4958847. Haplotype-susceptibility 
analysis and log-likelihood analysis (both in the overall Scottish CD cohort and the 
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adult onset CD cohort), confirmed the absence of association found on single-marker 
analysis. 
Although the association with germline variation of IRGM was not reported in any of 
the other genome-wide association studies from North-America, Germany/UK and 
Belgium/France, the results of the meta-analysis (involving all except the 
Germany/UK non-synonymous SNP study) of these studies has confirmed IRGM as 
a susceptibility gene with OR 1.35 (Barrett et al, personal communication). The 
smaller sample size of the other genome-wide association studies in comparison with 
the large WTCCC is then likely to have played a role and could also explain why, in 
the frantic world of complex disease genetics, one year on from the first association 
report, replication in an independent cohort has not been published.
471;472;687;688
 It is 
pertinent to point out that our power-calculations indicate that our study had 
adequate power to replicate the OR for all three IRGM variants, reported in the initial 
WTCCC study.   
 
Genetic heterogeneity between the Scottish population and populations of more 
southern latitude, is one possible explanation for not being able to replicate the 
association between CD susceptibility and germline variation of IRGM. The genetic 
precedents illustrated above (eg NOD2/CARD15, TLRs) should be considered 
together with the stiking finding in the WTCCC report of geographic variation within 
the UK of several genomic loci with significance values equal or greater than most of 




A more disconcerting possibility was recently raised by Terwilliger et al.
848
 These 
authors raised doubts about some of the fundamental assumptions of the HapMap in 
terms of estimation of r
2
 and importantly also about the fact that a causal association 
of a particular SNP with disease does not necessarily imply the absence of a three-
way interaction involving disease, the causal locus, and some other marker locus in 
LD with it.
849
 Thomas and Stram argued in response to the doubts raised by 
Terwilliger that „…Although there certainly are examples where gene–environment 
independence might be questionable in candidate gene association studies, this seems 
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unlikely for most situations involving genome-wide scans with SNPs for which there 
is no prior hypothesis about environmental modifiers...‟.
849
  
Whether the LD between loci and the etiological effect of the functional variant are 
independent of each other and whether they are statistically independent of all other 
etiological factors (in exposure and action), is very difficult to ascertain when we 
consider that the suscepitibility genes identified to date all impact on our ability to 
cope with infective exposures.
848
 Then, these caveats may impact on the ability to 
replicate associations in different populations (or even sub-populations of large 
cohorts), who have likely been subjected in the past to different selective (infection-
related) pressures. These caveats become even more important when we consider 
that the rise in incidence of CD over the last 4 decades is clearly 
environmental/epigenetic changes and when we consider how important germline 
variation of the autophagy pathway may have been in selecting out the European 
(and by virtue of migration also North-American) survivors of epidemics (as 
discussed in the Introduction of this chapter). 
 
It is also pertinent to address whether the recent genome-wide association studies in 
CD have provided evidence for the existence of specific childhood onset genes. 
Several adult CD susceptibility genes have been replicated in childhood onset disease 
(NOD2/CARD15, IBD5 locus and IL23R), but only for NOD2/CARD15 there is 
some evidence for a gene-dosage effect on age at diagnosis.
278;660;706;850
 It is 
noteworthy that relatively few early onset patients have been recruited in the 
consortia repositories so far (e.g. 206 children diagnosed with CD before their 17
th
 
birthday out of a total of 1902 in the Wellcome Trust Case Control Consortium).
700
  
Genome-wide association studies in CD to date have relied heavily on sporadic CD 
cases whereas familial disease is typically associated with younger age at diagnosis. 
A proxy-measure of success in identifying early onset IBD genes could thus be to 
assess how many genes have been identified on IBD loci. During the 1990s, these 
IBD loci were identified through the application of non-parametric linkage analysis 
in affected sibling pairs.
389
 Only the NOD2/CARD15 gene (IBD1), markers in the 
HLA locus (IBD3) and markers on the IBD5 locus map to previously identified 
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susceptibility loci.
14;285
 This suggests international collaborative efforts focussing on 
childhood onset IBD will be necessary to identify specific early onset genes on these 
IBD loci. 
 
In summary, we have presented evidence for the important role of disease phenotype 
rather than age at diagnosis in determining the true effect of germline variation of 
ATG16L1 on disease susceptibility. We conclude that ATG16L1 (rs2144880) is 
associated with ileal CD, a relationship that is independent of age at diagnosis. 
We have shown that germline variation of IRGM is not a strong determinant of CD 
susceptibility in Scotland. In contrast with our findings for ATG16L1, no clear 
phenotypic variation underlies this observation. As the genetic landscape of Crohn‟s 
disease is altered by the discovery of new determinants, these data illustrate that it 
remains critical to explore and define clearly genotype-phenotype relationships in at-
risk populations and to assess the contribution of these novel determinants in cohorts 
of different latitude and age at diagnosis.
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8 The role of Filaggrin loss-of-function variants in paediatric 
IBD 
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Introduction 
 
Great progress in our understanding of the genetic susceptibility to IBD has been 
made through the study of common germline variants in genome-wide association 
studies (GWAS).
851
 Barrett et al. have recently reported on the meta-analysis of three 
GWAS from North America, the United Kingdom and Belgium/France: more than 
30 loci have now been identified and replicated satisfying stringent genome-wide 
significance criteria.
694
 Novel pathogenic mechanisms are being proposed and 
genetic evidence is accumulating for the empirical overlap with other auto-immune 
diseases such as psoriasis, ankylosing spondylitis and type 1 diabetes. However, the 
odds ratios (OR) associated with these common variants are small (1.1-1.5) and the 
penetrance of these variants is likely to be very small.
852
 A current estimate of the 
variance in risk for Crohn‟s disease explained by the 32 identified loci is about 10% 
(which equates to about 20% of the genetic risk). Few of the common variants 
identified to date are thought to be the causal variants and while non-synonymous 
SNPs in linkage dysequilibrium or regulatory effects on gene expression are clearly 
important, they do not explain fully the genetic architecture of CD. Further fine 
mapping and direct sequencing are now indicated to search for rare variants on these 
loci. 
 
Rare variants are more likely to have a greater contribution to the individual‟s 
genetic susceptibility to common diseases.
852
 Fine mapping of regions identified 
through previous linkage analysis has elucidated causal variants with a low allelic 
frequency in two genetic success stories which are noteworthy in this context. 
 
In Crohn‟s disease, variants of the intracellular pathogen-associated molecular 
pattern receptor NOD2/CARD15 (especially the 1007 frameshift mutation, allelic 
frequency in healthy controls <2%) with OR of 3.99 in the recent meta-analysis and 
7.71 in our own childhood-onset CD population) dominate in explaining the variance 
in genetic risk to CD.
660;694;709
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In atopic dermatitis (eczema), null alleles of the epithelial barrier protein filaggrin 
(FLG) have been identified as the strongest genetic factor to date, for the 
development of atopic dermatitis.
853-855
 These mutations also cause the semi-
dominant skin-scaling disorder ichtyosis vulgaris.
854;856
 While each of the identified 
FLG null-alleles are relatively rare (minor allele frequency <3% in population 
controls of European ancestry), collectively up to 10% of the population carry at 
least one null-allele.(Figure 9-1) 
 
FLG is located within the epidermal differentiation complex on chromosome 1q21.3, 
a gene cluster expressed late in epidermal differentiation.
857
 Previous linkage 
analysis studies have implicated this locus in susceptibility to atopic dermatitis as 




Filaggrin is a crucial component of the cornified envelope in the outer layer of the 
epidermis.
859
 The cornified envelope is a specialised membrane structure that forms 
during terminal differentiation of keratinocytes and consists of epidermal proteins 
that are cross-linked extensively by transglutaminases and enmeshed with 
keratinocyte-derived lipids, and is as such essential for the barrier function and 




Epidemiological as well as genetic evidence is mounting for an important overlap 
between diseases associated with epithelial barrier dysfunction. Even though atopic 
disease affects up to 25% of the general population, it is more prevalent still among 
patients with IBD.
589;596;860-862
 Immune-mediated disease like atopy, psoriasis, IBD 
and multiple sclerosis have seen a sustained increase in incidence over the last 5 
decades.
597
 Most recently, the GWAS in childhood asthma has added the locus on 
chromosome 17q21 containing the ORMDL3 gene to the long list of shared genetic 
susceptibility determinants involved in both IBD and atopic disease (including 
among others the HLA-region, several interleukins (e.g. IL12B on the IBD5 locus), 
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prostaglandin-receptors, transforming growth factor beta, defensins, Toll-like 

















Figure 9-1: Filaggrin molecular structure, position of loss-of-function variants 
(‘null-alleles’) and respective DNA sequence changes are illustrated (adapted 





In the present study, we aimed to assess the contribution of the rare FLG null-alleles 
to the genetic susceptibility of IBD in the high incidence Scottish childhood-onset 
IBD population. As we have previously shown, this cohort of children with IBD is 
characterised by a high prevalence of atopic disease.
861
 Therefore, we wanted to 
assess what role FLG null-alleles play in the genetic susceptibility to atopic disease 
in childhood-onset IBD. 
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2082 individuals consisting of 403 children with IBD (263 CD, 97 UC, 44 IBD type 
unspecified), diagnosed before their 17th birthday (median age 11.3 years (8.8-
13.1)), their parents (n=683) and 996 unselected paediatric population controls 
(recruited from a birth cohort in a single District General Hospital in Whitehaven, 
West-Cumbria, UK) were genotyped for FLG null-alleles R501X and 2282del4. 
More than 95% of the subjects and population controls were Caucasian. 
IBD was diagnosed by standard criteria.
523
 Detailed sub-phenotypic data based on 
the Montreal classification, have been reported previously.
516;710
 During face-to-face 
interview with each family of which a child was diagnosed with IBD, a detailed 
history was taken by a member of the research team (LS, RKR or JVL) for the 
presence of any family-reported atopic disease: asthma, atopic dermatitis (eczema), 
allergic rhinitis(AR)/hayfever and food allergy (FA). Specifically before marking 
any food allergy, the food antigen and the allergic reaction after exposure to it were 
discussed with the family. As all paediatric IBD patients were recruited for an 
ongoing IBD genetics project, additional food challenges or specific IgE assays were 
not performed as they were not part of the original study protocol which was 
approved by the local ethics committees at the participating centres (Edinburgh, 
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8.1.2 Genotyping 
 
All individuals were genotyped for the FLG null-alleles R501X and 2282del4 using 
the TaqMan system (7900HT sequence detection system; Applied Biosystems, 
Foster City, CA, USA) at the Epithelial Genetics Group, Human Genetics Unit, 
University of Dundee. The FLG R501X and 2282del4 genotype frequencies in 
population controls conformed to the Hardy-Weinberg equilibrium (p>0.15).  
The 3 most common NOD2/CARD15 polymorphisms (R702W, G908R and 





8.1.3 Statistical analysis 
 
Allelic, genotype and carriage of any null-alleles frequencies were compared 
between cases and controls using Pearson‟s χ
2
 or Fisher‟s Exact test (when n<6) 
(Minitab software, Release 13.20, Minitab Inc., State College, PA, USA and 
GraphPad Instat software version 3.06, San Diego, Ca, USA). TDT analysis was 




Uncorrected p-values are given. In IBD and CD, multifactorial analysis (correcting 
for NOD2/CARD15 variant carriage) was performed using Minitab.  The Mann-
Whitney U test was used to assess the relationship between carriage of a FLG null-
alleles with z-score of height, weight and BMI at diagnosis. Z-scores were calculated 
using nomograms from the British 1990 growth reference (Child Growth Foundation, 




IBD Genetics in Scottish Children 
243 Ch.8: The role of Filaggrin loss-of-function variants in paediatric IBD   
8.1.4 Power calculations 
 
Power calculations were performed using QUANTO version 1.2 
(http://hydra.usc.edu/gxe).
528;529
 Based on the most recent prevalence data of Scottish 
paediatric IBD (23/100 000 of the population <17 years), our case-control analysis in 






8.1.5 IBD susceptibility & genotype-phenotype analysis  
 
Association analysis based on allelic, genotype or carriage of at least one FLG null-
alleles frequencies, showed no effect of FLG null-alleles on IBD, CD, UC or IBDU 
susceptibility. (Tables 9-1, 9-2 and 9-3). Family-based association analysis showed 
no distortion of transmission of either the R501X or 2282del4 null-alleles in IBD, 
CD or UC (R501X: all p>0.50; 2282del4: all p>0.40). 
 
Detailed genotype-phenotype analysis based on the Montreal classification, with 
stratification of the CD cases for the presence of atopic disease, showed no effect of 
FLG null-alleles on CD location or behaviour (data not shown). In IBD and CD 
cases, carriage of a FLG null allele had no effect on z-scores of height, weight and 
Body Mass Index at diagnosis (data not shown). 
Table 8-1: Case-control analysis of FLG R501X in childhood-onset IBD, CD, UC and IBDU. 
Table 8-2: Case-control analysis of FLG 2282del4 in childhood-onset IBD, CD, UC and IBDU. 
Table 8-3: Case-control analysis of carriage of at least one FLG null-alleles in childhood-onset 
IBD, CD, UC and IBDU. 
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0.82 0/245 0.48 1/92 
(1.1%) 




















































0.64 0/34 0.16 











0.65 0/68 0.16 
Table 8-2: Case-control: FLG 2282del4 in childhood-onset IBD, CD, UC, IBDU.  
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Table 8-3: Case-control analysis of carriage of at least one FLG null-alleles in 
childhood-onset IBD, CD, UC and IBDU. Out of 378 IBD patients, there were 
only 2 compound heterozygotes (1 CD / 1 UC). 
 
8.1.6 Atopy in childhood-onset IBD  
 
Asthma was present in 25% of IBD patients, eczema in 29%, allergic rhinitis in 21% 
and food allergy in 12% of IBD cases. In total, 52% of IBD patients had at least one 
manifestation of atopic disease. 
 
In IBD and CD cases, carriage of a FLG null-allele differed significantly between 
patients with and those without co-existent atopic disease (13.8% (27/195) vs 6.1% 
(11/179), p=0.01 OR 2.45 95%CI 1.18-5.11 and 16.3% (22/135) vs 7.6% (8/105), 
p=0.04 OR 2.36 95%CI 1.01-5.54, respectively). 
 
The atopic manifestations driving this association in both IBD and CD cases, were 
eczema and food allergy. In IBD cases, stratified for the presence of eczema, carriage 
of a FLG null-allele occurred in 19.3% (21/109) of IBD+eczema cases compared 
with 6.7% (17/254) of IBD without co-existent eczema (p=0.0003 OR 3.33 95%CI 
1.68-6.60). We also observed a significant difference of carriage of FLG null-allele 
between the subgroup of IBD+eczema patients and population controls (19.3% vs 
10.9%, p=0.01 OR 1.95 95%CI 1.16-3.27). 
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Stratifying IBD cases for the presence of food allergy, demonstrated the association 
of co-existent FA in IBD with carriage of a FLG null-allele (28.2% (11/39) vs 8.1% 
(26/322), p=0.0001 OR 4.47 95%CI 2.00-10.00)). The frequency of carriage of a 
FLG null-allele differed significantly between IBD+food allergy cases and 
population controls (28.2% vs 10.9%, p=0.0009 OR 3.21 95%CI 1.55-6.64). 
 
 Stratification for the presence of asthma and allergic rhinits, did not show a different 
carriage frequency of FLG LOFV between IBD cases affected by asthma or allergic 
rhinitis and IBD cases without co-existent asthma or allergic rhinitis. 
 
We demonstrated that atopic co-morbidity additional to the presence of eczema in 
IBD cases, increased the effect size (odds ratio) of the association. Carriage 
frequency of a FLG null-allele was significantly different between: 
 
1) IBD patients with co-existent asthma and eczema (22.9% (11/48) vs IBD 
without asthma and eczema 7.1% (15/210), p=0.001 OR 3.86 95%CI 1.65-
9.08 and vs population controls 10.9%, p=0.01 OR 2.43 95%CI 1.20-4.91) 
 
2) IBD+asthma+eczema+allergic rhinitis (29.2% (7/24) vs IBD without asthma, 
eczema and allergic rhinitis (7.1% (13/184), p=0.0006 OR 5.42 95%CI 1.90-
15.41 and vs population controls 10.9%, p=0.005 OR 3.16 95%CI 1.36-8.30) 
 
 
3) IBD+asthma+eczema+allergic rhinitis+food allergy (45.5% (5/11) vs IBD 
without asthma, eczema, allergic rhinitis and food allergy 6.4% (11/172), 
p=0.0009 OR 12.19 95%CI 3.21-46.35 and vs population controls 10.9%, 
p=0.004 OR 6.80 95%CI 2.04-22.69). 
 
In childhood-onset CD, carriage of a FLG null-allele differed between cases also 
affected by eczema or food allergy and CD cases without (20.3% (16/79) vs 8.7% 
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(14/161), p=0.01 OR 2.67 95%CI 1.23-5.79 and 29.0% (9/31) vs 9.6% (20/208), 
p=0.002 OR 3.85 95%CI 1.56-9.48, respectively). Like in IBD overall, co-existence 
of different manifestations of atopy in addition to eczema and food allergy increased 
the effect size associated with the association: asthma+eczema (p=0.007 OR 3.54 
95%CI 1.35-9.30), asthma+eczema+allergic rhinitis (p=0.0005 OR 7.00 95%CI 2.07-
23.71) and asthma+eczema+allergic rhinitis+food allergy (p=0.004 OR 12.12 95% 
CI 2.54-57.85). Like in IBD, these same associations were also seen when comparing 
paediatric CD cases with increasing atopic comorbidity in addition to eczema with 
population controls (data not shown).  
 
Multifactorial analysis (also correcting for carriage of any of the three CD associated 
variants of NOD2/CARD15) in both IBD and CD cases, showed an association of 
carriage of a FLG null-allele with co-existent atopic disease (p=0.01 OR 2.4 95%CI 
1.2-5.1) and co-occurrence of different forms of atopy (p=0.003 OR 3.5 95%CI 1.5-
8.1). These associations did not alter when NOD2/CARD15 variant carriage and 




We report the first study into the contribution of FLG null-alleles to childhood-onset 
IBD susceptibility and to the high prevalence of co-existent atopic disease in 
childhood-onset IBD. We have demonstrated that the two most common FLG null-
alleles and carriage of at least one FLG null allele, are not associated with increased 
inherited risk to the development of IBD per se. Our study was adequately powered 
to detect effect sizes greater than OR 1.40. 
Our study is consistent with a previous report in adult-onset IBD by  Ruether et al. in 
a population from Northern Germany, also showing no effect of these variants on 
disease susceptibility.
866
 These null-alleles have also been studied in psoriasis and 
rheumatoid arthritis (RA).
867-869
 Autoantibody formation to citrullinated 
(pro)filaggrin has been proven to be a highly specific serological marker for 
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rheumatoid arthritis and the FLG R501X and 2282del4 null-alleles may contribute to 
the development of humoral autoimmunity against citrullinated peptides.
870
 





FLG null-alleles have consistently been shown to be a major genetic risk factor for 
atopic dermatitis and asthma, particularly in the context of atopic dermatitis.
854;872-887
 
A recent meta-analysis has added further weight to this conclusion.
855
 
We have shown that FLG null-alleles influence co-existent atopic disease in IBD, 
particularly eczema and food allergy, with the novel finding of an increased effect 
size (odds ratio) with increasing atopic disease-load. Although decreasing numbers in 
the subgroups of IBD patients with more atopic co-morbidity lead to a widening of 
the confidence intervals associated with the increments in the corresponding odds 
ratios, this trend is noteworthy. 
 
The contribution of the two FLG null-alleles studied in the present report to atopic 
co-morbidity in childhood-onset IBD, is comparable to that in the non-IBD 
population. In the study by Palmer et al., 22.9% (64/279) of patients affected by 
asthma and eczema carried at least one null-allele.
872
 This is identical to the 
percentage of IBD patients affected by asthma+eczema carrying at least one FLG 
null allele in our study (11/48). 
 
The high prevalence of atopic disease in IBD, reported by our group and others, has 
cast further doubt on the relevance of the Th1-Th2 dichotomy to IBD.
583;618;861
 The 
progress made in our understanding of the differentiation of Th17-cells and the 
crucial role of IL23R in susceptibility to CD and UC, illustrate that merely relying on 
the cytokine profiles in immune mediated diseases to classify them as either Th1-
driven or Th2-driven does not do their complex pathogenesis justice.
694;697;702
 
Epidemiological considerations, particularly the „hygiene hypothesis‟, the 
geographical variation in incidence and the higher incidence of CD in more affluent 
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strata of the population, have further substantiated genetic and immunological 
objections to this old paradigm.
566;583;618;888;889
 Genetic overlap between susceptibility 
determinants in a number of immune-mediated diseases, notably different 
manifestations of allergic disease and IBD, have come to light in the course of the 
application of GWAS to the study of these complex polygenic diseases.
890;891
 For 
example, germline variation of the IL12B gene (on the IBD5 locus) has been 
associated with increased susceptibility to asthma and CD and UC.
694;702;727;864
 Also 
in the case of the most recent addition to the list of genetic determinants of asthma, 
the CHI3L1 (chitinase 3-like 1) gene, there is clear evidence for its potential role in 
IBD pathogenesis.
892
 Mizoguchi et al. have shown that CHI3L1 is up-regulated 
specifically in inflamed mucosa (both lamina propria and colonic epithelial cells) in 
several murine colitis models and ulcerative colitis and Crohn's disease patients but 
absent in normal controls. CHI3L1 is required for the enhancement of adhesion and 
internalization of bacteria in colonic epithelial cells CEC.
893
  
Further functional parallels can be drawn when we consider that recent insights into 
the genetic determinants of asthma/eczema susceptibility have illustrated how atopy 
could be the inappropriate adaptive immune process secondary to an altered (innate) 




Of note in our study, is the strong independent association of food allergy with 
carriage of a null-allele in the context of IBD. The expression of (pro)filaggrin in the 
gastrointestinal tract could potentially shed further light on this association. De 
Benedetto et al. recently demonstrated that FLG is not expressed in the oesophagus 
whereas our own data suggest FLG is expressed in the human colon (AT Evans, 
manuscript in preparation) (see Figure 9-2).
895
 The parallels with the absence of 
filaggrin expression in the bronchial mucosa and the strongest effect on asthma in the 
context of atopic dermatitis are striking.
896
 Allergic sensitisation through an altered 
epithelial barrier (either via the skin or the gastrointestinal tract (colon)) could 
conceivably result in local symptoms (in the case of eczema and colitis e.g. 
secondary to cow‟s milk protein allergy (CMPA)) and only secondarily, in organs 
where there is no demonstrable FLG-related epithelial barrier defect via an up-
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Akei et al. have demonstrated that epicutaneous exposure to allergens can potently 
prime for the subsequent development of eosinophilic esophagitis.
897
 In turn, 
gastrointestinal allergy can induce allergic pulmonary responses to specific and 
unrelated allergens.
898
 The intriguing recent observation that an altered colonic flora 
in infancy may precede the onset of atopic disease in the KOALA Birth Cohort 
study, adds further support to the central role in disease pathogenesis now awarded to 
an altered innate immune response (including the epithelial barrier integrity).
599
 The 
study of the innate immune response is therefore correctly receiving increasing 
research interest as a key contributor to the subsequent dysregulated inflammation 
which is of relevance to the pathogenesis of atopic disease and IBD alike. 
 
In summary, we have demonstrated that carriage of FLG null-alleles influences the 
high prevalence of atopic co-morbidity in childhood-onset IBD without a significant 
contribution to the inherited susceptibility of IBD itself. As the contribution of FLG 
null-alleles to atopic co-morbidity in paediatric IBD appears to be similar to that in 
the non-IBD population, other determinants (genetic/environmental) likely underlie 
the higher prevalence of atopic disease in IBD. The identification of relatively rare 
variants as major determinants of inherited susceptibility in both eczema (FLG) and 
CD (NOD2/CARD15) illustrate the need for detailed resequencing and fine mapping 
of the loci identified in the recent series of GWAS. The epidemiological evidence for 
clustering of diseases within families and in individual patients, will undoubtedly 
continue to prompt interest in molecular pathways, identified in co-existent immune-
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Figure 8-2: Expression of Filaggrin in the human gut (3 panels). 
 
Figure 8-2: Expression of Filaggrin in the human gut. Immunoperoxidase 
staining of paraffin-embedded sections was performed by using the ChemMate 
Peroxidase/DAB system (DakoCytomation, Hamburg, Germany). Mouse mAb 
15C10 (Novocastra, Newcastle, UK) was used to detect the human filaggrin 
repeat unit. Antigen retrieval of paraformaldehyde-fixed, paraffin-embedded 
sections was performed by heating sections under pressure for 10 to 15 minutes 
in 10 mmol/L citrate buffer, pH 6.0. (Images by Dr Alan T Evans, Department 
of Pathology, Tayside University Hospitals NHS Trust, Dundee) 
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9 An overview of recent developments in Crohn’s disease 
genetics and concluding remarks 
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Crohn‟s disease (CD) and ulcerative colitis (UC) are chronic relapsing and remitting 
diseases of the gastrointestinal tract, commonly referred to as inflammatory bowel 
disease (IBD). Due to a sharp rise in incidence in the last third of the 20
th
 century, 
IBD now affects up to 1 in 250 of the adult population in the Western world.
1
  
CD distinguishes itself from UC in that the inflammation of CD is characteristically 
discontinuous, transmural (affecting all layers of the bowel wall) and often 
granulomatous. CD inflammation can occur anywhere in the gastrointestinal tract 
from mouth to anus: whereas in adults, disease is often limited to the ileum (the last 
portion of the small bowel) and/or colon, in children, CD is typically more 
extensive.
710
 While treatment advances have reduced IBD mortality considerably, its 
residual morbidity and impact on health care resources can be significant.
565
 Onset 
during childhood and adolescence (up to 25% of all IBD patients) can have 
devastating effects on all aspects of the development of the young IBD sufferer and 
her/his family. The characteristically extensive involvement of the gastrointestinal 
tract in childhood onset IBD and rapid progression of disease are important 




Although the precise aetiology of CD remains elusive, epidemiological data 
conclusively point to a dysregulation of the immune response against the luminal 
flora in a genetically susceptible host. This dysregulation of the immune response is 
often heralded by an acute infective trigger.
97;899
 Although traditional pathogens are 
probably not responsible for IBD, alteration of the composition and function of the 
microbiome (as either a primary or a secondary phenomenon) is the subject of 
intense investigation.
96
 Other environmental factors are thought to be involved but 
there is only a substantive evidence base for smoking and appendicectomy, when it 
was performed without evidence of appendicitis or mesenteric lymphadenitis.
581;595
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Several genetic epidemiological observations provided the impetus to embark on 
larger-scale genetic studies. The high concordance for CD in monozygotic twins 
(36%, compared with 16% for UC), the higher risk of IBD to a first degree relative if 
the  proband has CD (relative risk (RR) 5-35) rather than UC (RR 10-15) as well as 
the high rate of a family history of IBD (up to 30%, especially in cohorts of 
childhood-onset IBD, characterised by a high proportion of CD) have provided 




These observations led to the application of non-parametric linkage analysis in 11 
genome-wide searches for regions of the genome involved in IBD during the 1990s 
(Figure 9-1).
389
 In these studies, cosegregation with CD of a (comparatively) limited 
set of markers spread across the genome was assessed in affected sibling pairs. A 
large number of putative and confirmed linkage regions were thus described and later 
subjected to a meta-analysis.(see figure 9-1)
107;389
 Recently, this family-based 
hypothesis-free linkage approach has come under scrutiny due to the failure of the 
recent genome-wide association studies (GWAS) to identify disease-associated 
variants in many of these previously identified regions. Two issues are noteworthy in 
this respect: the proportion of CD patients recruited into the recent GWAS with a 
family history has been low (e.g. 15% in the Wellcome Trust Case Control 
Consortium (WTCCC)) and linkage analysis was instrumental in the initial 
identification of several of the strongest signals in the recent GWAS, notably IBD1 
(and the subsequent discovery of NOD2/CARD15), IBD3 (including the HLA-
region) and the IBD5 region.(149) 
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Figure 9-1: IBD susceptibility loci and subchromosomal regions which were identified in genome-
wide scans using nonparametric linkage analysis. 
Figure 9-1: IBD susceptibility loci and subchromosomal regions which were 
identified in genome-wide scans using nonparametric linkage analysis 
Reductions in cost of genome-wide strategies with increasing „coverage‟ of the 
genome have facilitated the shift from hypothesis-driven candidate gene research to 
hypothesis-free genome-wide studies: initially using linkage analysis but more 
recently GWAS. The limitations of linkage analysis (access to a large set of affected 
siblings and the lack of power to identify genes of weak effect), have led researchers 
of all common complex polygenic conditions to turn to GWAS, which involves the 
analysis of several hundred thousand markers, distributed across the whole 
genome.(see Table 10-1 for an overview of the GWAS performed to date in CD) The 
scale of these GWAS has necessitated the setting of stringent statistical criteria for 
multiple testing (so called „Bonferroni‟-correction), thus requiring p-values smaller 
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Table 9-1: Overview of the GWAS performed to date in CD 









 IL23R, 10q21.1 „gene desert‟ 








 IRGM, NKX2-3, PTPN2, 3p21 












 TNFRSF6B, PSMG1 
Table 9-1: Overview of the GWAS performed to date in CD 
 
Following the recent „gold rush‟ in identifying common variants with small effect 
size on the genetic susceptibility to CD, interest has been renewed interest in 
„candidate-gene analysis‟ of loci identified through GWAS which can be very gene-
dense and characterised by an extended haplotype structure (e.g. the HLA-region), 
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both of which can hamper the identification of causal variants using classical genetic 
techniques. 
 
In this chapter, I will describe the loci, identified to date, which have made the 
strongest impact on our understanding of CD pathophysiology and/or provide strong 
therapeutic potential. These loci encode genes involved a number of homeostatic 
mechanisms:  innate pattern recognition receptors (NOD2/CARD15, TLR4, 
CARD9), the differentiation of Th17-lymphocytes (IL23R, JAK2, STAT3, CCR6, 
ICOSLG), autophagy (ATG16L1, IRGM, LRRK2), maintenance of epithelial barrier 
integrity (IBD5, DLG5, PTGER4, ITLN1, DMBT1 and XBP1) and the orchestration 
of the secondary immune response (HLA-region, TNFSF15/TL1A, IRF5, PTPN2, 
PTPN22, NKX2-3, IL12B, IL18RAP, MST1). 
 
Complementary to the GWAS performed to date focussed on adult CD, the 
assessment of individuals with a younger age of disease onset and a characteristically 
more extensive phenotype, is likely to prove valuable, as shown recently for 
asthma.(95) I will therefore also discuss the relevance of GWAS in determining the 
genetic susceptibility to childhood-onset IBD, as we have contributed nearly 500 
samples to the GWAS performed by the international pediatric IBD genetics 
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Further fine mapping of the region on chromosome 16 (IBD1), which was first 
identified by Hugot and colleagues in 1996, led to the identification of the 
NOD2/CARD15 gene (nucleotide-binding oligomerisation domain 2)/CARD15 
(caspase activation recruitment domain 15).
14
 Its discovery was one of the first 
success stories in complex polygenic disease genetics and has been responsible for a 




NOD2/CARD15 is a member of a family of intracellular pattern-recognition 
receptors (PRRs) which recognise microbial components. Muramyl dipeptide 
(MDP), a degradation product of peptidoglycan derived from the cell wall of Gram-
negative and Gram-positive bacteria, are recognised by the Leucine Rich Repeat 
(LRR) domain of NOD2/CARD15.(see Figure 9-2) NOD2/CARD15 expression 
appears to be limited to Paneth cells, which are located at the base of the intestinal 
crypts, and influenced by inflammatory cytokines like Tumour-Necrosis-Factor-
α.
193;435
 The three main CD associated NOD2/CARD15 variants (accounting for 
>80% of the identified germline variants) are situated in or close to the LRR-domain 
and are thought to interfere with bacterial recognition.
18;20
 The association of 
NOD2/CARD15 variants with increased susceptibility to CD was confirmed in two 
comprehensive meta-analyses.
468;469
 Initial optimism about the proportion of 
population attributable risk explained by these variants has been tempered by the 
observation that homozygosity/compound heterozygosity for the disease associated 
alleles is not underrepresented in Caucasian healthy controls.
902
 Nevertheless, 
germline variation of NOD2/CARD15 has remained the strongest genetic 
determinant of genetic CD susceptibility (Odds Ratio 3.99 in the recent GWAS meta-
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analysis).
694
 The association of NOD2/CARD15 variant carriage with disease 
phenotype has been driven especially by ileal disease and the reduced secretion of α-
defensins by ileal Paneth cells in patients carrying NOD2/CARD15 variants is 




Although functional analyses in human peripheral mononuclear cells point to a „loss 
of function‟ due to the CD associated polymorphisms, related to an MDP sensing 
defect, NOD2/CARD15 signalling is but one instrument in an orchestra of innate 
immunity signalling pathways.
17;666
 Illustrative of this complex regulation were the 
conflicting early results reported on the interaction between TLR-2 and wildtype 
NOD2/CARD15 signalling by Watanabe et al. and Netea et al. 
383;386
 More recently, 
additional experiments by Clark et al. have shown the crucial role of a MAP3K, 
MEKK4, in regulating the signal transduction beyond NOD2/CARD15 through the 
activation of RIP2 and NFkB.
903
 Uninhibited NOD2/CARD15 signalling is 
associated with hyporesponsiveness to both TLR2 and TLR4 ligands.
903;904
 This 
induction of cross-tolerance to TLR4 signalling is lost in CD patients homozygous 





Two additional ways of NOD2/CARD15 regulation have recently been described. A 
short isoform of NOD2/CARD15, NOD2-S, which lacks the third exon (thus 
encoding for a protein that is truncated within the second CARD domain), is 
preferentially expressed in the human colon and is up-regulated by the anti-
inflammatory IL10.
457
 Overexpression of NOD2-S down-regulates NOD2/CARD15-





A second type of regulation of NOD2/CARD15 function depends on the recently 
described 5' UTR splice forms of NOD2/CARD15.
905
 These isoforms not only show 
a TNF-α/intestinal inflammation-sensitive expression pattern but also link 
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NOD2/CARD15 regulation with the autophagy response (which will be discussed 
later), through a rapamycin-sensitive inhibitory effect of these novel upstream Open 




In view of the recent associations of CD genetic susceptibility with TLR4 and 
CARD9 polymorphisms (as discussed below and see figure 9-2), these single or dual 
pathway experiments are clearly not appropriate to understand the full complexity of 




The failure to reliably identify genetic interaction between the large number of 
genetic variants identified to date, does not necessarily mean an absence of 
interaction at the functional level.
694
 As the physiological mucosal immune response 
keeps the systemic immune response largely ignorant of the luminal epitopes and 
flora, and local immune responses are orchestrated in a tissue-specific manner in a 
complex interaction between intestinal epithelial cells and immune-effector cells, 
observations in transfected cell lines or even human peripheral blood mononuclear 
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Figure 99-2: Innate immunity pattern – recognition receptors and signal transduction pathways 
of relevance to IBD pathogenesis. 
Figure 9-2: Innate immunity pattern – recognition receptors and signal 
transduction pathways of relevance to IBD pathogenesis. TLR: Toll-like 
receptor. LPS (Lipopolysaccharide) triggers signalling through TLR4 after 
associating with LPS binding protein, CD14 (a glycosylphosphatidylinositol 
linked protein expressed on the cell surface of phagocytes) and MD2. Except for 
TLR3, all TLR signalling is MyD88-dependent. Activation of a collection of 
downstream kinases (IRAKs: IL-1 receptor associated kinases) leads to the 
degradation of the IKK complex and activation of NF-κB via TRAF-6 (TNF 
receptor-associated factor 6). NOD2/CARD15 (Nucleotide binding 
Oligomerisation Domain 2/ Caspase Recruitment Domain-containing protein 
15) is an intracellular receptor for Muramyl Dipeptide (MDP). RIPK2 
(Receptor-interacting serine/threonine-protein kinase 2) interacts with 
NOD2/CARD15 through a CARD-CARD interaction. This activation then 
further initiates various signalling pathways, including activation of NF-κB. 
CARD9 is located at a crossroads between TLR-NOD2/CARD15 receptors and 
connects NOD2/CARD15 also to MAPK signalling. 
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9.1.2 TLR4  
 
Germline variation of the TLR genes in CD has received much interest.
389
 TLR2 
(4q31.3), TLR3 (4q35.1), TLR4 (9q33.1) and TLR9 (3p21.3) are all located in 
regions associated with IBD by genome wide searches.
107
 While TLRs 1,2 and 6 
have been associated with extensive colonic IBD in a Flemish case-control study, it 
has been the inherited variation of TLR4 that has been studied most.
303
 Two 
independent meta-analyses have recently confirmed the association of the TLR4 
Asp299Gly polymorphism with CD.
395;909
 Genetic interaction with specific 
NOD2/CARD15 haplotypes, strengthening the association of this polymorphism 




TLR4, located on the cell membrane, binds a very divergent collection of ligands 
such as LPS, the fusion protein of respiratory syncytial virus, a subunit of bacterial 
fimbriae, fibronectin, β-defensin and heat-shock proteins.
666
 Matzinger et al. have 
proposed that these receptors have evolved to bind to specific hydrophobic portions 
of molecules like defensins, uric acid, LPS, peptidoglycan, lipoteichoic acid and 
many other immunostimulatory microbial products (e.g. flagellae) which are exposed 




In addition to the interaction between TLR4 signalling and NOD2/CARD15 
activation described above, TLR4 signal transduction is highly complex (Figure 10-
2).
666
 Of the large number of interacting molecules, associations of CD with germline 
variation of CD14, TIRAP (TIR domain-containing adapter protein) and MAST3 
(microtubule-associated serine/threonine-protein kinase gene-3) have been described 
but are awaiting further replication.
666;909;910
 Functional studies into the effects of 
TLR4 polymorphisms (mainly focussed on single marker analysis rather than the 
Asp299Gly/Thr399Ile-haplotype, which is more common in populations of European 
ancestry) have been legion but not conclusive to date.
911
 The cytokine phenotype of 
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the Asp299Gly/Thr399Ile-haplotype does not differ from the wildtype TLR4 
whereas the Asp299Gly/wt haplotype (found almost exclusively in Africa) has a 
stronger pro-inflammatory cytokine profile compared with wildtype TLR4. One 
hypothesis states that TLR4 Asp299Gly has evolved as a protective allele against 
malaria, explaining its high prevalence in sub-Saharan Africa,  whereas the same 
allele could have been disadvantageous after migration of modern humans into 






In their candidate-gene analysis of 85 genes involved in innate immune pathways in 
1851 IBD patients (1062 CD, 789 UC) and 1936 controls, Zhernakova and 
colleagues identified the locus on 9q34.3 containing the CARD9 gene (rs10870077) 
and confirmed replication in the Wellcome Trust Case Control Consortium(WTCCC) 
GWAS dataset.
901
 The implication of CARD9 as a CD susceptibility gene has been 
particularly interesting in view of its functional properties, linking TLR, 
NOD2/CARD15 and C-type lectins like Dectin-1 (and thus innate immunity against 
fungi e.g. C.Albicans) with the adaptive immune response, notably T-cell 
differentiation and the development of Th17-cells (via IL23).
747;913-915
 Furthermore, 
CARD9 is located at a crossroads between TLR-NOD2/CARD15 receptors on the 
one hand (via RIP2 it connects NOD2/CARD15 to MAPK signalling), and 
immunoreceptor tyrosine-based activation motif (ITAM)-tyrosine kinase receptors 




Acosta-Rodriguez et al. demonstrated that C.Albicans preferentially induced the 
differentiation of Th17 cells which expressed CCR6, a mucosa-homing receptor, and 
CCR4, a skin-homing receptor, as well as the transcription factor RORγt, which is 
essential for the differentiation of Th17 cells.
917
 Germline variation of CCR6 has also 
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Another member of the CATERPILLER family of genes, encoding proteins that 
comprise a nucleotide-binding domain and a leucine-rich repeat domain, NLRP3 (on 
Chromosome 1q44) encodes cryopyrin.
311;446
 Cryopyrin is involved in the 





The importance of cryopyrin in inflammation is highlighted by gain-of-function 
mutations within its NOD domain that are associated with three hereditary periodic 
fever syndromes: Muckle-Wells syndrome, familial cold autoinflammatory 
syndrome and neonatal-onset multisystem inflammatory disease.
410;411;919
 
Hyperproduction of IL-1β is thought to be a central event leading to symptoms in 
these three syndromes. Consistent with these observations is the successful use of IL-
1β targeted therapy for treating Muckle-Wells syndrome and familial cold 
autoinflammatory syndrome.
411;919
 Contrary to the gain-of-function mutations of 
these conditions, Villani and colleagues, using a candidate gene approach, uncovered 
a regulatory region downstream of NLRP3 that contributes to Crohn‟s disease 
susceptibility and is associated with hypoproduction of IL-1β and decreased NLRP3 
expression. The risk allele of rs6672995, located in a predicted regulatory region, 
was associated with a decrease in LPS-induced IL-1β production, and the risk allele 
of rs4353135 was associated with a decrease in baseline NLRP3 expression in two 
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The differentiation of Th17-lymphocytes: IL23R, JAK2, STAT3, CCR6, 
ICOSLG 
 
In response to the signalling of the innate immune response, the next level of 
coordination of defence against specific pathogens and the mediation of different 
types of tissue-specific inflammation is at the level of T helper (Th) cells which 
constitute an important arm of the adaptive immune system.
921
 Within this family of 
T helper cells, the recently discovered Th17 subgroup has received intense research 
interest of late.
618
 The antiquated Th1/Th2 dichotomy has now been replaced with a 
more appropriate set of CD4+ lymphocyte populations distinguished on the basis of 
Cluster of Differentiation-markers, effector cytokines-profile and transcription 
factors.  The differentiation of naïve CD4+ T cells can take several distinct paths. In 
Figure 10-3, we have illustrated the differentiation into pro-inflammatory Th1, Th2 
and Th17 cells. It is however important to remember that the same naïve CD4+ T 
cells can differentiate into regulatory and anti-inflammatory T cell populations such 
as the transcription factor FOXP3-expressing T regulatory cell population (Treg) and 
the FOXP3-negative T regulatory type 1 (Tr1) population.
921;922
 TGF-β 
(Transforming growth factor β) via SMAD molecules (Small Mothers Against 
Decapentaplegic), IL27 and ICOS (inducible T cell co-stimulator receptor) signalling 
are crucial in the regulation of this type of differentiation.
696;697;922
 ICOSLG 
(inducible T cell co-stimulator ligand), a co-stimulatory molecule expressed on 
intestinal (and other) epithelial cells, may therefore have a role in their antigen 
presentation to and regulation of mucosal T lymphocytes.
923
 Germline variation of 
ICOSLG has recently been identified as a contributor to the genetic susceptibility for 
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Figure 9-3: T helper cell differentiation from naïve T cell to Th1, Th2 and Th17 cells.  
 
Figure 9-3: T helper cell differentiation from naïve T cell to Th1, Th2 and Th17 
cells. Th1 differentiate into Th1 cells, under the influence of IL12 and IFNγ. Th2 
cells differentiate from naïve CD4+ T cells under the influence of IL4 and IL13.  
Th17 cells (characterised by the transcription factor ROR- γ-t) differentiate 
under the influence of TGF-β and IL6. Th17 cells produce not only IL17 
(IL17A, IL17F) but also IL22 and IL21. The role attributed to IL23 is not that 
of active induction of differentiation of naïve T cells, but rather to stabilise the 
already differentiated Th17 subpopulation. 
 
Along the pro-inflammatory axis, naïve CD4+ T cells can differentiate into Th1 
cells, under the influence of IL12 and  interferon-γ (IFN-γ).
921
 They typically 
produce interferon-γ (IFN-γ), regulated by the transcription factor T-bet, and mediate 
protection against intracellular pathogens (e.g. through the induction of autophagy as 
illustrated later).
921
 Th2 cells differentiate from naïve CD4+ T cells under the 
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influence of IL4 and IL13. Their effector cytokines are IL4, IL5 and IL13, produced 
under the influence of the transcription factor, GATA3. Th2 cells mediate clearance 
of extracellular pathogens and IgE-mediated immune responses and allergy.
860
 Th17 
cells (characterised by the transcription factor ROR- γ-t) differentiate under the 
influence of TGF-β and IL6.(see Figure 10-3) Th17 cells produce IL17A, IL17F, 
IL22 and IL21. The role attributed to IL23 is not that of active induction of 





IL23 is a binary complex of a four-helix bundle cytokine (p19) and a soluble class I 
cytokine receptor p40. IL23 and IL12 share p40 as an alpha-receptor subunit 
(encoded by the IL12B gene which will be discussed later), yet show only 15% 
sequence homology between their four-helix cytokines p19 and p35, respectively, 
and signal through different combinations of shared receptors.
924
 IL23 signals 
through a heterodimer-receptor composed of the IL12R β1 chain (also a portion of 
the IL12 receptor) and a specific IL23R subunit. Downstream of the IL23 receptor, 
autophosphorylation of JAK2 followed by homodimerisation of STAT3 are required 
for the STAT3-homodimer to translocate to the nucleus and exert its effects on gene 
transcription.(see Figure 10-3) The Th17 transcription factor ROR- γ-t induces the 
expression of IL23R in response to IL21, which itself depends on IL6-mediated 




In animal models, the Th17 T cell subset has been shown to mediate chronic and 
autoimmune inflammatory conditions, with a central role for IL23 in the 
development of intestinal disease.
741
 Increased expression of IL17 and IL23 has been 
demonstrated in IBD.
750;754
 A wide range of microorganisms, including Gram-
positive and Gram-negative bacteria, Mycobacterium tuberculosis as well as fungi 
(e.g. Candida Albicans) can trigger a Th17 response.
921
 The NOD2/CARD15 ligand, 
MDP, can also promote the production of Th17 cells.
746
  A swift influx of Th17 cells 
at sites of inflammation could indicate a crucial role in connecting the innate and 
adaptive immune responses. Khader and colleagues have shown that this is also the 
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case after Mycobacterium tuberculosis challenge: the Th17 response is required to 




The impetus for the detailed study of the IL23 signalling pathway in CD 
susceptibility came from the discovery of association of germline variation of the 
IL23R gene with CD in the first published GWAS by the North American IBD 
Genetics Consortium in 2006.
470
 Although initially identified in a cohort of ileal CD, 
IL23R germline variation has subsequently also been associated with UC.
700-702
 
Recently, germline variation of both JAK2 and STAT3 has been implicated in the 
pathogenesis of CD by the meta-analysis of GWAS.
694
 It is noteworthy that, before 
the studies discussed below implicated the IL23 signalling pathway in CD, functional 
data in the mouse model characterised by ileal inflammation, the Samp1/Yit mouse 
already demonstrated STAT3 activation via IL6.
695
 The first therapeutic trial of a 
monoclonal antibody, ustekinumab, targeting the common p40 subunit of IL12 and 
IL23 (encoded by the IL12B gene which will be discussed later), has shown 




The North American IBD genetics consortium performed a genome-wide association 
study testing 308,332 markers in 567 ileal CD patients and 571 controls of non-
Jewish European ancestry.
470
 The same authors demonstrated replication of the 
protective effect of the rare IL23R allele (Arg381Gln, frequency 1.9% in non-Jewish 
ileal CD vs. 7.0% in non-Jewish controls) in an independent case-control association 
study of Jewish ileal CD patients, as well as in a family-based association analysis 
(n=833). The first replication studies of this variant came from the UK. The 
Wellcome Trust Case Control Consortium (WTCCC) replicated the protective effect 
of the rare IL23R allele in CD (n=1902) and UC (n=975) versus healthy controls 
(n=1345).
700
 In our own cohort of childhood onset IBD, case-control analysis (IBD 
n=358, controls n=342) and family-based association analysis confirmed these 
findings.
706
 Since these initial studies, the association of CD with this locus has been 
replicated widely and confirmed recently in the GWAS where the rs11465804 
variant (D‟=1 and r
2
=0.88 with the Arg381Gln variant (rs11209026))achieved a 
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highly significant p value of 10
-63
 in the combined cohort, with in the case-control 




The index study by Duerr et al. had already shown that the signal of this locus was 
not limited to the Arg381Gln variant of the IL23R gene. Our own group and others 
have since performed haplotype-tagging strategies to confirm this effect of gene-
wide variation of IL23R on the genetic susceptibility to CD.
704;705;707
 As several 
variants across the IL23R gene contribute to the CD susceptibility signal, it is 
difficult to identify their genotype-phenotype relationship and their effect on IL23 
receptor function. Similar to the IL23R locus, the loci containing the JAK2 and 
STAT3 genes are currently the subject of detailed resequencing efforts and 
functional studies to identify the causal variants. 
 
IL17 producing T-cells have also been detected in the memory population of 
peripheral blood mononuclear cells, characterised by the combined expression of 
Chemokine Receptors 4 and 6 (CCR4 and CCR6).
917
 As mentioned above, germline 
varation of CCR6, which encodes a member of the G protein–coupled chemokine 
receptor family, has been found to predispose to CD in the meta-analysis of 
GWAS.
694
 CCR6 is a homing receptor, expressed by immature dendritic cells and 
memory T cells and is important for B-cell differentiation and tissue-specific 
migration of dendritic and T cells during epithelial inflammatory and immunological 
responses.
927
 The ligand of this receptor is CCL20, also known as macrophage 
inflammatory protein 3 a (MIP-3a). Colonic epithelial cells have been shown to 




As illustrated before for the innate immunity against fungi, linking C-type lectins 
with CARD9 signalling and the differentiation of Th17 cells, the innate immune 
system‟s priming of the secondary immune response is slowly being unravelled. 
Recently CCL20 dependent signalling (together with β-defensin-3) has been shown 
as crucial in the development of murine intestinal lymphoid follicles (ILFs) in 
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response to NOD1/CARD4-mediated recognition of the commensal intestinal 
flora.
929
 In the absence of these ILFs, the composition of the intestinal bacterial 
community is profoundly altered, demonstrating that intestinal bacterial commensals 
and the immune system communicate through an innate detection system to generate 




Autophagy: ATG16L1, IRGM, LRRK2 
 
Several loci containing autophagy genes (ATG16L1, IRGM and LRRK2) achieved 
genome-wide significance in the CD GWAS meta-analysis.
694
 Autophagy denotes 
several distinct processes involving the delivery of portions of the cytoplasm to the 
lysosome for degradation (chaperone-mediated autophagy, micro-autophagy and 
macro-autophagy) with emerging evidence for distinct regulation of selective 
(directed against micro-organisms or protein aggregates) and non-selective 
autophagy (induced in response to cellular starvation).
756
 Autophagy has been 
studied in a myriad of homeostatic mechanisms relevant to CD pathogenesis: 
containment of inflammation by eliminating pathogens and controlling NF-kB 
signalling, tumour biology, resistance against pathogen-induced cell death and 
recently also in the biology of the Paneth cell.
832;833
 The complex regulation of both 
selective and non-selective autophagy is illustrated in Figure 10-4. 
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Figure 9-4: The complex regulation of non-selective and selective autophagy. 
 
Figure 9-4: The complex regulation of non-selective and selective autophagy. A 
wide range of non-selective stimuli (e.g. glucose, insulin, nutritients and growth 
factors) can trigger non-selective autophagy. Rapamycin is one of the increasing 
number of available options to modulate the autophagy response. The 
autophagic response to bacteria, the interaction with pattern-recognition 
receptors (Toll-like and NOD-like) and the antigen-presentation to the adaptive 
immune system via MHC Class II molecules are illustrated 
 
Autophagy can eliminate invading microbes in a highly specific manner in a process 
termed xenophagy (Figure 10-4), rather than causing the organism to dispose of the 
infected cell.
761
 While autophagy has been implicated in the response against a wide 
range of invasive pathogens, the autophagic response against Mycobacterium 
tuberculosis is particularly relevant in CD pathogenesis.
930
 Singh et al. showed that 
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the murine Irgm1 protein (Immunity-related p47 guanosine triphosphatase, also 
called LRG47) is critical in the IFN-γ-induced autophagy response against M. 
tuberculosis.
837
The intracellular survival of  M. tuberculosis is dependent upon its 
ability to arrest phagolysosome biogenesis, avoid direct killing mechanisms in 
macrophages, and block efficient antigen processing and presentation.
931
 The 
Mycobacterium-imposed block in phagolysosomal maturation can be overcome by 




Recent reports by Sanjuan and Xu help explain how pathogens that have gained 
access to the cytosol are recognised by the autophagic machinery. Sanjuan et al. 
showed the link between Toll-like Receptor (TLR) signalling in macrophages and 
Atg5/Atg7-dependent autophagy and phagocytosis.
779
 Previously, Xu and colleagues 
had demonstrated that TLR4-induced autophagy was regulated through a Toll-
interleukin-1-receptor-domain-containing-adaptor-inducing-interferon-beta (TRIF)-
dependent signalling pathway also involving Receptor-interacting-protein-1 (RIP1) 
and p38 mitogen-activated-protein-kinase (MAPK), independent of the signal 




Interaction between NOD-like receptor signalling and autophagy was demonstrated 
by Nuñez et al: Shigella-induced caspase-1 activation and cell death in macrophages 
are mediated through Ipaf, a cytosolic pattern-recognition receptor of the NLR-
family and the adaptor protein apoptosis-associated speck-like protein containing a 
C-terminal caspase recruitment domain.
933
 How NOD2/CARD15-signalling and 
autophagy interact is currently the subject of intense investigation. 
 
Autophagy provides another type of protection from bacterial pathogenesis during 
Vibrio cholerae infection.
760
 Gut epithelial cell lines resist cell death in response to 
the haemolytic exotoxin cytolysin of this this noninvasive enteropathogen through 
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Autophagy also plays a role in the priming of the adaptive immune response. 
Autophagy promotes MHC class II presentation of cytosolic antigens whether 
endogenous, bacterial, viral or tumour-derived.
936-940
 This additional role of 
autophagy is important in the presentation of self-antigens in the newborn thymus 
(enabling thymic epithelial cells to present self-antigens to lymphocytes during 







Hampe et al. demonstrated association of CD with a coding variant of the Atg16L1 
gene (Autophagy-related 16-like 1 gene).
688
  Rioux et al. later showed that autophagy 
induced by S. Typhimurium was significantly different in Atg16L1 knockdown 
conditions.
687
 Glas et al. confirmed these findings in CD patients and in murine 
ileitis.
827
 This genetic association has now been replicated in several independent 
cohorts.
472;687;694;731;732;827;944
 Our own group and Fowler et al. have provided 
evidence that the widely replicated association of CD with ATG16L1 is driven by 
ileal disease.
945;946
 In the study by Hancock and colleagues into the genetic 




Recent reports by Cadwell, Saitoh and Kuballa constitute a real breakthrough in our 
understanding of ATG16L1 function.
832
 Cadwell and colleagues showed that, in the 
epithelium of the ileum, ATG16L1 and ATG5 are crucial for Paneth cell biology.
832-
834
 ATG16L1-deficient Paneth cells exhibit notable abnormalities in the granule 
exocytosis pathway and increased expression of genes involved in peroxisome 
proliferator-activated receptor (PPAR) signalling as well as several acute phase 
reactants and adipocytokines (notably leptin and adiponectin). Crohn‟s disease 
patients homozygous for the risk allele, identified by Hampe et al., displayed Paneth 
cell granule abnormalities like those observed in ATG16L1-deficient mice.
832
 Saitoh 
and colleagues, on the other hand, showed in ATG16L1-deficient mice that 
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ATG16L1 is required to survive the period of neonatal starvation, as shown before 
for ATG5 and ATG7, and that these mice displayed an increased severity of dextran 
sulphate sodium-induced colitis.
833
 Loss of ATG16L1 in macrophages caused 





Kuballa and colleagues demonstrated how in human epithelial cells, the CD-
associated ATG16L1 coding variant shows impairment in the capture of internalized 
Salmonella within autophagosomes.
834
 Together these studies show a number of 
autophagic defects in distinct cell types of the intestinal epithelium, thus attributing 
the increased risk of Crohn's disease to both impaired bacterial handling 




Another autophagy gene, IRGM, was implicated by the WTCCC study.
472
  IRGM 
belongs to the p47 immunity related GTPase family. Its mouse homolog, LRG-47 
(encoded by IRGM), critically controls intracellular pathogens by autophagy, and 
Irgm
–/–
 mice show markedly increased susceptibility to Toxoplasma gondii and 
Listeria monocytogenes.
838
 The role of IRGM in protecting mature effector CD4+ T-
lymphocytes against IFN-γ induced autophagic cell death, has demonstrated a 
feedback mechanism in the Th1 response that limits the detrimental effect of IFN-γ 




IRGM expression in macrophages is stimulated in vitro by bacterial LPS, one of the 
TLR4 ligands, via STAT1 and IFN-β.
948
 LPS-stimulated IRGM-deficient 
macrophages display enhanced phosphorylation of p38, a downstream response 
associated with TLR4/MyD88 rather than IFN-β /STAT-1 signalling.  
Bafica and colleagues therefore suggested that in LPS-stimulated (murine) 
macrophages, IRGM is induced by IFN-β and negatively regulates TLR4 signalling 
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to prevent excess proinflammatory cytokine production and shock.
948
 The parallel 
with NOD2/CARD15-mediated downregulation of TLR signalling, as discussed 
above, is noteworthy. A CD-related alteration in IRGM regulation, due to a common 
deletion polymorphism, identified recently by McCarroll et al. in the promoter region 
of IRGM, that affects the efficacy of autophagy or the downregulation of TLR4-




Our own data and a paediatric GWAS have not found an association between 
germline variation of IRGM and paediatric CD.
732;949
 This indicates that the 
contribution of IRGM to the genetic susceptibility is smaller than in adult CD (Odds 
Ratio <1.40). Larger pediatric cohorts are therefore necessary to confirm or exclude 




The meta-analysis of GWAS in CD identified the gene LRRK2 (leucine-rich repeat 
kinase 2).
694
 Little is known about the role of LRRK2 in autophagy.  The role of 
LRRK2 mutations in the pathogenesis of CD also remains undefined. Conversely, 
LRRK2 mutations are the single most common genetic cause of Parkinson disease, 
another autophagy-mediated condition.
841
 Transfection of LRRK2 cDNA containing 
the common G2019S mutation resulted in significant decreases in neurite length and 
increased autophagic vacuoles.
842
 RNA interference knockdown of key autophagy 
molecules reversed the effects of G2019S LRRK2 expression on neuronal process 
length, whereas rapamycin (an inducer of autophagy via inhibition of the mTOR 
regulatory molecule) potentiated these effects. 
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Maintenance of epithelial barrier integrity: IBD5, DLG5, PTGER4, 




Mutations within the organic cation transporter genes (OCTN1&2), located in the 
IBD5 locus on Chromosome 5q31,  were first identified by Peltekova et al.
281
 These 
authors identified mutations within OCTN1 (1672C/T) and OCTN2 (207G/C)) and 
found an association of the TC-haplotype and increased susceptibility to CD in the 
Canadian population.
281
 A large number of positive replication studies and 
identification in the meta-analysis of GWAS, have confirmed IBD5 as a CD 
susceptibility locus.
694;950
 Detailed analysis in the Canadian and other populations, by 
inclusion of other polymorphisms on the IBD5 locus, has demonstrated that several 
other genes within this cytokine gene cluster are as likely to be the causative 
gene.
269;285
 However, Barrett et al. showed, using eQTL (expression quantitative trait 
locus) analysis, an approach which seeks to correlate genotype and expression 
patterns and takes into account that such functional relationships need not respect the 
specific boundaries of LD around the association, that CD-associated SNPs were 
associated with decreased SLC22A5 mRNA expression.
694
 Several studies in adult 
and childhood onset CD, have suggested the IBD5 risk haplotype is associated with a 






DLG5 (Drosophila Discs Large Homolog 5) gene, a member of the MAGUK 
(Membrane Associated Guanylate Kinase) family located on the pericentromeric 
IBD locus on Chromosome 10, was first identified as a CD suscepitiblity gene by 
Stoll et al.
244
 MAGUK proteins are known to form scaffolds for other proteins 
involved in intracellular signal transduction and could therefore interfere with the 
integrity of the epithelial barrier.
950
 Since the index publication,  DLG5 variation in 
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CD has been studied in a large number of populations but replication has only been 
demonstrated in a few.
950
  
It is noteworthy that DLG5 was not confirmed as a susceptibility gene in the meta-
analysis.
694
 True genetic heterogeneity, phenotypic differences between patient 
populations and/or stratification of control groups remain possible explanations but a 
meta-analysis of most published studies suggests it does not have a major role to play 
in IBD susceptibility.
265
 A more recent meta-analysis of DLG5 variation showed a 
gender-stratified effect: the 30Q allele (rs 1248696) was found to be associated with 
a mildly decreased risk of CD in women. This gender-specific effect was confirmed 




9.1.10 PTGER4, ORMDL3 and the Gene Deserts 
 
A Belgian-French collaboration first identified a novel „gene desert‟ on Chromosome 
5p13.1 associated with CD.
471
 Although there have been no known genes or CpG 
islands described within this region, eQTL analysis showed that expression of one of 
the flanking genes PTGER4 (prostaglandin receptor EP4) was regulated by CD 
associated polymorphisms.
471
 The meta-analysis by Barrett et al. later confirmed the 




It is noteworthy that this locus and the PTGER4 gene have previously also been 
associated with asthma susceptibility.
953
 Genetic overlap between susceptibility 
determinants in a number of immune-mediated diseases, notably different 
manifestations of allergic disease and IBD, have come to light in the course of the 
application of GWAS to the study of these complex polygenic diseases.
890;954
 A 
GWAS in childhood asthma, followed by several replication studies, has added the 
locus on chromosome 17q21 containing the ORMDL3 gene to the long list of shared 
genetic susceptibility determinants involved in both IBD and atopic disease 
(including among others the HLA-region, several interleukins (e.g. IL12B on the 
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IBD5 locus), prostaglandin-receptors, TGF-β, defensins, Toll-like receptors, NOD-




In the meta-analysis by Barrett et al., the most significant CD-associated eQTL 
reported affected the ORMDL3 gene on chromosome 17. This suggests that the same 
polymorphisms might underlie susceptibility to both CD and asthma, possibly by 
perturbing ORMDL3 expression.
694
 Germline variation of ORMDL3, which encodes 
a protein of unknown function belonging to a family of transmembrane proteins 
anchored in the endoplasmic reticulum, was recently shown by Bouzigon and 
colleagues to confer increased risk of asthma, with a notable restriction to early-onset 
asthma.
956
 This risk was further increased by early-life exposure to environmental 
tobacco smoke.
956
 These findings are particularly intruiging when one considers the 
detrimental effect of smoking on CD susceptibility (notably age at diagnosis) and its 




At least 4 other gene deserts have satisfied stringent criteria of genome-wide 
significance in the meta-analysis.
694
 Detailed analysis of regions flanking these gene 
deserts is now ongoing to subject these intriguing deserts to eQTL as applied 
successfully in the case of the 5p13 locus. Whether these deserts contain long-range 




Intelectin (ITLN1) is a mammalian Ca2+-dependent, D-galactosyl-specific lectin 
expressed in Paneth and goblet cells of the small intestine and proposed to serve a 
protective role in the innate immune response.
957;958
 Structurally identical to the 
intestinal lactoferrin receptor, ITLN1 has been demonstrated in secretory granules of 
lysozyme-positive Paneth cells in the bottom of the crypts as well as goblet cells 
along the crypt-villus axis, but quantitatively, the major site of intelectin deposition 
was the enterocyte brush border.
958
 This strategic localization suggests that the 
IBD Genetics in Scottish Children 
280 Ch.9:  An overview of recent developments in Crohn’s disease genetics and 
concluding remarks   
intelectin serves as an organizer and stabilizer of the brush border membrane, 
preventing loss of digestive enzymes to the gut lumen and protecting the glycolipid 
microdomains from pathogens.
958
 The first genetic association with CD was recently 
demonstrated in the meta-analysis by Barrett et al.
694
 Detailed functional analysis of 




The heavily sulfated membrane glycoprotein mucin-like glycoprotein (Muclin) is a 
DMBT1 (Deleted in Malignant Brain Tumours 1) product that is strongly expressed 
in organs of the gastrointestinal (GI) system.
959
 A deletion allele of DMBT1 on 
chromosome 10q with a reduced number of scavenger receptor cysteine-rich domain 
coding exons was found by Renner et al. to be associated with an increased risk of 
CD, but not UC.
960
 In this study, Dmbt1(-/-) mice displayed enhanced susceptibility 
to dextran sulfate sodium-induced colitis and elevated TNFα, IL6, and 
NOD2/CARD15 expression levels during inflammation. More recently, de Lisle et 
al. demonstrated that DMBT1 deficiency was associated with an impairment of 
exocrine pancreas whereas no significant difference in DSS-induced colitis-severity 
was observed between Muclin-deficient mice and wildtype.
959
  
DMBT1 is strongly up-regulated in the inflamed intestinal mucosa of Crohn's disease 
patients with wild-type, but not with mutant NOD2/CARD15.
961
 DMBT1 inhibits 
cytoinvasion of Salmonella enterica and LPS- and muramyl dipeptide-induced NF-
kappaB activation and cytokine secretion in vitro. Dysregulated intestinal DMBT1 
expression,  due to mutations in the NOD2/CARD15 gene, may contribute to the 
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9.1.13 XBP1 and Endoplasmic Reticulum stress 
 
When cells are stimulated to secrete large amounts of protein, an excess of unfolded 
proteins accumulates in the endoplasmic reticulum (ER), triggering ER stress and 
activating three proteins (IRE1, PERK, and ATF6) that mediate the unfolded protein 
response, with a key role for the transcription factor XBP1 (X-box binding protein 
1).
962
 These signalling pathways expand the protein folding capacity of the cell in 
order to restore ER homeostasis. If the ER damage is extensive or prolonged, cells 
typically undergo programmed cell death. The loss of key proteins of the unfolded 
protein response also results in so-called “unresolved ER stress” and apoptosis. For 
example, in the absence of XBP1 (Xbp1−/−), unresolved ER stress leads to increased 
expression of select genes of the unfolded protein response (ATF4 and ATF6) and 
increased JNK signalling. These elevated signals increase cell susceptibility to 
programmed cell death and induce increased expression of proinflammatory genes 
leading to intestinal inflammation. 
 
Proof of principle has been provided in animal models (e.g. Mucin2 mutant mice and 
IL10
-/-
 mice) with replication in intestinal tissue from IBD patients.
963;964
  Not only is 
XBP1 deletion in IECs associated with spontaneous enteritis and increased 
susceptibility to induced colitis (secondary to both Paneth cell dysfunction and an 
epithelium that is overly reactive to mediators of inflammation in IBD such as 
flagellin and TNFα, also genetic association of XBP1 tagging variants with both CD 
and UC has been described by Kaser et al.
965
 In a total of 5322 controls, 2762 CD 
and 1627 UC patients, these authors identified a total of six SNPs associated with 
IBD that were robust after correction for multiple testing and significant after 10,000 
permutations. Multiple logistic regression analysis of the entire IBD panel including 
gender as a covariate revealed a best model fit with SNPs rs5997391 and rs35873774 
(intron 4/5 of XBP1). Deep sequencing of the XBP1 locus, characterised by weak 
linkage disequilibrium, in 282 CD, 282 UC and 282 healthy controls revealed a 
number of rare alleles of which two non-synonymous variants were only present in 
IBD patients and hypomorphic in detailed functional experiments.
965
 Taken together, 
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these studies provide functional and genetic evidence for the role of the ER stress 
response in the pathogenesis of IBD.  
 
Orchestration of the secondary immune response: HLA-region, 
TNFSF15/TL1A, IRF5, PTPN2, PTPN22, NKX2-3, IL12B, IL18RAP, 
MST1 
 
9.1.14 The HLA-region 
 
The region on chromosome 6p (IBD3) containing the Human Leukocyte Antigen 
(HLA) – genes as well as a wide range of functional IBD candidate genes like TNF, 
met the strong criteria for genome-wide significance in the meta-analysis by van 
Heel et al. of nearly 2000 affected sibling pairs and several SNPs achieved nominal 
significance in the GWAS meta-analysis by Barrett et al.
107;694
 The extensive linkage 
disequilibrium across the gene-dense region has complicated the identification of 
causal variants.
966
 In IBD, the HLA-DRB1 is the most studied region with the 
strongest associations observed between HLA-DRB1*0103 and colonic CD and even 
more so with severe, extensive UC in Caucasians.
702
 HLA-DRB1*07 is the most 





Fernando and colleagues recently performed an extensive pooled analysis and 
confirmed significant association signals arising from alleles/haplotypes related to 
HLA-DRB1*0103, HLA-DRB1*04, HLA-DR7, and HLA-DRB3*0301. In addition, 
these authors described association with HLA-B18, HLA-B21, HLA-DR6 
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Current treatment options for CD include several monoclonal antibodies (e.g. 
infliximab, adalimumab and certolizumab) against TNFα. It is therefore noteworthy 
that Fernando et al substantiate reports of association of several of the TNF promoter 
polymorphism (TNF-1031C, TNF-863A and TNF-857T with CD), as our group had 
previously reported.
254;967-969
 As the TNF gene lies at only 1Mb from the CD-
associated HLA class II alleles, it is unclear whether these effects are independent 




The association between CD and TNFSF15 (Tumour Necrosis Factor Superfamily, 
member 15 on 9q33.1 also
 
called TNF superfamily ligand A, TL1A or vascular 
endothelial
 
cell growth inhibitor, VEGI) was described in the first GWAS in CD and 
has since been widely replicated, including in the recent GWAS meta-
analysis.
694;900;970-973
 TNFSF15/TL1A is a TNF-like factor expressed
 
in endothelial 







 lymphocytes of the intestinal lamina propria of
 
IBD 
patients, especially CD. TNFSF15/TL1A synergizes with both the cytokine-
dependent IL12/IL18 pathway and with low-dose stimulation of the T cell receptor to 
significantly induce the secretion of IFN-gamma via an IL18-independent pathway 
and is involved in the development of chronic mucosal inflammation by enhancing 
Th1 and Th17 cell functions.
974;975
 Pappu et al have recently shown that the 
expression of a TNF receptor family member, death receptor 3 (DR3; also known as 
TNFRSF25), is selectively elevated in Th17 cells, and that its cognate ligand, 
TNFSF15/TL1A, can promote the proliferation of effector Th17 cells.
976
 Another 
member of this receptor family TNFRSF6B (tumor necrosis factor receptor 
superfamily member 6B) has recently been associated with childhood-onset CD and 
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The interferon regulatory factor 5 (IRF5) gene encodes a transcription factor that 
plays an important role in the innate as well as in the cell-mediated immune 
responses through the downstream regulation of the TLR-MyD88 signalling pathway 
for gene induction of proinflammatory cytokines, such as IL6, IL12 and TNFα.
355;977
 
The IRF5 gene has been shown to be associated with several other immune-mediated 
conditions including systemic lupus erythematosus, rheumatoid arthritis, multiple 
sclerosis and Sjögren syndrome. An association between CD and a 5 bp indel 
(CGGGG) polymorphism in the promoter region of the IRF5 gene was recenty 
described by Dideberg et al.
977
 The insertion of one CGGGG unit is predicted to 
create an additional binding site for the transcription factor SP1.
977
 To date, no 
further replication studies have been published. 
 
9.1.17 PTPN2 and PTPN22 
 
Protein tyrosine phosphatases (PTPs) are important regulators of many cellular 
functions and a growing number of PTPs have been implicated in human disease 
conditions, such as developmental defects, neoplastic disorders, immunodeficiency 
and autoimmunity.
978
 PTPN2 and PTPN22 (protein tyrosine phosphatase, 
nonreceptor types 2 and 22) have both been associated in the recent meta-analysis of 
GWAS.
694
 Interestingly, the 602W allele of PTPN22 is protective against CD, but 






Germline variants of the homeodomain-containing transcription factor NKX 2-3 (NK 
transcription factor related, locus 3) have been implicated in the genetic 
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susceptibility to both CD and UC.
694;702;727;979
 Mice deficient in the homeobox gene 
Nkx2-3, expressed in developing visceral mesoderm, showed a complex intestinal 
malabsorption phenotype, striking abnormalities of gut-associated lymphoid tissue 
and spleen suggestive of deranged leukocyte homing and down-regulation of 
mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in endothelial cells in 
which Nkx2-3 is normally expressed.
980;981
 MAdCAM-1 is a member of the 
immunoglobulin superfamily, acting as an endothelial cell ligand for leukocyte 
homing receptors L-selectin and α4β7-integrin. The humanised monoclonal antibody 
directed against α4-integrin, natalizumab, has been shown to be effective in moderate 
to severe CD in adolescents and adults, but concerns about its safety profile, notably 
in combination with other immunosuppressive treatment in view of case reports on 
the reactivation of JC-virus and the development of progressive multifocal 






The IL12B gene encodes the p40 subunit shared by the cytokines IL12 and IL23. 
IL12 is composed of two subunits p40and p35, resulting in a p70 bioactive 
cytokine.
985
 Recent data suggest that the IL12 p40 is also biologically active, notably 
via the induction of lymphotoxin-α in a IL12 receptor β1 (IL12 β1) dependent 
manner.
985
 The IL12 receptor β1 subunit is also a component of the heterodimer IL23 
Receptor. In contrast with the pro-inflammatory signal through IL12R β1, is the 
finding that signalling via IL12Rβ2 regulates both the number and functional 
maturity of Treg cells, thus illustrating the complex regulation of autoimmune 




The identification of IL12B as a susceptibility gene, shared by CD and UC, has 
added further significance to dedicating research interest to the elucidation of the 
complex IL12/IL23 pathways.
694;702;727
  In addition to the role of IL23 signalling in 
the differentiation of Th17 cells (as discussed above), IL12 signalling is crucial in the 
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orchestration of the immune response. Recently, Kang and colleagues demonstrated 
that the production of IFN-γ (which is elevated in CD mucosa and correlates with 
IL23p19 mRNA expression) by clustered NK cells was dependent on IL12 and IL18, 
and critical for the activation and maturation of colocalized monocytes to TNF- and 
inducible nitric oxide synthase-producing dendritic cells.
751;987
  Therapeutic targeting 
of the IL12 pathway (e.g. using the monoclonal antibody ustekinumab against the 
p40 subunit) is receiving renewed research interest through the identification of this 






The IL18RAP (IL18 receptor accessory protein) on chromosome 2q12.1 has been 
identified as a CD susceptibility gene in a candidate gene study by Zhernakova et al 
and as a nominally replicating CD risk locus in the meta-analysis by Barrett et 
al.
694;901
 IL18 signalling requires IL18receptor α, which binds specifically to the IL18 
and contains sequence homology to IL1 receptor and TLRs, and the IL18RAP.
988
 As 
is the case for many genes discussed above, it is pertinent that the IL18RAP locus 
(residing in a block of strong linkage disequilibrium which also contains IL1RL1, 
IL18R1 and SLC9A4) has also been implicated in a number of other immune-
mediated conditions, notably coeliac disease.
989
 Hunt et al. showed a large cis effect 
of rs917997 genotypes (the same SNP was identified in the studies by Zhernakova, 
Barrett and Hunt) on the level of IL18RAP mRNA expression in whole blood from 




IL18, which is produced by antigen presenting cells, unstimulated T-cells and NK-
cells, is of interest in CD pathogenesis for several reasons.
990
 Th1 cells lacking 
IL18RAP fail to produce IFNγ in response to IL18, IL18RAP-deficient neutrophils 
fail to respond to IL18-induced activation and cytokine production and IL18RAP is 
required for NK-mediated cytotoxicity induced by in vivo IL18 stimulation.
988
 IL18 
expression is increased in the mucosa of CD patients compared with controls and in 
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areas of macroscopic CD compared with normal mucosa in CD.
901;990;991
 Lastly, 







The MST1 gene encodes macrophage-stimulating protein (MSP), a protein 
regulating the innate immune responses to several bacterial ligands.
994
 Goyette and 
colleagues first identified a non-synonymous coding variant (rs3197999, R689C) in 
the macrophage-stimulating 1 (MST1) gene that accounts for the association signal 
on the chromosome 3p21-22 locus, and showed association with both CD and 
UC.
472;704;994
 This finding has since been replicated in CD and UC.
694;702
 MSP and its 
receptor MST1R have been reported to be involved in macrophage chemotaxis and 
activation, as well as inhibition of inflammatory responses (e.g. IL12p40 production) 
in response to LPS and other pro-inflammatory signals.
994
 While the association 
results and the identification of a coding variant suggest a potential role for MST1 in 
susceptibility to both CD and UC, other germline variants on this gene dense locus 
could also have an impact on disease susceptibility.
994
 Indeed, the MST1R and 
TRAIP (TRAF interacting protein, involved in TNFα signalling), which also reside 





Germline variants involved in susceptibility to childhood-onset CD 
 
Paediatric DNA repositories have long suffered from difficulties in recruiting enough 
children and adolescents with relatively uncommon conditions to allow for 
adequately powered genetic association studies. Even though up to a quarter of IBD 
patients present during childhood, they have been relatively underrepresented in the 
association studies to date. Our own group and others have shown that many variants 
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Kugathasan and colleagues published preliminary results of a subset of patients of 
the International Paediatric IBD Genetics Consortium. These authors carried out a 
GWAS in a cohort of 1,011 individuals with pediatric-onset IBD and 4,250 matched 
controls and identified previously unreported loci on chromosomes 20q13 and 21q22 
located close to the TNFRSF6B and PSMG1 genes, respectively.
732
 These loci 
contributed to both CD and UC susceptibility. 
 
Given the fact that that all the significantly associated SNPs occurred in noncoding 
regions, Kugathasan and colleagues considered the TNFRSF6B gene the most 
compelling candidate. mRNA expression of TNFRSF6B was shown to be markedly 
different in colonic biopsies obtained from individuals with IBD compared to 
disease-free controls and TNFRSF6B mRNA expression correlated with the degree 




The protein product for TNFRSF6B acts as a decoy receptor (DCR3) in preventing 
FasL-induced cell death which is pertinent in view of the resistance to FasL-
dependent apoptosis which has previously been shown for T lymphocytes in CD.
996
 
Serum DCR3 concentration differed between individuals with IBD and controls and, 
within the IBD group, between those with and without the identified at-risk variants 
captured by the TNFRSF6B tagging SNPs.
732
 Funke et al. have recently 
demonstrated increased expression of DCR3 in ileal biopsies of CD patients both at 
actively inflamed and at non-active sites and elevation of DCR3 serum levels in 
patients with active and non-active CD as compared to healthy controls.
997
 
Furthermore, these authors showed that expression of DCR3 in intestinal epithelial 
cells was induced by TNFα and that increased DCR3 expression was associated with 
activation of NF-kappaB and consequent protection of intestinal epithelial cells and 
lamina propria T cells from CD95L-induced apoptosis.
997
 They concluded therefore 
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that DCR3 may promote inflammation in CD by inhibiting CD95L-induced 





The international pediatric IBD genetics consortium, to which we have contributed 
374 cases (after quality control), will report on its findings in the near future. The 
analysis involved a total of 3426 patients and 11963 genetically matched controls, 
ascertained through international collaborations in Europe and North America. 
Several new loci will be reported including the discovery of 16p11 (near IL27) and 
four additional regions with susceptibility to pediatric onset IBD:  22q12, 10q22, 
2q37 and 19p13.11.  In addition, the association of 21 of 32 previously confirmed 
adult-onset CD loci and 8 of 17 adult-onset UC loci with susceptibility to childhood-
onset disease is described, highlighting the close pathogenetic relationship with 
adult-onset IBD.(Imielinski et al., Nature Genetics in press)   
 
 
Concluding remarks, reflection on my PhD and future directions 
  
From the early epidemiological observations of concordance in affected twins to the 
multi-million dollar efforts associated with GWAS, three decades of intensive 
research into the genetic susceptibility to CD have led to an exponentially increasing 
body of genetic knowledge. Somewhat disappointly, Barrett et al estimated in the 
meta-analysis of GWAS in CD that 20% of the genetic risk (about 10% of the overall 
risk) has been explained by the germline variants identified to date. This merely 
illustrates that in spite of recent progress, there is a lot of work ahead. The large 
number of confirmed susceptibility loci now requires detailed sequencing to 
ascertain the contribution of rare variants, which may not have been tagged well with 
the SNP set available on the different genotyping platforms. Due to its complex 
polygenic nature, unravelling of the pathogenesis of CD will require elucidation of 
gene-gene interactions using novel polygenic models rather than assessments of 
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pairwise interactions applied to date, which did not provide convincing evidence for 
interaction. 
 
A large number of CD susceptibility loci have been identified through the combined 
application of linkage analysis, fine mapping studies, candidate gene studies and 
most recently GWAS. Genetic association analysis has implicated several key 
mediators of the innate immune system, notably innate pattern-recognition receptors 
and their associated signal transductors, leading to a dysregulation of the mucosal 
immune respone against luminal flora. Disruption of epithelial barrier integrity has 
been implicated in CD pathogenesis through a wide range of mechanisms 
encompassing structural, metabolic and innate immune pathways. Several autophagy 
genes have been identified through GWAS triggering a number of recent functional 
studies into the role of autophagy in CD susceptibility. The discovery of the role of 
the IL23R gene in CD susceptibility has added further support to the large body of 
functional studies describing the central role of the Th17 cell in chronic immune-
mediated conditions like CD. 
 
The investigations performed in the course of my PhD have contributed in a number 
of ways to the different aspects of paediatric IBD research. The key focus of my PhD 
has been the use of the existing cohort of Scottish paediatric IBD patients for the 
study of genetic loci, implicated in IBD. Thus, I was able to study TNF-α, 
RICK/RIPK2, NOD1/CARD4, IL23R, ATG16L1, IRGM and FLG variants. From 
my first work on TNF- α promoter variants, it became clear that our paediatric 
sample size (even though at the start of my PhD, it was one of the largest repositories 
of paediatric IBD samples in the world) would not allow for small effect sizes to be 
picked up. Although later meta-analysis corroborated my findings with regards to 
TNF- α promoter variants, I chose not to include this as the analysis would not hold 
up to stringent correction for multiple testing. I was careful during later 
investigations to substantiate my genetic statistical findings with adequate power 
calculations. With the arrival of the GWAS, it became clear that even a large 
repository as the one we had collected over the preceding 4 years, would not allow us 
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to embark on a genome-wide investigation of genetic susceptibility to IBD in 
Scotland. Initially I focussed on studying the contribution of IL23R, ATG16L1 and 
IRGM in childhood-onset IBD. I was hoping to expand my work into the study of the 
epigenetic regulation of susceptibility loci. To this extent, I optimised the bisulphite-
sequencing protocol for the study of the CpG-island in the promoter region of 
NOD2/CARD15. My preliminary investigations were unable to show a difference in 
methylation status between CD patients and controls. I realised that practical 
difficulties with sequencing of this bisulphite-treated DNA and the limited scope of 
my investigation (looking only at about 35 promoter CpG sites), would not allow me 
to make firm conclusions about the role of epigenetics in IBD susceptibility. 
In the final months of my PhD, I helped in the preparation of samples for the 
international pediatric IBD genetics consortium, which will report its findings in the 
autumn of 2009. This collaboration made me appreciate some of the strengths of our 
repository even more, particularly with regards to our phenotypic data. 
 
My predecessor, Dr Richard Russell, had set up a comprehensive database including 
phenotypic and epidemiological data of paediatric IBD patients recruited for the 
genetic studies in Scotland, in collaboration with Mrs Hazel Drummond. Building on 
this work, I was able to increase the number of cases available for phenotypic and 
epidemiological studies to well over 400. Rigourous phenotyping at regular intervals 
allowed us to chart the natural evolution of paediatric IBD and to compare it with 
adult-onset IBD. This work was published in the journal Gastroenterology and 
contributed to the discussions, at the recent Pediatric IBD meeting in Paris (Sept 
2009), about the development of a paediatric IBD classification system. 
 
My PhD has given me to opportunity to take my first steps as a clinician scientist. I 
have really enjoyed dedicating myself to research linked with the care for my 
paediatric patients. I successfully obtained a clinical and research fellowship in 
paediatric gastroenterology at the Sick Kids hospital in Toronto where I plan to 
dedicate myself to the study of innate immune immunology. 
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Suggestions for the future research agenda: 
 
 The large number of loci identified in the genetic susceptibility to CD to date 
will require detailed deep sequencing to identify (rare) causal variants. 
 
 Tissue-specific functional studies will be required to appreciate the complex 
regulation of many signalling cascades identified in CD pathogenesis. 
 
 The study of the altered intestinal flora in CD, notably the mucosa-associated 
microbiome, will require integration of immunology and genetics to 
appreciate the complex interaction with the host mucosal immune response in 
CD patients. 
 
 Genetic susceptibility analysis of childhood-onset CD has identified 
additional loci, offering the real possibility of genetic modelling. This could 
allow the prediction of the course of disease and the stratification of young 
patients according to their genetic profile (and possibly microbiome) who 
would benefit from more aggressive treatment options.    
 
Whether these ongoing genetic efforts result in additional benefit for our patients, 
will depend on the success of integration of this progress in genetics with comparable 
paradigm shifts in the field of (mucosal) immunology (notably the regulation of T 
helper cell populations and autophagy) and the study of the microbiome, particularly 
the mucosa-associated flora. Eventually, the insights gained from these genetic and 
functional studies should help identify key environmental triggers and the 
establishment of a comprehensive gene-environmental model.  
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Appendix 1: Lennard-Jones Criteria-check list 
 
   Study Number 
 
Chronic granulomatous lip        1    Yes / No / Unknown 
Pyloroduodenal disease     Yes / No / Unknown 
Small bowel disease      Yes / No / Unknown 
Chronic anal lesion      Yes / No / Unknown 
……………………………………………………………………………. 
Discontinuous lesions          2    Yes / No 
……………………………………………………………………………. 
Fissuring ulcers           3    Yes / No 
Abscess       Yes / No 
Fistula       Yes / No 
……………………………………………………………………………. 
Strictures                4                              Yes / No 
……………………………………………………………………………. 
Aphthoid ulcers        5             Yes / No / Unknown 
Lymphoid aggregates     Yes / No / Unknown 
……………………………………………………………………………. 
Colonic mucin retention  6              Yes / No / Unknown 
……………………………………………………………………………. 
Granulomata    7       0 / 1-2 / 2-5 /6-10 / > 10 
…………………………………………………………………………….. 
 
Number of section criteria met 
 
 
Total number of criteria met 
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Appendix 2: Patient information leaflet 
 
Patient Information Leaflet 
The genetic influence in the development of Crohn’s disease 
and colitis in children 
 
We invite you to participate in research which we think may be 
important. The information which follows tells you about it. Try to make 
sure you understand what will happen to you if you decide to take part. 
Whether or not you do take part is entirely your choice. Please discuss 
this with your family and ask any questions you want to about the 
research and we will try our best to answer them. 
 
 
We would like to understand more about why people, specially children, develop Crohn‟s disease 
and colitis. These diseases are becoming more common in children, specially teenagers, and we 
want to try and work out why this is. We know that having a relative (either a parent or brother or 
sister) with Crohn‟s disease or colitis, gives you a higher chance of getting the disease. We want 
to examine the things that are passed onto you by your parents (your genes) and how these may 
result in the development of Crohn‟s disease or colitis. 
 
You are going to undergo tests on your blood, having been seen by one of the doctors in the 
clinic. 
 
What we are asking 
We would like to ask your permission to collect some extra specimens (two to four teaspoons of 
blood) which we can use for research in our laboratories. We are also asking both of your parents 
for blood samples too. 
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What are we going to do with them? 
We are going to use these specimens to help research into your genes and the part they play in the 
development of Crohn‟s disease and colitis. Some of these specimens will be tested in the 
laboratory soon after being taken while others may be stored in the freezer before testing. Any 
specimens stored will only be used for studies which examine your genes and the development of 
Crohn‟s disease and colitis. 
 
All our research is intended to increase understanding of how and why these diseases occur, how 
treatments work and how we may be able to improve treatments in the future. 
 
We also plan to study how genetic make-up may lead to children getting Crohn‟s disease or colitis 
and whether this make-up can alter how effective the treatments are. 
 
How will this affect me? 
We will always collect specimens needed for your planned tests before any research specimens. If 
there are any problems during the collection of these specimens ie in collecting blood then the 
doctors will not collect specimens for research. 
 
Taking extra blood will not cause you any problems. The research itself is not relevant to your 
care. If in the future we would like to perform research that may be directly relevant to you we 
will contact you to see if you agree. 
 
Do the specimens have my name on them? 
 
The people in the laboratory will not know your name as your specimens will have a number. 
Only Dr Van Limbergen or ward or outpatient staff supervised by him will be able to know this 
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What if I don’t want to be included or change my mind? 
You are entirely free to decide not to participate or drop out at any time and this will not affect 
your care in any way. If a specimen has been collected and you change your mind it will be 
destroyed at your request. 
 
Version 2 16/01/06 
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Appendix 3: Parent information sheet 
PARENT/CARER'S INVITATION TO PARTICIPATE IN A RESEARCH STUDY:  
THE GENETIC INFLUENCE IN THE DEVELOPMENT OF CROHN’S DISEASE 
AND COLITIS IN CHILDREN 
 
Dept of Paediatric Gastroenterology, Ninewells Hospital, Dundee 
Dept of Paediatric Gastroenterology, Royal Hospital for Sick Children Edinburgh 
Gastrointestinal Unit, Western General Hospital, Edinburgh 
 
 We invite your child to participate in research which we think may be important. The information 
which follows tells you about it.  It is important that you understand what is in this leaflet. It says 
what will happen if you take part and what the risks might be. Try to make sure you know what will 
happen to you if you decide to take part. Whether or not you do take part is entirely your choice. 
Please ask any questions you want to about the research and we will try our best to answer them. 
    
The Department of Paediatric Gastroenterology at the Royal Hospital for Sick Children together with the 
Department of Gastroenterology at the Western General Hospital and other paediatric gastroenterology units 
in Scotland have a major role in leading research into diseases of the bowel in children. Diseases which we 
see often in the clinics and have on-going research interest include inflammatory bowel disease namely 
Crohn's disease and ulcerative colitis.  
 
Your child is due to undergo tests involving collection of a blood sample as part of their on going 
care.  
What we are asking 
We would like your permission to collect extra blood (up to 20 ml = 4 teaspoons) which we will use 
for ongoing projects within our laboratories. Some of these specimens may be stored in a freezer for 
future projects. If specimens are stored they will only be used for studies relating to genetics and 
Crohns disease and ulcerative colitis. We will also collect and store important and relevant clinical 
details (e.g. age, sex, medication, disease, findings from the test) for analysis with the specimens. 
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How will this affect my child ? 
Priority will always be given to collecting specimens needed for our planned tests. If there are any 
difficulties during the collection of these specimens e.g. in collecting blood then the doctors will not 
collect specimens for research. Taking extra blood will not mean any significant extra risk or harm to 
your child.  
 
What research is being done ? 
Broadly speaking we are planning to study how the genetic make-up of children with inflammatory 
bowel disease (Crohn's disease or Colitis)  may lead to them getting the disease.  
 
The research included within this application will not have any impact on the care of your child 
(including any direct benefit or harm). All our research is aimed to increase understanding of how and 
why diseases occur, how treatments work and how we may be able to improve treatments in the 
future. If any studies may affect the care of individual children then a separate consent form will be 
produced. 
 
Can I help too ? 
Yes you can by giving blood too. We would like wherever possible to collect blood from both parents 
as well as your child to help get maximum information from your child‟s blood sample.  Your blood 
sample will expand the potential information we will gain from taking your children‟s blood. We 
appreciate your help with the study and so will arrange to take blood samples at a time and place that 
is convenient to you. 
Feedback 
As the information found is not of any clinical relevance to your child we will not routinely be feeding 
back any information to you directly. We will however feed the collective results back at local support 
group meetings (CICRA). 
 
Is this anonymous ?  
While collection of these specimens will not be anonymous only doctors or nurses involved in his/her 
clinical care will have access to his/her name. This allows us to go back to the hospital notes if we 
need to identify important and relevant information later on. Within the laboratory anonymity  will be 
maintained by allocating a number (rather than his/her name) to the specimens. Only Dr Van 
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Limbergen or other staff from the wards/clinics under his supervision will be able to link his/her name 
to the specimen.  
 
What happens if I or my child are not keen or change our minds ? 
You and your child are entirely at liberty to decide not to participate or drop out at any time and this 
will not affect his/her care in any way. If after specimens have been collected you change your minds 
contact us and the specimens will be discarded if they have not already been used. 
 
Is this ethical ? 
We have gained approval from the Local Ethics Committee for the collection and storage of these 
specimens and data. 
  
Any other Questions ? Any other questions can be addressed by writing to Dr Van Limbergen at 
the Dept of Paediatric Gastroenterology, Sciennes Road , Edinburgh or by contacting his secretary 
(0131 536 0615). 
We also have an independent adviser Professor S J Forsyth, a consultant paediatrician who can answer 
any concerns you have. Professor Forsyth  is based at the Ninewells Hospital in Dundee but is not a 
member of the research team.  
 
Version 1 – 4/1/6 
IBD Genetics in Scottish Children 
302 Appendices   
Appendix 4: Patient consent form 
 
CHILD'S INVITATION TO PARTICIPATE IN A RESEARCH STUDY: CONSENT  
 
THE GENETIC INFLUENCE IN THE DEVELOPMENT OF CROHN’S DISEASE 
AND COLITIS IN CHILDREN 
 





 I HAVE READ AND KEPT THE INFORMATION SHEET… 
 
 SPOKEN TO THE DOCTOR AND MY FAMILY AND ASKED ANY 
QUESTIONS I WOULD LIKE… 
 
 I REALISE I DO NOT HAVE TO DO THIS … 
 
 I REALISE ANY BLOOD SAMPLE STORED WILL ONLY BE USED TO 
STUDY THE EFFECTS OF GENES ON CROHNS DISEASE AND COLITIS 
… 
 
 AND CAN STOP OR WITHDRAW AT ANY STAGE WITHOUT 
AFFECTING MY TREATMENT…. 
 
 I AM HAPPY TO GO AHEAD. 
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Signed   …………………………… 
 
Name   …………………………… 
 
 
Witnessed  …………………………… 
 
 




Date   …………………………… 
 
 
Version 1 – 4/1/6 
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Appendix 5: Example of parent/older patient consent form 
 
PATIENT WRITTEN CONSENT FORM: 
 
Title of research proposal: 
 THE GENETIC INFLUENCE IN THE DEVELOPMENT OF CROHN’S DISEASE AND                 
     COLITIS IN CHILDREN 
 
LREC Number: LREC/2002/6/18 
 
 





 The study organisers have invited me to take part in this research.       Yes/No 
 
 I understand what is in the leaflet about the research.  I have a  Yes/No 
 copy of the leaflet to keep. 
  
 I have had the chance to talk and ask questions about the study. Yes/No 
 
 I know what my part will be in the study and I know how long it will take.  Yes/No 
 
 I know I will gain no direct benefit from taking part in the study. Yes/No 
 
 I know how the study may affect me. I have been told if there are possible risks.  Yes/No 
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 I understand that I should not actively take part in more Yes/No 
         than 1 research study at a time. 
  
 I know that the local Lothian Research Ethics Committee has seen and agreed  Yes/No 
         to this study. 
  
 .  
 I understand that personal information is strictly confidential:  I know the only people who may see 
information about my part in the study are the research team or an official representative of the 
organisation which funded the research. Yes/No 
 
 I freely consent to be a subject in the study.  Yes/No 
         No-one has put pressure on me. 
 
 I know that I can stop taking part in the study at any time. Yes/No 
 
 I know if I do not take part I will still be able to have my normal treatment. 
 Yes/No 
 
 I understand that the sample may be stored and held for future research aimed at understanding the 
genetic influence on inflammatory bowel disease only, and not for other studies without my 
permission. Yes/No 
 
 I know that if there are any problems, I can contact:  Yes/No 
 
Dr Van Limbergen 
 Tel. No.    0131 536 0615  
 
 
Patient Signature:   ........................................................ 
 
Witness‟s Name ...................................................... 
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Witness‟s Signature:   ........................................................ 
 
Date:     ........................................................ 
 
The following should be signed by the Clinician/Investigator responsible for obtaining consent 
 
As the Clinician/Investigator responsible for this research or a designated deputy, I confirm that I 
have explained to the patient/volunteer named above the nature and purpose of the research to be 
undertaken. 
 
Clinician‟s Name:   ..................................... 
 
Clinician‟s Signature:   .....................................     Date: ....................................... 
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Appendix 6: Patient/parent questionnaire 
 
Genetics of Inflammatory Bowel Disease 
Confidential 
QUESTIONNAIRE FOR PATIENTS WITH IBD 
Patient Identification Number    Sex:  Male   /   Female         
  
Date of Birth:       Hospital ID: 
Ethnic origin 
White European     Hispanic   
Jewish       Afro-Caribbean  
Japanese      Asian    
Other/Unknown   
Postcode: 
Name of present hospital consultant:   Hospital: 
Diagnosis:  Ulcerative Colitis/ Crohn‟s disease / indeterminate Colitis/OFG 
Date at symptom onset (month/year) 
Date of diagnosis: (month/year)  
Age at diagnosis: 
Year of diagnosis 
Years of disease at assessment: 
School year: 
Other medical problems: 
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SMOKING 
1. Patient 
Does patient smoke cigarettes?   YES    NO  
If Yes,  How many cigarettes a day?   
  What age did you start smoking?   
If No,  Have you ever smoked?   YES   NO 
 How many cigarettes a day?   
What age did you start smoking? (Year)  What age did you stop?  (Year) 
2. Mother:  
Did you smoke during pregnancy?   YES    NO  
If Yes, How many cigarettes a day?    
Where you smoking when patient born?  YES   NO  
If Yes, How many cigarettes a day? 
Do you currently smoke cigarettes?   YES    NO  
If Yes, How many cigarettes a day?    
What age did you start smoking?   
If No,  Have you ever smoked?   YES    NO  
How many cigarettes a day? 
 3. Father:  
Did you smoke during pregnancy?   YES    NO 
If Yes, How many cigarettes a day? 
Where you smoking when patient born?  YES    NO  
If Yes, How many cigarettes a day? 
Do you currently smoke cigarettes?   YES    NO  
If Yes, How many cigarettes a day? 
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What age did you start smoking?    
If No,   Have you ever smoked?  YES    NO  
How many cigarettes a day? 
Pregnancy and Breast-feeding 
Birth weight  kg 
Complications in pregnancy 
Was patient breast-fed at all?     YES    NO  
If so for how long? (Months)    
Vaccinations 
Have you given your child the following vaccinations? (Tick all that apply) 
DPT    HIB   MMR 
Hep B    Men c 
Family History 
Do you have?  
Coeliac disease?     YES   NO 
Colon cancer?      YES   NO 
Autistic spectrum disorder?    YES   NO 
Asthma/eczema/hay fever/food allergy?  YES   NO 
Does your mother or father have?  (List affected family members/age of onset) 
Crohn‟s disease?     YES    NO 
Ulcerative colitis?     YES   NO  
Coeliac disease?     YES   NO 
Colon cancer?      YES   NO 
Autistic spectrum disorder?    YES   NO 
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Brothers and sisters 
1.In total, how many brothers and sisters do you have? Sibling rank 
Do your brother or sisters have?(List affected family members/age of onset) 
Crohn‟s disease?     YES   NO  
Ulcerative colitis?     YES   NO  
Coeliac disease?     YES   NO 
Colon cancer?      YES   NO 
Autistic spectrum disorder?    YES   NO 
Do your grandparents, aunts, uncles, or cousins have? (List affected family 
members and age of onset) 
Crohn‟s disease?     YES    NO 
Ulcerative colitis?     YES   NO  
Coeliac disease?     YES   NO 
Colon cancer?      YES   NO 
Autistic spectrum disorder?    YES   NO 
Surgery   
Has patient had any operations for IBD?  YES    NO 
If yes, please list below, with year if possible. Date of surgery Type of operation 
Have you had your tonsils removed?       YES     NO  
If yes, when?   Age/year   
Have you had your appendix removed?    YES    NO  
If yes, when?   Age/year 
Any other surgery?     YES    NO 
Have you had any broken bones?   YES     NO 
If yes, how many? 
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Crohn’s disease site   Presentation / Follow-up Year 
        
Site            Behaviour         
Oral      Inflammatory  B1    
Oesophagus     Stricturing        B2   
Gastric body     Penetrating       B3   
Gastric antrum    Give details below 
Duodenal     Strictures 
Jejunal                Abscesses 
Ileal       TI     Fistulae 
Caecal      Inflammatory mass 
Ascending     Perianal ulcer 
Transverse     





DEXA      yes / no    
EIM‟s    yes / no                give details  
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Presentation / Follow-up  Date of Last Follow-up Clinic: 
Date of last investigation: 
Extent of UC 
Examination           satisfactory / unsatisfactory 
Examination type          colonoscopy / sigmoidoscopy 
Examination stopped at 
Ulceration     yes / no 
Crypt abscesses    yes / no 
Cryptitis     yes / no 
Goblet cell depletion    yes / no 
Disease years 
Extent changed    yes / no           





DEXA    yes / no    
EIM‟s    yes / no       give details 
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Appendix 9 : Laboratory data collection form 
 
 Study Number 
 








VITAMIN B12  
FOLATE  
 
For CRP please choose from  - normal or raised. 
 
Clinic Date:      Age at Diagnosis: 
Height :      Ht centile/Z-score 
Weight :      Wt centile/Z-score 
BMI:       BMI centile/Z-score 
  
Puberty progressing normally / delayed / not assessed / not appropriate  
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Appendix 10: The salting out method 
All steps were performed having taken universal precautions before handling blood 
and all stages were then performed in an appropriate “hood” within the laboratory. 
1. 10 mls of whole blood collected previously into an EDTA tube were added 
into a 50ml conical tube.  
2. 40 mls of red cell lysis buffer (RCLB) were then added to the conical tube. 
3. The resulting mixture was then mixed and re-suspended for 5 minutes.  
4. The solution was centrifuged at 3000 rpm for 10 minutes. 
5. The supernatant was then removed leaving a pellet in the “cone” of the tube. 
6. The pellet was re-suspended with a further 40 mls of RCLB and then re-
centrifuged at the same speed for a further 5 minutes.  
7. The resulting “white blood cell” pellet was then further re-suspended in 3 mls 
of nuclear lysis buffer and sodium dodecyl sulphate.  
8. To this solution 1ml of 6M sodium chloride and 3mls of chloroform were 
then added. 
9. The resulting mixture was then aggressively agitated to allow mixing. 
10. The solution was then centrifuged at 3000 rpm for 20 minutes.  
11. The solution then separated into 3 layers. The middle layer was then carefully 
pipetted out to avoid mixing with the other 2 layers.  
12. The layer was added to 20 mls of 100% ethanol resulting in precipitation of 
DNA.  
13. This DNA pellet was removed from the alcohol and dried in room air for 5 
minutes.  
14. The DNA was transferred into 0.5 mls of TE and stored at 4ºC until dissolves.  
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